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 ABSTRACT 
ABSTRACT 
 
 
 
The different life stages of Oreochromis mossambicus and their response to 
chronic exposure to pharmaceuticals: The HIV anti-retroviral drug nevirapine 
and the antibiotics sulfamethoxazole and trimethoprim 
Human pharmaceuticals and their metabolites in aquatic environments are 
considered as “contaminants of emerging concerns” as there is limited information 
on their behaviour in the environment. Consequently, their potential unintended 
effects on aquatic animals including fish are still largely unknown. The anti-retroviral 
drug nevirapine (NVP) and the antibiotics sulfamethoxazole (SMX) and trimethoprim 
(TMP) are amongst the most regular prescribed pharmaceuticals in South Africa. 
These drugs are also frequently detected in wastewater treatment plants’ effluents 
and in surface waters across Africa. Nevirapine is a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) used as a first-line treatment for the prevention of 
the Human Immunodeficiency Virus (HIV). The antibiotics SMX and TMP are 
amongst the most consumed antimicrobials globally because they are cheaper, and 
they have a broad range antimicrobial activity. They are commonly used in human 
health care, in animal farming and in crops production. In humans, they are 
combined in one pill, co-trimoxazole, which is part of the HIV therapy to treat and 
prevent opportunistic infections. Despite the health benefits NVP, SMX and TMP 
are listed amongst the top 10 human pharmaceuticals associated with liver toxicity 
and kidney injury. In addition, SMX and TMP are amongst the antibiotics suspected 
to cause antimicrobial resistance worldwide. Few studies are available on the 
potential effects of NVP, SMX, TMP and their mixtures on indigenous fish species 
in African surface waters.  
This study investigated the chronic effects of NVP as a single toxicant and in a 
mixture with SMX and TMP on the different life stages of Oreochromis mossambicus 
in a laboratory controlled exposure. Environmentally relevant concentrations of the 
pharmaceuticals in African surface waters from published literature were used in a 
static renewal system. Growth parameters (weight, length, condition factor and 
specific growth rate) were used to investigate the effects of the pharmaceuticals on 
 Uwineza Marie Clémentine Nibamureke    2019 vii 
 
 ABSTRACT 
early life stages while the semi-quantitative histological assessment protocol was 
used to assess the effects on both juveniles and adult fish liver, kidney and gonads.  
Early life stages of O. mossambicus exposed to NVP and to its mixture with the 
antibiotics showed no significant differences from the control fish in the hatching 
success, survival and behaviour (p > 0.05). There were also no significant 
differences in growth parameters up to 60 days post-hatching. Histological 
assessment of liver and kidney of 30 days old juveniles showed liver cells 
vacuolation and fatty change, vacuolation and necrosis of renal tubules as well as 
dilation of the Bowman’s space. Comparing the different groups, statistically 
significant differences were found in mean kidney (p < 0.001) and liver (p = 0.005) 
indices.  
Sexually mature adult O. mossambicus exposed to NVP and its mixture with 
antibiotics presented histopathological changes in the liver, kidney and ovaries. 
Those changes included nuclear alteration, vacuolation, fatty changes and a mild 
fibrosis around veins and bile ducts in the liver; vacuolation, necrosis, hyaline 
degeneration and dilation of the Bowman’s space in the kidney; and vacuolation, 
necrosis and extensive atresia in ovaries. In general, the liver tissue of adult fish 
was more affected than the kidney; and the fish exposed to the mixture of 
pharmaceuticals presented higher liver indices compared to the fish exposed to 
NVP alone. Statistically significant differences were noted in leukocrit values (p = 
0.019); hepatosomatic indices (p < 0.001); splenosomatic indices (p = 0.035); liver 
indices  
(p < 0.001); kidney indices (p < 0.001) as well as in ovary indices (p = 0.026) across 
the different groups.  
Comparing the 30 days old juveniles and adult O. mossambicus liver and kidney, 
the juvenile fish indices were lower than adult fish indices. This indicated that 
histological changes were more severe in adult fish than in juveniles. The fish 
exposed to the mixture of NVP and the antibiotics were more affected compared to 
those exposed to NVP alone in both juvenile and adult fish. Although a significant 
difference was found in liver and kidney indices for juvenile fish exposed to 
pharmaceuticals and the control, the histological changes were found to be in class 
1. This was characterised by mild changes to the normal organ histology not 
affecting the organ function. The mean kidney indices of adult fish were classified in 
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class 2 characterised by moderate changed to the normal histology. The liver 
indices were mainly classified in class 3 characterised by pronounced changes to 
the organ histology that may affect the organ function.  
In conclusion, the results from this study showed that NVP in African surface waters 
has long-term negative effects on all life stages of fish; and those effects may be 
increased by the presence of other pharmaceuticals as it occurs in a natural 
environment.  
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Parts of the results of this study were presented at National and International 
Conferences, followed by the submission to accredited journals for publication. 
Below is a list of the accepted articles as well as conference presentations of the 
research results. As the information is particularly relevant to South Africa, I also 
organised an Awareness Program as part of a Community Engagement Project. 
 
A. Journal and conference papers 
Published Research Papers: 
1. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. (2018). Hatching success 
and survival of fish early life stages in a chronic exposure to nevirapine: A case 
study of the Mozambique tilapia. International Journal of Environmental Health 
Research. Published online: 26 December 2018.  
doi:10.1080/09603123.2018.1548697    
2. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. (2019). Assessing the 
potential effects of nevirapine in South African surface waters on fish growth: A 
chronic exposure of Oreochromis mossambicus. South African Journal of 
Science, 115(3/4), Art. #5516, 6 pages. Published online: 27 March 2019. 
doi:10.17159/sajs.2019/5516  
3. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. (2019). Nevirapine induces 
liver histopathology in exposed Oreochromis mossambicus: A case study. African 
Journal of Aquatic Science, 44(1): 77-88. doi:10.2989/16085914.2019.1571477   
 
Conference Papers: 
1. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. The potential effects of 
pharmaceuticals on the growth of the early juveniles of Oreochromis 
mossambicus (Peters, 1852). In: Poleksic V, Raskovic B, Markovic Z, editors. 
Water & Fish, 8th International Conference Proceedings; 13-15 June 2018; 
Faculty of Agriculture, University of Belgrade, Serbia. Belgrade-Zemun: 
University of Belgrade, Faculty of Agriculture; 2018. p. 346-349. ISBN: 978-86-
7834-308-7. Available from: http://www.cefah.agrif.bg.ac.rs/conference/ 
conference.html 
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B. Conference presentations 
National: 
1. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. Investigating the potential 
effects of the HIV drug nevirapine in water on the hatching success and survival 
of the Mozambique tilapia larvae. Oral Presentation. Southern African Society 
for Aquatic Scientists (SASAqS) Congress 2017, Birchwood Hotel & OR Tambo 
Conference Centre, Johannesburg, South Africa, 25 June - 28 July 2017.  
2. Nibamureke UMC, Sihoka C, Barnhoorn IEJ & Wagenaar GM. Biometric indices 
and liver histology of the Mozambique tilapia (Oreochromis mossambicus) after 
a chronic exposure to the HIV drug nevirapine. Oral Presentation. Southern 
African Society of Aquatic Scientists (SASAqS) Congress 2018. Cape St Francis 
Bay Resort, South Africa, 25 – 28 June 2018. 
International: 
3. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. Growth evaluation of the 
Mozambique tilapia (Oreochromis mossambicus) larvae and juveniles in a 
chronic exposure to the HIV drug nevirapine. Oral presentation. International 
Women in Science Without Borders (WISWB) – Indaba, School of Tourism and 
Hospitality, University of Johannesburg, 21 – 23 March 2018. 
4. Nibamureke UMC, Barnhoorn IEJ & Wagenaar GM. The potential effects of 
pharmaceuticals on the growth of the early juveniles of Oreochromis 
mossambicus (Peters, 1852). Poster presentation. Water & Fish, 8th 
International Conference, Faculty of Agriculture, University of Belgrade, Serbia 
and International Aquatic Veterinary Biosecurity Consortium, University of 
Munich, Germany, 13 – 15 June 2018. 
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C. Impact on the community 
This study’s aim was to investigate the possible effects of selected human 
pharmaceuticals detected in South African surface waters on the health of fish. 
Published research papers emphasise that the source of pharmaceutical pollution 
in the environment is mainly anthropogenic. I therefore felt that it was my 
responsibility to make people aware about this new type of pollution. At present 
there are very little information and discussions in this domain outside the circle of 
scientists. In fact, this study is amongst the first few studies to investigate the effects 
of pharmaceuticals pollution in South African surface waters on aquatic animals. 
Therefore, I organised and conducted an “Awareness Program”, talks and 
discussions, about the risk of environmental pollution from the unsafe disposal of 
old and unused pharmaceutical products. This was done during the National 
Science Week hosted at the University of Johannesburg, Soweto Science Centre 
from 07 – 11 August 2017. The target groups were school children and their 
teachers from grade 5 to grade 11. In total, my message reached school children 
from 4 primary schools and 4 high schools from Soweto and some of their teachers. 
Using the results from this study and other studies around South Africa and around 
the world, I sensitized the students and their teachers about the problem of 
pharmaceutical pollution in the environment. The feedback was positive as shown 
by the many questions and the discussions that followed. As the learners were very 
interested in the occurrence of pharmaceuticals in the environment, I trust that in 
return and in future, they will sensitise their friends, families and teachers as well as 
their neighbours. The aim of this intervention and interaction was to make a 
difference in our communities as the core of the problem of environmental pollution 
is mainly the lack of awareness of the local population. 
I will continue to organise and participate in “awareness campaigns and 
discussions” in schools and public institutions on the problem of pharmaceutical 
pollution in aquatic environments. I hope this will make a difference by making 
people aware of the problem and lead them to take steps in finding solutions 
including stopping the misuses and overuse of pharmaceuticals as well as reducing 
the illegal disposition of old and unused pharmaceuticals in the environment.  
 Uwineza Marie Clémentine Nibamureke    2019 xii 
 
 ACKNOWLEDGEMENTS 
ACKNOWLEDGEMENTS 
The completion of this study was a result of not only my personal effort but also the 
contribution and support, moral and material, from the following people and 
institutions. I want to take a time and thank them. 
Firstly, my supervisor, Prof GM Wagenaar, for being a good mentor and a fantastic 
role model. You have been my source of motivation; working with you has been a 
fulfilling and memorable experience. I hope that I will be such a good mentor to 
others as you taught me. 
My co-supervisor, Prof IEJ Barnhoorn, your guidance has helped me to grow not 
only in research and writing skills but also in team working and collaboration skills.  
My colleagues from the “Aquatic Health Research Group”, department of Zoology 
at the University of Johannesburg, for your encouragements and technical support 
in laboratory work and results analysis. 
Mr Mkhacani M. Mathonsi and Ms Mmakoma L. Bogopa, the University of 
Johannesburg Research Aquarium technical staff, for training me in fish keeping 
and breeding, and helping me throughout my exposure experiments.  
The department of Zoology, University of Johannesburg, for giving me the 
opportunity to further my studies. 
The National Research Fund of South Africa (NRF) and the University of 
Johannesburg Global Excellence and Stature (GES) doctoral scholarships, for 
giving me the financial support that allowed me to realise my dream of becoming a 
researcher.  
Dr Motsidisi L. Mokae, for being there when I needed a friend to talk to when things 
got hectic; your reassuring and encouraging words kept me going. 
My husband Blaise, my sons Cedric and Emmanuel, for believing in me and always 
encouraging me even when I was doubting myself. Thank you for being my family; 
you are a blessing from God.  
God bless you all. 
“Nabuzwa n’ iki kugushimira Nyagasani?” (Psalm 145) 
 Uwineza Marie Clémentine Nibamureke    2019 xiii 
 
 DEDICATION 
DEDICATION 
 
 
 
 
 
 
 
To my father Elie 
and my mother, Léa (1947 - 1997) 
 who instilled in me the spirit of self-confidence 
 and the love of studying. 
 
  
 Uwineza Marie Clémentine Nibamureke    2019 xiv 
 
 LIST OF FIGURES 
LIST OF FIGURES 
 
Figure 1.1: Overview of the study ............................................................................ 9 
Figure 2.1: Main sources and pathways of pharmaceuticals into surface water 
(adapted from Boxall 2004 and Ebele et al. 2017) ................................................ 13 
Figure 2.2: Main pathways of absorption, distribution, and elimination of 
pharmaceuticals in fish (adapted from Di Giulio & Hinton 2008 p. 59) .................. 24 
Figure 3.1: Static renewal system for early life stages (EL) ................................... 49 
Figure 3.2: A-B. Receiving and acclimation tanks for adult fish; C. Environmental 
room, w. Tank for renewal water; D. Static renewal system for juvenile and adult fish
 .............................................................................................................................. 49 
Figure 3.3: A. Bw. Boxes to collect test media waste from exposer tanks; B. b. A 
bucket where the test media waste from the environmental room is dropped. ...... 50 
Figure 3.4: A. Embryos 24 hours post-fertilisation observed on a dissection 
microscope. ........................................................................................................... 50 
Figure 3.5: Adult fish necropsy and blood sampling. ............................................. 51 
Figure 3.6: Target organs sampling. ...................................................................... 52 
Figure 3.7: Tissue sampling for histological analysis. ............................................ 53 
Figure 4.1: Hatching success (%) of embryos in all the four repeats of each exposure 
group from the first experiment .............................................................................. 58 
Figure 4.2: Comparison of hatching success (%) of embryos across the groups in 
the 1st experiment .................................................................................................. 59 
Figure 4.3: Hatching success (%) of embryos in the two repeats of each exposure 
group in the 2nd experiment ................................................................................... 59 
Figure 4.4: Comparison of hatching success (%) of embryos across the groups in 
the 2nd experiment ................................................................................................. 60 
 Uwineza Marie Clémentine Nibamureke    2019 xv 
 
 LIST OF FIGURES 
Figure 4.5: The survival rate (%) of early life stages at the different stages in each 
exposure group in the 1st experiment .................................................................... 62 
Figure 4.6: The survival rate (%) of early life stages at the different stages in each 
exposure group in the 2nd experiment ................................................................... 63 
Figure 4.7: Mean total length of early life stages from the different groups of the 1st 
experiment at day 1, 30 and 60 post-hatching. ..................................................... 65 
Figure 4.8: Mean body weight of early life stages from the different groups of the 1st 
experiment at day 1, 30 and 60 post-hatching ...................................................... 65 
Figure 4.9: Mean total length of early life stages from the different groups of the 2nd 
experiment at day 1, 30 and 60 post-hatching. ..................................................... 66 
Figure 4.10: Comparison of total length of early life stages from the different groups 
of the 2nd experiment at day 30 post-hatching. ...................................................... 66 
Figure 4.11: Mean body weight of early life stages from the different groups of the 
2nd experiment at day 1, 30 and 60 post-hatching. ............................................... 67 
Figure 4.12: Comparison of body weight of early life stages from the different groups 
of the 2nd experiment at day 1 post-hatching........................................................ 67 
Figure 4.13: Comparison of body weight of early life stages from the different groups 
of the 2nd experiment at day 30 post-hatching. ..................................................... 68 
Figure 4.14: Scatterplot showing the strong positive correlation (linear shape with 
an upward position from left to right) between mean total length and weight 
measurements of fish in all the three groups in the 1st experiment from day 1 to day 
60 post – hatching ................................................................................................. 69 
Figure 4.15: Scatterplot showing the strong positive correlation (linear shape with 
an upward position from left to right) between means total length and weight 
measurements of fish in all the groups in the 2nd experiment from day 1 to day 60 
post – hatching ...................................................................................................... 70 
Figure 4.16: Mean condition factor (CF) of early life stages from the different groups 
of the 1st experiment at day 1, 30 and 60 post-hatching ........................................ 71 
 Uwineza Marie Clémentine Nibamureke    2019 xvi 
 
 LIST OF FIGURES 
Figure 4.17: Mean condition factor (CF) of early life stages from the different groups 
of the 2nd experiment at day 1, 30 and 60 post-hatching ....................................... 72 
Figure 4.18: Comparison of condition factor (CF) of early life stages from the 
different groups of the 2nd experiment at day 1 post hatching. .............................. 72 
Figure 4.19: C - F: Observed liver histology of the control and solvent control fish...
 .............................................................................................................................. 77 
Figure 4.20: Micrographs showing the different histological changes observed in 
exposed fish from the different groups. ................................................................. 78 
Figure 4.21: A. Micrograph showing the location of the kidney (k) in the fish visceral 
cavity in a longitudinal section ............................................................................... 79 
Figure 4.22: Histological changes in the exposed fish kidney tissue. .................... 80 
Figure 4.23: Comparison of liver indices of the 30 days old in the different groups…
 .............................................................................................................................. 84 
Figure 4.24: Mean reaction pattern indices in the liver of 30 days old from the 
different groups ..................................................................................................... 84 
Figure 4.25: Comparison of kidney indices of the 30 days old in the different groups. 
 .............................................................................................................................. 85 
Figure 4.26: Mean reaction pattern indices in the kidney of 30 days old from the 
different groups ..................................................................................................... 86 
Figure 4.27: Comparison of mean liver and kidney indices of fish from the different 
groups. .................................................................................................................. 87 
Figure 4.28: Macroscopic abnormalities observed during internal and external 
necropsy ................................................................................................................ 89 
Figure 4.29: Comparison of total length of all the fish from the different groups.... 89 
Figure 4.30: Comparison of body weight of fish from the different groups. ........... 90 
Figure 4.31: Comparison of the CF of the fish in the different groups. .................. 91 
 Uwineza Marie Clémentine Nibamureke    2019 xvii 
 
 LIST OF FIGURES 
Figure 4.32: HSI of female fish in all the different groups. ..................................... 91 
Figure 4.33: HSI of male fish in all the different groups. ........................................ 92 
Figure 4.34: Comparison of splenosomatic index (SSI) of the fish in the different 
groups. .................................................................................................................. 93 
Figure 4.35: Mean gonadosomatic index (GSI) (%) of fish from the different groups. 
 .............................................................................................................................. 94 
Figure 4.36: Mean haemoglobin (Hb) (mg/dl) values of both the female and male 
fish from each group. ............................................................................................. 95 
Figure 4.37: Presentation of mean haematocrit (Hct) (%) and leukocrit (Lct) (%) of 
female and male fish from the different groups. .................................................... 95 
Figure 4.38: Comparison of leukocrit (Lct) values of fish from the different groups….
 .............................................................................................................................. 96 
Figure 4.39: A – D. The structure of O. mossambicus liver tissue from a control fish..
 ............................................................................................................................ 106 
Figure 4.40: G. Non-lipid vacuolation in fish exposed to NVP (arrows; note the 
central nuclei and the clear non-uniform vacuoles). ............................................ 107 
Figure 4.41: M. Necrotic hepatocytes with fading nuclei in NVP exposed fish 
(karyolysis, arrows). ............................................................................................ 108 
Figure 4.42: A – C. Structure of the O. mossambicus kidney tissue in control fish…
 ............................................................................................................................ 109 
Figure 4.43: G. NVP exposed fish showing hyaline deposits in renal tubule cells 
(arrows) and necrotic tubules (star).. ................................................................... 110 
Figure 4.44: A & B. Organisation of the testis of O. mossambicus in a control fish: 
the tunica albuginea (TA). ................................................................................... 111 
Figure 4.45: A - C. Organisation of O. mossambicus ovarian tissue from a control 
fish. the tunica albuginea (TA). ............................................................................ 112 
 Uwineza Marie Clémentine Nibamureke    2019 xviii 
 
 LIST OF FIGURES 
Figure 4.46: G. Massive oocytes atresia (AO) in a fish exposed to NVPH. Note the 
younger oocytes stages still intact next to the atretic ones.. ................................ 113 
Figure 4.47: Comparison of liver indices of female fish across the different groups. 
The groups with significant difference between them (p < 0.05) are shown. ....... 115 
Figure 4.48: Comparison of liver indices of male fish across the different groups. 
The groups with significant difference between them (p < 0.05) are shown. ....... 115 
Figure 4.49: Mean reaction pattern indices for the liver across the different groups. 
 ............................................................................................................................ 116 
Figure 4.50: Comparison of kidney indices of fish in the different groups. The groups 
with significant difference between them (p < 0.05) are shown by the symbols. . 117 
Figure 4.51: Mean reaction pattern indices for the kidney in the different groups….
 ............................................................................................................................ 118 
Figure 4.52: Mean gonad indices from the female fish in the different groups.  The 
groups with significant difference between them (p < 0.05) are shown. .............. 119 
Figure 4.53: Mean gonad indices from the male fish in the different groups.  No 
significant difference was detected across the groups (p > 0.05) ........................ 119 
Figure 4.54: Mean reaction pattern indices for the gonads across the different 
groups for both female and male fish. ................................................................. 120 
Figure 4.55: Comparison of the different organ indices in the different groups…….
 ............................................................................................................................ 122 
 
  
 Uwineza Marie Clémentine Nibamureke    2019 xix 
 
 LIST OF TABLES 
LIST OF TABLES 
 
Table 3.1: Score values and frequency of occurrence of alteration ....................... 46 
Table 3.2: Importance factor values and their degrees of alteration ...................... 47 
Table 3.3: Classification of organ indices into histological alteration groups based 
on Zimmerli et al. (2007) system as adapted by van Dyk et al. (2009) .................. 47 
Table 4.1: Physical parameters and nutrients of the borehole water (in mg/L) ...... 54 
Table 4.2: Metals detected in borehole water at concentration > 0.010 mg/L* ...... 55 
Table 4.3: Mean ± SD recorded physico-chemical water parameters of the different 
exposure groups for early life stages experiments ................................................ 55 
Table 4.4: Mean ± SD recorded physico-chemical water parameters of the different 
exposure groups for adult fish experiments ........................................................... 56 
Table 4.5: Median time of hatching and mean hatching success (%) ± SD of embryo 
in the different exposure groups ............................................................................ 58 
Table 4.6: Median time of swim up, start of feeding and the mean survival rate (%) 
± SD of early life stages of fish in the different exposure groups at different stages
 .............................................................................................................................. 61 
Table 4.7: The mean daily specific growth rate (SGR - %) of fish from day 1 to day 
60 post-hatching (PH) in all the repeats and groups from both the experiments ... 73 
Table 4.8. Hepatocyte cytoplasmic staining characteristics of the juveniles in the 
different groups ..................................................................................................... 75 
Table 4.9: Percentage prevalence of histological changes observed in the liver and 
kidney of 30 days old O. mossambicus ................................................................. 76 
Table 4.10: Mean and median indices for the reaction patterns and the liver of 30 
days old juveniles in the different groups .............................................................. 82 
Table 4.11: Mean and median indices for the reaction patterns and the kidney of 30 
days old juveniles in the different groups .............................................................. 83 
 Uwineza Marie Clémentine Nibamureke    2019 xx 
 
 LIST OF TABLES 
Table 4.12: Percentage prevalence of the liver cytoplasmic characteristics and 
histological changes presented by the fish in the different groups ........................ 99 
Table 4.13: Percentage prevalence of the observed histological changes in the 
kidney in the different groups .............................................................................. 100 
Table 4.14: Percentage prevalence of histological changes in the ovarian tissue of 
the fish from the different groups ......................................................................... 103 
Table 4.15: Percentage prevalence of histological changes in the testis tissue of the 
fish from the different groups ............................................................................... 105 
Table 4.16: Classification of liver and kidney histological changes following the 
system defined by Zimmerli et al. (2007) as modified by van Dyk et al. (2009) ... 123 
 
  
 Uwineza Marie Clémentine Nibamureke    2019 xxi 
 
 LIST OF ABBREVIATIONS 
LIST OF ABBREVIATIONS 
 
1. Common abbreviations 
AAFP   American Academy of Family Physicians 
AIDS   Acquired immunodeficiency syndrome 
ANOVA  Analysis of variance  
ARV   Antiretrovirals 
CABI   Centre for Agriculture and Bioscience International 
CPY   Cytochromes P450 enzymes 
df   degree of freedom 
DNA   Deoxyribonucleic acid 
DO   Dissolved oxygen 
EC   Electronic conductivity 
FAO   Food and Agriculture Organization of the United Nations 
FDA   Food and Drug Administration 
GLASS  Global Antimicrobial Resistance Surveillance System 
HAART  Highly active antiretroviral therapy 
HIV   Human immunodeficiency virus 
HLB   Hydrophilic – Lipophilic Balance 
HSRC   Human Sciences Research Council 
ID No.   Identification number 
LOD   Limit of detection 
LOQ   Limit of quantification 
NNRTI  Non-nucleoside reverse transcriptase inhibitors 
NRTI   Nucleoside reverse transcriptase inhibitors 
NSAID  Non-steroid anti-inflammatory drugs 
OECD   Organisation for Economic Co-operation and Development 
OIE    World Organisation for Animal Health 
QTOF/MS  Quadrupole time-of-flight mass spectrometry 
RNA   Ribonucleic acid 
RSD   Residual standard deviation 
RT   Reverse transcriptase 
SA   South Africa 
SANAS  South African National Accreditation System 
SD   Standard deviation  
 Uwineza Marie Clémentine Nibamureke    2019 xxii 
 
 LIST OF ABBREVIATIONS 
SPE-DEX  Solid phase extraction system with automated extraction disks 
TB   Tuberculosis 
TDS   Total dissolved solid 
Temp   Temperature 
TWQR  Target Water Quality Range 
UNAIDS  United Nations Programme on HIV and AIDS 
UNICEF  United Nations Children's Fund 
UPLC   Ultra-performance liquid chromatography 
USA   United States of America 
USEPA  United States Environmental Protection Agency 
UV   Ultraviolet rays 
WHO   World Health Organization 
WWTP  Waste water treatment plants 
2. Histology related abbreviations 
AO   Atretic oocyte 
BD   Bile duct 
CD   Circulatory disturbances 
CF   Condition factor 
FCA   Focal area of cellular alteration 
GSI   Gonadosomatic index 
Hb   Haemoglobin  
Hct   Haematocrit  
HSI   Hepatosomatic index 
I   Inflammatory 
Iorg   Organ index 
Irp   Reaction pattern index 
IS   Intersex 
LC   Leydig cells 
Lct   Leukocrit 
LM   Lobule membrane  
LU   Lumen  
MMC   Melano-macrophage centres 
NO   Necrotic oocyte 
O   Oocyte 
 Uwineza Marie Clémentine Nibamureke    2019 xxiii 
 
 LIST OF ABBREVIATIONS 
OGN   Oogonial nest 
OM   Oocyte membrane / envelope 
org   Organ 
PC   Progressive changes  
PF   Post-fertilisation 
PH   Post-hatching 
RBC   Red blood cells 
RC   Regressive changes 
rp   Reaction pattern 
SC   Spermatocytes 
SD   Spermatids 
SG   Spermatogonia 
SGR   Specific growth rate 
SSI   Splenosomatic index 
SZ   Spermatozoa 
T   Tumour 
TA   Tunica albuginea  
WBC   White blood cells 
WBV   Whole blood volume  
3. Abbreviated chemicals and pharmaceuticals 
Ca    Calcium 
CaCO3  Calcium carbonate 
Cl    Chlorine 
DMSO  Dimethyl sulfoxide 
DPX    Distyrene, plasticizer and xylene mixture 
EE2   17 α-ethynyl oestradiol 
H&E   Haematoxylin and Eosin 
K    Potassium 
Mg   Magnesium 
N    Nitrogen 
Na    Sodium 
NBF   Neutral buffered formalin 
NVP   Nevirapine   
NVP H  Nevirapine high concentration 
 Uwineza Marie Clémentine Nibamureke    2019 xxiv 
 
 LIST OF ABBREVIATIONS 
NVP L   Nevirapine low concentration 
O2    Oxygen gas 
P    Phosphorus 
Si    Silicon 
SiO2   Silicon dioxide (silica) 
SMX    Sulfamethoxazole 
SO4   Sulphate  
Sr    Strontium 
TMP   Trimethoprim 
Zn   Zinc 
4. Measuring units 
%    percentage  
℃    degree Celsius 
µg    microgram 
µl    microlitre 
µ𝑆    microsiemens 
cm    centimetre 
dl   decilitre 
hrs    hours 
g    gram 
kg    kilogram 
L    litre 
mg    milligrams 
min    minute 
ml    millilitre 
mm    millimetres 
ng    nanogram 
ppm    part per million 
rpm    rotations per minute
 Uwineza Marie Clémentine Nibamureke    2019 1 
 
 CHAPTER 1. INTRODUCTION 
CHAPTER 1. INTRODUCTION 
 
1.1. The rationale of the study 
One of the most challenging environmental problems the modern world faces is the 
pollution of aquatic environments caused by pharmaceuticals wastes (Kümmerer 
2010; Boxall et al. 2012; aus der Beek et al. 2016). The increase in chronic and 
epidemic diseases has resulted in an upsurge in pharmaceuticals production, 
consumption, misuse and overuse all over the world in all sectors of everyday life 
(World Health Organization (WHO) 2018). Amongst pharmaceuticals that are 
consumed in considerable amounts are anti-retroviral drugs (ARVs), used to treat 
Human immunodeficiency virus / Acquired immunodeficiency syndrome (HIV/AIDS) 
infection (WHO 2011); antibiotics used to prevent different bacterial infections; 
antipsychotic drugs used in management of psychotic and bipolar disorders; non-
steroid anti-inflammatory drugs for pain and fever; antimalaria drugs; and 
antifungals (WHO/Food and Agriculture Organization (FAO)/ World Organisation for 
Animal Health (OIE) 2018). The extensive use of pharmaceuticals generates large 
amounts of pharmaceutical wastes. Studies from different regions of the world have 
shown that most of the pharmaceutical compounds including ARVs and other 
antimicrobials are present at quantifiable levels in aquatic environments (Ternes et 
al. 1999; Kolpin et al. 2002; Kim et al. 2007; Madureira et al. 2010; Brausch et al. 
2012; Agunbiade & Moodley 2014; Sun et al. 2014; Roberts et al. 2016; Madikizela 
et al. 2017; Subedi et al. 2017; Wood et al. 2017; Ondarza et al. 2018).  
The main source of human pharmaceuticals in the aquatic environments is through 
waste water treatment plants’ (WWTPs) effluents as most of those compounds and 
their metabolites pass through the entire process with minor change or removal 
(Prasse et al. 2010; Brausch et al. 2012; K’Oreje et al. 2016). This is mostly due to 
WWTPs’ disinfection techniques that were not initially designed to remove 
pharmaceuticals at the very low concentrations they appear in the aquatic 
environments (Swati et al. 2011; Wood et al. 2017). Another source of human 
pharmaceuticals in aquatic environments is through run-offs from waste dumping 
sites and from households in areas lacking proper sanitation infrastructures such as 
rural areas in developing countries (K’Oreje et al. 2016; Madikizela et al. 2017). 
Some classes of pharmaceuticals are very particular because of their multiple uses 
by both humans and the agriculture sector. Recent studies have shown that the 
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main source of antibiotics in the aquatic environments is through run-offs and landfill 
leachates from agricultural lands and farms (Boxall et al. 2012; Martin et al. 2015). 
The industrialisation era has introduced innovated technologies in agriculture and 
food production where antibiotics are used in larger amounts. In 2015, 80% of the 
antibiotics produced in the United States of America (USA) was used in meat 
production to promote growth rate and to prevent bacterial infections in livestock 
(Food and Drug Administration (FDA) 2014).  
Pharmaceuticals or their conjugate products are present in surface waters 
worldwide (aus der Beek et al. 2016). There is a growing concern that these 
pharmaceuticals may have unintended effects on aquatic animals including fish. 
Human pharmaceuticals are highly active chemical compounds designed to have 
specific physiological effects on target tissues infected by specific disease-causing 
micro-organisms (Boxall 2004). Therefore, serious concerns arise when non-target 
organisms such as fish come into contact with such highly active compounds which 
were not intended for them. Recent laboratory exposure studies have shown that 
some of those pharmaceuticals disrupt fish physiology and metabolism including 
disturbance of reproduction (Kidd et al. 2007; Triebskorn et al. 2007; Madureira et 
al. 2011; Madureira et al. 2012; Memmert et al. 2013; Schoenfuss et al. 2016; 
Robson et al. 2017). Some studies also emphasized that early life stages of fish 
may be more vulnerable to pollutants in the water which can impede their growth 
and development and could, therefore, have a negative impact on fish communities 
and populations (Lin et al. 2013; Gonzalez-Doncel et al. 2014; Stancova et al. 2014). 
Pharmaceutical pollution in aquatic environments is therefore of concern as they are 
important and in use in our everyday life to prevent and treat diseases (Boxall 2004). 
More researches are therefore required to investigate their effects on aquatic biota 
(Santos et al. 2010; WHO 2011). 
Studies on the effects of human pharmaceuticals on non-target aquatic animals in 
developed countries have mostly focused on some groups of pharmaceuticals 
including antibiotics, steroid hormones, non-steroid anti-inflammatory drugs and 
antidepressants (Brausch et al. 2012). However, the pattern of pharmaceutical 
levels in surface waters differs from one country to another and from one continent 
to another; mirroring the rate of pharmaceuticals consumption in each area (aus der 
Beek et al. 2016; K’Oreje et al. 2016). Therefore, studies on the potential effects of 
pharmaceuticals on non-target animals should consider the details of each area and 
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the risk for local species. In Africa, the classes of pharmaceuticals frequently 
detected in water include, in addition to those mentioned above, HIV anti-retrovirals 
(ARVs) and anti-malaria drugs (Swanepoel et al. 2015; Wood et al. 2015; Ngumba 
et al. 2016; Madikizela et al. 2017). Currently, South Africa is amongst the top 
countries with the highest HIV prevalence in the world, with approximately 7.9 million 
people infected (Human Sciences Research Council (HSRC) 2018). More than 60% 
(4.4 million) of people living with HIV are receiving ARVs making South Africa the 
largest ARV treatment program globally (WHO 2013; HSRC 2018). Recent studies 
have shown that most of the ARVs used in the country have been detected in 
surface waters throughout the country (Schoeman et al. 2015; Swanepoel et al. 
2015; Wood et al. 2017; Abafe et al. 2018; Rimayi et al. 2018). 
Fish are an important source of protein in South African rural communities; and 
globally, many communities rely on fishing and aquaculture as a source of food and 
economic income (Food and Agriculture Organization (FAO) 2016). Pharmaceutical 
pollution (detrimental effects on fish metabolism, reproduction and development) 
may therefore hinder economies of poorer communities if fish populations decline. 
Recently, studies have showed that pharmaceuticals in South African surface water 
may bioaccumulate in fish blood plasma and muscle tissues (Swanepoel et al. 2015; 
Rimayi et al. 2018). This may cause a health risk to fish consumers as there may 
be risks of pharmaceutical biomagnification and antimicrobial resistance (Silbergeld 
et al. 2008; American Academy of Family Physicians (AAFP) 2015; Martin et al. 
2015; WHO 2018). According to the WHO, antimicrobial resistance is becoming a 
serious threat to public health and economic development globally and is mainly 
due to the “overuse and misuse of antimicrobial drugs (antibiotics, antifungals, 
antivirals, antimalarials, antihelminthics) in humans, animals and plants” 
(WHO/FAO/OIE 2018). The WHO, the FAO and the OIE have urged countries to 
take actions by developing and implementing laws to monitor and regulate the 
consumption and use of antimicrobials in all sectors of life (WHO/FAO/OIE 2018).  
Chronic ecotoxicology studies using fish to investigate the effects of environmental 
relevant levels of pharmaceuticals is of great importance as it provides a 
representation of how the targeted pharmaceuticals may impact the biota not only 
at organism level, but also at the population level as well as the food web 
(Schoenfuss et al. 2016). Data from such studies could assist in putting measures 
in place to reduce or prevent the entry of pharmaceuticals and their residues into 
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the environment (Sumpter 2010). Therefore, investigating the potential effects of 
those pharmaceuticals of emerging concerns on local species that are most likely 
exposed and consumed will provide valuable information that authorities can use in 
developing plans to tackle the problem of pharmaceutical pollution locally.  
 
1.2. Problem statement and study questions 
The presence of pharmaceuticals in aquatic environments has been investigated 
since the early 80’s in Europe (Richardson & Bowron 1985; Aherne & Briggs 1989). 
It was only around three decades later that studies in Africa started to emerge 
showing the wide occurrence of human pharmaceuticals in surface waters 
(Hendricks & Pool 2012; Agunbiade & Moodley 2014; Matongo et al. 2015; 
Schoeman et al. 2015; Swanepoel et al. 2015; Wood et al. 2015; K’Oreje et al. 2016; 
Ngumba et al. 2016). Studies on the effects of those pharmaceuticals on African 
aquatic animals started much later (Robson et al. 2017; Nibamureke et al 2018; 
Nibamureke et al. 2019b). In South Africa, recent studies done on the quality of 
WWTPs’ effluents and on the effluent receiving aquatic ecosystems have showed 
that anti-retroviral drugs (ARVs) are not effectively removed by WWTPs processes 
across the country (Schoeman et al. 2017). Consequently, these compounds are 
present at ng/L to µg/L levels in surface waters as well as in fish tissues (Wood et 
al. 2016; Abafe et al. 2018; Rimayi et al. 2018). Nevertheless, information on the 
potential effects of those pharmaceuticals on aquatic animals’ health is still lacking. 
All those studies emphasized the need of further investigations on the potential 
effects of single pharmaceuticals as well as combined effects of pharmaceutical 
mixtures in African surface waters. 
Nevirapine is a NNRTI used as a first-line treatment for the prevention of HIV-1 
mother to child transmission since its approval by the FDA in 1996 (WHO 2011). It 
is also one of the human pharmaceuticals frequently detected in surface waters in 
Africa; with concentrations up to 1.48 µg/L in Roodeplaat Dam System, South Africa 
(Wood et al. 2015), and 6 µg/L in Nairobi River, Kenya (K’Oreje et al. 2016). The 
NNRTIs in HIV therapy have been successful in decreasing infant mortality rate from 
mothers living with HIV and to improve both mothers and infant health (Myer at al. 
2010; Bera & Mia 2012). Despite the health benefits, NVP is listed amongst the top 
10 human pharmaceuticals associated with liver toxicity (Bjornsson & Olsson 2006; 
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Rivero et al. 2007). However, there is no information on the potential effects of NVP 
on non-target aquatic animals including fish.  
The antibiotics SMX and TMP are amongst the most consumed antimicrobials 
globally because they are cheaper, and they have a broad range antimicrobial 
activity (Zhao et al. 2015).  Sulfamethoxazole and TMP are commonly used in 
human health care, in animal farming and in crops production (Thuy et al. 2011). In 
humans, they are combined in one pill, co-trimoxazole also known as “Bactrim”, 
which is part of the HIV therapy to treat and prevent opportunistic infections 
(Sibanda et al. 2011). Like NVP, SMX and TMP are also on the WHO list of top 10 
human pharmaceuticals causing liver and kidney injury (Bjornsson & Olsson 2006; 
Pazhayattil & Shirali 2014; Straub 2016). Sulfamethoxazole and TMP have been 
frequently detected in African surface waters with concentrations up to 38.9 µg/L 
and 6.95 µg/L respectively in Nairobi River, Kenya (K’Oreje et al. 2016). In South 
Africa, their concentrations were 6.01 µg/L and 0.87 µg/L in Umgeni River, Kwazulu-
Natal (Matongo et al. 2015). To our best knowledge, no studies are available on the 
potential effects of the mixtures of SMX and TMP with other pharmaceuticals of 
emerging concerns in African surface waters.  
The present study problem can therefore be summarized in the following four points: 
1) African surface waters have become cocktails of different types of highly active 
pharmaceuticals with different physiological effects; 2) Two of the most commonly 
detected types of pharmaceuticals in African waters are ARVs and antibiotics; 3) 
Fish species are exposed to that mixture of pharmaceuticals their whole life; 4) 
There is no information available on the potential effects of the ARVs and their 
mixtures with other  pharmaceuticals of emerging concern in African surface water 
on local fish species.  
With the intention to find solutions to this problem the present study was proposed 
to investigate the potential long-term effects of the HIV ARVs and their mixture with 
other pharmaceuticals such as antibiotics on the Mozambique tilapia,  
O. mossambicus. The four questions that have guided this study are:  
1. Which types of pharmaceuticals are present in South African surface water, 
with potential effects to fish, and what are those effects? 
2. What are the consequences of those effects to individual fish, fish 
populations and communities? 
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3. Do mixtures of these pharmaceuticals cause effects that single 
pharmaceuticals do not have? 
4. Which life stages of fish are more sensitive to the presence of these 
pharmaceuticals in surface water? 
The results from this study provide some answers to the above questions and 
explain the potential effects the selected pharmaceuticals, NVP, SMX and TMP, 
may have on local fish species health and reproduction. To our knowledge, no 
similar study has been done in Africa and elsewhere in the world. Therefore, results 
from this study will be used as a starting point for local authority and 
environmentalists in planning measures to protect water resources from further 
pharmaceutical pollution.  
 
1.3. Aim and objectives  
1.3.1. Aim 
To answer the above research questions, the study aim was to assess the 
responses of the different life stages of the indigenous fish species O. mossambicus 
in a chronic exposure to environmental relevant levels of NVP as a simple toxicant 
and in a mixture with SMX and TMP. 
 
1.3.2. Objectives   
To achieve the above aim, the following specific objectives were set up: 
i. Breed O. mossambicus and expose embryo 24 hours (hrs) post-fertilisation 
(PF) to selected pharmaceuticals till they reach the juvenile stage (at least 60 
days old);  
ii. Assess the embryo hatching success, physical morphology and survival by 
recording mortality cases, hatching rate, survival rate and physical 
abnormalities cases;  
iii. Investigate the larvae and juvenile behaviour, survival, growth and 
development by monitoring the fish behaviour daily and recording growth 
parameters (length, weight, condition factor and growth rate) at 1, 30 and 60 
days post-hatching (PH); 
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iv. Expose sexually mature O. mossambicus and determine their 
haematological parameters (haematocrit; leukocrit; haemoglobin) and 
biometric indices (condition factor and somatic indices); 
v. Conduct histological assessment of the liver, kidney and gonads of juveniles  
(30 days old) and adult fish. 
 
1.4. Hypotheses 
The main hypothesis tested in this study was that after a chronic exposure to the 
tested pharmaceuticals, the health of all life stages (embryo, larvae, juvenile, adult) 
of O. mossambicus will be negatively affected compared to the control fish. The 
specific effects expected on the different life stages were the following: 
i. Reduced hatching success of embryos and increased rate of physical 
deformation in hatched embryos; 
ii. Reduced survival of larvae and juveniles; 
iii. Reduced growth and development of larvae and juveniles; 
iv. Change in blood parameters of adult fish;  
v. Change in biometric indices (condition factor and somatic indices) of adult 
fish; 
vi. Histopathology in liver, kidney and gonads; 
It was also expected that: 
vii.  Nevirapine at higher concentration will have more negative effects than NVP 
at lower concentration; 
viii. Histopathology in selected organs of early juveniles will be more prominent 
than in adult fish; 
ix. The mixture of pharmaceuticals will cause more effects compared to NVP as 
a single toxicant. 
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1.5.  Thesis outline  
The outline of the study covered in this thesis is presented in Figure 1.1. The thesis 
content is divided into 6 chapters. In chapter 1, the general introduction, the 
motivation to conduct the study, the problem of pharmaceutical pollution in African 
surface waters, and the questions that guided the study are presented and 
discussed. The importance of using fish in ecotoxicology studies is discussed briefly; 
and the study aim, objectives and hypothesis are also stated and clarified. Chapter 
2 gives a detailed literature review on the problem of pharmaceuticals pollution in 
aquatic environments around the world in general, and in African surface waters in 
particular. The potential risks of pharmaceutical in surface waters to humans and 
non-target aquatic animals in particular fish are also discussed in detail as well as 
the importance of using fish as biomarkers in ecotoxicology studies. In chapter 3, all 
the materials and methods used to achieve the study objectives are explained and 
described in detail. The different statistical techniques used to analyse and compare 
the collected data are presented and discussed in this chapter. Chapter 4 presents 
the study results in detail; these include results of water quality analysis and results 
of fish exposure studies. The results from the statistical analysis are also presented 
in this chapter. The discussion of the study results and findings is done in chapter 
5. The conclusions and recommendations are stated in chapter 6. The reference list 
is given after chapter 6 and then the different documents containing extra 
information on the data from the study are annexed. 
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Figure 1.1: Overview of the study 
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2.1. Pharmaceuticals pollution in aquatic environments 
The Organisation for Economic Co-operation and Development (OECD) “Health at 
a glance 2017 report” showed that pharmaceutical production, use and consumption 
are increasing at an alarming rate worldwide. This is mainly caused by the increase 
in chronic and epidemic diseases and the advancement in food and agriculture 
technology (OECD 2017). In its “Global Antimicrobial Resistance Surveillance 
System (GLASS) 2017 report”, the WHO has announced that antimicrobial drugs 
are overused and misused in all sectors of everyday life (WHO 2017). This extensive 
use of pharmaceuticals is generating amounts of wastes that are loaded into the 
environment on a daily basis (Boxall et al. 2012; Li 2014; Tijani et al. 2016). As a 
matter of fact, today’s high standard life for supposedly “educated people” requires 
people to always be prepared. Therefore, hospitals, clinics, pharmaceutical stores 
as well as families and farm owners usually stock medicines every season or every 
year. Amounts of unused and old medicines are disposed in normal garbage 
collection bins, waste dumping sites or flashed through toilets, sinks and drains 
(Ebele et al. 2017). On the other hand, it is estimated that approximately 30 to 90% 
of the medicine we consume orally, is excreted from the body with little change 
(Halling-Sørensen et al. 1998; WHO 2011). One way or another, pharmaceuticals 
and the products of their degradation find their way into the aquatic environments 
either through WWTPs’ effluents, landfill leachates, and run-off from farms, 
agricultural lands, pharmaceutical facilities and hospitals/clinics (Boxall 2004; 
Kümmerer 2009).  
Different types of pharmaceuticals are present at quantifiable levels in aquatic 
environments around the world. Surface waters as receivers of WWTPs’ effluents 
have presented diversified amounts of pharmaceuticals: In the USA streams for 
example, more than 82 pharmaceuticals compounds were detected (Kolpin et al. 
2002); in China, sulfonamide antibiotics were among the pharmaceuticals detected 
in river water (Luo et al. 2011); in Australian rivers, carbamazepine was among the 
prevalent pharmaceuticals (Roberts et al. 2016); in South America, antidepressants 
and antibiotics were detected in rivers and fish tissues (Ondarza et al. 2018); in 
Greek rivers, approximately 55 pharmaceutical compounds including analgesics 
and non-steroid anti-inflammatory were quantified (Papageorgiou et al. 2016); and 
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African rivers and dams have also showed levels of antibiotics and ARVs higher 
than elsewhere in the world (Segura et al. 2015; Madikizela et al. 2017). Ground 
water from different countries also showed the presence of various levels of some 
of the above named pharmaceuticals (Zühlke et al. 2004; Sui et al. 2015; Swanepoel 
et al. 2015). Lastly, drinking water, both tap and bottled water, have also showed 
the presence of some of the above pharmaceuticals (Heberer et al. 2002; Ternes et 
al. 2002; Bull et al. 2011; Swanepoel et al. 2015).  
The presence of human and veterinary pharmaceuticals in the environment has 
been declared an emerging pollution problem after studies emerged on the effects 
of those compounds on non-target animals. One example is the near extinction (± 
95% decline) of 3 species of South Asia vultures, Gyps bengalensis, Gyps indicus 
and Gyps tenuirostris, after feeding on dead livestock treated with the NSAID 
diclofenac in India, Pakistan and Nepal (Swan et al. 2006). Another example is the 
collapsing of a whole population of fish in an experimental lake in Canada after 
exposure to a synthetic hormone, the 17 α-ethynyl estradiol (EE2) (Kidd et al. 2007). 
Aquatic environments around the world have become mixtures of different types of 
pharmaceuticals adding to water pollutants namely metals, pesticides and nutrients 
(Tijani et al. 2016; Schoenfuss et al. 2016).  
 
2.2. Pathways of pharmaceuticals discharge into surface water 
A big part of consumed pharmaceuticals (30 to 90%) is excreted from the body with 
little change (Halling-Sørensen et al. 1998; WHO 2011); and together with all the 
old and unused drugs dumped through the drain or flashed into the toilet, they end 
up in WWTPs (Figure 2.1). Studies have shown that WWTPs’ conventional 
techniques currently in use in many countries around the world were not initially 
designed to remove the pharmaceuticals and their metabolites from the WWTPs’ 
influents (Ternes et al. 2002; Prasse et al. 2010; Swati et al. 2011; Wood et al. 2017). 
Thus, most of those compounds pass through the entire processes with minor 
change (Brausch et al. 2012; Sun et al. 2014; K’Oreje et al. 2016). The main source 
of human pharmaceuticals into surface water in developed countries is therefore 
through WWTPs’ effluents (Figure 2.1). In developing countries, where proper 
sanitations and WWTPs are lacking in most parts (Segura et al. 2015), the effluents 
from the few available WWTPs cannot be declared as the main source of human 
pharmaceuticals in surface waters. In those countries, old and unused 
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pharmaceuticals are collected together with other domestic waste and dumped at 
designated waste dumping sites where they get into the soil (Ebele et al. 2017; 
Madikizela et al. 2017). In most of those countries, there are no municipal waste 
treatment facilities to treat toilet waste; people use simple pit latrines or practice 
open defecation (WHO & United Nations Children’s Fund (UNICEF) 2017). 
Therefore, the main source in developing and most of emerging countries, is through 
landfill leachates from waste dumping sites and pit latrines (Figure 2.1).  
Concerning veterinary pharmaceuticals, there are two pathways through which 
antimicrobials and growth hormones get in the aquatic environments. Firstly, the 
drugs used on farms for livestock care and those used at home for pet care are 
excreted from the animal body with little changes as it is for humans (Boxall et al. 
2002). Livestock and pet excrements are used as organic manure to produce crops; 
they then get in soil and are transported into surface water indirectly through runoffs 
and landfill leachates (Figure 2.1). Secondly, the drugs used in aquaculture are 
directly loaded in surface water (Figure 2.1). It is believed that the main source of 
antibiotics in the environment is through landfill leachates from agricultural lands 
and farms (Boxall et al. 2012; Martin et al. 2015). In fact, the industrialisation era 
has introduced novel technologies in agriculture and food production where 
antibiotics are used in larger amounts in developed and emerging countries as well 
as in developing countries (Martin et al. 2015). In 2015, it was found that 80% of 
antibiotics produced in the USA was used in meat production to promote growth rate 
and to prevent bacterial infections in livestock (Martin et al. 2015). 
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Figure 2.1: Main sources and pathways of pharmaceuticals into surface water (adapted 
from Boxall 2004 and Ebele et al. 2017) 
 
2.3. Pharmaceuticals removal from WWTPs influent  
The rate of removal of pharmaceuticals and their metabolites in WWTPs is 
dependent on the type of pharmaceutical, its properties, the types of techniques 
used and the temperature as well as pH of the interior environment (Prasse et al. 
2010; Schoeman et al. 2017). Conventional treatment techniques by activated 
sludge used in municipal and hospital WWTPs in many countries have shown to be 
rather ineffective in removing many types of pharmaceuticals (Ternes et al. 2002; 
Swati et al. 2011; Prasse et al. 2010; Kosma et al. 2014; Schoeman et al. 2017). 
The objective of the treatment of waste water by activated sludge process is to 
remove suspended solids and fats, organic chemicals and toxic microorganisms or 
to reduce them to levels that are safe for the environment (Prasse et al. 2010; 
Mehinto 2009; Schoeman et al. 2017). The activated sludge treatment used in South 
African WWTPs involves 4 following steps:  
a) Primary treatment: The waste water passes through screens to remove 
plastics and other big solid debris that can damage the plant equipment. After 
that, the waste water is collected in tanks where it is mixed slowly to allow 
sedimentation and removal of suspended solid and floating fats. The removed 
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solids are collected in suitable closed containers and disposed at designated 
sites.   
b) Secondary treatment: The waste water is transferred into aerated tanks where 
it is continually mixed with a solid medium rich in active microorganisms  
(= activated sludge) to allow the biological digestion of organic compounds or 
their sorption to the sludge. During this stage, nitrogen is also removed 
biologically using nitrification and denitrification reactions. After this step, the 
treated water is separated from the solid sludge by sedimentation and then 
channelled into disinfection tanks or ponds for the next treatment process.  
c) Disinfection: This step consists of removing toxic microorganisms and other 
dissolved organic compounds that are still present in the water. Different 
disinfection processes can be used: Chlorination, ultraviolet (UV) radiation, 
oxidation by ozonation and natural biological disinfection in maturation ponds. 
In South Africa the most used method in municipal WWTPs is chlorination. 
After this step the treated water is discharged into receiving rivers. 
d) Sludge digestion: The solid sludge generated through the treatment is also 
submitted to an anaerobic digestion and transformed into dried solid material 
that can be used as biogas or fertiliser or can be disposed in landfill. 
Pharmaceutical removal efficiency will therefore depend on their capacity of 
sorption to solid sludge and their biodegradability by microorganisms 
(Hendricks & Pool 2012; Schoeman et al. 2017; Wood et al. 2016).  
The final effluent from the WWTPs is normally supposed to be compliant with the 
water quality guidelines. However, WWTPs’ effluents from various countries have 
showed that many types of pharmaceuticals are still present in the final treated water 
at comparable levels and in some special cases higher than those in the influent 
(Abafe et al. 2018). This means that those pharmaceuticals pass through the whole 
activated sludge process without or with minor change. Studies done on WWTPs 
influent and effluent in Germany, Greece, Kenya and South Africa have shown 
variable removal rates of SMX by the conventional activated sludge treatment with 
an average removal of 49% (Lindberg et al. 2006; Gobel et al. 2005; Gobel et al. 
2007; Hendricks & Pool 2012; Kosma et al. 2014; Segura et al. 2015; Straub 2016). 
For TMP and NVP, most of the studies have classed both drugs as resistant to the 
activated sludge treatment as their levels in effluents showed almost a null and 
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sometimes a negative removal rate (Lindberg et al. 2006; Gobel et al. 2005; Pérez 
et al. 2005; Gobel et al. 2007; Kosma et al. 2014; K’Oreje et al. 2016; Wood et al. 
2016; Schoeman et al. 2017; Abafe et al. 2018). Some of those studies found that 
the disinfection treatment contributes to the formation of transformation products of 
some pharmaceuticals including SMX, TMP and NVP (Kosma et al. 2014; Straub 
2016; Wood et al. 2016). Other studies suspected that some steps of the activated 
sludge treatment may cause some pharmaceuticals metabolites, including SMX and 
NVP, transforming back into the parent compounds (Gobel et al. 2007; K’Oreje et 
al. 2016; Straub 2016). The above mentioned review explains why these three 
pharmaceuticals, NVP, SMX and TMP are amongst the most commonly detected 
pharmaceuticals in surface water worldwide. They are added continuously in 
surface water through WWTPs’ effluent as they are resistant to waste water 
treatment.  
 
2.4. Pharmaceuticals occurrence in African surface water 
The occurrence of pharmaceutical compounds in surface water around the world is 
very diversified from one region to another as the rate of pharmaceuticals use is 
also different (aus der Beek et al. 2016; Ebele et al. 2017; Madikizela et al. 2017). 
Globally, approximately 630 pharmaceutical compounds and their metabolites have 
been detected in aquatic environments around the world (aus der Beek et al. 2016). 
Most of the pharmaceuticals occurring in African surface water are common to the 
other parts of the world, and those pharmaceuticals include antibiotics, steroid 
hormones, non-steroid anti-inflammatory drugs, antidepressants and antipsychotics 
(Ebele et al. 2017; Madikizela et al. 2017). However, there are some groups of 
pharmaceuticals that are occurring mostly in African surface water compared to the 
rest of the world. Those include HIV anti-retrovirals (ARVs) drugs (Swanepoel et al. 
2015; Wood et al. 2015; Ngumba et al. 2016; Madikizela et al. 2017) as this is one 
of the serious endemic diseases with high incidence and prevalence in Africa. 
Not only the occurrence of pharmaceuticals differs from one region to another, but 
also the levels of pharmaceuticals in surface waters differ in the United States, 
Europe, Asia, Africa and South America. Levels of pharmaceuticals in surface water 
in the United States and Europe are lower compared to levels of pharmaceuticals in 
African and Asian surface water (Madikizela et al. 2017). This is not surprising as 
most of the rural areas from Africa and Asia do not have proper sanitation and waste 
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water treatment programs (Ncube et al. 2018). Sulfamethoxazole and TMP are 
amongst pharmaceutical compounds that have been commonly detected in surface 
water around the world, however their highest levels were detected in the Nairobi 
River basin, Kenya, 14 - 39 µg/L for SMX and 2.5 – 7 µg/L for TMP (K’Oreje et al. 
2016; Ngumba et al. 2016). Nevirapine is the most commonly detected 
pharmaceutical in African surface water, with levels up to 5 - 6 µg/L in Nairobi River 
basin (K’Oreje et al. 2016; Ngumba et al. 2016). In Germany, NVP was detected in 
WWTPs’ effluents at low concentrations of 0.5 – 32 ng/L (Prasse et al. 2010). The 
hormonal compound 17 α-Ethinylestradiol is also among the pharmaceuticals 
commonly occurring in surface water around the world; its highest average 
concentration (1.175 µg/L) was detected in surface water in South America (aus der 
Beek et al. 2016). These examples illustrate why it is important when studying the 
effects of pharmaceuticals on aquatic animals, to consider the particularity of each 
region. It is with this thought in mind that this study was conducted.  
In South Africa, recent studies on the quality of WWTPs’ influents and effluent 
receiving aquatic ecosystems have showed that various types of human 
pharmaceuticals are not effectively removed by WWTPs processes across the 
country. Consequently, these compounds are present in surface waters (Hendricks 
& Pool 2012; Agunbiade & Moodley 2014; Matongo et al. 2015; Schoeman et al. 
2015; Swanepoel et al. 2015; Wood et al. 2015; Schoeman et al. 2017; Abafe et al. 
2018; Rimayi et al. 2018). This study discussed only two groups of pharmaceuticals 
that are amongst the most widely used in Africa and the most commonly occurring 
in surface waters across the continent. These are antibiotics (SMX and TMP) and 
ARVs (NVP). 
 
2.4.1. Antibiotics  
The term “antibiotics” refers to a wide range of drugs or chemicals used to treat or 
prevent bacterial infections by killing them or inhibiting their growth (Lindberg et al. 
2006; Kümmerer 2009; WHO 2018). Sulfamethoxazole and TMP are amongst the 
most consumed antibiotics globally because they are cheaper, and they have a 
broad range antimicrobial activity (Zhao et al. 2015). Sulfamethoxazole and TMP 
are commonly used in human health care, in animal farming and in crops production 
(Thuy et al. 2011). In humans, they are used to treat diverse bacterial infections 
including opportunistic infections in HIV patients (Kaplan et al. 1973; Vilcheze & 
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Jacobs 2012; Autmizguine et al. 2018). A broad range of antibiotics have been 
detected in African surface water at higher levels compared to elsewhere in the 
world (Segura et al. 2015; Madikizela et al. 2017). Amongst the commonly detected 
antibiotics are SMX and TMP with concentrations up to 38.9 µg/L and 6.95 µg/L 
respectively in Nairobi River, Kenya (K’Oreje et al. 2016); and 6.01 µg/L and  
0.87 µg/L in Umgeni River, Kwazulu-Natal in South Africa (Matongo et al. 2015).  
 
2.4.1.1. Sulfamethoxazole and trimethoprim mode of action, metabolism  
and excretion 
To understand the potential effects of SMX and TMP in aquatic environments one 
needs to know their mode of action, metabolism and excretion in humans. 
Sulfamethoxazole is an antibiotic from the family of sulfonamides (Straub 2016). It 
is mostly used in combination with TMP as “co-trimoxazole” (5:1 ratio) to treat a 
broad range of bacterial infections including urinary and respiratory tracts infections 
(Vilchѐze & Jacobs 2012). The combination SMX-TMP is also prescribed to 
HIV/AIDS patients for the treatment or prevention of opportunistic infections caused 
by Pneumocystis jirovecii mostly and Staphylococcus aureus sometimes 
(Autmizguine et al. 2018).  
Sulfamethoxazole –TMP combination has bactericidal properties; the two drugs act 
synergistically on two successive steps of bacterial nucleic acid synthesis by 
inhibiting the uptake of folic acid which is needed for DNA replication (Straub 2013 
and 2016). Directly after oral administration, SMX and TMP are absorbed and 
distributed in all the body tissues and fluids; they pass the placenta and distribute in 
the foetus tissues (Straub 2016). Both SMX and TMP bind to plasma proteins, 
approximately 70% and 44% respectively; and 24 hours after taking the medication, 
both drugs can be detected in blood (Kaplan et al. 1973; Kielhofner 1990). The 
metabolism of both SMZ and TMP happens mostly in the liver (± 70% and ± 15% to 
25% respectively) and they are excreted mainly by the kidney (± 25% to 40% and ± 
75% to 85% as unchanged parent drug respectively) (Vilchѐze & Jacobs 2012; 
Tačić et al. 2017). Sulfamethoxazole metabolism produces at least 5 different 
metabolites in humans (Kielhofner 1990). The hydroxylamine metabolites produced 
through the cytochrome P450 are believed to be the ones causing side effects in 
humans because they are still active (Autmizguine et al. 2018). Trimethoprim 
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metabolism also produces different metabolites; in vitro studies showed 11 
metabolites, but they are not biologically active (Kaplan et al. 1973; Straub 2013).  
The side effects presented by patients on SMX-TMP treatment include liver toxicity, 
changes in haematological parameters, kidney failure and a high risk of abortion or 
malformation during the first semester of pregnancy (Andersen et al. 2013; 
Pazhayattil & Shirali 2014; Straub 2016). In addition, SMX-TMP are associated with 
antimicrobial resistance in humans (WHO 2017). The excretion of SMX and TMP 
produces a mixture of metabolites and parent drug (Kielhofner 1990; Tačić et al. 
2017) and all those compounds end up into surface water (Lindberg et al. 2006).  
 
 2.4.2. HIV anti-retroviral drugs 
According to the WHO, of the 36.7 million of people living with HIV in 2016, 70% 
were from Africa (UNAIDS 2016). South Africa and Kenya are among the countries 
with the largest ARV treatment program, currently at the first and third place 
respectively (Ncube et al. 2018). Most of the ARVs used in HIV therapy have been 
detected in surface waters throughout Africa at levels higher than elsewhere in the 
world (Swanepoel et al. 2015; K’Oreje et al. 2016; Wood et al. 2017; Abafe et al. 
2018; Rimayi et al. 2018).  
The ARV NVP was the most commonly detected pharmaceutical in investigated 
aquatic environments in South Africa and in Kenya (K’Oreje et al. 2016; Wood et al. 
2017). The highest level of NVP detected in South Africa was 1.48 µg/L in the 
Roodeplaat Dam System, South Africa (Wood et al. 2015). In Kenya, NVP was 
detected up to 6 µg/L in Nairobi River (K’Oreje et al. 2016). Following the rate of 
ARVs consumption in South Africa, it is estimated that approximately 380 000 kg of 
ARVs could be loaded into South African aquatic environments every year 
(Swanepoel et al. 2015). As the goal of WHO is for each country to reach at least 
90% of its HIV patients on ARVs therapy by 2020 (HSRC 2018); the presence of 
ARVs in African surface waters will continue to go up if nothing is done to reduce or 
prevent the daily upload of pharmaceuticals wastes into aquatic environments.  
 
2.4.2.1. Nevirapine mode of action, metabolism and excretion  
Nevirapine is an ARV from the group of non-nucleoside reverse transcriptase 
inhibitors (NNRTI) used as a first-line treatment for adults and for the prevention of 
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HIV- 1 mother to child infection transmission (Mirochnick et al. 2000; Sluis-Cremer 
& Tachedjian 2008; Antunes et al. 2010). Nevirapine is used in combination with two 
nucleoside reverse transcriptase inhibitors (NRTI) ARVs in the highly active 
antiretroviral therapy (HAART) regimen (Clumeck et al. 2014; Dalal et al. 2015; 
Ayele et al. 2017). Nevirapine was the first NNRTI approved for use by the FDA in 
1996; the other most used first line NNRTI in developing countries is efavirenz which 
was approved for use in 1998 (Antunes et al. 2010; de Béthune 2010; WHO 2011). 
Until recently, NVP was the first choice first line NNRTI in developing countries due 
to its affordability and efficacity (de Béthune 2010; Mugabo et al. 2011); however, 
as it has been associated with severe liver toxicity and skin rash (Ritchie et al. 2006; 
Rivero et al. 2007; Antunes et al. 2012), the WHO has been encouraging the use of 
efavirenz instead as it has showed to be less toxic compared to NVP (WHO 2013; 
Clumeck et al. 2014; Ayele et al. 2017).  
The mode of action of ARVs is to inhibit the deoxyribonucleic acid (DNA) replication 
of the HIV- 1 virus by targeting the different enzymes involved in the virus replication 
(Sluis-Cremer & Tachedjian 2008; Dalal et al. 2015). Among the enzymes involved 
in HIV- 1 virus DNA synthesis are the reverse transcriptase (RT) enzymes; their 
function is to create a double-stranded DNA copy from a single-stranded ribonucleic 
acid (RNA), a process known as reverse transcription (Hu & Hughes 2012). The 
NNRTI ARV drugs action is to target the RT enzymes and prevent them from 
completing the HIV- 1 virus RNA reverse transcription into DNA (Sluis-Cremer & 
Tachedjian 2008).  
After oral administration in human, NVP is well absorbed (> 90%) and distributed in 
the body fluids, lipids and crosses the placenta barrier in pregnant women 
(Mirochnick et al. 2000). Up to 60% of NVP in blood plasma is bound to proteins 
and most of NVP (> 80%) is eliminated in urine as metabolites with the parent drug 
representing only about 3% (Riska et al. 1999b). Nevirapine main routes of 
metabolism is through hydroxylation and glucuronidation by the cytochrome P450 
(CYP) enzymes in the liver (Eloy et al. 2017). The metabolism of NVP in humans as 
well as in rats, dogs, monkeys and rabbits produces 5 main metabolites eliminated 
in the urine: 4 hydroxylated metabolites (2-, 3-, 8-, and 12 hydroxy-NVP) and the 4-
carboxy-NVP metabolite resulting from further oxidation of 12-hydroxy-NVP (Riska 
et al. 1999a; Mirochnick et al. 2000; Eloy et al. 2017). The hydroxylated metabolites 
go through further processes to produce related hydroxy-NVP glucuronide 
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metabolites which are also eliminated in the urine mostly (Riska et al. 1999a; 
Antunes et al. 2010). 
All NNRTI ARV drugs have been associated with liver toxicity, however, the 
frequency and severity of toxicity was found to be higher in NVP treated patients 
than in those treated with other NNRTIs (Rivero et al. 2007; Ayele et al. 2017). The 
mechanisms of NVP induced hepatotoxicity are not well known; but some studies 
have suggested that drug hypersensitivity maybe one of the pathways which are 
responsible of hepatitis and skin rash presented by patients on NVP treatment 
(Ritchie et al. 2006; Dalal et al. 2015). Other studies have attributed the toxicity of 
NVP to synergistic effects of NVP parent drug and the 2- hydroxy-NVP in sulfonation 
of the 12- hydroxy-NVP metabolite to produce a toxic metabolite named 12-sulfoxy-
NVP (Antunes et al. 2012; Pinheiro et al. 2017). Due to the insufficiency of 
information on NVP toxicity mechanisms, NVP is used cautiously in new-borns  
(< 2 weeks old) (Antunes et al. 2012; Shubber et al. 2013; Bolaris et al. 2017).  
Wood et al. 2016, in their study on the environmental fate and NVP in South African 
surface water were able to detect the chlorination metabolites of NVP in surface 
water resulting from the disinfection of waste water by the activated sludge process. 
The same study also showed that some of those chlorination metabolites still had 
their antiviral activity but were not found to be more toxic compared to the parent 
drug (Wood et al. 2016). Thus, fish and other aquatic animals are exposed to a 
complex combination of ARVs, antibiotics and other different types of 
pharmaceuticals as well as their different metabolites (Schoenfuss et al. 2016).  
 
2.5. Fate of pharmaceuticals in surface water 
The concentration of pharmaceutical compounds in WWTPs effluents is different 
from that of the same pharmaceuticals when they attain surface water (Mehinto 
2009). Once they have landed in surface water, the concentration of 
pharmaceuticals will decline due to dilution (Mehinto 2009). The future of the 
pharmaceutical compounds and their metabolites in surface water will depend on 
different factors including the properties of the compound, the physico-chemical 
parameters of the aquatic environment and the weather (Ying et al. 2013). 
Nevertheless, the main processes that will determine the fate of pharmaceuticals in 
surface water are biodegradation, sorption to solid particles, and photolysis. 
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Following their properties, most of the pharmaceutical compounds will go through 
one of these processes.  
 
2.5.1. Biodegradation 
The degradation of pharmaceutical compounds in surface water is done by aquatic 
microorganisms (bacteria and fungi). The biodegradation of pharmaceuticals will 
result in a decrease of the concentration of the pharmaceuticals and in the formation 
of new degradation and transformation products which maybe more or less toxic 
than the parent drug (Gašo-Sokač et al. 2017). Biodegradation is one of the main 
pathways of elimination of pharmaceuticals, however many pharmaceuticals have 
been found to be resistant to biodegrading processes (Daneshvar 2012), those 
include SMX and TMP, as well as NVP (Lindberg et al. 2006; Schoeman et al. 2017). 
For those pharmaceuticals which are resistant to biodegradation in surface water, 
they will be exposed to other processes such as photodegradation or they will 
deposit into the sediments or other suspended solids in the water (Gašo-Sokač et 
al. 2017). 
 
2.5.2. Photodegradation  
Photodegradation, photolysis or photo-transformation of pharmaceuticals in surface 
water by sunlight is one of the most common degradation process for many 
pharmaceuticals (Mehinto 2009). The pharmaceuticals which are sensitive to 
photodegradation absorb energy photons from the sunlight and that energy will 
initiate photodegradation reactions of the compound (Gašo-Sokač et al. 2017). 
However, besides helping in eliminating some types of pharmaceuticals and 
reducing the concentration of many others, photodegradation also results in the 
formation of new transformation and degradation products less or more toxic than 
the initial compound (Daneshvar 2012). Studies have shown that SMX undergoes 
photodegradation in surface water and results in non-toxic transformation products, 
but some environmental conditions such as high pH and acidic conditions may 
inhibit or slow the process (Niu et al 2013; Straub 2016).  
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2.5.3. Sorption to solid particles 
Some types of pharmaceuticals are able to bound to suspended solids and to 
sediment in water; for those pharmaceuticals, sorption to solid particles may be the 
best way to be removed from the water column (Lindberg et al. 2006). The sorption 
of pharmaceuticals to solid particles depends among others on the sediment or solid 
particles properties including their type and size (Gašo-Sokač et al. 2017). 
Therefore, those compounds that exist in water in their ionised form and dissolved 
in water will not be able to be removed by sorption to solids (Gašo-Sokač et al. 
2017). Studies have shown that most antibiotics have high sorption properties as 
they are found in the solid sludge generated through the WWTPs (Mehinto 2009). 
Nevirapine was nor found in the solid sludge from WWTPs throughout South Africa, 
it is considered to be unable to bind the solid particles in water (Schoeman et al. 
2017). However, SMX and TMP are known to possess a strong adsorption capacity 
(Boxall et al. 2002; Zhang et al. 2014; Straub 2016). 
 
2.5.4. Bioaccumulation  
All the above processes, biodegradation, photodegradation, sorption to solid 
particles in water contribute in decreasing the concentration of pharmaceuticals in 
surface water at some point (Mehinto 2009; Straub 2016). However, as the 
pharmaceuticals are loaded in the environment daily, there is always going to be a 
certain quantity of the pharmaceuticals available for bioaccumulation in aquatic 
biota. According to researchers, many of the pharmaceuticals that have been 
detected in water are bioavailable to fish (Mehinto et al. 2010; Lahti et al. 2012; 
Madureira et al. 2012; Memmert et al. 2013; Ondarza et al. 2018). Sulfamethoxazole 
and TMP were found to be highly bioavailable for fish and can bioaccumulate in the 
different tissues (Zhao et al. 2015; Straub 2016). Antiretrovirals have also been 
detected in blood plasma of fish from South Africa surface waters (Swanepoel et al. 
2015; Rimayi et al. 2018). 
 
2.6. Potential risks of pharmaceuticals in surface water 
2.6.1. Potential risks to humans 
Although pharmaceuticals and their transformation products are present at low 
concentrations in surface waters worldwide, there is a growing concern that these 
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pharmaceuticals may pose a health risk to the environment including humans 
(Schoenfuss et al. 2016; Robson et al. 2017). Studies have showed that 
pharmaceuticals in surface water may bioaccumulate in fish blood plasma and 
muscle tissues (Zhao et al. 2014; Swanepoel et al. 2015; Rimayi et al. 2018). This 
is a public health problem as large communities around the world rely on fishing as 
a source of economy and animal proteins (FAO 2016). Consuming fish that were 
exposed to pharmaceuticals may pose a risks of pharmaceutical biomagnification 
and antimicrobial resistance in humans (Silbergeld et al. 2008; AAFP 2015; Martin 
et al. 2015; WHO 2018). According to the WHO, the problem of antimicrobial 
resistance is becoming a serious threat to public health and economic development 
globally. Antimicrobials drugs (antibiotics, antifungals, antivirals, antimalarials, 
anthelmintics) are being misused and overused around the world in humans, 
animals and plants (FAO/OIE/WHO 2018). In the USA, it is estimated that 
approximately 2 million people are infected with antibiotic resistant bacteria and 
around 23 000 people die due to antibiotic resistant bacteria every year (AAFP 
2015). This shows that the problem of pharmaceuticals occurrence in the 
environment is a serious one that needs to be addressed before it is too late. 
 
2.6.2. Potential risks to aquatic animals 
Human pharmaceuticals are highly active chemical compounds designed to have 
specific physiological effects on target tissues infected by specific disease-causing 
micro-organisms in humans (Boxall 2004; Kümmerer 2010). Serious concerns arise 
when animals come into contact with such highly active compounds which were not 
intended for them. Nobody can predict what kind of effects these compounds may 
have. Despite their health benefits, NVP, SMX and TMP are known to cause liver 
and kidney injury in human and rats (Osterreicher & Trauner 2012; Adaramoye et 
al. 2012). Aquatic animals which pass their whole life in the water contaminated by 
cocktail of pharmaceuticals of different types and different physiological activities 
are the most at risk (Schoenfuss et al. 2016).  
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2.6.3. Pharmaceuticals in surface waters and fish health 
2.6.3.1. Pharmaceuticals uptake, metabolism and distribution in fish 
There are two main pathways the pharmaceuticals in water are taken up by the fish; 
through ingestion together with the food or through inhalation transported by water 
(Di Giulio & Hinton 2008). As it is for humans, once pharmaceuticals compounds in 
water have been taken up by the fish, they are distributed in the different tissues 
and organs as shown in Figure 2.2. While conducting ecotoxicology studies, it is 
important to know which tissues or organs are more vulnerable to those chemicals 
and the effects that can be expected in those tissues (Hinton et al. 1992). After 
uptake and distribution of pharmaceuticals in the tissues and bodies, the 
compounds will go through the mechanisms of transformation or degradation into 
transformation or degradation compounds which may be sometimes more toxic than 
the parent compound (Mehinto et al. 2010; Vilchѐze & Jacobs 2012). These 
transformation compounds will then be eliminated from the body and reach the 
environment as unchanged parent substances or their transformation products 
(Vilchѐze & Jacobs 2012). For humans, the amount of a pharmaceutical compounds 
used by the body and the amount eliminated can be estimated from the dose taken 
as showed by different toxicokinetic studies (Straub 2016). For the fish living in 
natural environments, it is not known how much of the parent pharmaceuticals or 
the transformation products are taken up from the water every day and how much 
is eliminated (Di Giulio & Hinton 2008). Only in laboratory-controlled conditions, 
toxicokinetic studies of pharmaceutical compounds in fish can be done for few 
species. 
 
 
Figure 2.2: Main pathways of absorption, distribution, and elimination  
of pharmaceuticals in fish (adapted from Di Giulio & Hinton 2008 p. 59) 
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2.6.3.2. Potential effects on early life stages  
Like any other toxicant, pharmaceuticals can have adverse effects on the structure 
of fish organs; and if the organ structure is changed it may lead to changes in the 
organ function which possibly will affect organism survival and development 
(Zimmerli et al. 2007; Di Giulio & Hinton 2008; Marchand et al. 2012; Stancova et 
al. 2014). Studies have emphasized that early life stages of fish may be more 
vulnerable to pollutants in water which can impede their growth and development 
and could, therefore, have a negative impact on fish populations (Kidd et al. 2007; 
Gonzalez-Doncel et al. 2014). Zebrafish (Danio rerio) embryo exposed to 
sulfonamides have presented altered behaviour and reduced hatching success (Lin 
et al. 2013). Nevirapine has not yet been approved by the FDA to be used in new-
borns less than 2 weeks old because its pharmacokinetic and safety profile are not 
available for that age category (Panel on Antiretroviral Therapy and Medical 
Management of HIV-Infected Children 2017). Therefore, there is concern about 
potential long-term toxicity effects on the growth and development of infants who 
are given NVP treatment at that early age (Shubber et al. 2013; WHO 2014; Bolaris 
et al. 2017). The lack of information on potential long-term effects in children raises 
questions about the possibility of threats that NVP may have on fish early life stages. 
The same problem is risen with SMX-TMP exposure to fish embryo. As discussed 
previously, these two antibiotics are not prescribed to pregnant women in their first 
semester of pregnancy as studies have shown high risks of abortion or embryo 
malformation if those antibiotics are used at that stage (Andersen et al. 2013; Straub 
2016). There is therefore concerns for fish and other aquatic animals which are 
exposed to the mixtures of these pharmaceuticals from their early age. 
 
2.6.3.3. Potential effects on adult fish physiology and morphology 
Adult fish exposed to pharmaceuticals have shown impaired organ morphology 
leading to impaired organ physiology in case of chronic exposure. One interesting 
case study discussed previously include the feminisation of male fish and the 
collapsing of a fish population in an experimental lake in Canada after exposure to 
a synthetic hormone, the 17 α-ethynyl oestradiol (EE2) (Kidd et al. 2007). Fish 
exposed to a mixture of pharmaceuticals have also found to be more at risk as these 
pharmaceuticals may act synergistically to affect the organism both morphologically 
and physiologically. Madureira et al. (2012) observed changes in the gonads of 
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zebrafish (Danio rerio) exposed to a mixture of pharmaceuticals (Carbamazepine, 
fenofibric acid, propranolol, sulfamethoxazole and trimethoprim) after 21 days of 
exposure; the fish showed decreased mature stages of gametes which my lead to 
reduced reproduction. Other examples of pharmaceuticals effects on adult fish 
include histological changes observed in the kidney, liver and gills of rainbow trout 
(Oncorhynchus mykiss) and common carp (Cyprinus carpio) exposed to diclofenac, 
carbamazepine and metoprolol (Triebskorn et al. 2007; Mehinto et al. 2010). 
Oreochromis mossambicus exposed to the ARV efavirenz have also showed 
impaired general health after an acute exposure (Robson et al. 2017). Although 
those examples include few types of pharmaceuticals, they show that the 
pharmaceutical compounds potential effects on fish should not to be underestimated 
or ignored. 
 
2.6.4. The complex problem of pharmaceutical mixtures 
In humans, most of the prescriptions, for example the treatment of HIV infection or 
TB, use a combination of two or more drugs in order to give a strong combined 
response to the infection. All those compounds and their transformation products 
end up in the aquatic environments creating a cocktail of multiple drugs with multiple 
physiological effects (Schoenfuss et al. 2016). It is believed that these mixtures of 
pharmaceuticals may have combined effects on fish as they pass their whole life in 
water (Geiger et al. 2016). Drugs combination in prescriptions targets two kind of 
effects in the receiving organism, either a synergistic interaction or an antagonistic 
interaction (Yin et al. 2014). Aquatic animals exposed to the mixtures of drugs may 
also experience the combined drugs interaction. 
 
2.6.4.1.  Synergistic interaction 
The synergistic interaction between two or more pharmaceuticals consists in a 
greater physiological effects of the drugs used together compared to single drug 
effect (Cascorbi 2012). For example, when using two combined drugs, the two drugs 
maybe designed to have effects on two different pathways of a bacteria 
developmental process, and when the drugs are combined, they will have a strong 
combined effect on the disease causing bacteria (Cascorbi 2012). This is the case 
of SMX-TMP combined effects, the two drugs are both bacteriostatic, but when used 
together they act synergistically on two successive steps of bacterial nucleic acid 
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synthesis to inhibiting DNA replication and kill the bacteria. Thus, their combined 
effect becomes bactericidal (Straub 2013 and 2016). 
 
2.6.4.3.  Antagonistic interaction 
Antagonistic drug interaction happens when two drugs are combined, and the 
resulting action is a decrease or inhibition of one of the drugs or both of the drugs 
physiological effects (Yin et al. 2014). This may happen when the two drugs for 
example use the same types of receptors, they will not be enough receptors for both 
the drugs, which will result in one drug or both of them being not absorbed as 
desired, thus the desired action of one or both drugs will not be achieved (Cascorbi 
2012). As an example, efavirenz is used with a double dose of isoniazid for the 
treatment of TB in HIV patients due to the fact that efavirenz inhibits the absorption 
of isoniazid (Chirehwa et al. 2019). 
 
2.7.  Fish as biomarkers in chronic ecotoxicology studies 
Chronic ecotoxicology studies using fish to investigate the effects of environmental 
relevant levels of pharmaceuticals is of great importance. In fact, these studies give 
a picture of how the targeted pharmaceuticals may impact the biota not only at 
organism level, but also at the population level as well as the food web (Schoenfuss 
et al. 2016; Răsković & Poleksić 2017). Fish are amongst the most used organisms 
in biomonitoring studies (Di Giulio & Hinton 2008). Fish can react to changes in the 
water at all the different levels of their life namely the molecular, subcellular, cellular, 
tissue, organ and whole organism level (Răsković & Poleksić 2017). The responses 
of the fish to the changes in their environment maybe biochemical, physiological or 
morphological (Schwaiger et al. 1997). Those responses or “biomarkers” are used 
in toxicology studies as “early warning” signs to determine sublethal levels of 
chemical compounds in water that may harm fish health both at short and long term 
(van der Oost et al. 2003; Kroon et al. 2017). Fish biomarkers include among others 
physiological and pathological biomarkers. Physiological biomarkers consist of 
blood parameters, condition factor (CF) and organ somatic indices, while 
pathological biomarkers involve histological and morphological changes in organ 
tissues (Schlenk et al. 2008). The choice of the types of biomarkers used will depend 
mainly on the type of the pollutant investigated, the type of fish species used and 
the selected organ indices (van der Oost et al. 2003; Kroon et al. 2017). Data from 
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fish exposure studies to pharmaceuticals in water can help to put in place measures 
to prevent further pharmaceutical pollution in the aquatic environment (Sumpter 
2010).  
 
2.7.1. Histopathology as a biomarker  
Histopathology as a biomarker is widely used in ecotoxicology studies and has 
proved to be one of the most reliable method for early detection of chemical 
exposure effects on fish organs (Schwaiger et al. 1997; Teh et al. 1997; Marchand 
et al. 2012; van Dyk et al. 2012; Răsković & Poleksić 2017). As mentioned above, 
pollutants in the water can stimulate different biochemical and physiological 
responses which can cause changes in the fish body metabolism and physiology; if 
those pollutants are not removed, they will cause a change in target organs histology 
(Hinton et al. 1992; Răsković et al. 2013). If the normal histology of the target organ 
is known, it can be compared to that of the exposed fish to evaluate the magnitude 
of the pollutant damage to the organs. Semi-quantitative histopathological 
assessment protocols have been established and are widely used internationally 
(Schwaiger et al. 1997; Bernet et al. 1999; Zimmerli et al. 2007; van Dyk et al. 2009; 
Răsković et al. 2013). The advantage of using histopathology as a biomarker is that 
the response of the organism body to toxicants start at the molecular levels, then 
physiological changes follow, and later the morphology of the organ will be affected 
(Răsković & Poleksić 2017). Therefore, histological assessment of the organ will 
provide early warning signs of the reaction of the organism to pollutants (Hinton et 
al. 1992). If the morphology of the organ is affected severely, its function will also 
most likely be affected which may lead to a decreased development or reproduction 
(Zimmerli et al. 2007). To back up histological finding in fish health assessment 
studies, blood parameters, the CF and organ somatic indices are also evaluated 
(van Dyk 2006; Tresise 2014; Robson et al. 2017). 
 
2.7.2. Blood parameters as biomarkers  
Studies have shown that as the blood comes in direct contact with chemicals from 
the water, its parameters will react to those chemicals and their responses can be 
used to estimate the effects of the chemical to the fish (Kroon et al. 2017). The 
haemoglobin (Hb) is an iron content protein in the red blood cells (RBC) which 
functions as a carrier of oxygen to tissues and it is measured in g/dl (Billett 1990; 
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Ruas et al. 2008). The level of Hb gives a picture of the amount of oxygen delivered 
to tissues. The haematocrit (Hct) is the percentage (in volume) of RBC in blood. 
Together with Hb, the Hct levels can give information on how the fish blood is 
reacting to pollutants in water; low Hb and Hct levels are often signs of anaemia 
(Billett 1990; Witeska 2015; Sihoka & Wagenaar 2018). The Hb response to 
chemical exposure is amongst the most reliable physiological biomarkers in fish  
(Di Giulio & Hinton 2008). The percentage volume of white blood cells (WBC) or 
leukocrit (Lct) is measured together with the Hct and may give information on how 
the immune system is responding to chemical exposure (Bekker et al. 2012; Robson 
et al. 2017).  
 
2.7.3. Body and organ indices as biomarkers 
As it is the case for fish blood parameters, the CF and somatic indices for certain 
organs are also influenced by water quality. The CF is the ratio between the fish 
body length and wet weight and is frequently used in aquaculture and fisheries to 
evaluate the health of the fish (Carlander 1969; Froese 2006). Different factors 
including food shortage, water quality changes and chemical exposure are known 
to induce changes in metabolic and energy intake rates which can lead to a 
decreased CF (Di Giulio & Hinton 2008; Sadauskas-Henrique et al. 2011). An organ 
somatic index is the ratio of the organ mass and the fish body mass expressed in 
percentage (Kroon et al. 2017). The most used organ somatic indices are the 
hepatosomatic index (HSI) for the liver, the gonadosomatic index (GSI) for the 
gonads and the splenosomatic index (SSI) for the spleen (van Dyk 2006). The bio-
chemical and physiological responses of fish to chemicals in water often lead to 
changes in organ metabolism activity and histology. These changes can have 
effects on the involved organs somatic indices (Hinton et al. 2008; Răsković et al. 
2013). Thus, organ somatic indices are used as biomarkers to assess the responses 
of fish to water quality changes and may give a more accurate picture of the fish 
health compared to the CF (Di Giulio & Hinton 2008). The HSI is the most commonly 
evaluated somatic indices in toxicology studies because of the function of the liver 
in xenobiotic metabolism and excretion (Hinton et al. 2001; Schoenfuss et al. 2016). 
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2.7.4. Oreochromis mossambicus as a test organism 
Previous studies on the effects of pharmaceuticals on fish conducted in the USA, 
Europe and Asia have been using small fish species recommended by the 
Organisation for Economic Co-operation and Development (OECD) such as zebra 
fish (Danio rerio), Japanese medaka (Oryzias latipes), rainbow trout (Oncorynchus 
mykiss) and fathead minnow (Pimephales promelas) (OECD 2012). However, most 
of those fish species are not found in African freshwaters. The Mozambique tilapia,  
O. mossambicus, was chosen as the test organism for this study firstly because it is 
an indigenous species to the Southern Africa region, and secondly, it is one of the 
most popular fish species in aquaculture and commercial fishing throughout Africa 
(Skelton 2001; Weber 2010). In addition, O. mossambicus is easy to keep in 
laboratory conditions as it is resilient to harsh environmental conditions; it has been 
successfully used in toxicology studies in South Africa (Nussey 1994; van Dyk et al. 
2007; Mlambo 2009; Weber 2010; Tresise 2014; Robson et al. 2017; Sihoka & 
Wagenaar 2018). Therefore, extensive information on this fish species biology, 
haematology, histology and toxicological responses served as a reference to this 
study. 
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CHAPTER 3. MATERIALS AND METHODS 
 
The following chapter gives detailed information on the nature, types and duration 
of the conducted experiments. The choice of fish species, test pharmaceuticals as 
well as the different protocols applied including the statistical analyses are also 
described. 
 
3.1. Ethical clearance 
The ethical clearance to conduct this research was obtained from the University of 
Johannesburg’s Ethical Committee on the 20th November 2015 (Protocol No: 
November 2015).  
 
3.2. Exposure period   
The study was a partial life-cycle exposure of O. mossambicus and it was done in 
three main experiments. The first experiment concerned the breeding of fish and 
trial blank exposures of embryo 24 hrs post-fertilisation (PF) till the newly hatched 
larvae were 14 days old. The second experiment included the exposure of early life 
stages (embryo 24 hrs PF to 60 days old juveniles) to test pharmaceuticals at the 
chosen concentrations. The third experiment involved the exposure (30 days) of 
sexually mature adult fish to test pharmaceuticals at the same concentrations and 
in the same conditions as early life stages. The setting up of the environmental room 
where the experiments were conducted, at the University of Johannesburg 
Research Aquarium, took place from January to March 2016. The trial experiments 
started on the 22 March 2016 and were concluded on 12 July 2016. The exposure 
of early life stages took place from the 31st August 2016 to the 30th September 2017. 
The adult fish exposure started on the 25th January 2017 and concluded on the 23 
September 2017.  
 
3.3. Test water choice 
Before starting the exposure studies, trial experiments were conducted to determine 
which type of water [tap water or borehole water currently used at the University of 
Johannesburg aquarium] is suitable to maximise the rate of hatching and survival of 
fish embryo and larvae. The Organisation for Economic Co-operation and 
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Development recommends that any type of water in which the hatching success of 
embryos is maximal can be used for the toxicological test of early life stages (OECD 
2013). The preliminary experiments were conducted in the same environmental 
controlled room as the exposure and lasted till 14 days after the hatching of 
embryos. These experiments were repeated 4 times and the results showed that 
the borehole water had higher embryos hatching success and survival (> 70%) 
compared to the tap water (≤ 50%). Thus, borehole water was used for all the 
exposure experiments.  
 
3.3.1. Borehole water quality analysis  
To make sure that the guidelines for fish toxicity test water were observed (OECD 
2013), the full chemical and biological quality of the borehole water used in the 
experiments was analysed prior to exposure. The analysis was done by 
WATERLAB (Pty) Ltd, a South Africa National Accreditation System (SANAS) 
accredited laboratory, No. T0391. Tables 4.1 and 4.2 give an overview of the quality 
of the borehole water used for this study. The full chemical and biological quality 
analysis results are provided in Annexure 2. 
 
3.4. Test pharmaceuticals 
3.4.1. Test pharmaceuticals description 
The HIV anti-retroviral nevirapine (NVP) (C15H14N4O; molecular weight: 266.30 
g/mol; CAS-No. 129618-40-2; purity: ≥ 98%); the antibiotics sulfamethoxazole 
(SMX) (C10H11N3O3S; molecular weight: 253.28 g/mol; CAS-No. 723-46-6; purity: ≥ 
98%) and trimethoprim  (TMP) (C14H18N4O3, molecular weight: 290.3 g/mol; CAS-
No. 738-70-5; purity: ≥ 98%) were used as test pharmaceuticals for this study. The 
pharmaceuticals were purchased from Sigma-Aldrich, South Africa. The three 
pharmaceuticals appeared as solid white powder. Since NVP and SMX are not 
readily soluble in water, dimethyl sulfoxide (DMSO) (solubility rate ≥ 22 mg/ml, 
purity: ≥ 99,7%) was used as a solvent to prepare stock solutions.  
 
 3.4.2. Exposure doses determination 
The exposure doses were chosen from the environmental relevant concentrations 
of each compound as reported in accredited peer reviewed journals. The highest 
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concentration of NVP (1.48 µg/L) reported in South African surface waters, which 
occurred in the Roodeplaat Dam (Wood et al. 2015), was used as the lower NVP 
concentration. On the other hand, the higher NVP concentration used (3.74 µg/L) 
was chosen in-between the highest concentration in South Africa (1.48 µg/L) and 
the highest concentration in the Nairobi river system (6 µg/L) in Kenya (K’Oreje et 
al. 2016). The highest environmental concentration (3.68 µg/L and 0.870 µg/L) 
reported in South African aquatic environments (Umgeni River System) was used 
for SMX and TMP (Agunbiade & Moodley 2014; Matongo at al. 2015).  
The concentration of DMSO in the solvent-control media was calculated to be the 
same as in the corresponding exposure media with pharmaceuticals. However, 
DMSO concentration was always kept under 0.01% v/v by first mixing the test 
pharmaceutical with DMSO to homogeneity and secondly filling up to required 
volume with distilled water. This was done to avoid bias in our results as studies 
have shown that DMSO concentrations above 0.01% v/v can have negative effects 
on fish (Hallare et al. 2006; Triebskorn 2007). The calculated highest concentration 
of DMSO used was 0.003 ml per 100 ml of water. 
 
3.4.3. Preparation of stock solution and test medium 
The stock solutions with a concentration of 100 ppm were prepared for each test 
pharmaceutical by mixing 10 mg of the pharmaceutical powder in 100 ml of the 
solvent. DMSO mixed with distilled water (70 ml:30 ml) was used as solvent for NVP 
and SMX while only distilled water was used for TMP as the drug is readily soluble 
in water (400 mg/L). The stock solutions were then kept in glass bottles at – 20℃ 
for NVP while SMX and TMP were kept at 4℃ to avoid freezing. The amount of stock 
solution (V1) used to prepare the exposure media at the desired concentrations was 
calculated using the dilution formula:  
 
C1 × V1 = C2 × V2     (a) 
 
Where: C1 = the concentration of the prepared stock solution (100 ppm or 100 000 
µg/L); V1 = the volume of the stock solution to put in the tank/bottle; C2 = the 
expected concentration of the test pharmaceutical (e.g. 1.48 µg/L for NVP ); and 
 V2 = the volume of the water in the tank/bottle.  
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The stock solution was introduced in the exposure tank/bottle using a finn pipette. 
The stock solution was firstly mixed with water from the tank/bottle in a 50 ml glass 
bottle for homogenisation and then it was introduced into the exposure tank/bottle. 
For embryo exposure, the test media were prepared 30 min before the introduction 
of the embryo into the exposure bottles to give the test media time to homogenise 
and to avoid any direct contact of the stock solution with the eggs.  
 
3.4.4. Analysis of nevirapine in test media 
3.4.4.1. Collection of samples  
In order to be sure that the fish were exposed to the expected concentrations of the 
test pharmaceuticals, water samples for analysis were collected in 2 L glass bottles. 
For the exposure of fish embryo/eggs, water samples were collected at the 
beginning of the exposure and at the end of hatching (± 5 days) to avoid stressing 
the embryo. As the exposure of embryo was done in 2 L glass bottles, the exposure 
media was prepared in duplicate so that the duplicate can be used for the test 
pharmaceutical analysis. For the larval, juvenile and adult stages exposure, water 
samples were collected at four separate times from three different tanks: at the 
beginning of the exposure (recorded as 0 hour 30 min), at the end of the first 96 hrs 
period, directly after the renewal of the exposure media and at the end of the 
experiment. In addition, samples from the control and the solvent control groups 
were also collected for analysis.  
 
3.4.4.2. Analysis of nevirapine 
Fish toxicological exposure experiments to human pharmaceuticals are just starting 
in South Africa, there are not many laboratories in the country doing the analysis of 
those pharmaceuticals from water and fish tissue samples. In addition, those few 
laboratories that can do those analyses are expensive and they have to develop 
and validate the method for each one of the pharmaceuticals to be analysed. The 
analysis of the water samples from this study was done at North-West University 
Potchefstroom Campus, South Africa. The laboratory has for now developed and 
validated methods for the analysis of NVP. However, water samples for the analysis 
of the other two pharmaceuticals from the present study, SMX and TMP, have been 
collected and will be analysed once the methods are developed and validated. 
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Therefore, only NVP analysis was done. The ultraperformance liquid 
chromatography (UPLC) coupled to quadrupole time-of-flight mass spectrometry 
(QTOF/MS) method was used. As the NVP concentration used was very low (1.48 
µg/L), it was extracted and concentrated in order to be quantified by the instrument. 
The extraction of NVP from water was done following a method by Ferrer & Thurman 
(2012) for pharmaceuticals by automated solid phase extraction (SPE-DEX) 4790 
system (Horizon Technology, Salem, NH, USA). The Oasis hydrophilic-lipophilic 
balance (HLB) disks were used for the extraction of NVP; these disks have been 
validated by the US EPA method 1694 (US EPA 2007) for the analysis of 
pharmaceuticals and personal care products. During extraction, samples were 
concentrated 500 times, and the extracts obtained were analysed using ultra-high-
pressure liquid chromatography (UPLC) coupled to quadrupole time-of-flight mass 
spectrometry (QTOF/MS) (Agilent Technologies, Santa Clara, CA, USA). This 
method has been previously validated by Schoeman et al. (2015) to determine the 
limits of detection (LOD) and quantification (LOQ). This method is used in different 
studies across Europe and US to detect and quantify targeted and untargeted 
pharmaceuticals as well as their metabolites in water samples (Ferrer & Thurman 
2012; Swanepoel et al. 2015). 
 
3.5. Oreochromis mossambicus exposure studies 
3.5.1. Fish breeding  
Sexually mature O. mossambicus were chosen from the University of Johannesburg 
Research Aquarium fish stock. Those fish were organised into breeding pairs, 1 
male for 2 females, in 700 L glass aquaria breeding tanks (1 breeding pair per tank) 
under controlled conditions (Figure 3.1 A). The temperature of the environmental 
room was maintained at 30 ± 1℃ and each experimental tank was kept at 27 ± 1℃; 
a day/night photoperiod cycle of 14:10 hrs was maintained to simulate summer 
conditions. Water quality parameters were monitored daily during the breeding 
process and the fish were fed complete tilapia pellets (Tilapia Grower Pellets 3 mm, 
AVI Products (Pty) LTD 2001/015923/07) three times per day. The nutritional quality 
of the food is provided in Annexure 3.  
 
The females were checked for any sign of eggs every morning at 7 o’clock. As  
O. mossambicus are mouth brooders, available eggs were collected from the mouth 
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of female approximately 24 hrs after fertilization. The female was caught with a net 
and the mouth was hold open by applying a smooth pressure on the lateral sides 
with two fingers. Then it was rinsed in water from the breeding tank in a plastic tray 
to collect all the eggs. After collection, the eggs were counted and triaged following 
the different exposure groups using petri dishes with water from the breeding tank 
and a 3 ml plastic transfer pipette (the tip was cut to get a 3 – 4 mm opening). After 
the triage and removal of suspected unfertilized eggs, the eggs were put in the 
different hatching jars containing the test media.  
 
3.5.2. Exposure set-up and procedures 
This study was carried out in different exposure experiments where the different life 
stages of O. mossambicus (embryo, larvae, juvenile and adults) were exposed to 
the different pharmaceuticals. The exposure of early life stages was done in two 
groups of experiments; the 1st experiment included three exposure groups: The 
control group (referred to as control 1), the solvent control group and the NVP 1.48 
µg/L group (referred to as NVP L). The 2nd experiment included four exposure 
groups: The control group (referred to as control 2), the NVP 3.74 µg/L group 
(referred to as NVP H), the group of NVP L + SMX 3.68 µg/L + TMP 0.870 µg/L 
mixture (referred to as Mixture 1) and the group of SMX + TMP mixture (referred to 
as Mixture 2). The exposure of adult fish was done in one experiment containing 5 
exposure groups: The first group consisted of NVP L, the second group was NVP 
H, the third group was the Mixture 1, the fourth and fifth groups included the control 
(water) and the solvent control (diluted DMSO) respectively. The required minimum 
guidelines as per the OECD Test No 95: Detailed Review Paper on Fish Life-Cycle 
Tests (OECD 2008) and the US Environmental Protection Agency (EPA): Ecological 
Effects Test Guidelines OCSPP 850.1400 Fish Early-Life Stages Toxicity Test (US 
EPA 2016) were consulted and used as guidelines.  
All the experiments were conducted in an environmental controlled room where the 
temperature of the room was maintained at 30 ± 1℃ and a day/night photoperiod 
cycle of 14:10 hrs was maintained as it was for the breeding pairs. An oxygen line 
was connected to each tank/bottle to provide oxygen during the whole experiment.  
The dissolved oxygen was monitored regularly to keep it between 80% - 120% 
(OECD 2008). 
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3.5.2.1. The static renewal system 
As this was a chronic exposure that lasted over 60 days for early life stages and 30 
days for the adult fish, a static renewal system was chosen for this study. Using the 
static renewal system minimized the work load of changing the water manually and 
the amount of the test pharmaceutical waste generated by the experiments (Mehler 
et al. 2018). The main test pharmaceutical for this study, NVP, has a half-life of 48 
to 64 hrs in blood plasma (Mirochnick et al. 2000) and it is known to have a low 
biodegradability in water (Vankova 2011; Wood et al. 2017). Considering that, it was 
decided to change the test media every 96 hrs to keep NVP near the nominal 
concentration. The other advantage of changing the test media periodically is that it 
helps maintaining the water quality in acceptable guidelines for fish toxicity (US EPA 
2016). The renewal water was kept in big tanks in the same environmental 
controlled room where the experiments were conducted two days before the 
renewal. This was done to keep the renewal water at the same temperature as the 
exposure water and to make sure that the fish are not submitted to a sudden change 
in water temperature when renewing the test media. At the end of 96 hrs, ¾ of the 
water was manually removed from the exposure tank/bottle slowly using a plastic 
pipe and care was taken not to stress the fish. Then, the renewal water was slowly 
introduced in the tank using another plastic pipe, and the test pharmaceutical was 
topped according to the quantity of the renewal water. For embryo stages, the 
renewal of the test media was done on the morning of the first day after hatching 
was completed to avoid disturbing the hatching process. The newly hatched 1-day 
old larvae were transferred to newly prepared test media in new 1 L bottles. During 
the experiment, the bottles were checked every morning and the test media was 
topped when necessary. The test media used for topping was kept in a separate 1 
L bottle in the same conditions.  
 
The set-up and details of the different static renewal systems used in the study are 
showed in the Figures 3.1 and 3.2. The exposure of embryo and newly hatched 
larvae was carried out in 1 L glass jars/bottles fitted with a small glass hatching cups 
with a plastic mesh at the bottom as shown in Figure 3.1 (designed by Kruger 2002). 
An oxygen pipe was introduced in the glass jars to supply the embryo with oxygen 
and to keep the water moving to prevent the eggs from lying motionless on the 
mesh. Swimming larvae and early juveniles up to 30 days old were exposed in 20 L 
glass tanks (Figure 3.1 F), while juveniles above 30 days old and adult fish exposure 
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was conducted in 90 L glass tank (Figure 3.2 D) covered with a glass plate to prevent 
fish from jumping out of the tanks. Both the 20 L and 90 L tanks were supplied with 
oxygen through a plastic pipe. For the 90 L tanks, the oxygen pipe was connected 
to a plastic filter containing cotton wool and gravel to remove solid waste (Figure 3.2 
E). The test media wastes were kept in 100 L black plastic boxes awaiting to be 
disposed according to the University of Johannesburg Research Aquarium protocol 
illustrated in Figure 3.3. 
 
3.5.2.2. Early life stages exposure 
A. Embryo exposure 
After the triage of fertilized eggs, the embryos were introduced into the different 1 L 
hatching jars containing the exposure media prepared 30 min prior the experiment. 
This experiment was carried out in four repeats and each repeat included three 
groups: (i) the control group with only dilution water (borehole water); (ii) the solvent 
control group (DMSO, under 0,01%v/v) and (iii) the test pharmaceutical(s).  
For each experiment repeat only eggs provided by one female were used. This 
means that when a female had eggs (± 180 eggs), those eggs were organised in 
the different exposure groups (control, solvent control and the test pharmaceutical) 
and that represented one repeat of the experiment. For the next repeat of 
exposures, eggs from another female were used. This had the advantage of using 
eggs from the same brood for each repeat. At the start of each repeat experiment, 
fertilised eggs were organised randomly in hatching jars with ± 30 eggs per each jar 
and two jars per group, which makes ± 60 eggs per group. The temperature of water 
was kept at 27 ± 1℃ in the different hatching jars. Each jar was checked twice daily 
for signs of start hatching and to remove dead embryos in case there were any. The 
term “embryo” will be used for early life stages from fertilisation to the end of 
hatching.  
 
B. Larval and early juvenile stages exposure 
After hatching, the newly hatched larvae were kept in the hatching jars till when they 
started swimming up, then they were transferred to 20 L glass tanks to allow more 
space for swimming and adequate growth. Approximately 12 days post-fertilisation 
(PF) the yolk sac was almost depleted, then the exogenic feeding started in all 
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groups. According to Holden and Bruton 1992, the period from the depletion of the 
yolk sac to two or three weeks beyond that, is a critical stage in a fish life as larvae 
are introduced to exogenic feeding. During this period, as observed in the 
preliminary experiments, larvae may die in numbers due to the introduction to 
exogenic food and/or due to the degradation of water quality if care is not taken to 
remove all organic wastes and keep the water fresh and aerated. During our 
experiments, care was taken to remove solid and organic wastes including the 
remaining of the previous day food and the fish wastes. They were removed 
carefully using a small plastic pipe taking care to not stress the larvae. The larvae 
were fed three times per day with complete tilapia fry crumble # 1 (500 – 750 µm) 
(Tilapia Fry Crumble, AVI Products (Pty) LTD 2001/015923/07). The nutritional 
quality of the food is provided in Annexure 3. The tanks were checked twice a day, 
morning and evening, for any death, stress, and abnormal behaviour including 
hyperventilation; uncoordinated swimming; atypical quiescence and atypical feeding 
behaviour (OECD 2013). Short 60 seconds long videos were recorded daily from 
each tank to observe the behaviour of the fish. The exposure was concluded 60 
days post-hatching. Throughout this thesis, the term “larvae” is used to refer to early 
life stages from 1 day post-hatching (PH) to the start of exogenic feeding, 12 days 
PH while the term “early juveniles” is used from this stage to the end of the 
experiments.  
 
3.5.2.3. Adult stages exposure 
A. Fish acclimation 
Fifty-two sexually mature O. mossambicus were purchased from the Hartbeespoort 
Fisheries in Gauteng Province, South Africa. The fish (50% female and 50% male) 
were kept for 3 months in holding tanks (Figure 3.2 A-B) at the University of 
Johannesburg’s Research Aquarium Facilities for observation and acclimation to 
the aquarium conditions. During this period, the fish were fed complete tilapia pellets 
(Tilapia Grower Pellets 3 mm, AVI Products (Pty) LTD 2001/015923/07) two times 
per day. At the end of this acclimation period, the fish were moved into an 
environmental controlled room (Figure 3.2 C) where they were acclimated for further 
12 days before the start of the exposure experiments. This second acclimation 
period allowed the fish to adapt to the environmental room conditions where the 
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temperature and the photoperiod were controlled as those conditions were different 
from the holding tanks.  
 
B. Fish exposure 
At the end of the second acclimation period, the right amount of the stock solution 
was introduced into the exposure tanks. Before being introduced into the tanks, the 
stock solution was mixed with a little water from the tank in a 50 ml glass bottle to 
help quick homogenisation. During the exposure experiments, the number of fish 
was kept at one fish per 75 L of water in a 90 L glass tank covered with a glass plate 
to keep the fish from jumping out. The fish were arranged in 5 groups: control  
(4 fish), solvent control (4 fish), NVP L (6 fish), NVP H (6 fish) and Mixture 1 (6 fish). 
The experiment was done in two repeats and the sex ratio in each group was 
maintained at 1:1 if possible. Each exposure period lasted 30 days, and during this 
period the fish were fed tilapia pellets (Tilapia Grower Pellets 3 mm, AVI Products 
(Pty) LTD 2001/015923/07) twice a day. The feeding was stopped 24 hrs before the 
termination of the exposure. Throughout the experiment, the fish were checked 
every day for any sign of stress or abnormal behaviour in swimming and feeding.  
 
3.5.2.4. Water quality monitoring 
Water parameters including the temperature (Temp), pH, electrical conductivity 
(EC), total dissolved solids (TDS) and dissolved oxygen (DO) were monitored daily 
using Eutech Instruments ISO9001 certified water quality meters, model CyberScan 
300 (Figure 3.2 F-H). To keep those parameters in acceptable guidelines, the test 
media in each tank was renewed every 96 hrs and oxygen was supplied to each 
tank/bottle by aeration through plastic tubes. A filter was installed in each tank to 
help remove solid wastes (Figure 3.2 E). Each tank/bottle was checked every 
morning and solid wastes from food remains and fish excrements were removed 
using a plastic pipe before feeding the fish. Before each water renewal, the filters 
were cleaned with distilled water and new cotton wool were put in. To avoid drastic 
change in water temperature, the renewal water was kept in clean tanks (Figure  
3.2 C) two days prior to the renewal to allow it to get to the same temperature as the 
exposure media.  
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3.5.2.5. Test media waste water disposal 
Figure 3.6 shows the system used for the disposal of the test media waste. After 
test media renewal, the waste was collected in plastic boxes and removed from the 
environmental room. The waste was dropped into a 5000 L tank which is used at 
the aquarium to collect all the exposure water waste. The tank is connected to a 
triple canister water filter with activated charcoal to filter waste water before pouring 
it into the drain. After this stage, the filtered waste joins the aquarium general waste 
water collection to the university waste water collection facility where more treatment 
was applied.  
 
3.6. Early life stages health assessment 
3.6.1. Hatching success assessment 
Once the hatching had started in each group, the time of start hatching was 
recorded; and when the hatching was done, the time of end hatching was recorded. 
The embryo that failed to hatch were counted, recorded and removed from the 
jar/bottle. Then, the hatching success (%) was calculated for each group following 
formula (b) and the number of embryos with morphological abnormality, if any, was 
recorded.  
 
 
Hatching success (%) =
No.of hatched embryos
No.of eggs at start
  × 100    (b) 
 
 
The hatched embryos were also checked for any physical abnormality, if there was 
any, it was recorded. The number of embryo that failed to hatch was also recorded 
for each group and for each repeat.   
 
3.6.2. Survival and behaviour assessment 
From the 1st day after hatching till the end of the experiment the tanks/bottles were 
checked two times per day to record any mortality case. The survival rate of larvae 
(%) was calculated in each group at three different periods during the exposure;  
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at the start of exogenic feeding, at the end of the first 30 days and at the end of the 
experiment (60 days). The following formula was used: 
 
Survival (%) =
No.  of fish at the Ta   
No.  of hatched larvae 
× 100    (c) 
 
With Ta = time at which the recording was done (1, 30 or 60th day PH).  
The fish were also monitored every day for any sign of stress and abnormal 
behaviour, if there was any, it was recorded.  
 
3.6.3. Growth and development evaluation 
At day 1, 30 and 60 PH, at least 10 larvae from each group were sampled by 
dropping them in ice water for ± 3 min; then the wet weight and total length (TL) 
were measured using an electronic scale at 0,001 g (Figure 3.6 H) and a graduated 
board (in mm) (Figure 3.4 A). After that, the physical assessment for possible 
morphological abnormality (Figure 3.4 E) was done on each individual fish under a 
dissection microscope. Weight and length measurements were then used for the 
calculation of the condition factor (CF) of each individual according to Formula (d) 
below. The CF is a rapid measure used to estimate the health condition or degree 
of well-being of fish; it mostly depends on water quality and food availability (Froese 
2006). For adult fish, a CF value equal or closer to 1 indicates a healthy fish grown 
in good conditions while a low CF (< 1) is an indication of poor health state due to 
compromised environmental conditions in general (Carlander 1969). The CF 
formula used is: 
 
CF =  
Total body mass (g) × 105
Total body length (mm)3
     (d) 
 
The mean specific growth rate (SGR) was also calculated for each group on day 30 
and on day 60 PH following Bagenal & Tesch (1978) method: 
 
SGR =
 Ln Final weight − Ln Initial weight
T2 − T1
 × 100    (e) 
 
Where: Ln = the natural logarithm, T1 = the time of previous measurement, and  
T2 = the time of last measurement.  
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The SGR is a quantitative measure of fish body mass increase per unit of time, it is 
used in fisheries to evaluate how fish are growing (Sparre & Venema 1998). The 
sampled larvae and juveniles were fixed as whole individuals in 10% Neutral 
Buffered Formalin (NBF) for further histological assessments.  
 
3.6.4. Histological assessment 
The whole larvae and juveniles were fixed in 10% NBF for 72 hrs. To allow the 
fixative to reach the abdominal cavity, an incision was made in the fish abdomen 
using a surgical blade and taking care not to damage the internal organs. The 
tissues were then processed and histologically analysed following the methods 
described in sections 3.8.4.2; 3.8.4.3; and 3.8.4.4. The histological sections were 
longitudinally orientated and each wax block was sectioned completely. The 
histological analysis of early life stages was done only on 30 day old juveniles; this 
allowed to compare the effects with adult fish as they were also exposed for 30 days. 
Only the kidney and the liver tissues were assessed. The gonadal tissue of most of 
the 30 days old fish was lost or not recognisable; therefore, it was not assessed. 
 
3.7. Adult fish health assessment 
3.7.1. Necropsy  
At the end of the 30 days exposure period, the fish were sampled, weight recorded, 
total length measured and blood samples collected (Figure 3.5). Then the fish were 
killed by severing the spinal cord, dissected, and the standard necropsy was 
performed (Adams et al. 1993).  
 
3.7.2. Biometric indices assessment 
3.7.2.1. Condition factor 
The total weight (including viscera) of each fish and the total length were used to 
calculate the condition factor (CF) using formula (d). 
 
 3.7.2.2. Somatic indices 
The target organs including the liver, spleen, gonads and posterior kidney were 
removed (Figure 3.6). Those organs were weighed and measured in order to 
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calculate the liver somatic index (hepatosomatic index = HSI), the splenosomatic 
index (SSI) and the gonadosomatic index (GSI). A somatic index of a selected organ 
is expressed as the percentage of the organ wet weight of the total fish body weight 
(Adams et al 1993):   
 
Organ somatic index (%) =  
Organ mass (g)
Total body mass (g)
 × 100    (f) 
 
Somatic indices of some organs including the liver, spleen and gonads have been 
previously used as biomarkers of water pollution (Dekic et al. 2016; Schoenfuss 
2016; Robson et al. 2017).  
 
3.7.3. Blood parameters analysis  
Before the fish were killed, blood was drawn from the caudal vein using 0.5 x 16 mm 
needles (25 G) and 1.5 ml plastic syringe. A drop from the collected blood was used 
to measure haemoglobin (Hb) (g/dl) directly using a Hemo - Control machine (EKE 
Diagnostic, Model: 3000-00310-0801) (Figure 3.5 H). The collected blood was kept 
on ice and used to calculate haematocrit (Hct) and leukocrit (Lct) using glass 
microhematocrit capillaries (75 mm / 75 µl), a microhematocrit centrifuge (Model: 
HCD – 2000) at 60 x 100 rpm for 5 min and a Hawksley microhematocrit reader. 
The following standard formulae were used:  
 
Hct (%) =
RBCV
WBV
 × 100    (g) 
 
Lct (%) =
WBCV
WBV
  × 100    (h) 
 
Where: RBCV = the volume occupied by red blood cells in the microhematocrit 
capillary; WBCV = the volume occupied by white blood cells; and WBV = the volume 
of the whole blood cells in the microhematocrit capillary.  
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3.7.4. Histological assessment 
3.7.4.1. Tissue sampling and fixation 
The tissues for histological analysis (approximately 5 mm thick) were sampled from 
the liver and posterior kidney and fixed in 10% NBF for 48 hrs. Six samples were 
taken from the liver at different areas of the organ while only 3 samples were taken 
for the kidney. For each fish, the same number of tissue samples were taken from 
the same areas of the organ in order to keep the sampling consistent. The gonads 
of each fish were fixed as whole in Bouin’s solution for 24 hrs. Figure 3.7 shows how 
the different organs were sampled. 
 
3.7.4.2. Tissue processing  
All tissues samples were processed following the standard histological processing 
technique (Humason 1979). The tissue samples were removed from 10% NBF, 
washed in slow running water over night, dehydrated in a series of increasing 
ethanol concentrations (30% to 100%), cleared with xylene and imbedded in paraffin 
wax. After fixation, the whole gonads were removed from the fixative. Using a 
surgical blade each gonad was cut into 4 to 6 small pieces (± 5 mm long) depending 
on the length of the organ. Then, the gonads tissues were processed following the 
same standard techniques as the liver and kidney. Each piece of tissue was 
imbedded and the wax blocks were sectioned with a rotary microtome. The 5 µm 
thick tissue sections were mounted on microscopic slides using DPX Mountant and 
stained with a Haematoxylin and Eosin rapid staining method (van Dyk & Pieterse 
2008). From each wax block, 10 slides were made from the start of the sampled 
tissue with a ± 30 µm distance in between.  
 
3.7.4.3. Qualitative histological assessment 
Histological changes in tissues were assessed using a light microscope (multi-
headed Olympus camera) and micrographs were taken using a Leica 020-518.500 
DM/LS microscope mounted with a Leica DMC 2900 camera (Figure 3.6 J). To avoid 
subjectivity in slides assessment, three assessors were involved in the process. 
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3.7.4.4. Semi-quantitative histological assessment 
A semi-quantitative histological assessment of the observed histological changes 
was done using the protocol by Bernet et al. (1999) as adapted by van Dyk et al. 
(2009).  Firstly, a score value (S) representing the frequency of occurrence of the 
histological change in the tissue was assigned to each type of histological change 
(Table 3.1). Secondly, an importance factor (F) value representing the level of the 
damage of each change to the tissue was also assigned (Table 3.2). Thirdly, the 
histological changes were grouped into reactions patterns (rp), namely: circulatory 
disturbances, regressive changes, progressive changes, inflammatory reactions, 
neoplasms, focal area of cellular alterations (FCA), and intersex (for gonads only). 
Lastly, those values were multiplied for each histological change and summed for 
each reaction pattern to give a reaction pattern index (Irp). All the Irp were summed 
for each organ to give the organ index (Iorg) representing the degree of severity of 
histological changes to the organ tissue. According to Bernet at al. (1999), a high 
Iorg corresponds to a high degree of damage to the organ. 
 
𝐈rp = ∑chan(𝐒org rp chan x 𝐅org rp chan)    (i) 
 
 
𝐈org =  ∑rp∑chan(𝐒org rp chan x 𝐅org rp chan)    (j) 
 
 
Where: org = organ; rp = reaction pattern; chan = change; S = score value;  
F = importance factor; I = index.  
 
 
Table 3.1: Score values and frequency of occurrence of alteration 
Score value (S) Frequency of occurrence of alteration on the tissue 
0 Absent 
2 Appear a few times (mild / focal) 
4 Appear on approximately half of the tissue (moderate) 
6 Appear all over the tissue (severe) 
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Table 3.2: Importance factor values and their degrees of alteration 
Importance factor (F) Degree of alteration 
1 Reversible with time 
2 Reversible if the stressor were removed 
3 Irreversible 
 
 
The calculated Iorg for each fish were grouped in classes of severity of histological 
alteration using a scoring system developed by Zimmerli et al. (2007) for the liver 
and kidney of brown trout (Salmo trutta L.) and adapted by van Dyk et al. (2009) for 
Clarias gariepinus and O. mossambicus (Table 3.3). The importance of using these 
scoring systems to evaluate histological alterations in fish is that the degree and 
extent of morphological changes were determined in the studied organs and 
transformed into quantitative values (Zimmerli et al. 2007). 
 
 
Table 3.3: Classification of organ indices into histological alteration groups based 
on Zimmerli et al. (2007) system as adapted by van Dyk et al. (2009)  
Class Organ index 
  (Iorg) 
Description 
1 <10 Normal tissue structure with mild histological alterations 
2 10 - 25 Normal tissue structure with moderate histological alterations 
3 26 - 35 Pronounced alteration of the organ histology 
4 >35 Severe alteration of the organ histology 
 
 
3.8. Statistical data analysis 
The IBM SPSS Statistics software (version 25) was used for statistical data analysis 
at a significance probability of p < 0.05 for all tests. The experiment was repeated 4 
times for early life stages exposed to NVP L, 2 times for early life stages exposed 
to NVP H and to both mixtures and 2 times for adult fish exposure. For early life 
stages, analyses and measurements were taken from different individuals sampled 
at different period of times (1, 30 and 60 days PH). Therefore, independent-samples 
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analysis techniques were used. The data was checked for normality of distribution 
using Kolmogorov-Smirnov for large sample size data (early life stages, sample size 
> 500) and Shapiro-Wilk test for small sample size data (adult fish, sample size  
< 55). Normal Q-Q Plots graphs were also used. The homogeneity of variances was 
tested using Levene’s test. To compare exposed fish to the control fish, all biological 
parameters and water parameters were analysed using one-way analysis of 
variance (ANOVA) with post-hoc test Tukey HSD for parametric data. For non-
parametric data the Kruskal–Wallis followed by Mann-Whitney U tests were used. 
For early life stages growth evaluation, linear regression analyses were applied to 
determine the relationship between weight and length measurements as the fish in 
the different groups were ageing.  
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Figure 3.1: A. Breeding tank; B. Female fish with eggs in its mouth; C. i. Hatching glass 
cup, ii. Plastic mesh, iii. Tube for oxygen line; D. iv. Glass jar fitted with the hatching cup;  
E. v. Oxygen line; vi. Fertilised eggs in hatching jar, F. Static renewal system for early life 
stages (EL) and for larval and juvenile stages (LJ). 
 
 
Figure 3.2: A-B. Receiving and acclimation tanks for adult fish; C. Environmental room,  
w. Tank for renewal water; D. Static renewal system for juvenile and adult fish; E. Filter;  
F-H. Water quality meters. 
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Figure 3.3: A. Bw. Boxes to collect test media waste from exposer tanks; B. b. A bucket 
where the test media waste from the environmental room is dropped. The bucket contains 
a pump to pump waste into the tank; Tw. Tank where the waste is collected; p. Pump to 
remove waste from the tank; f. Triple canister water filter with activated charcoal to filter test 
media waste from the tank; d. Drain where the waste is poured after filtration.   
 
 
Figure 3.4: A. Embryos 24 hours post-fertilisation observed on a dissection microscope;  
B. Start hatching; C. Hatching completed; D. 1 day old larvae; E. Larvae with physical 
deformation; F. 5 days old larvae. A graduated board was used to measure the length;  
G. Free swimming juveniles (12 days post-fertilisation) with almost depleted York sac. 
Exogenic feeding starts; H.30 days old juvenile; I. 60 days old juvenile.  
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Figure 3.5: Adult fish necropsy and blood sampling. A. Adult O. mossambicus; B. Fish 
presenting a skin rash on the mouth; C. Internal necropsy; D. Electronic scale used to weigh 
adult fish; E. Blood drawn from the caudal vein; F. Blood collected in heparinised 
vacutainers; G. Cooler box containing ice to keep the blood cold before analysis; H. Hemo-
Control machine to measure haemoglobin concentration. 
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Figure 3.6: Target organs sampling. A. Ovaries; B. Testes; C. Posterior kidney; D. Liver;  
E. Spleen; F. Fixative in 50 ml bottles; G. Gallbladder with bile stones; H. Electronic scale 
used to weigh organs; I. Data recoding sheet; J. Microscope with Camera and computer 
used to assess the slides and taking pictures. 
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Figure 3.7: Tissue sampling for histological analysis. The numbers show how many pieces 
were sampled and the different sampling areas. 
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CHAPTER 4. RESULTS  
 
4.1. Water quality analyses 
This section reports on all the water analyses and the physico-chemical water 
parameter measurement results. These include borehole water analysis results 
(physico-chemical parameters, nutrients, metals, organic chemicals), physical 
parameters of the exposer water (temp, pH, TDS, EC, DO) as well as NVP analysis 
results. The results are presented in tables as mean values per exposure groups 
and the variation ranges of the parameters are given in the text. Supplementary data 
on water quality analyses are given in Annexure 2. 
 
4.1.1. Borehole water parameters 
The mean values for physicochemical parameters, inorganic and organic, of the 
borehole water used for the experiments are presented in Table 4.1 and Table 4.2 
below. Organochlorine and organophosphorus pesticides were under the limits of 
quantification of the instrument (< 0.0001 mg/L). The full report of the borehole water 
quality analysis is provided in Annexure 2 A & B.  
 
Table 4.1: Physical parameters and nutrients of the borehole water (in mg/L) 
Parameter Mean value SD* 
pH – Value at 25°C   6.9 0.00 
Total Dissolved Solids at 180°C  149.0 12.73 
Total Alkalinity as CaCO3 56.0 0.00 
Chloride as Cl   14.0 0.00 
Sulphate as SO4  7.0 0.00 
Nitrate as N  2.95 0.07 
Nitrite as N  < 0.05 
 
Silica as SiO2  24.0 0.00 
Ortho Phosphate as P  < 0.10 
 
Dissolved Oxygen as O2  8.0 0.14 
Free & Saline Ammonia as N  0.20 0.00 
*SD = Standard deviation 
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Table 4.2: Metals detected in borehole water at concentration > 0.010 mg/L* 
Parameter Ca K Mg Na P Si Sr Zn 
Mean value 14.0 1.15 10.0 3.50 0.16 11.60 0.07 0.04 
SD 1.41 0.07 0.0 0.71 0.11 0.42 0.0 0.01 
               * The limit of quantification of the instrument 
 
4.1.2. Physico-chemical water parameters monitoring during experiments 
The experiment was conducted in a controlled environmental room where the 
temperature of the room was maintained at 30 ± 1℃. For early life stages, the pH in 
all the test vessels varied from 6.8 - 8.2, the TDS varied from 89 – 120 mg/L, the EC 
from 185 – 216 µS/cm and the temperature recorded was 27 ± 1℃. For adult fish 
exposure, the temperature ranged from 26.7 - 28.2 ℃, the pH from 6.9 – 8.2, the 
EC from 184 - 228 µS/cm and the TDS from 87 - 122 mg/L. For both early life stages 
and adult fish, the DO saturation was maintained between 80% and 120% as an 
oxygen line was provided to each exposure vessel. Statistical analysis revealed no 
significant differences (p > 0.05) in water quality parameters between groups for 
both early life stages and adult fish. The means and standard deviation (± SD) of 
the monitored physico-chemical water parameters during the experiments in all 
groups are presented in Table 4.3 and 4.4. A detailed report of the physico-chemical 
water parameters monitoring is annexed (Annexure 2 C & D). 
 
Table 4.3: Mean ± SD recorded physico-chemical water parameters of the different 
exposure groups for early life stages experiments 
Exposure 
Groups 
Temp 
 (℃) 
pH EC  
(µS/cm) 
TDS  
(mg/L) 
DO  
(%) 
Control 1 27.40 ± 0.15 7.91 ± 0.11 209.7 ± 3.3 99.6 ± 2.07 > 80% 
Solvent control 27.32 ± 0.11 7.88 ± 0.17 212.5 ± 5.0 101.2 ± 2.68 > 80% 
NVP L 27.34 ± 0.09 7.87 ± 0.12 213.3 ± 5.9 101.5 ± 3.62 > 80% 
Control 2 27.89 ± 0.06 7.99 ± 0.04 214.5 ± 0.8 104.7 ± 1.52 > 80% 
NVP H 27.81 ± 0.10 7.98 ± 0.02 213.6 ± 1.2 102.1 ± 1.14 > 80% 
Mixture 1 27.68 ± 0.13 7.98 ± 0.01 215.2 ± 2.2 103.9 ± 2.32 > 80% 
Mixture 2 27.65 ± 0.08 7.99 ± 0.02 216.3 ± 2.1  106.1 ± 1.90 > 80% 
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Table 4.4: Mean ± SD recorded physico-chemical water parameters of the different 
exposure groups for adult fish experiments 
Exposure 
Groups 
Temp 
 (℃) 
pH EC  
(µS/cm) 
TDS  
(mg/L) 
DO  
(%) 
Control 27.52 ± 0.57 7.70 ± 0.03 201.1 ± 6.1 96.00 ± 9.22 > 80% 
Solvent control 27.69 ± 0.47 7.63 ± 0.11 204.9 ± 3.2 97.86 ± 3.19 > 80% 
NVP L 27.12 ± 0.49 7.68 ± 0.08 203.5 ± 10.6 96.86 ± 1.74 > 80% 
NVP H 27.79 ± 0.58 7.60 ± 0.24 205.5 ± 9.6 103.71 ± 8.41 > 80% 
Mixture 1 27.96 ± 0.14 7.63 ± 0.16 208.7 ± 3.3 108.00 ± 0.72 > 80% 
 
 
4.1.3. Analysis of nevirapine  
Nevirapine was present in all the exposure water samples collected at different 
intervals (at the start of the exposure, after 96 hrs and after water and NVP renewal). 
The average recovery of NVP from water samples was 79% with an average 
recovery standard deviation (RSD) of 10%. The instrument limit of detection (LOD) 
was 86 µg/L and the chemical test limit of quantification (LOQ) was 288 µg/L. All the 
extracts concentrations were above the LOQ.  
The average concentrations of NVP L (1.48 µg/L) at the start of the experiment was 
1.78 µg/L, 1.46 µg/L after 96 hrs and 2.16 µg/L 30 minutes after renewal of the test 
media. For NVP H (3.74 µg/L) the average concentrations were 3.85 µg/L, 4.24 µg/L 
and 3.94 µg/L. These results were between 90% and 150% of the nominal 
concentrations of the test pharmaceutical. NVP was below the instrument detection 
limits in the control and solvent control water samples.  
 
 4.2. Health assessment of early life stages 
As specified in the methodology section, the exposure of early life stages was 
conducted in two experiments. The 1st experiment included three groups: control 1, 
solvent control and NVP L. The second experiment included four groups: control 2, 
NVP H, Mixture 1 (NVP L + SMX + TMP) and Mixture 2 (SMX + TMP).  The 1st 
experiment was repeated four times while the 2nd experiment could only be repeated 
twice because the breeding pairs stopped breeding and the time was running out. 
New breeding pairs were then acquired. However, the eggs used in the second 
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experiment were visibly bigger compared to those used in the first experiment and 
the number of eggs produced by the breeding pairs used in the 2nd experiment were 
low compared to the number of eggs produced in the 1st experiment. This explains 
why the data from the two experiments were analysed separately. The second 
experiment also included a control group. 
 
4.2.1. Hatching success  
Hatching started in the morning of the fourth day of the exposure, approximately 96 
hrs post-fertilisation (PF) in all the repeats of the control group. By late afternoon of 
the fifth day, all the embryos from the control group were hatched. The hatching of 
embryos in the solvent control group and those in the NVP and Mixtures groups 
started hatching at different times. For some repeats hatching started in the morning 
of the fourth day of the exposure (96 hrs PF) while for others, it started in the morning 
of the fifth day (± 120 hrs PF). Late afternoon of the fifth day, the embryos which 
started hatching on the fourth day were done hatching except for the first repeat of 
NVP L and the Mixture 1. The embryo which started hatching on the fifth day, on the 
following day afternoon, ± 140 hrs PF, they were all hatched. In general, the hatching 
took approximately 36 hrs from the start to the end in all the groups. A delay in 
hatching was observed in hatching of embryo from the first repeat of NVP H and 
mixture groups where the hatching started on the fourth day and was complete on 
the sixth day PF (± 48 hrs).  
A Kruskal-Wallis test showed no statistically significant difference in hatching time 
across all the groups from the 1st experiment (control 1, solvent control and NVP L; 
p = 0.488, n = 350). However, there was a significant difference in hatching time of 
embryos from the 2nd experiment (control 2, NVP H, Mixture 1 and Mixture 2; p = 
0.001, n = 256). Post-hoc Mann-Whitney test indicated that the time of start hatching 
was significantly different between the exposed groups and the control as follow: 
control 2 – NVP H at the p = 0.001; control 2 – Mixture 1 at the p = 0.007; control 2 
– Mixture 2 at the p = 0.007. For the time of end hatching, the significant difference 
was as follow: control 2- NVP H at the p < 0.001, control 2 – Mixture 1 at the p < 
0.001, control 2 – Mixture 2 at the p = 0.007, NVP H – Mixture 2 at the p = 0.007 
and Mixture 1 – Mixture 2 at the p = 0.007. The median time of start and end hatching 
in each group is reported in Table 4.5. 
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The mean hatching success rate in all the groups and experiments was high and 
varied from 81% to 90% (Figures 4.1 to 4.4). A one-way analysis of variance 
(ANOVA) between groups was conducted and revealed no significant differences at 
the p > 0.05 in hatching success for the different groups in both the experiments:  
F (2, 350) = 0.133, p = 0.877 for the first experiment, and F (3, 256) = 0.115, p = 
0.947 for the second experiment.  
 
Table 4.5: Median time of hatching and mean hatching success (%) ± SD of embryo 
in the different exposure groups 
Exposure 
Groups 
Start of Hatching 
(days PF) 
End of Hatching 
(days PF) 
Hatching success 
(%) 
Control 1 4 5 85.2% ± 11.06 
Solvent control 4 5 81.4% ± 10.60 
NVP L 4 5 84.5% ± 11.30 
Control 2 4 5 87.4% ± 3.64 
NVP H 5 6 88.2% ± 4.55 
Mixture 1 5 6 89.7% ± 0.37 
Mixture 2 5 6 88.2% ± 0.54 
 
 
 
 
Figure 4.1: Hatching success (%) of embryos in all the four repeats of each exposure group 
from the first experiment: control 1, solvent, NVP L (low concentration) 
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Figure 4.2: Comparison of hatching success (%) of embryos across the groups in the  
1st experiment: the control 1, solvent control and NVP L (low concentration).  
No statistically significant difference was found at the p > 0.05 
 
 
Figure 4.3: Hatching success (%) of embryos in the two repeats of each exposure group  
in the 2nd experiment: control 2, NVP H, Mixture 1 and Mixture 2 
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Figure 4.4: Comparison of hatching success (%) of embryos across the groups in the  
2nd experiment: control 2, NVP H (high concentration), Mixture 1, Mixture 2. No statistically 
significant difference was found at the p > 0.05 
 
4.2.2. Survival and behaviour  
The newly hatched larvae started swimming up on day 8 post-hatching (PH) in some 
of the repeats of the control, solvent control and NVP L groups while the first 
swimming up in the NVP H and mixtures groups was observed on day 9. Late 
afternoon on day 10 PH all the newly hatched larvae in all groups were swimming 
up. A Kruskal-Wallis test showed no statistically significant difference in swimming 
up time across the groups in the 1st experiment (p > 0.05, n = 350). On the other 
hand, in the 2nd experiment, there was a significant difference in swimming up time 
across the groups (p < 0.001, n = 256). Pairwise comparisons using Mann-Whitney 
test showed a significant difference between groups as follow: control 2 – NVP H at 
the p < 0.001, control 2 – Mixture 1 at the p < 0.001 and control 2 – Mixture 2 at the 
p < 0.001. The median time of start swimming up in all groups is reported in Table 
4.6. 
The control, solvent control and NVP groups fish were introduced to exogenic 
feeding on day 11 PH while those from the mixture groups the feeding started on 
day 12 PH. The exogenic feeding was introduced when the yolk sac was almost 
depleted. This corresponded to the end of the larval life and the start of the juvenile 
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life as explained in the methodology section. On day 14 PH all fish in all the groups 
and repeats had started exogenic feeding. It was noted that for those embryos which 
started swimming up on day 8 PH, on day 11 PH their yolk sac was almost depleted 
while those that swam up on day 9 and 10 the yolk sac was exhausted by day 12 to 
day 14 PH. No statistically significant difference was found in time of start exogenic 
feeding across the groups in the 1st experiment (Kruskal-Wallis test: p > 0.05, n = 
350). Yet, in the 2nd experiment, a significant difference was found between the 
Control 2 group and all the other groups at the p < 0.001, n = 256. The median time 
of start exogenic feeding in all groups is given in Table 4.6.  
The period from hatching to the start of feeding was characterised by a low mortality 
rate in all groups and repeats as shown by the high mean survival rate (Table 4.6). 
After the introduction of exogenic feeding, the juveniles in all groups started dying 
mostly in the 1st experiment compared to the 2nd experiment. Still, the mean survival 
rate on day 30 PH was above 78% in all groups (Table 4.6). From day 30 to day 60 
PH there was practically no change in the survival rate in all the groups and repeats 
(Table 4.6). Most of the fish that were alive on day 30 PH were still alive on day 60 
PH. The survival rate of the early life stages in all groups and repeats at the start of 
feeding, at day 30 and day 60 PH is illustrated by the Figures 4.5 and 4.6. 
 
Table 4.6: Median time of swim up, start of feeding and the mean survival rate (%) 
± SD of early life stages of fish in the different exposure groups at different 
stages 
Exposure 
Groups 
Swim up 
(days PH) 
Start Feeding 
(days PH) 
Survival rate (%) 
Start of 
Feeding 
30 days PH 60 days PH 
Control 1 9 11 98.5% ± 2.1 78.9% ± 2.1 78.9% ± 2.1 
Solvent 
control 
9 11 97.8% ± 2.8 82.1% ± 9.2 82.1% ± 9.2 
NVP L 9 11 97.2% ± 1.9 78.8% ± 8.7 78.8% ± 8.7 
Control 2 8 11 98.6% ± 2.1 98.6% ± 2.1 96.8% ± 0.6 
NVP H 9 12 97.1% ± 4.2 97.1% ± 4.2 95.5% ± 0.1 
Mixture 1 9 12 94.4% ± 7.8 92.9% ± 5.8 92.9% ± 5.8 
Mixture 2 10 13 97.2% ± 4.1 97.2% ± 4.1 97.2% ± 4.1 
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A statistical analysis (one-way ANOVA) was conducted and revealed no significant 
difference in the survival rate at the different stages (start of feeding, day 30 and 
day 60 PH) across all the groups in the 1st experiment at the p = 0.758, p = 0.849 
and p = 849 respectively.  No significant difference in the survival rate at the different 
stages (start of feeding, day 30 and day 60 PH) between all the groups was found 
as well in the 2nd experiment at p = 0.893, p = 0.911 and p = 0.877 respectively 
(Figure 4.5 and 4.6). The mean survival rate in each group at the different periods 
of life are given in Table 4.6. Very few cases of physical abnormality were observed 
in each experiment, but they were not statistically significant (p = 1.000) and no 
abnormal swimming and feeding behaviour were observed in all groups and 
experiments. 
 
 
 
 
Figure 4.5: The survival rate (%) of early life stages at the different stages in each exposure 
group in the 1st experiment: control 1, solvent, NVP L (low concentration). 
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Figure 4.6: The survival rate (%) of early life stages at the different stages in each exposure 
group in the 2nd experiment: control 2, NVP H (high concentration), Mixture 1 and Mixture 
2. 
 
4.2.3. Growth and development  
4.2.3.1. Length and weight measurements 
The total length and body weight measurements of larvae in all groups of the 1st 
experiment (control 1, solvent control and NVP L) were very similar for 1 day old 
larvae. For the 30 and 60 days old juveniles, variations were observed in body 
measurements in the same tank and in all groups. The mean total length and weight 
of 60 days old juveniles was 26.5 ± 8 mm and 0.410 ± 0.30 g for the control 1 group, 
26 ± 6.1 mm and 0.336 ± 0.24 g for the solvent control and 25.1 ± 7 mm and 0.319 
± 0.33 g for the NVP L group. The mean total length and body weight of 1, 30 and 
60 days old early life stages fish in all the groups of the 1st experiment are presented 
in Annexure 4 A. The largest and heaviest 60 days old juvenile was from the NVP L 
exposed fish with a total length of 49 mm and 1.976 g weight while the smallest fish 
was from the control 1 group with a total length of 13 mm and a body weight of  
0.032 g. A Kruskal-Wallis test showed no statistically significant difference in total 
length and body weight measurements across the three groups for all the stages at 
the p > 0.05.  For 1 old (n = 105) the body measurement were not statistically 
different at the p = 0.825 and p = 0.092 for total length and body weight respectively, 
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at the p = 0.822 and p = 0.630 for 30 days old (n = 105) and at the p = 0.470 and  
p = 0.180 for the 60 days old (n = 140). Figures 4.7 and 4.8 represent the mean total 
length and weight of the 1, 30 and 60 days old fish from all the groups in the 1st 
experiment. 
In the second experiment (control 2, NVP H, Mixture 1 and Mixture 2) a significant 
difference was found in body weight across the groups (Kruskal-Wallis: p = 0.001,  
n = 80) for 1 day old larvae. The groups with a significant difference between them 
were the control 2 and the NVP H at the p < 0.001. The total length and body weight 
of 30 days old juveniles were also significantly different across the groups at the  
p = 0.005, n = 80 and p = 0.001, n = 80 respectively. The difference was between 
the control 2 and the Mixture 1 groups at the p = 0.005 for total length and p = 0.001 
for the weight. However, no significant difference was found in length and weight 
measurements of 60 days old juveniles at the p = 0.477, n = 96 and p = 0.468, n = 
96 respectively. Mean length and weight of 1 day to 60 days old fish in all the groups 
are presented in Annexure 4 B. The heaviest 60 days old juvenile was from the 
Mixture 1 group with a total length of 43 mm and 1.332 g body weight while the 
smallest fish was from the NVP H group with a total length of 23 mm and a body 
weight of 0.200 g. In general, the fish from the 2nd experiment were larger and 
heavier compared to those from the 1st experiment. The mean length and weight 
measurements for the 60 days old in all the groups were 33.05 ± 5.7 mm and 0.678 
± 0.34 g for the control 2 group, 33.04 ± 5.9 mm and 0.670 ± 0.31 g for NVP H group, 
31.44 ± 5.2 mm and 0.574 ± 0.26 g for the Mixture 1 group and 31.60 ± 2.7 mm and 
0.546 ± 0.13 g for Mixture 2 group. Mean total length and weight of the 1, 30 and 60 
days old fish from all the groups in the 2nd experiment are shown in Figures 4.9 to 
4.13. A significant difference between pairs of groups is shown by (*).   
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Figure 4.7: Mean total length of early life stages from the different groups of the  
1st experiment at day 1, 30 and 60 post-hatching.  
 
 
 
 
 
Figure 4.8: Mean body weight of early life stages from the different groups of the  
1st experiment at day 1, 30 and 60 post-hatching. 
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Figure 4.9: Mean total length of early life stages from the different groups of the 2nd 
experiment at day 1, 30 and 60 post-hatching. A significant difference was found between 
the marked groups (*) at the p = 0.005.  
 
 
Figure 4.10: Comparison of total length of early life stages from the different groups of the 
2nd experiment at day 30 post-hatching. A significant difference was found between the 
marked groups (*) at the p = 0.005.  
 
 
* 
* 
* 
* 
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Figure 4.11: Mean body weight of early life stages from the different groups of the 2nd 
experiment at day 1, 30 and 60 post-hatching. Significant difference was found between the 
marked groups (*) at the p < 0.001. 
 
 
 
 
Figure 4.12: Comparison of body weight of early life stages from the different groups of the 
2nd experiment at day 1 post-hatching. Significant difference was found between the 
marked groups (*) at the p < 0.001.  
 
* 
* 
* * 
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Figure 4.13: Comparison of body weight of early life stages from the different groups of the 
2nd experiment at day 30 post-hatching. A significant difference was found between the 
marked groups (*) at the p = 0.001.  
 
As the fish were ageing in all groups and repeats from both experiments, they were 
also growing in length and gaining weight. To investigate the relationship between 
length and weight measurements in all the groups of each experiment, the 
nonparametric Spearman correlation coefficient rho was used. A strong positive 
correlation with high total length associated with high body weight was found 
between the two body measurements from day 1 to day 60 PH in all the groups from 
both experiments. In the 1st experiment, the Spearman rho for the control 1 group 
was 0.958, 0.955 for the solvent control group and 0.949 for the NVP L group at a 
statistically significant level p < 0.001 (Figure 4.14). In the 2nd experiment, the 
correlation coefficient rho was 0.970, 0.983, 0.974 and 0.965 respectively for the 
control 2 (n = 62), NVP H (n = 64), Mixture 1 (n = 65) and Mixture 2 (n = 65) groups 
at the p < 0.001 which is strongly significant (Figure 4.15).  
The relationships length - age and weight - age were also investigated and proved 
to be significantly strong and positive in all groups and both experiments with fish 
older in age associated with high total length and high body weight. For the 1st 
experiment the rho for length - age and weight - age was respectively 0.883 and 
0.691 for the control 1 group; 0.917 and 0.696 for the solvent control and 0.890 and 
0.574 for the NVP L group all at the p < 0.001. For the 2nd experiment, the rho for 
* 
* 
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length - age and weight - age relationships were 0.952 and 0.943, 0.936 and 0.938, 
0.933 and 0.929; and 0.946 and 0.941 respectively for the control 2, NVP H, Mixture 
1 and Mixture 2 groups at the p < 0.001. In general, the length - age relationship 
was stronger than the weight - age relationship. A standard multiple regression 
showed that in all groups both length and weight measurements may be used to 
predict the age of the fish as all groups in both experiments scored a high adjusted 
R2. However, the total length may be a better predictor of the fish age than the 
weight as the total length showed high standardised coefficients (Beta). In the 1st 
experiment, the adjusted R2 was 0.862 for the control 1 group (Beta = 1.54), 0.918 
for the solvent control group (Beta = 1.447) and 0.872 for the NVP L group (Beta = 
1.303). For the 2nd experiment, the adjusted R2 and Beta values were 0.964 and 
1.49 for the control 2 group, 0.948 and 1.447 for NVP H, 0.925 and 1.244 for Mixture 
1 group and 0.970 and 1.094 for the Mixture 2 group, all with a statistical significance 
at the p < 0.001. 
 
 
Figure 4.14: Scatterplot showing the strong positive correlation (linear shape with an 
upward position from left to right) between mean total length and weight measurements of 
fish in all the three groups in the 1st experiment from day 1 to day 60 post – hatching. 
 
rho = 0.958 rho = 0.955 rho = 0.949 
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Figure 4.15: Scatterplot showing the strong positive correlation (linear shape with an 
upward position from left to right) between means total length and weight measurements of 
fish in all the groups in the 2nd experiment from day 1 to day 60 post – hatching. 
 
4.2.3.2. Condition Factor (CF) and Specific Growth Rate (SGR) 
The calculated mean CF for the 60 days old juveniles was 1.8 ± 0.6, 1.7 ± 0.1 and 
1.7 ± 0.8 for the control 1, the solvent control and NVP L groups (Figure 4.16). For 
the control 2 group the 60 days old juveniles had a mean CF of 1.7 ± 0.08, 1.7 ± 
0.12 for the NVP H group, 1.7 ± 0.12 for the Mixture 1 Group and 1.7 ± 0.11 for the 
Mixture 2 group (Figure 4.17). A Kruskal-Wallis test revealed no significant 
difference in CF across the groups for both the 30 days and 60 days juveniles in 
both the experiments as well as for the 1 day old larvae in the 1st experiment at the 
p > 0.05.  However, a significant difference in CF across the groups for 1 day old 
larvae was found in the 2nd experiment. The difference was detected between the 
control 2 group and the NVP H group at the p = 0.018 (Figure 4.18). As discussed 
above, those larvae also showed a significant difference in body weight (p < 0.001). 
The 30 days old juveniles from the control 2 and the Mixture 1 groups, although they 
showed a significant difference in total length (p = 0.005) and body weight  
(p = 0.001), their CF showed no significant difference at the p = 0.218. Comparing 
the CF of all the 60 days old juveniles from both the experiments together, no 
significant difference was found across all the groups with the p = 0.423. The mean 
rho = 0.974 rho = 0.970 rho = 0.983 rho = 0.965 
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CF values for the fish in each of the groups and experiments at the different stages 
are presented in Annexure 4 A & B. 
The mean daily specific growth rate (SGR) of the fish was calculated in percentage 
using weight measurements from day 1 to day 30 and from day 30 to day 60 PH.  
It shows the mean percentage increase in body weight per day. In the first 
experiment, the mean SGR for the first month was 8.4 ± 1.6%, 8.4 ± 1.5% and 8.9 
± 2.3% for the control 1, solvent control and NVP L groups respectively. For the 
second month, it was 7.5 ± 0.7%, 7.2 ± 0.8% and 6.4 ± 0.7 % (Table 4.7). In the 
second experiment, the mean SGR from day 1 to day 30 was 8.2 ± 0.0 for the control 
2 group, 8.3 ± 0.2 the NVP H group, 9.1 ± 0.1 the Mixture 1 group and 8.7 ± 0.0 for 
the Mixture 2 group. From day 30 to day 60, the mean SGR was 7.0 ± 0.1, 6.4 ± 0.1, 
5.3 ± 0.2 and 5.5 ± 0.2 for the control 2, NVP H, Mixture 1 and Mixture 2 groups 
respectively. The SGR for NVP L, NVP H, Mixture 1 and Mixture 2 groups between 
the 30th and 60th day was lower compared to control and the solvent control groups. 
However, comparing all the groups from the two experiments, no significant 
difference in SGR was found (p = 0.423). 
 
 
 
Figure 4.16: Mean condition factor (CF) of early life stages from the different groups of the 
1st experiment at day 1, 30 and 60 post-hatching. 
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Figure 4.17: Mean condition factor (CF) of early life stages from the different groups of the 
2nd experiment at day 1, 30 and 60 post-hatching. 
 
Figure 4.18: Comparison of condition factor (CF) of early life stages from the different 
groups of the 2nd experiment at day 1 post hatching. A significant difference was found 
between the marked groups (*) at the p = 0.018.  
 
 
 
 
* 
* 
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Table 4.7: The mean daily specific growth rate (SGR - %) of fish from day 1 to day 
60 post-hatching (PH) in all the repeats and groups from both the 
experiments  
 
SGR (%) 
Exposure 
Groups 
From day 1 to day 30 PH 
1st Repeat 2nd Repeat 3rd Repeat 4th Repeat Mean SD 
Control 1 10.6 8.1 8.3 6.6 8.4 1.7 
Solvent Control 10.6 8.2 7.2 7.6 8.4 1.5 
NVP L 11.8 8.9 8.6 6.3 8.9 2.3 
Control 2 8.2 8.1 n.d n.d 8.2 0.0 
NVP H 8.2 8.5 n.d n.d 8.3 0.2 
Mixture 1 9.1 9.0 n.d n.d 9.1 0.1 
Mixture 2 8.6 8.7 n.d n.d 8.7 0.0 
 From day 30 to day 60 PH 
Control 1 6.5 7.9 8.1 7.5 7.5 0.7 
Solvent Control 7.5 6.0 7.6 7.5 7.2 0.8 
NVP L 6.9 6.4 5.4 6.9 6.4 0.7 
Control 2 6.9 7.1 n.d n.d 7.0 0.1 
NVP H 6.3 6.5 n.d n.d 6.4 0.1 
Mixture 1 5.1 5.5 n.d n.d 5.3 0.2 
Mixture 2 5.4 5.6 n.d n.d 5.5 0.2 
      n.d = not done 
 
 
4.2.4. Qualitative histological assessment 
As discussed in the methodology, section 3.7.4, the histological analysis of early life 
stages was done only on 30 day old juveniles and only the posterior kidney and the 
liver tissues were assessed to allow comparison with the adult fish. Histological 
analysis of the liver and kidney tissues was done for 64 juveniles (30 days old): 12 
from the control group (control 1 and control 2), 11 from the solvent control, 11 from 
the NVP L group, 10 from the NVP H, 10 from the mixture 1 and 10 from the mixture 
2 group. Each fish was given an ID No. from 1 to 64 and the ID No. was used in a 
blind histological analysis to avoid bias.  
 
4.2.4.1. Liver  
The liver of O. mossambicus is situated in the visceral cavity, extending from the 
anterior to the posterior region of the cavity between the other visceral organs as 
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seen in Figure 4.19 A & B. Observed under the light microscope, the liver tissue of 
the 30 days old juveniles consists mostly of hepatocytes arranged in plates 
separated by sinusoids draining into small central veins (Figure 4.19 C & D). A few 
small lipids droplets can be seen in the liver of 30 days juveniles in all groups (Figure 
4.19 E). The hepatocyte cytoplasm of 59.37% of the juveniles stained basophilic, 
7.81% eosinophilic, 15.62% had a mixture of basophilic and eosinophilic stained 
cytoplasm and 17.18% had a predominantly clear cytoplasm. Table 4.8 presents the 
percentage prevalence of cytoplasmic staining characteristics of all the fish in the 
different groups. 
Histological analysis of the liver tissue of 30 days old juveniles showed few changes 
compared to adult fish. The most prevalent change observed in the liver was 
vacuolation of hepatocytes, both lipid (Figures 4.19 E, 4.20 G & 4.20 K) and non-
lipid (Figure 4.20 H) vacuolation. They were observed in 53.12% and 54.68% of the 
fish respectively (Table 4.9). Both the control and the exposed fish presented 
hepatocyte vacuolation, however, non-lipid vacuolation was more prevalent in the 
fish exposed to NVP H and to the mixtures of pharmaceuticals (Table 4.9). Vascular 
blood congestion and single cell necrosis were observed in 25% and 20.31% of the 
fish respectively, all exposed to pharmaceuticals (Table 4.9, Figure 4.20 J & Figure 
4.20 I). Other histological changes presented by the 30 days old juveniles but were 
not predominant include few cases of nuclear alteration (9.37%) and one case of 
focal necrosis in a fish exposed to NVP H (Figure 4.20 I). One fish from those 
exposed to the mixture of antibiotics presented a tumour-like growth in the liver. 
However, the growth was considered as benign as there was no sign that it can 
grow and extend to the rest of the tissue. No inflammatory response was observed 
in the tissue surrounding the growth. A narrowing lumen can be seen at the centre 
of the growth (Figure 4.20 K & L). This may suggest that the growth probably 
developed around a bile duct. The observed liver histology of the control and solvent 
control fish is presented in Figure 4.19 while the histological changes observed in 
exposed fish are shown in Figure 4.20. 
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Table 4.8. Hepatocyte cytoplasmic staining characteristics of the juveniles in the 
different groups 
Cytoplasmic 
staining 
Control Solvent 
control 
NVP 
L 
NVP 
H 
Mixture 
1 
Mixture 
2 
Total % 
n 12 11 11 10 10 10 64  
Clear 1 0 1 4 0 5 11 17.18 
Basophilic 9 11 9 6 2 1 38 59.37 
Eosinophilic 2 0 1 0 2 0 5 7.81 
Mixed 
hepatocytes 
0 0 0 0 6 4 10 15.62 
 
 
4.2.4.2. Kidney 
The O. mossambicus kidney is situated in the dorsal region of the body cavity, it is 
thin, elongated and stretches on top of the spinal cord behind the swim bladder. It 
is situated ventrally of the spinal cord and extends from the anterior to the posterior 
part of the cavity (Figure 4.19 A & 4.21 A). The posterior part of the kidney is the 
one mostly studied in toxicology because of its function in toxicant metabolism and 
elimination. It is mostly made of tubules of different sizes and multiple glomerulus in 
charge of urine filtration (Figure 4.21 B - D).  
Histological analysis of the 30 days old juvenile kidney tissue also showed few 
histological changes as it was for the liver. The most prevalent histological changes 
were the vacuolation of the renal tubule in 37.5% of the juveniles (Figure 4.21 E &  
4.22 L), dilation of the Bowman space around the glomerular in 35.93% (Figure 4.22 
I & K) and single tubule necrosis in 45.31% (Figure 4.22 L). Vacuolation of renal 
tubule cells was observed in all the groups but was more frequent in the NVP H 
group (100%), dilation of the Bowman space was also observed in all the groups 
but was more frequent in the exposed fish, tubule necrosis was only observed in the 
exposed fish. The observed histological changes in the kidney are shown in Figures 
4.21 & 4.22 and the percentage prevalence of each histological change is given in 
Table 4.9. 
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Table 4.9: Percentage prevalence of histological changes observed in the liver and 
kidney of 30 days old O. mossambicus  
 
Control Solvent 
control 
NVP L NVP H Mixture 1 Mixture 2 Total 
Histological 
changes 
n % n % n % n % n % n % n % 
LIVER 12 11 11 10 10 10 64 
Vascular 
congestion 
0 0.00 0 0.00 0 0.00 2 20.00 8 80.00 6 60.00 
1
6 
25.00 
Single cell 
necrosis 
0 0.00 0 0.00 1 9.09 1 10.00 7 70.00 5 50.00 
1
4 
21.88 
Nuclear alteration 0 0.00 0 0.00 1 9.09 2 20.00 0 0.00 3 30.00 6 9.38 
Steatosis 
5 41.67 9 81.82 8 72.73 4 40.00 4 40.00 4 40.00 
3
4 
53.13 
Vacuolation  
non-steatosis 
5 41.67 5 45.45 2 18.18 9 90.00 8 80.00 6 60.00 
3
5 
54.69 
Tumour 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 10.00 1 1.56 
Focal necrosis 0 0.00 0 0.00 0 0.00 1 10.00 0 0.00 0 0.00 1 1.56 
KIDNEY 12 11 11 10 10 10 64 
Congestion  0 0.00 0 0.00 0 0.00 0 0.00 1 10.00 1 10.00 2 3.13 
Tubule cell 
vacuolation 
2 16.67 4 36.36 2 18.18 
1
0 
100.0 4 40.00 2 20.00 
2
4 
37.50 
Tubule cell 
nuclear alteration 
0 0.00 0 0.00 4 36.36 0 0.00 0 0.00 0 0.00 4 6.25 
Single tubule 
necrosis 
0 0.00 0 0.00 9 81.82 7 70.00 7 70.00 6 60.00 
2
9 
45.31 
Dilation of the 
Bowman Space 
1 8.33 3 27.27 0 0.00 6 60.00 8 80.00 5 50.00 
2
3 
35.94 
Glomerulus 
atrophy 
0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 10.00 1 1.56 
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Figure 4.19: C - F: Observed liver histology of the control and solvent control fish. The liver 
tissue (l) is situated in the visceral cavity. ac: visceral/abdominal cavity; cc: cavity containing 
the heart; i: intestines; gi: gills; l: liver; k: kidney; md: dorsal muscle; m: muscle; mv: ventral 
muscle; o: oesophagus; s: stomach; sw: swim bladder cavity. Hepatocytes nuclei are shown 
by the thin arrows; sinusoids separating lows of hepatocytes are shown by the thick arrows; 
central veins are visible (cv); a few lipid droplets remnants from the yolk sac are also visible 
(asterisk).  
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Figure 4.20: Micrographs showing the different histological changes observed in exposed 
fish from the different groups: G. NVP L fish liver showing the presence of lipid droplets 
(asterisks); H. NVP H fish showing non-steatosis vacuolation around the nucleus of 
hepatocytes (long arrow) and nuclear alteration (short arrow); I. Necrotic area in the liver of 
a fish exposed to NVP H. Note the fading nuclei of the cells around the necrotic tissue;  
J. Blood congestion in vein of fish from the Mixture 1 group and a single cell necrosis (short 
arrow); K. A tumour like growth on the liver of a Mixture 2 group fish (circled area), note the 
minor fatty change near the tumour (asterisk), cv: central vein; L. A magnification of the 
micrograph in K to show the structure of the growth. Note the absence of inflammatory 
response around the growth and the lumen. 
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Figure 4.21: A. Micrograph showing the location of the kidney (k) in the fish visceral cavity 
in a longitudinal section; i: intestines; k: kidney; md: dorsal muscle; s: stomach;  
B – D. Observed kidney histology of the control and solvent control fish dominated by renal 
tubules of different size (t), glomeruli (g) and the Bowman Space around the glomeruli 
(arrows); E. Micrograph of the kidney tissue of a NVP H exposed fish showing vacuolation 
of renal tubule cells (arrows); F. A fish from the NVP L group showing dilation of the Bowman 
Space (thick arrow) and vacuolation of tubule cells (thin arrows).  
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Figure 4.22: Histological changes in the exposed fish kidney tissue. G&H. Micrographs 
showing renal tubule cells vacuolation (thin arrow) and dilation of the Bowman Space (thick 
arrow) in a fish from the Mixture 1 group; I - K. Kidney tissue of fish from the Mixture 2 group 
presenting renal tubule vacuolation (thin arrow) and a pronounced vacuolation of the 
Bowman Space. In the micrograph K the glomerulus looks like it is shrinking; L. Necrotic 
renal tubules following multiple vacuolation of tubule cells in the kidney tissue of NVP H 
exposed fish (thin arrows). 
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4.2.5. Semi-quantitative histological assessment 
The observed histological changes in the liver and kidney tissues of the 30 days old 
juveniles were quantified using the semi-quantitative protocol by Bernet at al. (1999) 
as adapted by van Dyk et al. (2009). For each histological change an index was 
calculated. Histological changes were grouped in functional groups (reaction 
patterns) and the reaction pattern index was calculated as the sum of the indices of 
the histological changes in the reaction pattern. Then, an organ index which is the 
sum of reaction pattern indices in the tissue was calculated for each organ and for 
each fish. A high organ index corresponds to a high degree of damage to the tissue. 
The calculated mean and median liver and kidney indices for the different groups 
are presented in the Table 4.10 & 4.11.  
The highest mean liver index recorded was 14 and was from the Mixture 1 and 
Mixture 2 groups while the highest mean kidney index was 12 and was recorded at 
least in one fish in all the exposed groups (NVP L, NVP H, Mixture 1 and Mixture 2). 
In all the groups the lowest organ index recorded for the liver and the kidney was 0. 
This means that in all the groups there were fish which did not present any 
histological change in their liver or kidney. For both the organs, liver and kidney, 
regressive changes associated with the functioning of the organ were more 
prominent compared to other reaction patterns (Figures 4.24 & 4.26).   
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Table 4.10: Mean and median indices for the reaction patterns and the liver of 30 
days old juveniles in the different groups  
Exposure Groups 
Liver 
index 
CD 
index 
RC 
index 
PC 
index 
I index T index FCA 
index 
Control 
n 12 12 12 12 12 12 12 
Mean 2.0 0.0 2.0 0.0 0.0 0.0 0.0 
Median 2.0 0.0 2.0 0.0 0.0 0.0 0.0 
SD 1.2 0.0 1.2 0.0 0.0 0.0 0.0 
Solvent 
control 
n 11 11 11 11 11 11 11 
Mean 2.9 0.0 2.9 0.0 0.0 0.0 0.0 
Median 2.0 0.0 2.0 0.0 0.0 0.0 0.0 
SD 2.1 0.0 2.1 0.0 0.0 0.0 0.0 
NVP L 
n 11 11 11 11 11 11 11 
Mean 2.7 0.0 2.7 0.0 0.0 0.0 0.0 
Median 2.0 0.0 2.0 0.0 0.0 0.0 0.0 
SD 2.7 0.0 2.7 0.0 0.0 0.0 0.0 
NVP H 
n 10 10 10 10 10 10 10 
Mean 5.4 0.4 5.0 0.0 0.0 0.0 0.0 
Median 5.0 0.0 5.0 0.0 0.0 0.0 0.0 
SD 3.5 0.8 3.0 0.0 0.0 0.0 0.0 
Mixture 1 
n 10 10 10 10 10 10 10 
Mean 7.6 1.6 6.0 0.0 0.0 0.0 0.0 
Median 8.0 2.0 6.0 0.0 0.0 0.0 0.0 
SD 4.1 0.8 3.5 0.0 0.0 0.0 0.0 
Mixture 2 
n 10 10 10 10 10 10 10 
Mean 7.8 1.2 6.2 0.0 0.0 0.4 0.0 
Median 10.0 2.0 8.0 0.0 0.0 0.0 0.0 
SD 5.8 1.0 4.8 0.0 0.0 1.3 0.0 
CD: Circulatory disturbances; RC: Regressive changes; PC: Progressive changes; I: Inflammatory;  
T: Tumour; FCA: Focal area of cellular alteration. SD: Standard Deviation. 
 
 
 
 
 
 
 
 
 
 Uwineza Marie Clémentine Nibamureke    2019 83 
 
 CHAPTER 4. RESULTS 
Table 4.11: Mean and median indices for the reaction patterns and the kidney of 30 
days old juveniles in the different groups 
Exposure Groups 
Kidney 
index 
CD 
index 
RC 
index 
PC 
index 
I index T index 
Control 
n 12 12 12 12 12 12 
Mean 0.5 0.0 0.5 0.0 0.0 0.0 
Median 0.0 0.0 0.0 0.0 0.0 0.0 
SD 1.2 0.0 1.2 0.0 0.0 0.0 
Solvent control 
n 11 11 11 11 11 11 
Mean 1.3 0.0 1.3 0.0 0.0 0.0 
Median 2.0 0.0 2.0 0.0 0.0 0.0 
SD 1.0 0.0 1.0 0.0 0.0 0.0 
NVP L 
n 11 11 11 11 11 11 
Mean 6.7 0.0 6.7 0.0 0.0 0.0 
Median 6.0 0.0 6.0 0.0 0.0 0.0 
SD 3.3 0.0 3.3 0.0 0.0 0.0 
NVP H 
n 10 10 10 10 10 10 
Mean 7.6 0.0 7.6 0.0 0.0 0.0 
Median 10.0 0.0 10.0 0.0 0.0 0.0 
SD 4.0 0.0 4.0 0.0 0.0 0.0 
Mixture 1 
n 10 10 10 10 10 10 
Mean 7.0 0.2 6.8 0.0 0.0 0.0 
Median 8.0 0.0 8.0 0.0 0.0 0.0 
SD 4.2 0.6 4.2 0.0 0.0 0.0 
Mixture 2 
n 10 10 10 10 10 10 
Mean 5.6 0.2 5.4 0.0 0.0 0.0 
Median 8.0 0.0 8.0 0.0 0.0 0.0 
SD 4.6 0.6 4.4 0.0 0.0 0.0 
CD: Circulatory disturbances; RC: Regressive changes; PC: Progressive changes; I: Inflammatory;  
T: Tumour. SD: Standard Deviation. 
 
 
Organ indices for the liver and kidney of the juvenile fish in the different exposure 
groups were statistically compared using the non-parametric Kruskal-Wallis test to 
detect differences across treatment groups. A statistically significant difference was 
detected in the liver indices (Chi-square = 16.603, p = 0.005, df = 5, n = 64) and 
kidney indices (Chi-square = 28.330, p < 0.001, df = 5, n = 64) across the different 
groups. Post-hoc pairwise comparisons using Mann-Whitney test indicated 
significant differences in liver indices between pairs of groups as follow: control – 
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NVP H at the p = 0.011, control – Mixture 1 at p = 0.001, solvent control – Mixture 
1 at p = 0.009, NVP L – NVP H at p = 0.046 and NVP L – Mixture 1 at the p = 0.005. 
It is important to indicate that no significant difference in mean liver indices was 
found between the two groups of Mixtures at the p = 0.789. Figure 4.23 shows the 
comparison of liver indices of the 30 days old in the different groups.  
 
 
Figure 4.23: Comparison of liver indices of the 30 days old in the different groups. The 
different markers indicate groups pairs which are significantly different at the p < 0.05. 
 
 
Figure 4.24: Mean reaction pattern indices in the liver of 30 days old from the different 
groups. 
 
* 
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For the kidney indices, post-hoc Mann-Whitney test detected significant differences 
as follow: control – NVP L at the p < 0.001, control – NVP H at the p < 0.001, control 
– Mixture 1 at p = 0.001, control – Mixture 2 at p = 0.005, solvent control – Mixture 
1 at the p = 0.007, solvent control – NVP H at p = 0.001 and solvent control - NVP 
L at the p = 0.001.  
Although a significant difference was detected in mean liver indices between the 
NVP L and the NVP H groups (p = 0.046) and between the NVP L and the Mixture 
1 groups (p = 0.005), no significant difference in mean kidney indices was found 
between those two pairs of groups at the p = 0.426 and p = 0.591 respectively. It 
was also noticed that the two groups of Mixtures did not show a significant difference 
in both the liver and kidney indices at the p = 0.789 and p = 0.434 respectively. 
Figure 4.25 shows the comparison of kidney indices of the 30 days old juveniles in 
the different groups while the different mean and median values of the liver and 
kidney indices in the different groups are presented in Tables 4.10 & 4.11.  
 
 
Figure 4.25: Comparison of kidney indices of the 30 days old in the different groups. The 
different markers indicate groups pairs which are significantly different at the  
p < 0.05. 
* 
* 
 + 
+ 
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x 
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Figure 4.26: Mean reaction pattern indices in the kidney of 30 days old from the different 
groups. 
 
Comparing mean liver and kidney indices in all groups (Figure 4.27), it is obvious 
that mean liver indices were higher than kidney indices in the control, the solvent 
control and both the Mixture groups. The highest recorded mean liver index was 7.8 
and was from the Mixture 2 group (Table 4.10). On the other side, the NVP L and 
NVP H groups recorded mean kidney indices higher than mean liver indices. The 
highest mean kidney index was 7.6 and was recorded from NVP H group (Table 
4.11). For both organs, the mean indices of the NVP H and the Mixture groups were 
higher than mean indices in both the control groups (Figure 2.27).  As a high organ 
index corresponds to a high degree of damage to the organ, this suggests that more 
histological changes were present in the liver and kidney tissues of the juveniles 
exposed to pharmaceuticals compared to the control fish.  
It is important to also note that no progressive changes (PC), inflammatory 
responses (I), focal area of cellular alteration (FCA) were found in both the organs, 
liver and kidney, of the fish in all groups. Only circulatory disturbances (CD) and 
regressive changes (RC) were found. In addition, only one case of tumour like 
change was found in a Mixture 2 exposed fish (Tables 4.10 & 4.11). 
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Figure 4.27: Comparison of mean liver and kidney indices of fish from the different groups. 
In general, the organ indices of fish exposed to pharmaceuticals and their mixtures showed 
higher organ indices compared to the control and the solvent control groups. 
 
4.3. Adult fish health assessment 
In total there were 52 sexually mature adult fish at the start of the experiment.  As 
one fish from the solvent control group jumped out of the tank and died only 51 
sexually mature fish were assessed. It was the only fish that was lost and after that 
incident all the tanks were covered with glass leads to avoid another incident. The 
exposure of adult fish was done in two repeats and only four exposure groups were 
included in the experiment. These included the control (n = 12), solvent control (n = 
8), NVP L (n = 12), NVP H (n = 12) and Mixture 1 (n = 12) groups. The statistical 
analysis of the biometric data was mostly done with all the fish grouped together 
without separating the sex. The reason is that the 50:50 sex ratio of the fish was 
disturbed after fish dissection and it was found that some of the fish which were 
identified as male or female before the start of the experiment turned out to be the 
other way. However, for some parameters such as the gonadosomatic index (GSI), 
the hepatosomatic index (HSI) and the liver index statistical analysis was also done 
inside each sex group as previous studies showed sex differences mostly with those 
three parameters (Schoenfuss et al. 2016). All the adult fish biometric data are 
presented in the Annexure 5.  
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4.3.1. Necropsy  
At the start and end of the exposure each fish was checked for any physical 
abnormality of eyes, fins, mouth, skin, gills and opercula as well as for any presence 
of ectoparasite. The external necropsy of the fish before the exposure showed no 
abnormality. However, at the end of the exposure few abnormalities were noted in 
the external examination. Those included two fish from the NVP H group presenting 
a red skin rash on the mouth (Figure 4.28 C) and one of these fish had a swollen 
abdomen. The internal necropsy of this fish revealed swollen ovaries filled with a 
greenish liquid (Figure 4.28 G). The swollen ovaries filled the whole abdominal 
cavity leaving a small space for the rest of the visceral organs, the liver was therefore 
very small. Another fish again from the NVP H group had an enlarged spleen 
compared to other fish. A fish from the Mixture 1 group had one of its ovaries 
shrunken and was attached to the liver (Figure 4.28 D). The same fish had also 
frayed gills on both sides (Figure 4.28 E). A few numbers of fish presented 
discoloration of the liver (Figure 4.28 A & B) and bile stones in the gallbladder 
(Figure 4.28 F), they were from both the exposed fish and the control fish. All other 
fish and organs had no macroscopic abnormalities and presented a < 50% 
mesenteric fat. A full report of the external and internal necropsy is given in 
Annexure 5.  
At the end of the experiment, after the external necropsy each fish was weighed (the 
whole body including viscera) and both the total and standard length were 
measured. A Kruskal-Wallis test revealed no significance difference in body weight, 
total length and standard length across the four groups (control, n = 8, solvent 
control, n =7, NVP L, n = 12, NVP H, n = 12 and Mixture 1, n = 12) with Chi-square 
= 4.569, p = 0.334, df = 4 for the weight; Chi-square = 2.666, p = 0.581, df = 4 for 
the total length and Chi-square = 4.147, p = 0.386, df = 4 for the standard length. 
The Figure 4.29 and 4.30 shows the comparison of the total length and body weight 
of the fish from the different groups. The mean and median values of the body 
measurements for both female and male fish in the different groups are given in the 
Annexure 5 A & B.  
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Figure 4.28: Macroscopic abnormalities observed during internal and external necropsy:  
A. Focal (arrow) discoloration of the liver of a fish from the NVP H group;  
B. Whole liver discoloration of a solvent control fish; C. Red skin rash on the mouth (arrow) 
of a fish exposed to NVP H; D & E. Shrunken ovary and frayed gills from a Mixture 1 fish; 
E. Bile stones in the gallbladder of fish exposed to NVP ; G. Swollen ovaries from a fish 
exposed to NVP H.  
  
 
 
Figure 4.29: Comparison of total length of all the fish from the different groups. No 
significant difference was found across the groups (p > 0.05). Outliers values are marked 
(dot). 
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Figure 4.30: Comparison of body weight of fish from the different groups. No statistically 
significant difference was found across the groups. Outliers values are marked. 
 
4.3.2. Condition factor (CF) and somatic indices  
4.3.2.1. Condition factor 
The means and medians of the CF in the different groups are given in Annexure  
5 A & B for both female and male fish. Figure 4.31 shows the comparison of the CF 
of the fish in the different groups. The highest and lowest CF recorded for female 
fish were respectively 1.76 (in NVP H group) and 1.22 (in Mixture 1 and NVP H 
groups), for male fish they were 1.64 and 1.23 respectively and were from the 
solvent control group. The mean CF for all female fish (n = 27) was 1.42 ± 0.18 while 
for male fish (n = 24) it was 1.37 ± 0.08 (Annexure 5 A & B). Kruskal-Wallis test 
revealed no statistically significant difference in CF across the five groups,  
Chi-square = 2.366, p = 0.669, df = 4, n = 51. 
  
4.3.2.2. Hepatosomatic index (HSI) 
The mean HSI for female fish (n = 27) was 1.08 ± 0.30 while for male fish (n = 24) 
it was 1.06 ± 0.39. The highest recorded HSI for male fish was 2.03 (in NVP L group) 
and the lowest was 0.38 from a control fish. The highest HSI for female fish was 
1.81 (in Mixture 1 group) and the lowest was 0.53 also from the Mixture 1 group. 
Kruskal-Wallis test revealed a significant difference in HSI across the groups (all fish 
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together) with Chi-square = 21.586, p < 0.001, df = 4, n = 51. Figure 4.31 shows the 
comparison of HSI of the fish in different groups.   
 
 
 
Figure 4.31: Comparison of the CF of the fish in the different groups. No significant 
difference was found across all the five groups (p = 0.669, n = 51). The dots markers show 
outliers. 
 
 
Figure 4.32: HSI of female fish in all the different groups. The markers show a significant 
difference between pair of groups (p < 0.05). 
 
* * 
+ 
+ 
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Figure 4.33: HSI of male fish in all the different groups. The markers show a significant 
difference between pair of groups (p < 0.05). 
 
Post – hoc pairwise comparisons with Mann-Whitney test revealed a significant 
difference in HSI across both female and male fish. For female fish, the significant 
difference was revealed as follow: control – NVP L at the p = 0.014, control – NVP 
H at p = 0.035, Mixture 1 – NVP L at the p = 0.013 and Mixture 1 – NVP H at  
p = 0.039. No significant difference was found between the solvent control group 
and both the NVP L (p = 0.215) and the NVP H (p = 0.438). For male fish the 
significant difference was located as follow: Control – NVP L at the p = 0.019, control 
– NVP H at p = 0.008, solvent control – NVP L at p = 0.030 and solvent control – 
NVP H at the p = 0.014. The Annexure 5 C shows the different mean ranks for each 
group for the HIS. Both NVP L and NVP H groups recorded a high mean rank 
compared to the other groups. 
 
4.3.2.3. Splenosomatic index (SSI) 
The mean SSI for female and male fish was 0.14 ± 0.07 and 0.136 ± 0.062 
respectively. The highest SSI recorded for female and male fish were 0.29 (Mixture 
1) and 0.28 (NVP H) respectively while the low values were 0.06 (Mixture 1) and 
0.05 (solvent control) correspondingly. Statistical analysis using Kruskal-Wallis test 
showed a significant difference in SSI across all the groups with Chi-square = 
10.360, p = 0.035, df = 4, n = 51 (Figure 4.34). Post-hoc Mann-Whitney test 
indicated that the median SSI from the NVP H group was significantly different from 
* 
+ 
+ * 
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the other groups as follow: control – NVP H at the p = 0.036, solvent control – NVP 
H at p = 0.008 and NVP L – NVP H at the p = 0.007. No significant difference was 
found between the Mixture 1 group and the NVP H group at the p = 0.060.  
 
 
 
Figure 4.34: Comparison of splenosomatic index (SSI) of the fish in the different groups.  
A significant difference was found across all the five groups. The markers show the pairs of 
groups with significant differences (p < 0.05). 
 
4.3.2.3. Gonadosomatic index (GSI) 
Female fish recorded a mean GSI of 3.44 ± 1.002 while the mean GSI for male fish 
was 0.43 ± 0.13. The female fish with the highest GSI (5.25) and the one with the 
lowest GSI (0.61) were both from the Mixture 1 group. The highest GSI in male fish 
was 0.67 presented by a fish from the Mixture 1 group while the lowest male GSI 
was 0.18 from a control fish. Kruskal-Wallis test revealed no significant difference in 
GSI across the groups for both female (Chi-square = 2.804, p = 0.591, df = 4,  
n = 27) and male (Chi-square = 7.006, p = 0.136, df = 4, n = 24). Figure 4.35 
compare the mean GSI of fish from each one of the groups. All the mean biometric 
data including the GSI for each group are given in Annexure 5 A & B. 
 
* 
* 
+ 
+ 
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Figure 4.35: Mean gonadosomatic index (GSI) (%) of fish from the different groups. No 
statistically significant difference was found between the groups (p > 0.05). 
 
4.3.3. Blood parameters  
The recorded mean values for the assessed blood parameters, namely the Hct, Lct 
and Hb for female fish were 27.38 ± 5.77, 2.32 ± 0.56 and 7.08 ± 0.66 respectively. 
For male fish they were 28.05 ± 4.3, 2.68 ± 0.89 and 7.17 ± 1.005 in the same order. 
No significant difference was detected in Hct and Hb across the groups after 
analysis with Kruskal-Wallis test, with Chi-square = 5.206, p = 0.267, df = 4, n = 51 
for the Hct and Chi-square = 6.161, p = 0.187, df = 4, n = 51 for the Hb. On the other 
hand, a significant difference was found in Lct values across the 5 groups, Chi-
square = 11.772, p = 0.019, df = 4, n = 51. The Figures 4.36 to 4.38 give a 
comparison of the assessed blood parameters in all groups. Post-hoc pairwise 
comparison detected a significant difference in Lct values between the Mixture 1 
group (n = 12) and the control group (n = 8) at the p = 0.032 and between the Mixture 
1 group (n = 12) and the NVP L (n = 12) at the p = 0.001. The difference was defined 
by the Mixture 1 group which recorded a low mean rank compared to other groups 
(Annexure 5 A & B).  
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Figure 4.36: Mean haemoglobin (Hb) (mg/dl) values of both the female and male fish from 
each group. No significant differences were found between the groups (p > 0.05). 
 
 
 
Figure 4.37: Presentation of mean haematocrit (Hct) (%) and leukocrit (Lct) (%) of female 
and male fish from the different groups.  
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Figure 4.38: Comparison of leukocrit (Lct) values of fish from the different groups. A 
significant difference was found between the marked groups at the p < 0.05. The Mixture 1 
group recorded a low mean rank compared to other groups. 
 
4.3.4. Qualitative histological assessment 
The qualitative histological assessment of adult fish histology revealed a number of 
histological changes in the assessed organs (liver, kidney, ovary and testis). The 
different histological changes detected in each organ are described and their 
percentage prevalence is given. The micrographs showing the details of each 
histological change in each organ are presented in Figures 4.39 – 4.46 at the end 
of this section.  
 
4.3.4.1. Liver  
The liver tissue of adult O. mossambicus is predominantly made of liver cells or 
hepatocytes that appear to be oval or hexagonal and of the same size with a central 
nuclei. The hepatocytes are organised in one cell thick plates separated by a 
network of small blood vessels, sinusoids, that run throughout the organ and drain 
in the nearest central vein (Figures 4.39 A to D). Blood veins are dispersed in the 
liver tissue and can be recognised as the big blood vessels mostly oval shaped 
(Figure 4.39 A). Central veins in which drain the sinusoids are differentiated from 
portal veins by the presence of the haematopoietic tissue, dark stained granulated 
cells, that surrounds the latter (Figure 4.39 A & D). Bile ducts are present throughout 
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the liver tissue, they are clearly visible near the portal vein (Figure 4.39 D). The 
lumen of the bile duct is surrounded by a single line of columnar epithelial cells. 
Hepatic arteries can also be seen in the liver tissue, they are mostly circular shaped 
and smaller compared to veins. In Figure 4.39 D a small artery can be seen in the 
portal area near the portal vein.  
The nuclei of hepatocytes stained dark purple while the cytoplasm stained differently 
in different fish as well as in the same organ. Some livers stained dark or clear purple 
(basophilic), while others stained dark or clear pink and for some the cytoplasm 
stayed clear (non-stained). In addition, some hepatocyte appeared to be granulated, 
others had a dense cytoplasm and some were a mixture of all the above 
characteristics. Table 4.12 presents the different characteristics of the cytoplasm of 
the fish included in this study and their percentage prevalence in each group.  
The main histological changes observed in the liver tissue of adult fish included 
intracellular deposits in 80.5% of the fish, nuclear alteration (mostly karyolysis) in 
70.59% of the fish, lipid vacuolation in 70.59% fish, non-lipid vacuolation in 88.24% 
of fish, an increase in melano-macrophage centres (MMCs) in 96.08% fish and 
fibrosis around veins and bile ducts in 62.75% of the fish. The percentage 
prevalence of each alteration per group and per the whole sample group is given in 
the Table 4.12. 
Intracellular deposits in the liver tissues can be clearly seen as brown deposits of 
different forms in the cytoplasm of the hepatocytes near the dark nucleus (Figure  
4.41 N and 4.41 O). Intracellular deposits appeared both in the control and the 
exposed fish. They were abundant in the fish exposed to the solvent and the NVP 
exposed fish. Karyolysis, observed as dissolution of the chromatin in the nucleus 
was observed in necrotic cells. The nucleus appeared faded and brown (Figure 4.41 
M) and it was observed in the exposed fish only. Vacuolation of the hepatocyte 
cytoplasm, both lipid and non-lipid, were observed in most of the fish. However, they 
were intensified in the exposed fish. The main difference between the two types of 
vacuolation is that the vacuolation caused by lipid deposits will result in the 
compression and displacement of the nuclei to the periphery of the cell living the 
rest of the cytoplasm looking like a clear empty balloon (Figure 4.40 I). Non-lipid 
vacuolation can be recognised by non-uniform clear vacuoles in the cytoplasm 
around the central nucleus (Figure 4.40 G). Most of the fish, exposed and control, 
presented with MMCs, which appeared as large areas of darkly stained brown areas 
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around the portal area in the hepatopancreatic tissue (Figure 4.40 K) of the exposed 
fish liver. Fibrosis was observed in the exposed fish only and was observed as thick 
pinkish layers of fibrous tissues surrounding some veins and bile ducts (Figure 4.41 
P to R). Other changes that were observed include congestion of blood in vessels, 
single cell necrosis, infiltration, hepatocyte hypertrophy and focal areas of clear cells 
or fatty change. However, they were present in only a few fish. It is important to 
emphasize that each one of these changes may appear focal or with other changes 
in the same fish.  
 
4.3.4.2. Kidney  
The posterior kidney tissue of adult O. mossambicus observed on light microscope 
appeared dark red or dark purple. The tissue consists in a network of numerous 
renal tubules of different size and types, renal corpuscles (glomerulus) and blood 
vessels (Figure 4.42 A & B). No hematopoietic tissue was observed in the posterior 
kidney tissue. The renal tubule consists in a single layer of columnar or cuboidal 
epithelial cells organised in a circle around the lumen with different size (Figure 4.42 
A). The renal tubule cells nuclei are dark and can be seen in the basal or apical 
region of the cells. The glomerulus is distinctive in the kidney tissue, as a small 
group of blood capillaries surrounded by a small space, the Bowman space (Figure 
4.42 A).  
The main histological changes observed in the posterior kidney tissue included 
circulatory disturbances such as dilation of the glomerulus capillaries in 60.78% of 
the fish, regressive changes in renal tubules (vacuolation in 84.31% fish, hyaline 
degeneration in 31.37%, nuclear alteration - mostly pyknosis in 58.82% and 
necrosis in 58.82%) and regressive changes in the glomerulus (dilation of the 
Bowman space in 84.31% fish and glomerulus atrophy in 33.33%). Other changes 
observed included MMCs increase in the interstitial tissues in 90.20% fish and 
lymphocytes infiltration in 21.57% fish. The percentage prevalence of all the 
changes observed in the kidney tissue are presented in the Table 4.13.  
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Table 4.12: Percentage prevalence of the liver cytoplasmic characteristics and 
histological changes presented by the fish in the different groups  
 
Control Solvent NVP L NVP H Mixture 1 Total 
N 8 7 12 12 12 51 
 
n % n % n % n % n % n % 
Cytoplasmic characteristics 
Clear  1 12.50 3 42.86 3 25.00 6 50.00 1 8.33 14 27.45 
Granular - 
Basophilic 
0 0.00 1 14.29 1 8.33 2 16.67 2 16.67 6 11.76 
Granular - 
Eosinophilic 
3 37.50 0 0.00 2 16.67 1 8.33 3 25.00 9 17.65 
Dense - 
Basophilic 
0 0.00 0 0.00 0 0.00 2 16.67 1 8.33 3 5.88 
Dense - 
Eosinophilic 
3 37.50 2 28.57 0 0.00 1 8.33 3 25.00 9 17.65 
Clumped  0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 
Mixed  1 12.50 1 14.29 6 50.00 0 0.00 2 16.67 10 19.61 
Histological changes 
Vascular 
congestion 
0 0.00 0 0.00 3 25.00 1 8.33 0 0.00 4 7.84 
Intracellular 
deposits 
5 62.50 3 42.86 11 91.67 10 83.33 12 100.00 41 80.39 
Single cell 
necrosis 
4 50.00 5 71.43 0 0.00 0 0.00 0 0.00 9 17.65 
Nuclear 
alteration 
(karyolysis) 
0 0.00 0 0.00 12 100.00 12 100.00 12 100.00 36 70.59 
Vacuolation 
(lipid) 
5 62.50 4 57.14 9 75.00 9 75.00 9 75.00 36 70.59 
Vacuolation 
(non-lipid) 
6 75.00 6 85.71 12 100.00 11 91.67 10 83.33 45 88.24 
Increase in 
MMCs   
8 100.00 5 71.43 12 100.00 12 100.00 12 100.00 49 96.08 
Hypertrophy  0 0.00 0 0.00 2 16.67 0 0.00 1 8.33 3 5.88 
Fibrosis 0 0.00 0 0.00 10 83.33 11 91.67 11 91.67 32 62.75 
Infiltration 0 0.00 0 0.00 5 41.67 10 83.33 5 41.67 20 39.22 
Clear cell foci  0 0.00 0 0.00 4 33.33 2 16.67 6 50.00 12 23.53 
Steatosis foci   0 0.00 0 0.00 0 0.00 2 16.67 1 8.33 3 5.88 
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Most of those histological changes, except renal tubule necrosis and glomerulus 
atrophy) were observed in the exposed fish as well as in the control fish. However, 
some of the changes were increased and intensified in the exposed fish compared 
to the control fish. Contrary to what has been observed with the liver tissue, MMCs 
in the kidney were not massive in the exposed fish (Figure 4.42 A). They were 
present almost at the same frequency and intensity as in the control group. Necrosis 
of the renal tubules was only observed in the exposed fish and was most prevalent 
in the fish exposed to the mixture of pharmaceuticals (100%). The necrotic tubule 
can be seen with the cytoplasm content of the cells disappearing progressively from 
the periphery towards the centre of the cell (Figure 4.43 J - L). The atrophic 
glomerulus can be seen in Figure 4.42 D where in addition of the dilation of the 
Bowman space around the glomerulus, the glomerulus itself is shrinking. This 
phenomenon was also more frequent in the Mixture 1 group (66.67%). 
 
Table 4.13: Percentage prevalence of the observed histological changes in the 
kidney in the different groups 
  Control Solvent NVP L NVP H Mixture 1 Total 
8 7 12 12 12 51 
Histological 
changes 
n % n % n % n % n % N % 
Dilation of 
glomerulus 
capillaries 
4 50.00 6 85.71 6 50.00 7 58.33 8 66.67 31 60.78 
Tubules  
Vacuolation 4 50.00 6 85.71 10 83.33 11 91.67 12 100.00 43 84.31 
Hyaline droplet 
degeneration 
2 25.00 0 0.00 4 33.33 5 41.67 5 41.67 16 31.37 
Nuclear alterations 1 12.50 2 28.57 8 66.67 10 83.33 9 75.00 30 58.82 
Necrosis 0 0.00 0 0.00 8 66.67 10 83.33 12 100.00 30 58.82 
Glomerulus  
Dilation of Bowman 
Space 
7 87.50 6 85.71 9 75.00 9 75.00 12 100.00 43 84.31 
Glomerulus atrophy 0 0.00 0 0.00 5 41.67 4 33.33 8 66.67 17 33.33 
MMCs 8 100.00 7 100.00 10 83.33 10 83.33 11 91.67 46 90.20 
Infiltration 2 25.00 1 14.29 2 16.67 4 33.33 2 16.67 11 21.57 
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4.3.4.3. Gonads  
a. Ovary 
Ovaries of O. mossambicus observed under a light microscope appeared dark red 
or purple. They consist in multiple ovarian follicles in different stages of development 
surrounded by a thin connective tissue, the tunica albuginea (Figure 4.45 A). The 
ovarian follicles in different stages of development vary in size following the 
developmental stage. The younger follicles, oogonia, are usually grouped in oogonia 
nests, spaces between the more developed follicles (Figure 4.45). The more 
developed follicles, oocytes, become bigger in size as they are developing. They 
were the most observed in the fish from the present study. Using Wallace & Selman 
(1981) classification of ovarian developmental stages in teleosts as described by 
van Dyk (2009), the different stages of development of oocytes that were observed 
in this study included: 
- Stage I oocyte (O I): Oval shaped, with a dark red or purple cytoplasm and a 
large nucleus and nucleolus (Figure 4.45 B). They appear in groups between 
mature follicles. 
- Stage II oocyte (O II) or peri-nucleolar stage: A little bit larger and less darkly 
stained with multiple nucleoli at the periphery of the nucleus (Figure 4.45 B). 
- Stage III oocyte (O III) or cortical alveoli stage: Oocytes are visibly bigger 
compared to stage II; they appear light purple. Numerous lipid vesicles can 
be seen close to the periphery of the egg. (Figure 4.45 A). 
- Stage IV oocyte (O IV) or vitellogenic stage: Oocytes are bigger than stage 
III oocytes; their nucleus is in the centre and small yolk globules are present 
in the periphery of the cytoplasm. The wall of the follicle is thicker (Figure 
4.45 A). 
- Stage V oocyte (O V) or maturation stage: Slightly bigger than stage IV, many 
large yolk globules are distributed throughout the cytoplasm and the germinal 
vesicle breaks down and is inexistent in fully mature oocytes (Figure 4.45 B).  
- Atretic oocyte (AO): The follicle wall is folding and the follicle is shrinking 
(Figure 4.46 K). 
 Uwineza Marie Clémentine Nibamureke    2019 102 
 
 CHAPTER 4. RESULTS 
Although most of the above oocyte stages were observed in this study, most of the 
female fish were found to be in stage 4 and 5. Oocytes in stages I, II, and III were 
also present in few numbers between the mature stages, however, mature stages 
were more frequent in the ovaries of most of the fish. The sexual maturity of the 
female fish in the present study was determined using Mc Donald et al. (2000) 
criteria. Most of the fish were classed in stage 3 (late development) with late 
vitellogenic oocytes being the predominant stage in the ovaries of most of the fish.  
The most prominent histological changes observed in ovaries were atresia of mature 
oocytes (88.89%) and vacuolation of oogonial nests (88.89%). Although these 
changes were observed both in the exposed and the control fish, they were more 
prominent in the exposed fish. Atretic oocytes can be seen in Figures 4.45 A and  
4.46 G & I. The first micrograph shows an atretic mature oocyte from a control fish; 
while the other micrographs show massive oocytes atresia in ovaries from fish 
exposed to NVP H. In the exposed fish, the envelope of the atretic mature oocytes 
appear to be dissolving and letting the content of the follicle spread in the free 
spaces of the ovary. This phenomenon was only observed in exposed fish. 
Vacuolation of oogonia nests can be observed in the micrograph C and D in the 
Figure 4.45. The oogonial nest in micrograph C is from a control fish, very few clear 
circular vacuoles can be seen; the small oogonia are present in high number 
throughout the nest. In micrograph D from a fish exposed to NVP L, the empty 
vacuoles are increased and are bigger causing the shrinking of the normal tissue 
containing oogonia cells, thus few oogonia can be seen. All the exposed fish 
presented with vacuolation of oogonia nests. Other observed histological changes 
in the ovarian tissue worth to mention include haemorrhage noticed in the oogonial 
nests blood vessels in few exposed fish (14.81%), necrosis of the oogonial nests 
(11.11%) in exposed fish only and necrosis of oocytes observed in two fish one 
exposed to NVP H (Figure 4.46 H) and the other one exposed to the Mixture 1 
(Figure 4.46 L). Those two fish presented also macroscopic abnormalities of the 
ovaries. The fish exposed to NVP H had very big ovaries filled with a greenish liquid. 
The other fish exposed to the Mixture 1 had one ovary shrunken and was attached 
to the liver. In both the fish ovaries it was visible microscopically that the oogenesis 
could be inhibited as most of the ovarian tissue was occupied by necrotic tissue and 
atretic mature oocytes.  
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Table 4.14: Percentage prevalence of histological changes in the ovarian tissue of 
the fish from the different groups 
  Control Solvent NVP L NVP H Mixture 1 Total 
3 4 5 7 8 27 
Histological 
changes  
n % n % n % n % n % n % 
Haemorrhage 0 0.00 0 0.00 0 0.00 1 14.29 3 37.50 4 14.81 
Ovary 
 
Inhibition of 
oogenesis 
0 0.00 0 0.00 0 0.00 1 14.29 1 12.50 2 7.41 
Oocytes 
 
Atresia  3 100.00 3 75.00 5 100.00 6 85.71 7 87.50 24 88.89 
Necrosis 0 0.00 0 0.00 0 0.00 1 14.29 1 12.50 2 7.41 
Interstitial 
tissue 
 
Vacuolation 2 66.67 2 50.00 5 100.00 7 100.00 8 100.00 24 88.89 
Necrosis 0 0.00 0 0.00 0 0.00 1 14.29 2 25.00 3 11.11 
Infiltration 0 0.00 0 0.00 0 0.00 0 0.00 2 25.00 2 7.41 
 
 
b. Testis 
The testis tissue of adult O. mossambicus consists of multiple seminiferous lobules 
containing all the stages of male reproductive cells. Each stage of development 
forms a distinctive group inside the seminiferous lobule. All the seminiferous lobules 
in the testis are enclosed by the tunica albuginea. The different stages of 
spermatogenesis observed in the fish from the present study were: Spermatogonia 
(SG), spermatocytes (SC), spermatids (SD) and spermatozoa (SZ) (Figure 4.44 A). 
The spermatogonia, the young, bigger and oval cells with a large clear nucleus and 
a large clear cytoplasm, are situated in the periphery of the seminiferous lobules 
while the mature cells, spermatozoa, small cells (look like small dots) with a dark 
blue nucleus (the cytoplasm not visible) are located in the lumen of the seminiferous 
lobules with dark blue nuclei. In contrary of the ovary developmental stages, as they 
are developing, the male reproductive cells become smaller in size and move 
towards the seminiferous lobule lumen. The space between lobule cysts contains 
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blood vessels and Leydig cells responsible for secreting male reproductive 
hormones (Figure 4.44 A & B). 
The sexual maturity of a male fish is determined by the amounts of each one of the 
spermatogenesis stage in the testis. Sexually immature fish contain testes lobules 
with cysts showing younger stages of spermatogenesis while in the testes of 
sexually mature fish, spermatozoa are predominant (Figure 4.44 E). Following the 
criteria to determine the sexual maturity of fish determined by McDonald et al. 
(2000), male fish from the present study were determined to be in stage 2 (mid-
spermatogenic stage) and stage 3 (late spermatogenic stage) mostly. Stage 2, mid-
spermatogenic, is characterised by the presence in the testis tissue of an equal mix 
of spermatocytes, spermatids and spermatozoa while in stage 3, late development 
cells, spermatozoa, are the most predominant despite the presence of all stages of 
development throughout the testis.  
The most predominant histological changes observed in the testis tissue of the fish 
in this study were vascular congestion (58.33%, Figure 4.44 B), Leydig cells 
vacuolation (83.33%, Figure 4.44 E), spermatocytes vacuolation (75%, Figure 4.44 
D), spermatids vacuolation (79.17%, Figure 4.44 F) and intersex (41.67%, Figure 
4.44 C). All these changes were detected in all the exposed fish as well as in the 
control groups. There was a slight increase of the changes in the exposed fish 
compared to the control fish. Vacuolation of the different types of cells in the testis 
are characterised by the clear vacuoles of different size around the nucleus (Figure 
4.44 D to F). Intersex in the testis is characterised by the presence of oocytes in the 
seminiferous lobules (Figure 4.44 C). The percentage prevalence of all the 
histological changes observed in the testis are presented in the Table 4.15. 
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Table 4.15: Percentage prevalence of histological changes in the testis tissue of the 
fish from the different groups 
  Control Solvent NVP L NVP H Mixture 1 Total 
5 3 7 5 4 24 
n % n % n % n % n % n % 
Histological 
changes  
 
Vascular 
congestion  
2 40.00 2 66.67 3 42.86 4 80.00 3 75.00 14 58.33 
Interstitial 
tissue 
 
Leydig cells 
vacuolation 
4 80.00 2 66.67 6 85.71 5 100.00 3 75.00 20 83.33 
MMC 0 0.00 0 0.00 1 14.29 0 0.00 0 0.00 1 4.17 
Spermatogonia  
Vacuolation  0 0.00 0 0.00 1 14.29 0 0.00 0 0.00 1 4.17 
Spermatocytes  
Vacuolation 3 60.00 0 0.00 6 85.71 5 100.00 4 100.00 18 75.00 
Nuclear 
alterations 
2 40.00 0 0.00 0 0.00 2 40.00 1 25.00 5 20.83 
Spermatids  
Vacuolation 3 60.00 3 100.00 6 85.71 4 80.00 3 75.00 19 79.17 
Intersex 2 40.00 1 33.33 3 42.86 2 40.00 2 50.00 10 41.67 
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Figure 4.39: A – D. The structure of O. mossambicus liver tissue from a control fish.  
A. The central vein (cv) (arrow); pv: portal vein; B & C. Details of the hepatocytes: a central 
dark nucleus surrounded by a pinkish cytoplasm (thick arrow). The hepatocytes are 
arranged in rows separated by sinusoids (thin arrow); D. Details of the portal area: the portal 
vein (pv) surrounded by a hepatopancreatic tissue (thick arrow), a bile duct (circled) and an 
artery (a). Melano-macrophage centres (MMCs) are frequent in the portal area (star).  
E & F. Micrographs from fish exposed to NVP: Blood congestion in veins and sinusoids 
(arrows). 
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Figure 4.40: G. Non-lipid vacuolation in fish exposed to NVP (arrows; note the central nuclei 
and the clear non-uniform vacuoles). H. Hepatocytes hypertrophy in a fish exposed to NVP. 
One side is made by big, clear hepatocytes and the other side contains dark normal size 
hepatocytes. I. Lipid vacuolation in a fish exposed to NVP (thick arrows, note the 
compression and displacement of the nuclei to the periphery); intracellular deposit in 
hepatocytes (thin arrow). J. A focal area of cellular change (FCA, lipid vacuolation).  
K. Increase in MMCs in the portal area of a Mixture 1 exposed fish (stars). L. Necrotic 
hepatocytes around an artery (a) and vein (v, arrow) in NVP exposed fish. 
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Figure 4.41: M. Necrotic hepatocytes with fading nuclei in NVP exposed fish (karyolysis, 
arrows). N. Intracellular deposits in hepatocytes (arrows, NVP exposed fish). O. NVP 
exposed fish presenting necrosis and deposits around a vein (arrow); MMCs are present 
(star). P. Mild fibrosis following necrosis around a vein (V, arrow). Q & R. Mild fibrosis 
around a bile duct (BD, arrow) in NVP and Mixture exposed fish. 
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Figure 4.42: A – C. Structure of the O. mossambicus kidney tissue in control fish; t: renal 
tubules; g: glomerulus surrounded by the Bowman space (green arrow); v: vein;  
cd: collecting duct. D. A fish exposed to the Mixture presenting atrophied glomerulus (note 
the dilation of the Bowman space, green arrow) and vacuolation of renal tubule cells (dark 
arrows). E & F. Fish exposed to NVP showing dilation of the Bowman space (green arrow), 
vacuolation of renal tubule cells (dark thin arrows) and MMCs (dark thick arrows). 
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Figure 4.43: G. NVP exposed fish showing hyaline deposits in renal tubule cells (arrows) 
and necrotic tubules (star). H. A fish exposed to the Mixture showing hyaline deposits (dark 
arrows), vacuolation of renal tubule cells (green arrow) and necrotic tubules (stars).  
I – K. NVP exposed fish presenting a pronounced alteration of the kidney tissue with 
necrotic tubules (stars), and vacuolation of renal tubule cells (green arrows). Note the 
presence of MMCs (thick arrows). L. Fish exposed to the Mixture with a pronounced degree 
of alteration same as in J. 
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Figure 4.44: A & B. Organisation of the testis of O. mossambicus in a control fish: the tunica 
albuginea (TA); seminiferous lobule (SL) containing different stages of development of the 
male reproductive cells: spermatogonia (SG) at the periphery of the lobule; primary (SCI) 
and secondary (SCII) spermatocytes enclosed in a membrane sac; spermatids (SD) near 
the lumen (LU) and spermatozoa (SZ) dark blue stained, in the lumen. The lobule 
membrane (LM) and the Leydig cells (LC) in interstitial space are shown. The thick arrow 
shows haemorrhage in the interstitial space. C. Intersex (the presence of oocytes in the 
testis tissue) in a solvent control fish (thick arrows); blood congestion in the interstitial tissue 
(thin arrow). D. Vacuolation of spermatocytes (arrows) in a fish exposed to NVP L.  
E. Vacuolation of Leydig cell in a fish exposed to NVP H (arrows). F. Vacuolation of 
spermatids (thick arrow).  
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Figure 4.45: A - C. Organisation of O. mossambicus ovarian tissue from a control fish. the 
tunica albuginea (TA); follicles in different stages of development: small primordial germ 
cells; oogonia (arrows) in oogonial nest (OGN); stage 1 oocytes (OI); stage 2 oocytes (OII); 
stage 3 oocytes (OIII); stage 4 oocytes (OIV); stage 5 oocyte (OV) and atretic oocyte (AO). 
Note the envelope with an irregular shape. OM = the follicular envelope. D. Vacuolation of 
the oogonial nest tissue in a fish exposed to NVP L; blood vessels (stars) and oogonia 
(arrows). E & F. Fish exposed to NVP L showing atretic oocytes (AO); stage 5 oocyte (OV); 
haemorrhage in the oogonial nest (stars) and folding of the follicular envelope (arrow). 
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Figure 4.46: G. Massive oocytes atresia (AO) in a fish exposed to NVPH. Note the younger 
oocytes stages still intact next to the atretic ones. H. A necrotic ovary (NO) in a fish exposed 
to NVP H. Note the folded tunica albuginea. I. A fish exposed to NVP H showing a dissolved 
follicle envelope of the atretic oocytes (AO, arrows). Note the intact stage 4 oocytes near 
the atretic mass. J. Atretic oocytes from a fish exposed to the mixture of pharmaceuticals 
(AO); normal stage 2 oocytes can be seen between the mature oocytes. The double arrows 
show the collapsing of the content of stage 5 oocytes. K. A higher magnification of the atretic 
oocyte (AO) in micrograph (J). The arrows show the folded follicle envelope. Note the 
separation of the envelope layers. L. A necrotic ovary (NO) from a fish exposed to the 
mixture of pharmaceuticals. Most of the tissue is necrotic.   
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4.3.5. Semi - quantitative histological assessment 
The observed histological changes in the different tissues of O. mossambicus were 
quantified using the scoring system defined by Bernet et al. (1999) as modified by 
van Dyk et al. (2009). Then, the different organ indices were statistically compared 
between the different groups using Kruskal – Wallis omnibus test and the post-hoc 
pairwise comparison test Mann – Whitney. All the mean organ indices for all the 
groups are given in Annexure 5.  
 
4.3.5.1. Liver 
The calculated mean liver index for female fish was 23.04 ± 8.81. The minimum 
index was 8 from a fish in the control group and the maximum index was 36 from a 
fish exposed to the Mixture 1. For male fish, the mean liver index was 22.75 ± 11.04. 
The minimum index was 6 shown by a fish from the control group and the highest 
index was 36 from a fish in the Mixture 1 group. In general, for both female and 
male, the fish exposed to pharmaceuticals showed higher liver indices compared to 
the control and the solvent control fish as shown in the Figures 4.47 and 4.48. The 
highest mean liver index for both female and male fish was 30.25 ± 5.28 and 31.60 
± 2.6 in the Mixture 1 and NVP H groups respectively. Regressive changes 
susceptible of causing changes in the organ function were the most prominent in all 
the groups. However, they were more intensified in the exposed fish (Figure 4.49).  
Statistical analysis revealed a significant difference in fish liver indices across the 
groups (Chi-square = 33.627, p < 0.001, df = 4, n = 51). The NVP L, NVP H and 
Mixture 1 groups recorded higher mean ranks (29.08, 33.58, 37.83) compared to 
the control and the solvent control groups (6.75 and 9.43). Post-hoc pairwise 
comparisons showed significant differences in liver indices for both female and male 
fish. For female fish, the significant difference was as follow: control – NVP H at the 
p = 0.016, control – Mixture 1 at the p = 0.001, solvent control – NVP H at p = 0.016 
and solvent control – Mixture at p = 0.001. No significant difference was detected 
between the NVP L group and both the control and the solvent control groups at the 
p > 0.05. For male fish, the significant difference was as follow: control – NVP L at 
the p = 0.010, control – NVP H at the p = 0.002, control – Mixture 1 at p = 0.003, 
solvent control – NVP H at the p = 0.014 and solvent control – Mixture at p = 0.018. 
Although there was a significant difference between the control and the NVP L 
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groups (p = 0.010), no significant difference was detected between the NVP L and 
the solvent control groups (p > 0.05). In addition, for both female and male fish, no 
significant difference was found between the NVP L and NVP H groups as well as 
between the NVP L and the Mixture 1 groups at the p > 0.05.  
 
 
 
Figure 4.47: Comparison of liver indices of female fish across the different groups. The 
groups with significant difference between them (p < 0.05) are shown. 
 
 
 
Figure 4.48: Comparison of liver indices of male fish across the different groups. The 
groups with significant difference between them (p < 0.05) are shown. 
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Figure 4.49: Mean reaction pattern indices for the liver across the different groups. 
Regressive changes (RC) were more prominent in all groups compared to other reaction 
pattern (circulatory disturbances – CD, progressive changes – PC, inflammatory reactions 
– I, tumour – T, focal area of cellular alteration – FCA). 
 
 
4.3.5.2. Kidney 
The calculated mean kidney index for female fish was 17.9 ± 6.3. The minimum 
index was 8 presented by fish from the control and solvent control group and the 
maximum index was 26 from a fish exposed to the Mixture 1. For male fish, the 
mean kidney index was 15.92 ± 6.14. The lowest index was 6 shown by a fish from 
the control group and the highest index was 28 from a fish in the NVP L group. The 
NVP H group recorded the highest mean kidney index (20.40 ± 1.67) compared to 
the other groups for male fish while for female, the highest mean kidney was 
recorded for the Mixture 1 group (21.50 ± 3.16). In general, for both female and 
male, the fish exposed to the test pharmaceuticals showed higher kidney indices 
compared to the control and the solvent control fish as shown in the Figures 4.50. 
Regressive changes susceptible of causing changes in the organ function were the 
most prominent in all the groups; however, they were more intensified in the 
exposed fish (Figure 4.51). 
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Statistical analysis revealed a significant difference in fish kidney indices across the 
groups (Chi-square = 31.945, p < 0.001, df = 4, n = 51). The NVP L, NVP H and 
Mixture 1 groups recorded higher mean ranks (30.54, 34.50, 35.25 respectively) 
compared to the control and the solvent control groups (7.56 and 8.86 respectively). 
Post-hoc pairwise comparisons showed significant differences in kidney indices for 
both female and male fish. For female fish, the significant difference was as follow: 
control – NVP H at the p = 0.014, control – Mixture 1 at p = 0.006, solvent control – 
NVP L at p = 0.36, solvent control – NVP H at p = 0.005 and solvent control – Mixture 
at the p = 0.002. No significant difference was detected between the NVP L group 
and the control at the p = 0.062. For male fish, the significant difference was as 
follow: control – NVP L at the p = 0.005, control – NVP H at p = 0.001, control – 
Mixture 1 at the p = 0.012, solvent control – NVP L at p = 0.033, solvent control – 
NVP H at p = 0.012 and solvent control – Mixture at the p = 0.049. For both female 
and male fish, no significant difference was found between the NVP L and NVP H 
groups (p = 0.533) as well as between the NVP L and the Mixture 1 groups (p = 
0.958). 
 
 
 
Figure 4.50: Comparison of kidney indices of fish in the different groups. The groups with 
significant difference between them (p < 0.05) are shown by the symbols. 
 
* 
* 
+ 
+ 
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Figure 4.51: Mean reaction pattern indices for the kidney in the different groups. Regressive 
changes (RC) were more prominent in all groups compared to other reaction patterns 
(circulatory disturbances – CD, progressive changes – PC, inflammatory reactions – I, 
tumour – T). 
 
 
4.3.5.3. Gonads 
Female fish recorded a mean gonad index of 14.67 ± 8.1; the minimum index was 
0 from a fish in the solvent control group and the maximum index was 38 from a fish 
exposed to the NVP H. Female fish exposed to pharmaceuticals showed higher 
gonad indices compared to the control and the solvent control fish as shown in the 
Figure 4.52. The highest mean gonad index for female fish was recorded by the 
NVP H group as 19.43 ± 8.38.  
Statistical analysis revealed a significant difference in female gonad index across 
the groups (Chi-square = 11.020, p = 0.026, df = 4, n = 27). Post-hoc analyses 
detected the significant difference between the solvent control group and the NVP 
H group at the p = 0.002 and between the solvent control group and the Mixture 1 
group at the p = 0.009. The NVP H group recorded a high mean rank of 19.21 while 
the solvent control group had the lowest mean rank of 4.00 for the ovary indices.  
 
 
 Uwineza Marie Clémentine Nibamureke    2019 119 
 
 CHAPTER 4. RESULTS 
 
 
Figure 4.52: Mean gonad indices from the female fish in the different groups.  
The groups with significant difference between them (p < 0.05) are shown. 
 
 
 
 
Figure 4.53: Mean gonad indices from the male fish in the different groups.  
No significant difference was detected across the groups (p > 0.05). 
 
 
* 
* 
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For all the male fish, the mean gonad index was 9.67 ± 4.63; the lowest index was 
2 shown by fish from the solvent control and the Mixture 1 groups and the highest 
index was 18 from a fish in the Mixture 1 group. Male exposed fish showed slightly 
higher mean gonad indices compared to the control fish. The highest mean gonad 
index for male fish per group was recorded by the NVP H group as 11.60 ± 4.56. 
The control group recorded a mean gonad index of 9.20 ± 3.89. No significant 
difference in male fish gonad indices across the group was found (Chi-square = 
3.021, p = 0.554, df = 4, n = 24). Figure 4.53 presents the comparison of mean testis 
index of male fish from the different groups. 
However, for both female and male fish, regressive changes susceptible of causing 
changes in the organ function were the most prominent in all the groups, and they 
were more intensified in the NVP H and the Mixture 1 groups (Figure 4.54). 
 
 
 
Figure 4.54: Mean reaction pattern indices for the gonads across the different groups for 
both female and male fish. Regressive changes (RC) were more prominent in all groups 
compared to other reaction pattern (circulatory disturbances – CD, progressive changes – 
PC, inflammatory reactions – I, tumour – T, intersex - IS). 
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4.3.6. Summary on adult fish histological assessment 
In general, for both female and male adult fish, liver indices were higher compared 
to the other organ indices mostly for the exposed fish (Figure 4.55, Table 4.16). The 
order of the histological changes severity in the assessed organs can therefore be 
reported as liver > kidney > gonads. Comparing the effects of NVP as a single 
toxicant and NVP in mixture with antibiotics, for all the groups the mean organ 
indices in the Mixture 1 group were higher than the mean indices in the NVP L group. 
This suggest that the fish exposed to the mixture of NVP and antibiotics showed 
severe histological changes in all the assessed organs compared to the fish 
exposed to NVP L alone. Comparing the NVP L and NVP H groups mean organ 
indices, it was noticed that mean organ indices in the NVP H group were higher 
compared to those for the NVP L group only for the kidney and gonad indices. For 
the liver, the NVP L group recorded a higher mean organ index than the NVP H. 
This suggests that for the liver, the fish exposed to the low concentration of NVP 
showed severe histological changes compared to those exposed to the high 
concentration of NVP. For the kidney and gonads, it was the inverse (Table 4.16). 
Finally, the mean gonad index for the female fish exposed to NVP H was higher 
compared to the mean gonad indices in the other groups. This suggests that the 
sensitivity of female fish ovaries to the tested pharmaceuticals may be reported as 
follow: NVP H > Mixture 1 > NVP L. The suggested sensitivity of the other organs 
on the tested pharmaceuticals is: Mixture 1 > NVP L > NVP H for the liver and 
Mixture 1 > NVP H > NVP L for the kidney. 
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Figure 4.55: Comparison of the different organ indices in the different groups. For all the 
exposed fish the mean organ indices for both female and male were in the order: Liver > 
Kidney > Gonads.  
 
4.4. Classification of organ histological changes 
Using the classification of histological changes defined by Zimmerli et al. (2007) and 
van Dyk et al. (2009) (Table 3.3 in the methodology section), the mean liver and 
kidney indices of 30 days old fish were classified in class 1 for all the groups. The 
mean liver index of the adult fish was classified in class 1 for the control group, class 
2 for the solvent control and NVP H groups and class 3 for NVP L and the Mixture 
1 groups. For the kidney, the mean index of adult fish was classified in class 1 for 
the control and the solvent control groups while all the exposed group mean kidney 
indices were grouped in class 2. Table 4.16 shows the classification of all the organ 
indices in the different groups for both the 30 days old juveniles and the adult fish. 
The classes of histological alteration defined by Zimmerli et al. (2007) and modified 
by van Dyk et al. (2009) are: class 1 (index < 10) for a mild change in organ 
histology, class 2 (index from 10 – 25) for moderate changes, class 3 (index from 
25 – 35) for pronounced changes and class 4 (index > 35) for severe changes to 
the organ histology. In this study, a colour code was used to simplify the table.  
 Uwineza Marie Clémentine Nibamureke    2019 123 
 
 CHAPTER 4. RESULTS 
The dark and light green colours were used for class 1 and class 2 respectively to 
represent the mild and moderate change to normal histology, a light red colour was 
used for class 3 representing a pronounced modification of the normal histology and 
a dark red colour was used for class 4 characterised with severe histological 
changes.  
 
 
Table 4.16: Classification of liver and kidney histological changes following the 
system defined by Zimmerli et al. (2007) as modified by van Dyk et al. 
(2009)  
 
    30 days old Adult 
Exposure 
Groups 
Mean organ index (Iorg) 
  Liver Kidney Liver Kidney Ovary Testis 
Control 2.0 0.5 9.5 8.5 11.3 9.2 
Solvent control 2.9 1.3 10.6 8.9 5.5 6.0 
NVP L 2.7 6.7 26.3 18.8 13.2 9.4 
NVP H 5.4 7.6 17.2 20.3 19.4 11.6 
Mixture 1 7.6 7.0 29.5 20.7 17.3 11.0 
Mixture 2 7.8 5.6 n.d n.d n.d n.d 
n.d = not done 
  
1 
4 
3 
2 
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South Africa has the largest HIV/AIDS treatment program involving the 
administration of ARVs together with antibiotics for the prevention of opportunist 
infections in HIV positive patients (UNAIDS 2016). The ARV NVP and the antibiotics 
SMX and TMP are frequently prescribed for people living with HIV/AIDS and they 
are amongst the pharmaceuticals commonly detected in surface waters across the 
country (Madikizela et al. 2017; Wood et al. 2017). As the 2020 target of the UNAIDS 
is to get 90% of all people living with HIV on ARV treatment (HSRC 2018), the levels 
of HIV therapy drugs in aquatic environments are expected to go up too if nothing 
is done to prevent that. This was the first study conducted to investigate the potential 
long-term effects of the ARV drug NVP and its mixture with the antibiotics SMX and 
TMP on the different life stages of O. mossambicus. Early life stages (embryo, 
larvae, juveniles) and sexually mature adults were exposed to two different 
environmental relevant concentrations of NVP (1.48 and 3.74 µg/L) as a single 
toxicant first, and to a mixture of NVP (1.48 µg/L) and the antibiotics SMX (3.68 
µg/L) and TMP (0.87 µg/L). The early life stages exposure started with ± 24 hrs 
fertilised eggs continued through hatching and stopped when the early juveniles 
were 60 days old. Adult fish exposure lasted 30 days. This section provides a 
detailed discussion on the results in chapter 4.  
 
5.1. Water quality analyses 
One of the reasons why fish are used in ecotoxicology studies is because their 
bodies are able to react on changes in the water parameters such as changes in 
food availability as well as changes in the physico-chemical parameters (Di Giulio & 
Hinton 2008). Laboratory exposure studies that investigate the effects of toxicants 
on fish health are conducted in controlled environments where all the water 
parameters are kept constant for all the treatment groups. This is done in order to 
have only one variable, the tested compound, and determine its effects when all 
other parameters are controlled. The established international guidelines for water 
quality parameters in fish laboratory experiments recommend that the water quality 
of the dilution water be done before the experiments start and during the 
experiments to determinate the quality of water (US EPA 2016; OECD 2012; OECD 
2013). In addition, those guidelines specify acceptable range of water quality 
parameters to consider during fish experiments. For example, the variation in 
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temperature between containers and between days should not go over ± 1.5℃, the 
pH should be 6.5 – 8.5; the DO from 60 - 120% and the total hardness (CaCO3) 
from 40 - 180 mg/L (US EPA 2016; OECD 2012; OECD 2013). Furthermore, the 
water tolerance parameters for optimum survival, growth and reproduction for the 
O. mossambicus species are: Temperature: 22 – 30℃, pH: 6 – 9.5 and DO > 60% 
(Russell et al. 2012; Centre for Agriculture and Bioscience International (CABI) 
2019). All the results from the borehole water quality analysis (metals; nutrients; 
organic chemicals) were in the guidelines for the fish toxicity tests and for the South 
African target water quality range for aquatic ecosystems (SA. Department of Water 
Affairs and Forestry 1996).  
The monitoring of physico-chemical water parameters during the exposure 
experiments showed that the temperature, pH, EC, TDS, DO stayed inside the 
guidelines for the fish toxicity tests and were within the O. mossambicus species 
optimal water parameters for growth and reproduction (Russell et al. 2012; CABI 
2019). Therefore, there was no variation in water quality parameters that could 
cause unwanted effects for both the early life stages and adult fish exposures during 
this study.  
The international guidelines for fish toxicity testing recommend the analysis of the 
test media at the start and at the end of the exposure or every week at least for 
chronic exposures to confirm exposure of the fish to the tested chemical (US EPA 
2016; OECD 2012; OECD 2013). For NVP two concentrations were used; low (1.48 
µg/L) and high (3.74 µg/L) concentrations. The analysis of NVP was done at different 
times during the exposures; at the beginning of the exposure, after 96 hrs and 
directly after the renewal of the exposure media. The results showed that the 
concentration of NVP after 96 hrs, was higher than the initial concentration for NVP 
3.74 µg/L. This was not expected because the low concentration (NVP 1.48 µg/L) 
was slightly reduced after 96 hrs. Studies on NVP pharmacokinetics have revealed 
that the half-life of NVP in human plasma is ± 45 hrs (Riska et al. 1999a). Other 
studies have demonstrated that NVP is well absorbed (> 90%) in humans and 
animals after oral administration and the parent compound excreted is only about 
3% (Riska et al. 1999b; Eloy et al. 2017). Thus, as only the NVP parent compound 
was analysed in the water samples, it was supposed to be clearly lower after 96 hrs 
because some of NVP would have been taken up by the fish and submitted to 
biodegradation. Likewise, a certain amount of NVP was also supposed to go through 
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a transformation process in water. These two processes would have contributed to 
the reduction in NVP parent compound concentration in water after 96 hrs (Gašo-
Sokač et al. 2017). There is no explanation why the NVP concentration was higher 
after 96 hrs. However, it is documented that NVP is resistant to WWTPs disinfection 
methods as its levels in effluent were found higher than the levels in the influent 
(Prasse et al. 2010; K’Oreje et al. 2016; Wood et al. 2016). Some authors have 
argued that some of the NVP metabolites may have transformed back into the 
parent compound (Mosekiemang et al. 2019). Nevertheless, this argument has not 
been be confirmed with certainty. Thus, it cannot be confirmed with certainty what 
happened here, more studies are needed to clarify this matter and determine if the 
observed increase in NVP concentration is not artificial. It is also worth to emphasize 
that the mean recovery rate of NVP from water samples was elevated (79%) which 
shows the accuracy and precision of the method. The high recovery rate of NVP in 
water samples confirmed the presence of the test pharmaceuticals in the media. 
What is important to note is that, the fish were constantly exposed to NVP 
concentrations near the nominal dose (90 - 150%) which still reflects 
environmentally relevant concentrations in African surface waters (K’Oreje et al. 
2016).  
 
5.2. Early life stages health assessment 
5.2.1. Hatching success and survival 
Toxicity studies using fish to determine the effects of chemicals in the aquatic 
environments are commonly conducted nowadays. To our knowledge, this study 
was amongst the first ones to use early life stages of O. mossambicus to test the 
effects of environmental levels of the ARV NVP and its mixture with the antibiotics 
SMX and TMP on hatching success and survival. Following the conditions of the 
test, no negative effects of the tested pharmaceuticals and their mixtures on the 
hatching and survival of embryos and larvae up to 60 days old were observed. No 
statistically significant differences (p > 0.05) in hatching success and survival were 
found between the control and the exposed fish.  
Previous studies on the development of O. mossambicus and O. niloticus early life 
stages have shown that embryos hatching in this genus happens between the third 
and the sixth day (approximately from 72 to 140 hrs) post fertilisation (Holden & 
Bruton 1992; Tachihara & Obara 2003; Fujimura & Okada 2007). For this study, the 
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embryo started hatching in the morning of the fourth day (± 96 hrs) post fertilisation 
and was complete on the sixth day (± 140 hrs). The embryos in all the groups and 
repeats did not start hatching at the same time but on the sixth day they were all 
hatched. This corroborates with Morrison et al. (2011) who reported that in the 
genus Oreochromis, embryos do not start hatching on the same day in the same 
brood (Morrison et al. 2001). The day following the end of hatching in each group 
was recorded as the first day post hatching and represented the first day of the larval 
stage (Fujimura & Okada 2007). Hatching time of embryos in the present study 
corresponded to the period of hatching reported for the genus Oreochromis (Holden 
& Bruton 1992; Kruger 2002).  
The guidelines for fish toxicity tests using early life stages state that for a test to be 
acceptable, the overall hatching success of embryos in the control group should be 
at least 70% (US EPA 2016; OECD 2013). For the present study, the mean hatching 
success was above 80% in all groups and experiments. There was no significant 
difference found in the hatching success of embryos across all the groups (p > 0.05) 
in all the experiments. Thus, NVP and its mixture with the antibiotics SMX and TMP 
did not have an effect on the hatching success of O. mossambicus embryos.  
Nevirapine in pregnant women and new-borns is used carefully due to concerns 
about long-term toxicity effects as there is a lack of data on its effects on the children 
development when they are started on the treatment at such an early age (Panel on 
Antiretroviral Therapy and Medical Management of HIV-Infected Children 2017). In 
addition, NVP is able to pass through the placenta barrier and is taken up by the 
foetus (Shubber et al. 2013; WHO 2014; Bolaris et al. 2017). Likewise, SMX and 
TMP are not prescribed to pregnant women in their first semester of pregnancy as 
they increase the risk of abortion or foetus deformity (Straub 2016). In fish, there are 
no available information on the effects of NVP or any other ARV on the hatching 
success of embryos and survival of larvae. But some other pharmaceuticals, 
including sulfonamides, have been found to affect fish embryos hatching success. 
Lin et al. (2013) reported a decline in the hatchability of zebrafish embryos exposed 
to a higher concentration of SMX (1 mg/L). The same study found no effect in 
hatchability of embryos exposed to lower concentrations of SMX (0.001 mg/L to 0.1 
mg/L). Memmert et al. (2013) also reported no effect in hatchability of rainbow trout 
and zebrafish embryos exposed to diclofenac up to 1000 µg/L. Similarly, this study 
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used environmental concentrations of NVP (1.48 and 3.74 µg/L), SMX (3.68 µg/L), 
TMP (0.87 µg/L) and no effects on embryo hatchability were observed. 
The mean survival rate in all groups and in both experiments varied between 94% 
and 100% on the start of exogenic feeding (± 12 days PH) which is considered as 
the first day of the juvenile stage (Holden & Bruton 1992; Fujimura & Okada 2007). 
According to previous studies on the early ontogeny of the Mozambique tilapia 
(Holden & Bruton 1992), the transition to exogenic feeding is the most crucial period 
in a fish life as fish larvae are very sensitive to changes in the environment. There 
are normally three main environmental factors that can affect the survival of fish 
larvae; the availability of food, oxygen and population pressure (Holden & Bruton 
1992; Morrison et al. 2001). During the experiments, all treatment groups and 
repeats received the same type and quantity of food at the same time and oxygen 
was supplied (80% – 120%) to all fish. In addition, in each repeat, all the groups had 
equal number of embryos at the start of the exposure. The care was taken to remove 
solid and organic wastes every morning before feeding the fish and the exposure 
media was renewed at regular intervals after cleaning carefully the filters. Despite 
that, after the introduction of feeding, mortality happened in all groups and repeats 
at a comparable rate mostly in the 1st experiment compared to the 2nd experiment. 
On the 30th and 60th day PH the lowest mean survival was 79% in the first 
experiment, while it was 93% for the 2nd experiment. However, statistically no 
significant differences were found when comparing the mean survival rate across 
the groups in both experiments (p > 0.05). This means that the tested 
pharmaceuticals cannot be held accountable for variations observed in the larvae 
survival rate.  
It is worth mentioning that studies investigating the effects of pharmaceuticals on 
the survival of early life stages of fish are available but only for a few 
pharmaceuticals including diclofenac and antibiotics such as sulfonamides. Studies 
on zebra fish (Danio rerio) or rainbow trout (Oncorhynchus mykiss) have showed 
that neither of the fish species early life stages survival were affected by the 
pharmaceuticals in surface waters (Praskova et al. 2011; Lin et al. 2013; Memmert 
et al. 2013). Lastly, the guidelines for toxicity test using early life stages specify that 
mortality is common during this period of life and suggest the validity of the test 
when the survival in the control group is ≥ 70% (US EPA 2016; OECD 2013). For 
the current study, the survival rate in both the experiments was above 78% at the 
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end of the exposure (60th day post-hatching) which confirm that NVP as a single 
toxicant and in a mixture with SMX and TMP do not have negative effects on the 
survival of early life stages of O. mossambicus. 
Furthermore, the assessment of the larvae and juveniles swimming and feeding 
behaviour did not show any significant difference between the exposed fish and the 
control (p > 0.05). This confirm that the pharmaceuticals did not affect the early life 
stages. 
 
5.2.2. Growth and development 
Fish growth is closely related to environmental factors such as food availability and 
the physico-chemical quality of water (Holden & Bruton 1992; Stancova et al. 2014). 
When conditions become unfavourable as in the case of pollution or food scarcity 
for example, fish will show impaired growth (Bagenal & Tesch 1978; Morrison et al. 
2001; Sadauskas-Henrique et al. 2011). In fisheries, weight and length 
measurements are important growth parameters which are recorded frequently to 
calculate weight-length relationship to estimate the well-being and age of the fish 
(Carlander 1969; Froese 2006; Dekic et al. 2016; Peyton et al. 2016). The weight-
length relationship of a healthy fish should show a strong positive correlation as the 
fish is growing (Bagenal & Tesch 1978; Sparre & Venema 1998). Pharmaceuticals 
which may affect fish growth by disturbing the body metabolism may lead to reduced 
growth which may be noticed in changed growth parameters (Sadauskas-Henrique 
et al. 2011; Schoenfuss et al. 2016). 
The growth of early life stages from the present study was assessed using body 
measurements including the total length and body weight of larvae and juveniles at 
day 1, 30 and 60 PH. After hatching, the one day old larvae were almost the same 
size in all groups and experiments. But variations were observed in the total length 
and body weight measurements of juveniles in the same group as well as in the 
same tank for 30 and 60 days old in all experiments. This is in agreement with 
Morrison et al. (2001) who studied various developmental stages (embryos, larvae 
and juveniles) of O. niloticus from several broods. They have indeed noticed that 
variations in development and growth rate among fish from the same brood were 
more prominent during the late stages and were mostly caused by the density of 
fish and the inadequate quality of food (Morrison et al. 2001). Nevertheless, the 
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number of larvae and the quality of food were not the cause of this discrepancy as 
the exposure started with the same numbers of embryos in each repeat and each 
group and all larvae and early juveniles were fed the same tilapia fry specific 
commercial food. However, as the larvae started dying in each group at the start of 
feeding, the equal density in the tank was disturbed; this may have been one of the 
probable causes of the variations in the growth rate. Despite the variations 
observed, the weight and length of fish in the first experiment were not significantly 
different across the groups (p > 0.05). Only the weight of one day old exposed to 
NVP 3.73 µg/L and the weight and length of 30 days old exposed to the mixture of 
NVP and antibiotics in the 2nd experiment were significantly different from the control 
fish (p < 0.05). The weight and length of the 60 days old were comparable in all the 
groups for both the experiments. These findings are comparable to those from 
Tachihara & Obara (2003) study on O. mossambicus grown in natural conditions.  
The strong positive correlation between length and weight measurements, and 
between the fish age and both length and weight measurements in all groups, 
confirmed that as the larval and juvenile stages of O. mossambicus were getting 
older, they were also increasing both in length and in weight as it is the case for 
healthy fish (Froese 2006; Peyton et al. 2016; Makori et al. 2017). If the 
pharmaceuticals in water had a negative impact on fish growth, the relationship 
between length and mass measurement would have been affected. In fisheries, 
healthy fish are characterised by strong positive weight-length; age-length and age-
weight relationship (Bagenal & Tesch 1978; Sparre & Venema 1998). The length 
measurements are the most used in regressive models to predict either fish age or 
fish weight (Sparre & Venema 1998; Lederoun et al. 2018). Similarly, the present 
study found that length measurements in all groups were good predictors of the age 
of fish compared to the weight. 
One of the most used weight-length relationships in fisheries is the CF which is 
expressed as the ratio between fish weight and length. The calculated CF showed 
that larvae and juvenile fish from all the three groups had a high mean CF around 4 
and 5 for 1 day old larvae in the 1st and the 2nd experiments respectively. One day 
old larvae showed a high mean CF in all groups (> 3,5), which is higher than 1, the 
normal CF for healthy adult fish from a healthy environment. However, this is not 
abnormal, as studies have shown that only adult healthy fish will have a CF closer 
to 1, while for early life stages, the CF will be > 1 as they increase more in length 
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than they do in other dimensions (Froese, 2006; Hernández-Serna et al. 2014; 
Peyton et al. 2016). From day 1 to day 60 post-hatching, the CF in all groups, was 
getting closer to 1. Although a statistically significant difference was found in the CF 
of day 1 old larvae exposed to NVP H in the 2nd experiment. On the other hand, 
there was no significant differences in 60 days old juveniles. This may suggest that 
NVP H (3,74 µg/L) and the mixtures of the pharmaceuticals used may have slowed 
the growth of early life stages of O. mossambicus in their early larval stages, but the 
fish recovered.  
The fish in all the three groups recorded a high and rapid mean SGR from day 1 to 
day 30. However, from day 30 to day 60 the mean SGR decreased in all groups, but 
it was still high compared to the SGR recorded for O. niloticus in natural environment 
(Makori et al. 2017). The early life stages of O. mossambicus are known to have a 
fast and high initial growth rate to allow them to attain large sizes quickly in order to 
avoid predation (Weyl & Hecht 1998). According to Sparre and Venema (1998), the 
growth rate of a healthy fish decreases as the fish gets older, becoming zero when 
the fish gets to its maximal growth in normal conditions. Thus, even though the NVP 
exposed juveniles showed a reduced mean SGR between the 30th and the 60th day 
of their life, statistical analysis showed no significant differences between the three 
groups. It is therefore evident that, despite the observed variations in the rate of 
development, the fish in all the three groups showed comparable growth rates from 
the first day of their life. Therefore, NVP as a single toxicant and in mixture with SMX 
and TMP at their environmentally relevant concentrations did not significantly affect 
the growth and development of the fish up to 60 days PH. Likewise, Lin et al. (2013) 
did not find any effect of SMX up to 1 mg/L on the growth of early life stages of zebra 
fish. In addition, other studies on the effects of environmentally relevant 
concentrations of different types of pharmaceuticals and their mixtures on either 
zebra fish or rainbow trout also did not find any effect on the survival and growth of 
early life stages (Praskova et al. 2011; Memmert et al. 2013; Schoenfuss et al. 
2016).  
 
 5.2.3. Histopathology 
The liver and kidney are amongst the important organs in a fish life as both are 
involved in maintaining the homeostasis of the organism (Di Giulio & Hinton et al. 
2008). The liver has many functions including the storage, metabolism and excretion 
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of most of the substances that enter the body including pharmaceuticals (Hinton et 
al. 2008). The kidney also has a complex function which includes the excretion of 
the surplus of water and ions as well as the elimination of the waste products of 
metabolism (Bonga & Lock 2008). By their functions of metabolism and excretion, 
the liver and kidney are able to detoxify the body. These organs are in direct contact 
with toxicants that enter the body making their tissues the target of toxicants 
(Tanaka & Miyajima 2016; Pinheiro et al. 2017). The pharmaceuticals used, NVP, 
SMX and TMP are mainly metabolised in the liver and excreted through the kidney 
(Pazhayattil & Shirali 2014; Autmizguine et al. 2018). Their main secondary effects 
to human are liver toxicity and kidney injury (Bjornsson & Olsson 2006; Assaram et 
al. 2018). Toxicological studies using the fish liver and kidney as target organs have 
shown that these two organs are good biomarkers of water pollution as they show 
histopathological changes related to toxicant exposure (Zimmerli et al. 2007; 
Marchand et al. 2012; van Dyk et al. 2012; Nibamureke et al. 2016; Răsković & 
Poleksić 2017).  
The histological assessment of the liver and kidney tissues of the 30 days old 
juveniles revealed a number of changes in both organs. The main changes 
observed in the liver included lipid vacuolation in most of the fish as well as in the 
control fish, non-lipid vacuolation mainly in the fish exposed to NVP 3.74 µg/L and 
to the mixtures of pharmaceuticals, single cell necrosis and vascular congestion 
observed mainly in the fish exposed to NVP 3.74 µg/L and the mixtures. The 
changes observed in the kidney were mostly the vacuolation of the renal tubule cells 
mainly in the exposed fish, necrosis of renal tubule observed only in the exposed 
fish and the dilation of the Bowman space observed mostly in the fish exposed to 
NVP 3.74 µg/L and the mixtures as well in the control fish to some extent. The liver 
indices of the 30 days old exposed to NVP 3.74 µg/L and to both the mixtures were 
higher compared the those of the control fish and the NVP 1.48 µg/L. The kidney 
indices were higher in the exposed fish groups than in the control.  
Significant differences were found in liver and kidney indices across all the groups  
(p < 0.05) showing that the pharmaceuticals had affected the tissues of the exposed 
fish. It was expected that the NVP 3.74 µg/L would cause more and severe effects 
compared to NVP 1.48 µg/L in both the liver and kidney and that NVP in mixture 
with the antibiotics would cause even more effects than NVP as a single toxicant. 
Indeed, the liver tissue in the exposed juveniles revealed significant differences 
 Uwineza Marie Clémentine Nibamureke    2019 133 
 
 CHAPTER 5. DISCUSSION 
between the two concentration of NVP as well as between NVP single toxicant and 
NVP in mixture with SMX and TMP. However, for the kidney there was no significant 
difference between those groups. The lack of dose - response relationship in the 
kidney was not expected, but it is not unheard of (Triebskorn et al. 2004). In fact, 
some of pharmaceutical exposure studies have reported the same results for the 
kidney, gills and liver of rainbow and brown trout exposed to different concentrations 
of diclofenac (Triebskorn et al. 2004; Hoeger et al. 2005). Although there was no 
dose - response relationship for the kidney following statistical analysis, comparing 
the kidney indices in the different groups, the NVP 3.74 µg/L (single toxicant) and 
the mixture of NVP and antibiotics groups had slightly higher kidney indices 
compared to NVP 1.48 µg/L (single toxicant).  
These histological changes observed in the 30 days old fish liver and kidney were 
previously observed by other researchers. For example, zebra fish exposed to a 
mixture containing SMX–TMP in a chronic exposure presented vacuolation and 
nuclear alteration in hepatocytes (Madureira et al. 2012), rainbow trout exposed to 
diclofenac (1 µg/L) in chronic exposure showed dilation of the Bowman space, 
vacuolation and necrosis of renal tubules (Schwaiger et al. 2004; Triebskorn et al. 
2007; Memmert et al. 2013), fathead minnows exposed to a mixture of 
pharmaceuticals (antidepressants and opioids) at environmental relevant 
concentrations showed lipid vacuolation in the liver (Schoenfuss et al. 2016) and O. 
mossambicus exposed to efavirenz (20.6 ng/L) in an acute exposure revealed single 
cell necrosis and lipid vacuolation in the liver (Robson et al. 2017). In addition, these 
histological changes have also been observed in humans and rats on NVP and on 
SMX–TMP treatment (Rivero et al. 2007; Hanses et al. 2009; Adaramoye et al. 
2012). 
Studies have shown that histological changes in an organ such as the liver and the 
kidney are likely to cause a decrease in the fish health as they disturb the organism 
homeostasis and functioning if the exposure is chronic (Di Giulio & Hinton 2008; 
Zimmerli et al. 2007). Thus, an impaired growth may result from the impaired 
histology of the liver and the kidney (Wahli 2002; Stancova et al. 2014). Zimmerli et 
al. (2007) investigated the health status of brown trout (Salmo trutta) in Swiss rivers 
and developed a classification system of organ indices to separate the normal and 
altered histology of the liver and kidney. van Dyk et al. (2009) modified Zimmerli et 
al. (2007) classifying system and adapted it to O. mossambicus and Clarias 
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gariepinus organs (liver, kidney, gills, gonads). The highest kidney index observed 
in the 30 days old was 12 and the highest liver index was 14. The mean liver and 
kidney indices of all the groups in both the experiments were still < 10. Organ indices 
< 10 and those from 10 to 25 are classified in class 1 and class 2 corresponding to 
mild and moderate changes of the normal organ histology which cannot affect the 
organ function (Zimmerli et al. 2007; van Dyk et al. 2009). This means that the 
changes observed in the liver and kidney tissues of the 30 days old juveniles were 
minor and may not cause changes to the organ morphology and physiology with no 
effects to fish growth and survival. Thus, these histological assessment results 
support the results from the first part of this study on fish survival and growth 
published in Nibamureke et al. (2018) and Nibamureke et al. (2019a). NVP as a 
single toxicant and in a mixture with the antibiotics (SMX and TMP) did not have 
negative effects on early life stages of O. mossambicus in terms of hatching 
success, survival and growth in the first two months of their life, although they may 
have caused minor changes in the liver and kidney histology. However, as the 
exposed fish showed increased organ indices compared to the control fish, a full 
life-cycle exposure would give a better picture of how these pharmaceuticals may 
impact or not the fish health as the fish are exposed their whole life.  
 
5.3.  Adult fish health assessment 
5.3.1. Necropsy 
The external and internal necropsy of the adult fish revealed few macroscopic 
abnormalities. The body measurements including the total length, standard length 
and body weight did not significantly differ across all the groups (p > 0.05). This was 
not unexpected as the organism reaction to toxicant exposure usually starts on the 
molecular level, then the cellular and tissue levels before showing on the organ and 
the whole organism levels (Răsković & Poleksić 2017). Thus, macroscopically no 
differences were observed between the fish exposed to NVP as a single toxicant 
and to NVP mixture with antibiotics and the control fish. All the fish appeared to be 
in good health.  
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5.3.2. Blood parameters 
Blood parameters are amongst the physiological biomarkers used to assess the 
effects of toxicants in water to the fish (Schwaiger et al. 1997). The blood is the main 
pathway through which toxicants are distributed in the organism tissues. Therefore, 
the blood is always in direct contact with toxicants from the water. Blood parameters 
reaction to those chemicals can be used to estimate the effects of the chemicals to 
the fish (Ruas et al. 2008; Kroon et al. 2017). 
Although no significant differences were found in assessed blood parameters, a 
slight decrease in mean Hb concentration of fish exposed to NVP was observed 
compared to the control group fish. In addition, a minor increase in mean Lct levels 
in fish exposed to NVP L and a decrease in mean Lct levels of the fish exposed to 
the mixture were noticed compared to the control. Haemoglobin levels are indicative 
of the quantity of oxygen supplied to tissues by the red blood cells. A low Hb 
concentration is a sign of anaemia (Billett 1990; Ruas et al. 2008; Sihoka & 
Wagenaar 2018) and may be caused by various factors including toxicants in water 
(Witeska 2013 & 2015). The observed slight decrease in Hb concentration in fish 
exposed to NVP may indicate that the fish were reacting to the pharmaceuticals. 
Whereas NVP induced liver toxicity mechanisms are still not well understood, 
experiments conducted on rats have shown that NVP can disturb the immune 
system which can lead to liver injury (Rivero et al. 2007). Previously, rats on chronic 
NVP treatment showed high levels of lymphocytes associated with liver 
histopathology (Bekker et al. 2012). The minor increase in Lct level observed in the 
present study from NVP L group may be an indication that the fish immune system 
was reacting to NVP exposure. Robson et al. (2017) observed similar results in Lct 
levels of O. mossambicus exposed to efavirenz in acute exposure. In fact, she found 
a slight increase in Lct with low concentration (10.3 ng/L) of efavirenz while the 
exposure to a high dose (20.6 ng/L) did not show any changes in exposed fish 
compared to the control group. The decrease in Lct for the fish exposed to the 
mixture of NVP and antibiotics may have been caused by SMX and TMP as they 
are known to cause neutropenia in humans (Hanses et al. 2009). 
5.3.3. The condition factor and somatic indices  
Studies have shown that somatic indices of some organs including the liver, the 
spleen and the gonads can be used as biomarkers of water pollution (Sanchez & 
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Porcher 2009; Sadauskas-Henrique et al. 2011; Dekic et al. 2016). Indeed, in case 
of stress caused by food scarcity or any change in environment conditions including 
water pollution, these organs will likely be affected and this can be reflected in their 
mass (increase or decrease). The fish exposed to NVP (both concentrations) had 
significant different HSI values compared to the control fish. The fish exposed to the 
higher concentration of NVP were significantly different in SSI compared to the other 
groups. However, no significant differences were found in the CF and the GSI. 
These results are in agreement with a study by Schoenfuss et al. (2016) which found 
significant differences in the HSI of adult fathead minnows exposed to 
pharmaceuticals and their mixtures (tramadol, methocarbamol, temazepam, 
fluoxetine, paroxetine, venlafaxine) for 21 days in a laboratory exposure. The same 
study did not find any significant differences in GSI. Another study conducted by 
Robson et al. (2017) on O. mossambicus exposed to 20.6 ng/L efavirenz (96 hrs) 
did not find significant differences in CF, HSI, SSI and GSI. However, this study 
noted significant histopathological changes in the fish liver tissue. Furthermore, 
Nibamureke et al. (2018 and 2019a) found no significant differences in CF of 30 and 
60 days old juveniles O. mossambicus exposed to NVP L (1.48 µg/L).  
The fish exposed to NVP and to the mixture showed a high mean HSI compared to 
the control. The observed high values of the HSI indicate an increase in liver size of 
fish exposed to NVP. Hepatomegaly is a known side effect of NVP in humans 
(Ostrreicher & Trauner 2012). The reduced SSI values of fish from the NVP H group 
could be explained by the complex immune factors decreasing the size of the spleen 
as a result from pharmaceutical exposure (Rivero et al. 2007).  
5.3.4. Histopathology 
The liver and kidney as the main sites of detoxification and excretion of most 
pharmaceuticals are exposed to diverse types of toxicity from those compounds and 
their metabolites which may lead to injury (Fisher at al. 2015; Pinheiro et al. 2017). 
Liver hypertrophy due to hepatocyte vacuolation or fatty changes is one of the 
changes that can be caused by pharmaceuticals exposure and this can lead to 
impaired liver functions and overall health problems (Nayak et al. 1996; Fisher et al 
2015; Schoenfuss et al. 2016). Depending on the severity of the lesions due to 
pharmaceutical exposure, renal osmoregulatory functions are affected and this may 
lead to renal and general health impairment (Bonga & Lock 2008). 
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Nevirapine bio-transformation, elimination and toxicity mechanisms have been 
widely investigated in humans (Riska et al. 1999b; Bjornsson & Olsson 2006; Ford 
et al. 2013; WHO 2014). In animals, the available information is mostly on rats 
(Adaramoye et al. 2012). The liver is the main site for NVP bio-transformation and 
the different metabolites are eliminated mostly in the urine (Riska et al. 1999a; 
Pinheiro et al. 2017). The pharmaceutical compounds are processed in the liver via 
blood plasma and bile, and they can damage liver cells since they are still active 
(Ostrreicher & Trauner 2012). NVP toxicity in humans includes liver hepatitis which 
is characterised by necrosis, inflammation, jaundice, mild fatty change and liver 
swelling (Rivero et al. 2007). In addition, chronic liver injury due to pharmaceuticals 
can sometimes lead to fibrosis around blood vessels and bile ducts (Fisher et al. 
2015; Tanaka & Miyajima 2016). In rats, reported NVP and other ARVs toxicological 
effects include inflammatory responses necrosis of the liver cells, alteration of the 
kidney and gonads weight as well as degeneration of seminiferous tubules in the 
testis (Azu et al. 2014; Adaramoye et al. 2012). Assaram et al. (2018) have shown 
that most of the ARVs used in South Africa are associated with renal impairment in 
humans. The kidney also plays a role in the excretion of the metabolism products of 
those compounds (Pazhayattil & Shirali 2014). As it is for NVP, SMX and TMP are 
also metabolised in the liver and excreted through the kidney (Pazhayattil & Shirali 
2014; Autmizguine et al. 2018). Their effects to humans and rats include liver toxicity 
and kidney injury (Bjornsson & Olsson 2006; Fraser et al. 2012; Assaram et al. 
2018). Some of the histopathology caused by SMX–TMP on the liver tissue include 
inflammation in the portal area observed in humans and rats (Bjornsson & Olsson 
2006; Yang et al. 2014), single cell necrosis (Hanses et al. 2009) and lipid 
vacuolation (Osterreicher & Trauner 2012). In the kidney, SMX-TMP are known to 
cause hyaline degeneration in humans and necrosis of renal tubules (Pazhayattil & 
Shirali 2014).  
Comparing the present study findings with the above cited literature on NVP, SMX 
and TMP toxicity in humans and rats, the fish exposed to both low (1.48 µg/L) and 
high (3.74 µg/L) concentrations of NVP presented some of the above cited 
histopathology including hepatocytes vacuolation (lipid and non-lipid), necrosis of 
hepatocytes surrounding blood vessels, karyolysis (nucleus death) which is followed 
by frank necrosis (cell death) in the liver. As this was a chronic study, the fish also 
had developed progressive changes, namely mild fibrosis around blood vessels and 
bile ducts which may have been caused by recurring inflammatory response to 
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hepatocytes necrosis (Hinton et al. 2008; Tanaka & Miyajima 2016; David & 
Hamilton 2010). However, regressive changes were the most prevalent histological 
changes in all groups. These types of changes are related to the functioning of the 
tissue (Bernet et al. 1999; van Dyk et al. 2007; Marchand et al. 2009; Răsković et 
al. 2013). The high prevalence of these changes could be interpreted as a warning 
sign that the liver tissue is burdened by the tested pharmaceuticals which can 
impede the organ function. Progressive changes such as fibrosis around blood 
vessels and bile ducts were observed in the fish exposed to NVP and to the mixture 
only. The hepatocytes surrounding the blood vessel become necrotic as the tissue 
reacts with an inflammatory response followed later by fibrosis to limit the damage 
(David & Hamilton 2010). Fibrosis may lead to the narrowing of the blood vessel or 
bile ducts making it difficult for the blood or the bile to flow (Thoolen et al. 2010; 
Ostrreicher & Trauner 2012). 
Regarding the kidney, the main histological changes observed in exposed fish 
included circulatory disturbances (dilation of the glomerulus capillaries), regressive 
changes in renal tubules (vacuolation, hyaline degeneration, nuclear alteration and 
necrosis), regressive changes in the glomerulus (dilation of the Bowman space, 
glomerulus atrophy) and MMCs increase in the interstitial tissues. Renal tubules 
necrosis and glomerulus atrophy were only observed in the exposed fish and were 
more prevalent and severe in the fish exposed to the mixture of NVP and the 
antibiotics. These results are in line with Bonga and Lock (2008) who reported that 
the organic chemicals can cause extensive alterations to the kidney histology 
starting with the renal tubules and moving to the glomeruli in case of chronic 
exposure or exposure to higher concentrations. Regressive changes associated 
with the organ function were also the most prevalent in the kidney; this implies that 
the kidney function could be impaired if the exposure were to continue.  
Significant differences were found between the liver indices of exposed fish and the 
control fish. Dose - response relationship in liver histopathology and the effects of 
the mixture of pharmaceuticals were not statistically significant although for both 
female and male, the fish exposed to NVP H (3.74 µg/L) and to the mixture showed 
higher liver indices compared to the control fish and compared to NVP L (1.48 µg/L). 
However, for the kidney, NVP L (1.48 µg/L), NVP H (3.74 µg/L) and the mixture all 
caused significant changes in exposed fish compared to the control. Although the 
exposed fish kidney indices were generally higher compared to the control, NVP 
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dose - response relationship as well as the mixture effect were not significant. 
Comparing these results to a recent study done by Robson et al. (2017) on O. 
mossambicus acutely exposed to efavirenz, histological changes were found in the 
liver after only 96 hrs of exposure. However, the negative impact of NVP on fish liver 
observed in the present study was more intensified with the presence of progressive 
changes and the high frequency of karyolysis in liver cells. This is no surprise as the 
concentrations of NVP used by this study were higher than efavirenz concentrations 
used in Robson et al. (2017) study (1.48 µg/L and 3.74 µg/L versus 10.3 ng/L and 
20.6 ng/L). In addition, this was a chronic exposure compared to Robson et al. 
(2017) acute exposure study (30 days versus 96 hrs).  
Concerning the gonads, there is little information on ARVs affecting the reproductive 
system in humans. Kushnir & Lewis (2011) have mentioned that the HAART 
regimen may cause alterations in the reproductive system leading to cases of 
infertility observed in HIV/AIDS patients. Other few studies involving autopsy on the 
male reproductive system in HIV/AIDS patients have observed histopathological 
changes including seminiferous tubules atrophy (Da Silva et al. 1990; Azu 2012). In 
contrast, studies on rats treated with NVP and other ARVs are widely available and 
have reported testicular alterations including degeneration of seminiferous tubules 
as well as a decrease in sperm motility (Adaramoye et al. 2012; Azu et al. 2014; 
Oyeyipo et al. 2018). Furthermore, SMX-TMP is known to cause a risk of abortion 
and physical deformation of the foetus if they are taken during the first semester of 
pregnancy (Straub 2016). A study conducted by Madureira et al. (2011) which 
exposed female and male fish to a mixture of pharmaceuticals [carbamazepine (178 
ng/L), fenofibrate (70.3 ng/L), propranolol hydrochloride (3.18 ng/L), SMX (53.3 
ng/L) and TMP (15.7 ng/L)] found an increase in immature gametes and a decrease 
in mature gametes in both female and male. In addition, the same study showed a 
high prevalence of oocyte atresia in female fish (Madureira et al. 2011). Likewise, 
the exposed female fish from the present study recorded high gonad indices 
compared to males. A significant difference was detected in gonad indices of female 
fish exposed to NVP H (3.74 µg/L) and those exposed to the mixture of 
pharmaceuticals compared to the control group (p < 0.05). Male fish did not show 
significant differences in gonad indices compared to the control. The main 
histological change detected in the ovaries of female fish was oocyte atresia 
occurring mainly in the fish expose to NVP H (3.74 µg/L) and to the mixture. This 
study also observed vacuolation of the oogonia nest which was more prevalent in 
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the exposed fish, but the GSI was not affected. These results are keeping with the 
findings of Madureira et al. (2011) who reported strong evidences of non-steroid 
pharmaceuticals that can sometimes disrupt the reproductive system by causing 
change in the histology of the reproductive cells without affecting the GSI. For some 
reasons not clear, the presence of NVP and the antibiotics (SMX and TMP) triggered 
atresia of late vitellogenic and mature oocytes in exposed fish. One can argue that 
these pharmaceuticals have acted as oestrogenic substances which induced atretic 
oocytes at an abnormal high rate and could result in impaired fish reproduction as 
observed by Diniz et al. (2005) and Madureira et al. (2011).  
Using the classification by Zimmerli et al. (2007) as modified by van Dyk et al. 
(2009), the adult fish kidney, ovary and testis histopathology were classified in class 
1 and 2 (normal tissue histology with mild or moderate alteration) while the liver 
histopathology of the fish exposed to NVP L (1.48 µg/L) and to the mixture were in 
class 3 (pronounced alteration of the tissue). Notwithstanding the significance of the 
changes observed in the kidney and the ovaries of the exposed fish, the alteration 
of the tissues was moderate and might not disturb the organ function as reported by 
van Dyk et al. (2009). But, for the liver of fish exposed to NVP L (1.48 µg/L) as a 
single toxicant and those exposed to the mixture of NVP and antibiotics, the 
histological changes of the organs were pronounced (class 3) and could lead to 
impaired liver function (Schoenfuss et al. 2016). 
 
5.4. Pharmaceutical exposure and different life stages of O. mossambicus 
Histological assessment of the liver and kidney tissue of O. mossambicus 30 days 
old showed that the exposed fish recorded high organ indices compared to the 
control fish except for the fish exposed to NVP 1.48 µg/L. The same was found with 
adult fish liver and kidney tissues. However, comparing liver and kidney indices of 
the 30 days old juveniles to those of the adult fish, there is a very big difference.  
The sensitivity of the liver of the adult fish to the tested pharmaceuticals was in the 
following order: Mixture 1 > NVP L > NVP H. For the kidney, the sensitivity was as 
follow: Mixture 1 > NVP H > NVP L.  For the 30 days old juveniles, the sensitivity of 
the liver to the pharmaceuticals was in the order: Mixture 2 > Mixture 1 > NVP H > 
NVP L. While the pharmaceutical sensitivity for the juvenile kidney was: NVP H > 
Mixture 1 > NVP L > Mixture 2. Following the classification by Zimmerli et al. (2007) 
as adapted by van Dyk et al. (2009), the liver and kidney of early life stages were 
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classified in class 1 of normal histology with mild changes to the organ histology. As 
discussed before these findings support the results on the growth evaluation and 
survival (Nibamureke et al. 2018 and 2019a). The kidney of adult fish was classified 
in class 2 characterised by moderate changes to the organ histology while the liver 
was classified in class 2 for the NVP H exposure and in class 3 (pronounced 
histological change to the organ) for NVP L and Mixture 1. It is thus clear that 
histological changes in the liver and in the kidney were more advanced in adult fish. 
This was not expected as most of studies have stated that early life stages are more 
sensible to pollutants in the water than adult fish (Lin et al. 2013; Mohammed 2013; 
Gonzalez-Doncel et al. 2014; Stancova et al. 2014). In fact, different studies done 
on early life stages of aquatic animals including fish have maintained that early life 
stages are highly sensitive to different toxicants in water compared to adult fish 
mostly because their body and organs are not yet well developed to cope with the 
high load of toxicants in water (Gopalakrishnan 2008; Macova et al. 2008; 
Mohammed 2013). The different detoxifying enzymes involved in the metabolism of 
organic compounds are found mostly in the liver and the kidney (Di Giulio & Hinton 
2008). While those enzymes are well developed in adult fish, allowing their liver and 
kidney to detoxify their body, in early life stages those organs are not yet well 
developed or fully functional (Mohammed 2013). Thus, adult fish are biologically 
more equipped to deal with the different toxic compounds present in water 
compared to juvenile fish. However, in light of the current study results one can 
argue that the divergence from the mentioned studies can be explained by the fact 
that the adult fish were purchased from a private fishery company while the early 
life stages used were bred and grown in a controlled environmental room. It could 
not be guaranteed that the purchased fish had no pre-existent histological changes 
in their tissues even though physically they looked healthy. Previous researchers 
who conducted studies on different fish species showed that even the control fish 
may present some degree of histological changes in their tissue (Zimmerli et al. 
2007; Di Giulio & Hinton 2008; van Dyk et al. 2009).  
It can therefore be asserted that the changes observed in the liver, kidney and 
gonads of adult fish exposed to NVP as a single toxicant and in mixture with the 
antibiotics SMX and TMP have been caused by the exposure to the pharmaceuticals 
as there was a significant difference between the control and the exposed fish for 
both the 30 days old and the adult fish. However, as the control adult fish also 
showed regressive changes in the liver and kidney tissues, it can also be argued 
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that NVP and the antibiotics played a role in worsening pre-existent liver and kidney 
condition as it has been revealed to be the case in humans (Rivero et al. 2007; 
Kress 2005). It is therefore not surprising that the adult fish recorded higher organ 
indices compared to the 30 days old juveniles after exposure to pharmaceuticals.  
The results from this study demonstrated that histopathology as a biomarker was a 
useful tool in detecting effects of pharmaceutical exposure in fish. This agrees with 
Walubo et al. (2006) study which reported that the liver histopathology was more 
accurate in diagnosing NVP toxicity compared to other biomarkers in rats.  
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6.1. Conclusion 
Pharmaceuticals presence in aquatic environments are being investigated in 
different parts of the world. Some of the investigations focus on their potential 
ecotoxicological effects. African surface waters have shown extraordinarily high 
levels of some types of pharmaceuticals including ARVs and antibiotics such as 
sulfamethoxazole and trimethoprim. The potential effects of those pharmaceuticals 
on aquatic animals are still largely unknown.  
Chronic ecotoxicology studies using fish to investigate the effects of environmental 
relevant levels of pharmaceuticals are of great importance. They give a picture of 
how the targeted pharmaceuticals may impact the biota not only at organism level, 
but also at the population level as well as the food web. Data from such studies can 
assist to put measures in place to reduce or prevent the entry of pharmaceuticals 
and their residues in the environment. 
This study assessed the potential effects of the HIV ARV NVP and its mixtures with 
the antibiotics SMX and TMP in African waters on the different life stages of  
O. mossambicus (Mozambique tilapia). There is a limited information on the effects 
of ARVs on the health of exposed O. mossambicus. The present study is the first 
one to examine the effects of NVP as a single toxicant and in mixture with antibiotics 
(SMX and TMP) on all life stages of O. mossambicus in a chronic exposure. 
This study hypothesised that environmental relevant concentrations of NVP and its 
mixtures with the antibiotics SMX and TMP would negatively affect all the life stages 
of O. mossambicus after a chronic exposure. It was therefore expected that exposed 
early life stages would present reduced hatching success, survival and growth rate 
compared to the control fish. It was also anticipated that significant histopathological 
changes in the liver and kidney tissues would be observed in the exposed fish. 
Furthermore, it was predicted that blood parameters, biometric indices, liver, kidney 
and gonad tissues of exposed adult fish would present significant changes 
compared to the control fish. In addition, NVP H (3.74 mg/L) and the mixtures of 
pharmaceuticals were expected to cause more effects than NVP L (1.48 mg/L). 
Likewise, the exposed early life stages liver and kidney histology were anticipated 
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to be more affected compared to the adult fish. Drawing on the results from this 
study, the following conclusions can be made: 
i. The tested pharmaceuticals did not have effects on the hatching success 
of embryo and did not cause physical deformity. 
ii. Early life stages survival was not affected by the exposure to 
pharmaceuticals. 
iii. Early life stages growth and development were not affected by the 
presence of the pharmaceuticals in water. 
iv. Adult fish blood parameters showed varied responses to the presence of 
pharmaceuticals in water. In fact, the Hb and Hct were not affected by the 
presence of pharmaceuticals in water while the Lct levels were significantly 
different across the groups.  
v. Adult fish biometric indices showed diverse responses to pharmaceutical 
exposure. Actually, the CF and the GSI were not affected by the 
pharmaceuticals while the SSI and HSI were significantly different across 
the groups. 
vi. Early life stages and adult fish showed significant histological changes in 
the liver and kidney. However, the histological changes in the early life 
stages were classified as minor (class 1). Adult fish histological changes 
in the kidney and ovary were in class 2 (moderate changes). While the 
liver histopathology was in class 2 for NVP H (3.74 µg/L), it was in class 3 
(pronounced changes) for NVP L (1.48 µg/L) and for the pharmaceutical 
mixture. 
vii. Dose - effects relationship between NVP L (1.48 mg/L) and NVP H (3.74 
mg/L) presented discrepant results. Indeed, NVP H did not cause severe 
effects to the liver tissue in both early life stages and adult fish compared 
to NVP L as it was expected. However, for the kidney in adult fish, the 
dose - effects relationship was observed. 
viii. Early life stages were not more sensitive to the pharmaceuticals; adult fish 
recorded higher liver and kidney indices compared to early life stages. This 
is the opposite of what was expected.  
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ix. Nevirapine in a mixture with the antibiotics SMX and TMP caused 
pronounced histological changes in all organs compared to NVP L  
(1.48 mg/L) as a single toxicant in both early life stages and adult fish as 
it was expected.  
As a general conclusion, the results from the present study have shown that current 
environmentally relevant concentrations of the ARV NVP in African surface waters 
may negatively affect fish life, both as a single pollutant and in mixture with other 
pharmaceuticals such as SMX and TMP. The study showed that there is a potential 
threat of synergistic effects of NVP in mixture with other pharmaceuticals in aquatic 
environments on both early and adult life stages in the case of chronic exposure. 
 
6.2. Recommendations 
The data from the present study contributes to the scarce information available, 
locally and internationally, on the potential effects of ARVs as well as of the mixtures 
of pharmaceuticals in the environment. This study provides exclusive baseline 
information on the unintended effects of some of the most used pharmaceuticals in 
Africa on one of the most consumed indigenous fish species, O. mossambicus.  
These results show that the presence of ARVs (NVP) and antibiotics (SMX and 
TMP) in African aquatic environments is an environmental health problem which 
needs to be taken seriously and investigated further. It is therefore recommended 
that: 
1. The problem of ARVs and antibiotics pollution in the African aquatic 
environments should be investigated further to determine which species are 
more sensitive and the extent of the effects of those pharmaceuticals on 
aquatic life. This will help finding sustainable measures and strategies to 
protect the environment.  
2. The sex specific effects of the tested pharmaceuticals should be investigated 
further using a large sample size.  
3. The effects of the tested pharmaceuticals on the fish female reproductive cells 
should be investigated further using a large sample size. 
4. The laboratory studies on effects of pharmaceuticals on different life stages 
of a selected fish species should involve the whole life cycle and must use 
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own laboratory bred fish to minimize bias in results as fish purchased outside 
may have undetected health conditions.  
5. The authority in charge should look for sufficient treatment processes at 
WWTPs as the current techniques do not remove most of the 
pharmaceuticals including ARVs and antibiotics. 
6. A monitoring program for ARVs and other pharmaceuticals of interest in 
surface water should be initiated to plan for the safeguard guidelines of 
cleaner water for future generations.  
7. The authorities should put in place measures of awareness to sensitize the 
population on the safe disposal of old and unused pharmaceuticals. 
8. The programs for safe disposal and collection of old and unused 
pharmaceuticals should be put in place. Their use in Europe have been 
successful in collecting huge number of unused drugs. 
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 ANNEXURES 
ANNEXURE 1: EXPOSURE CONDITIONS 
 
A. Early life stages 
 
Test type:  Static renewal system 
Room temperature: 30 ± 1 ℃ 
Water temperature: 27 ± 1℃ 
pH range: 6.8 – 8.2 
Dissolved oxygen saturation: 80 – 120% 
Aeration: Through plastic tubes 
Total dissolved solids:  89 – 120 mg/l 
Electric conductivity: 185 – 210 µS/mg  
Photoperiod: 14 hrs light / 10 hrs dark 
Test chamber size: 1 L; 20 L; 90 L 
Test media volume: 820 ml; 17.5 L; 75 L 
Test media renewal frequency: Every 96 hrs 
Renewal volume: ± 3/4 test media 
Repetitions: ± 4 times 
Test organisms:  Oreochromis mossambicus 
Age of fish at start:  Fertilised eggs (± 24 hrs) 
Number of treatment groups:  6 groups (control; DMSO; NVP L; NVP 
H; Mixture 1; Mixture 2) 
Number of eggs per group at start: ± 60  
Feeding regime: Tilapia fry crumble # 1 (500 -750 µm 
AVI-Product (Pty) Ltd) 3 times / day 
Dilution water: Borehole water 
Solvent:  DMSO (± 0.003 ml /100 ml water) 
Start time: 24 hrs post - fertilisation 
Termination time:  60 days post - hatching 
Exposure duration: ± 65 days 
Endpoints: Hatching success; hatch time; survival; 
physical deformity; behaviour; growth; 
histopathology (liver and kidney) 
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B. Adult fish 
Test type:  Static renewal system 
Room temperature: 30 ± 1℃ 
Water temperature: 26.81 - 28.20 ℃ 
pH range: 6.5 – 8.5 
Dissolved oxygen range: 80 – 120% 
Aeration: Through plastic tubes 
Total dissolved solids: 96 ± 18.13 mg/dl 
Electric conductivity: 203 ± 1.87 µS/cm 
Photoperiod: 14 hrs light / 10 hrs dark 
Test chamber size: 90 L 
Test media volume: 75 L 
Test media renewal frequency: Every 96 hrs 
Renewal volume: ± ¾ of test media 
Repetitions: 2 times 
Test organisms:  Oreochromis mossambicus 
Age of fish:  11 months old 
Number of fish per test chamber: 1 
Number of treatment groups:  5 (control; DMSO; NVP L; NVP H; 
Mixture 1) 
Number of fish per group: Control: 8; DMSO: 8; NVP L: 12; 
NVP H: 12; Mixture 1: 12 
Feeding regime: Tilapia grower pellets (1 mm; AVI- 
Products (Pty) Ltd) 2 times/day 
Dilution water: Borehole water 
Solvent:  DMSO (± 0.003 ml /100 ml water) 
Exposure duration: 30 days 
Endpoints: Blood parameters (Hb; Hct; Lct); 
Condition factor (CF); 
histopathology (liver; kidney; 
gonads) 
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ANNEXURE 2: WATER ANALYSIS DATA 
 
A. Borehole water metal analysis (in mg/L) 
 
Ag  Al  As  Au  B  Ba  Be  Bi  Ca  Cd  Ce  Co  
Sample 1 < 0.010 < 0.100 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 13 < 0.010 < 0.010 < 0.010 
Sample 2 < 0.010 < 0.100 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 15 < 0.010 < 0.010 < 0.010 
 
            
Cr Cs  Cu  Dy  Er Eu Fe  Ga Gd  Ge  Hf Hg  
Sample 1 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.025 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 
Sample 2 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.025 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 
             
Ho In  Ir  K  La  Li  Lu  Mg  Mn  Mo  Na  Nb  
Sample 1 < 0.010 < 0.010 < 0.010 1.1 < 0.010 < 0.010 < 0.010 10 < 0.025 < 0.010 3 < 0.010 
Sample 2 < 0.010 < 0.010 < 0.010 1.2 < 0.010 < 0.010 < 0.010 10 < 0.025 < 0.010 4 < 0.010 
             
Nd Ni  Os P  Pb Pd  Pr  Pt  Rb  Rh  Ru Sb  
Sample 1 < 0.010 < 0.010 < 0.010 0.082 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 
Sample 2 < 0.010 < 0.010 < 0.010 0.234 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 
             
Sc  Se  Si   Sm  Sn  Sr  Ta  Tb  Te  Th  Ti  Tl  
Sample 1 < 0.010 < 0.010 11.9 < 0.010 < 0.010 0.068 < 0.010 < 0.010 < 0.010 < 0.010 0.017 < 0.010 
Sample 2 < 0.010 < 0.010 11.3 < 0.010 < 0.010 0.069 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 
             
Tm  U  V W  Y  Yb  Zn  Zr 
    
Sample 1 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 0.037 < 0.010     
Sample 2 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 < 0.010 0.052 < 0.010     
             
Laboratory: WATERLAB (Pty) Ltd    
Method: ICP-MS Scan WLAB050 (Report: 70247-A) 
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B. Borehole water physical and organic chemical analysis (in mg/L) 
 
Analyses in mg/ℓ 
(Unless specified otherwise) Method 
Identification 
Sample Identification 
1 2 
Sample Number 16047 16048 
pH – Value at 25°C     WLAB065 6.9 6.9 
Total Dissolved Solids at 180°C  WLAB003 140 158 
Total Alkalinity as CaCO3 WLAB007 56 56 
Chloride as Cl     
  
WLAB046 14 14 
Sulphate as SO4  WLAB046 7 7 
Nitrate as N   WLAB046 2.9 3.0 
Nitrite as N  WLAB046 <0.05 <0.05 
Silica as SiO2  WLAB046 24 24 
Ortho Phosphate as P  WLAB046 <0.1 <0.1 
Dissolved Oxygen as O2  WLAB040 8.1 7.9 
Free & Saline Ammonia as N  WLAB046 0.2 0.2 
ICP-MS Scan  WLAB050 Report: 70247-A 
% Balancing  --- 93.7 97.7 
 
 
Organic Analyses: Organochlorine Pesticides  
Analyses in mg/ℓ 
(Unless specified otherwise) 
Sample Identification 
1 2 
Sample Number 16047 16048 
Aldrin  <0.0001 <0.0001 
Alpha-HCH  <0.0001 <0.0001 
Alpha-Chlordane  <0.0001 <0.0001 
Beta-HCH  <0.002 <0.002 
Delta-HCH  <0.002 <0.002 
Dieldrin  <0.0002 <0.0002 
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Endrin  <0.001 <0.001 
Gamma-HCH  <0.001 <0.001 
Gamma-Chlordane  <0.0001 <0.0001 
Heptachlor  <0.0001 <0.0001 
Heptachlor Epoxide Isomer B  <0.0001 <0.0001 
Methoxychlor  <0.0001 <0.0001 
4,4’-DDD  <0.0001 <0.0001 
4,4’-DDE  <0.0001 <0.0001 
4,4’-DDT  <0.0001 <0.0001 
 
 
Organic Analyses: Organophosphorus Pesticides  
Analyses in mg/ℓ 
(Unless specified otherwise) 
Sample Identification 
1 2 
Sample Number 16047 16048 
Dichlorvos  <0.020 <0.020 
Fenchlorphos (Ronnel)  <0.001 <0.001 
Methyl Parathion  <0.001 <0.001 
Chlorpyrofos (Dursban)  <0.001 <0.001 
Proyhiofos (Tokuthion)  <0.001 <0.001 
Mocap (Enthoprofos)  <0.001 <0.001 
Disulfoton  <0.001 <0.001 
Guthion  <0.020 <0.020 
ICP-MS Scan  WLAB050 Report: 70247-A 
Laboratory: WATERLAB (Pty) Ltd    
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C. Exposure water physico-chemical parameters (means and SD) – Adult fish 
TANK  
No 
Groups Repeats Temp  
(°C) 
SD EC  
(mS/L) 
SD TDS  
(mg/L) 
SD pH SD 
7 1 1 26.67 0.13 203.78 7.33 97.06 3.62 7.95 0.30 
8 1 1 26.88 0.15 215.28 12.26 102.44 5.83 7.85 0.39 
23 1 1 27.20 0.45 184.15 3.08 87.54 1.51 7.70 0.00 
24 1 1 27.05 0.41 191.38 4.70 90.85 1.86 7.65 0.07 
39 1 2 28.05 0.34 207.33 11.93 99.22 4.24 7.38 0.41 
40 1 2 28.03 0.41 211.14 16.91 100.71 10.70 7.25 0.45 
42 1 2 27.84 0.45 225.31 4.89 107.46 2.47 7.72 0.24 
43 1 2 27.63 0.47 222.62 3.48 105.69 2.36 7.82 0.22 
9 2 1 26.73 0.13 205.78 4.05 98.28 1.90 7.70 0.51 
10 2 1 26.71 0.16 223.15 10.87 120.15 13.42 7.28 0.39 
25 2 1 27.25 0.42 209.23 19.09 99.62 9.14 7.00 0.28 
26 2 1 28.00 0.37 220.80 5.25 104.10 3.41 7.28 0.39 
41 2 2 28.07 0.40 220.75 11.06 106.88 8.56 7.28 0.43 
44 2 2 27.87 0.43 225.92 8.55 109.15 6.23 7.60 0.07 
45 2 2 27.75 0.48 228.23 4.87 112.38 6.50 7.53 0.09 
1 3 1 26.75 0.21 202.11 6.69 96.11 3.27 7.95 0.30 
2 3 1 26.66 0.19 203.11 3.95 96.61 1.69 7.95 0.30 
3 3 1 26.74 0.15 200.89 4.00 95.56 1.95 7.95 0.30 
4 3 1 26.73 0.17 204.89 3.97 97.50 1.89 7.95 0.30 
5 3 1 26.77 0.15 197.67 3.24 94.17 1.54 7.90 0.27 
6 3 1 26.74 0.17 203.44 5.80 96.94 2.90 7.93 0.32 
17 3 2 27.28 0.49 200.77 12.54 95.08 5.57 6.95 0.21 
18 3 2 27.18 0.45 199.77 11.97 94.69 5.25 6.85 0.07 
19 3 2 27.02 0.44 199.38 9.27 94.85 4.54 7.10 0.14 
20 3 2 27.15 0.44 200.85 11.44 95.15 4.96 6.95 0.07 
21 3 2 27.18 0.43 194.77 9.29 92.62 4.59 7.00 0.14 
22 3 2 27.12 0.40 197.15 8.85 93.85 4.12 7.15 0.21 
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TANK  
No 
Groups Repeats Temp  
(°C) 
SD EC  
(mS/L) 
SD TDS  
(mg/L) 
SD pH SD 
11 4 1 26.68 0.17 222.69 9.40 111.31 7.23 7.50 0.35 
12 4 1 26.74 0.16 199.00 8.75 94.69 4.31 7.38 0.40 
13 4 1 26.82 0.15 200.62 8.83 95.54 4.22 6.95 1.18 
14 4 1 26.85 0.40 209.92 3.80 99.92 1.80 7.46 0.41 
15 4 1 26.75 0.20 202.46 7.10 96.31 3.38 7.36 0.43 
16 4 1 27.54 0.17 213.08 6.14 101.54 3.02 7.01 0.12 
33 4 2 28.17 0.40 219.33 9.49 108.56 8.23 7.41 0.37 
34 4 2 28.04 0.40 209.86 11.51 102.71 8.34 7.30 0.42 
35 4 2 27.81 0.29 219.00 13.99 107.75 10.69 7.29 0.46 
36 4 2 28.03 0.49 218.83 10.98 108.33 11.00 7.35 0.38 
37 4 2 27.93 0.32 220.75 15.42 106.50 8.60 7.37 0.47 
38 4 2 27.90 0.40 220.17 15.74 105.33 7.58 7.33 0.45 
27 5 1 27.88 0.44 217.00 10.32 101.67 6.83 7.50 0.35 
28 5 1 28.20 0.35 219.00 9.14 103.89 6.07 7.38 0.40 
29 5 1 28.09 0.55 222.38 14.70 104.88 8.64 6.95 1.18 
30 5 1 28.20 0.35 216.50 7.65 102.20 5.03 7.46 0.41 
31 5 1 28.06 0.46 214.14 12.59 100.57 5.59 7.36 0.43 
32 5 1 27.92 0.34 223.11 14.96 105.33 8.50 7.01 1.12 
46 5 2 27.75 0.47 222.31 6.99 109.38 8.09 7.46 0.15 
47 5 2 27.82 0.36 226.92 9.02 111.69 8.72 7.30 0.29 
48 5 2 27.78 0.39 227.31 7.38 109.54 6.06 7.40 0.15 
49 5 2 27.80 0.39 225.46 4.70 117.31 4.03 7.40 0.14 
50 5 2 27.69 0.39 227.54 8.11 122.15 5.83 7.33 0.21 
51 5 2 27.60 0.40 227.85 5.70 114.00 6.07 7.37 0.16 
Groups: 1 = control; 2 = solvent control; 3 = NVP L; 4 = NVP H; 5 = Mixture 1 
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 ANNEXURES 
D. Exposure water physico-chemical parameters (means and SD) – Early life stages 
   REPEATS MEAN SD 
PARAMETERS GROUPS  1 2 3 4   
TEMPERATURE (℃) 
Control 1 
Mean 27.50 27.18 27.52 27.40 27.40 0.15 
SD 0.57 0.33 0.44 0.49   
DMSO 
Mean 27.40 27.18 27.42 27.28 27.32 0.11 
SD 0.42 0.41 0.35 0.51   
NVP L 
Mean 27.45 27.26 27.28 27.36 27.34 0.09 
SD 0.64 0.38 0.42 0.47   
Control 2 
Mean 27.85 27.94 n.d n.d 27.89 0.06 
SD 0.56 0.54 n.d n.d   
NVP H 
Mean 27.74 27.88 n.d n.d 27.81 0.10 
SD 0.61 0.46 n.d n.d   
Mixture 1 
Mean 27.59 27.77 n.d n.d 27.68 0.13 
SD 0.62 0.48 n.d n.d   
Mixture 2 
Mean 27.60 27.71 n.d n.d 27.65 0.08 
SD 0.65 0.55 n.d n.d   
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   REPEATS MEAN SD 
PARAMETERS GROUPS  1 2 3 4   
EC (µS/mg) 
Control 1 
Mean 208.00 206.00 212.33 212.63 209.74 3.27 
SD 2.83 5.05 6.77 9.57   
DMSO 
Mean 219.50 207.80 212.50 210.25 212.51 5.04 
SD 14.85 4.49 6.92 7.59   
NVP L 
Mean 220.00 206.00 215.67 211.38 213.26 5.99 
SD 14.14 5.52 6.98 9.85   
Control 2 
Mean 215.13 213.92 n.d n.d 214.52 0.85 
SD 7.66 7.16 n.d n.d   
NVP H 
Mean 214.50 212.73 n.d n.d 213.62 1.25 
SD 8.83 8.13 n.d n.d   
Mixture 1 
Mean 216.75 213.58 n.d n.d 215.16 2.24 
SD 9.02 8.87 n.d n.d   
Mixture 2 
Mean 217.75 214.77 n.d n.d 216.26 2.11 
SD 10.82 8.45 n.d n.d   
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   REPEATS MEAN SD 
PARAMETERS GROUPS  1 2 3 4   
 
TDS (mg/L) 
Control 1 
Mean 99.00 97.00 101.33 101.25 99.65 2.07 
SD 1.41 4.47 3.20 6.91   
DMSO 
Mean 104.50 98.00 101.50 100.63 101.16 2.68 
SD 7.78 4.53 3.33 4.82   
NVP L 
Mean 104.50 96.20 102.83 102.25 101.45 3.62 
SD 7.78 5.67 3.66 8.26   
Control 2 
Mean 105.88 103.73 n.d n.d 104.80 1.52 
SD 8.94 7.00 n.d n.d   
NVP H 
Mean 103.00 101.38 n.d n.d 102.19 1.14 
SD 5.35 4.29 n.d n.d   
Mixture 1 
Mean 105.63 102.35 n.d n.d 103.99 2.32 
SD 9.93 6.76 n.d n.d   
Mixture 2 
Mean 107.50 104.77 n.d n.d 106.13 1.93 
SD 13.14 8.35 n.d n.d   
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   REPEATS MEAN SD 
PARAMETERS GROUPS  1 2 3 4   
         
pH 
Control 1 
Mean 7.80 7.96 8.03 7.85 7.91 0.11 
SD 0.00 0.23 0.31 0.17   
DMSO 
Mean 7.75 7.90 8.02 7.84 7.88 0.11 
SD 0.21 0.20 0.33 0.11   
NVP L 
Mean 7.75 7.96 7.98 7.79 7.87 0.12 
SD 0.21 0.22 0.29 0.14   
Control 2 
Mean 7.96 8.02 n.d n.d 7.99 0.04 
SD 0.27 0.26 n.d n.d   
NVP H 
Mean 7.96 8.00 n.d n.d 7.98 0.02 
SD 0.29 0.27 n.d n.d   
Mixture 1 
Mean 7.98 7.99 n.d n.d 7.98 0.01 
SD 0.31 0.26 n.d n.d   
Mixture 2 
Mean 7.98 8.01 n.d n.d 7.99 0.02 
SD 0.31 0.28 n.d n.d   
SD = Standard Deviation; n.d = not done 
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 ANNEXURES 
E. Nevirapine analysis in water samples 
Sample ID Target Conc. (µg/L) Tank No. Time % Recovery % RSD Final Conc. (µg/L) 
1 1.48 11a Start 44 3 1.82 
2 3.74 11b Start 58 10 3.85 
3 1.48 1a Start 43 14 1.5 
4 3.74 1b Start 97 3 4.3 
5 1.48 1a Renewal 89 3 2.12 
6 3.74 1b Renewal 80 10 5.2 
7 3.74 1b 96 hrs 102 10 4.24 
8 1.48 1a 96 hrs 77 6 1.43 
9 3.74 3b Start 78 18 4.16 
10 1.48 3a Start 60 8 1.78 
11 1.48 3a Renewal 76 15 3.41 
12 3.74 11b Renewal 86 12 5.89 
13 1.48 3a 96 hrs 89 11 1.86 
14 3.74 3b 96 hrs 91 10 5.39 
15 1.48 5a Start 80 12 1.9 
16 3.74 3b Renewal 87 14 5.01 
17 3.74 5b Renewal 83 1 5.39 
18 1.48 5a 96 hrs 93 9 1.5 
19 3.74 5b 96 hrs 84 48 5.92 
20 1.48 10a Start 76 12 2.89 
21 3.74 5b Start 95 5 4.51 
22 Blank 8 Start 76 8 < LOD 
23 Blank 8 96 hrs 93 15 < LOD 
24 Blank 8 Renewal 69 13 < LOD 
25 DMSO 9 Start 51 16 < LOD 
26 1.48 5a Renewal 85 2 3.8 
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 ANNEXURES 
ANNEXURE 3: FISH FOOD QUALITY 
 
A. EARLY LIFE STAGES FOOD 
 
Tilapia fry crumble # 1 (500 – 750 µm) containing: 
Protein Min 450 g/kg 
Lysine Min  25 g/kg 
Fat Min  50 g/kg 
Moisture Max  100 g/kg 
Crude fibre Max  30 g/kg 
Calcium  Max  30 g/kg 
Phosphorus  Min  7 g/kg 
 
B. ADULT FISH FOOD  
 
Tilapia grower pellets # 1 (3 mm) containing: 
Protein Min 350 g/kg 
Lysine Min  20 g/kg 
Fat Min  50 g/kg 
Moisture Max  100 g/kg 
Crude fibre Max  30 g/kg 
Calcium  Max  30 g/kg 
Phosphorus  Min  7 g/kg 
 
Company: AVI-Products (Pty) Ltd 2001/015923/07, Durban, KwaZulu-Natal 
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 ANNEXURES 
ANNEXURE 4: EARLY LIFE STAGES STUDIES DATA 
 
A. Early life stages biometric data – 1st experiment 
Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
1 1 1 1 7.00 0.0040 1.166 3 4 10 13 0 
2 1 1 1 5.00 0.0040 3.200 3 4 10 13 0 
3 1 1 1 6.00 0.0030 1.389 3 4 10 13 1 
4 1 1 1 4.00 0.0040 6.250 3 4 10 13 0 
5 1 1 1 6.00 0.0040 1.852 3 4 10 13 0 
6 1 1 2 7.00 0.0050 1.458 3 4 9 11 0 
7 1 1 2 6.10 0.0050 2.203 3 4 9 11 0 
8 1 1 2 4.50 0.0040 4.390 3 4 9 11 0 
9 1 1 2 4.00 0.0030 4.688 3 4 9 11 0 
10 1 1 2 5.00 0.0030 2.400 3 4 9 11 0 
11 1 1 2 4.00 0.0040 6.250 3 4 9 11 0 
12 1 1 2 4.00 0.0030 4.688 3 4 9 11 0 
13 1 1 2 6.00 0.0030 1.389 3 4 9 11 0 
14 1 1 2 5.00 0.0040 3.200 3 4 9 11 0 
15 1 1 2 5.00 0.0040 3.200 3 4 9 11 0 
16 1 1 3 4.50 0.0030 3.292 3 4 10 14 0 
17 1 1 3 4.50 0.0044 4.829 3 4 10 14 0 
18 1 1 3 5.00 0.0039 3.120 3 4 10 14 0 
19 1 1 3 6.00 0.0042 1.944 3 4 10 14 0 
20 1 1 3 6.20 0.0038 1.594 3 4 10 14 0 
21 1 1 3 5.00 0.0040 3.200 3 4 10 14 0 
22 1 1 3 6.00 0.0040 1.852 3 4 10 14 0 
23 1 1 3 5.20 0.0042 2.987 3 4 10 14 0 
24 1 1 3 5.00 0.0038 3.040 3 4 10 14 0 
25 1 1 3 5.70 0.0040 2.160 3 4 10 14 0 
26 1 1 4 5.00 0.0059 4.720 3 4 8 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
27 1 1 4 5.00 0.0041 3.280 3 4 8 11 0 
28 1 1 4 5.10 0.0045 3.392 3 4 8 11 0 
29 1 1 4 3.00 0.0044 16.296 3 4 8 11 0 
30 1 1 4 5.00 0.0043 3.440 3 4 8 11 0 
31 1 1 4 4.00 0.0039 6.094 3 4 8 11 0 
32 1 1 4 4.00 0.0040 6.250 3 4 8 11 0 
33 1 1 4 5.00 0.0040 3.200 3 4 8 11 0 
34 1 1 4 4.00 0.0040 6.250 3 4 8 11 0 
35 1 1 4 4.00 0.0041 6.406 3 4 8 11 0 
36 30 1 1 14.00 0.038 1.385 3 4 10 13 0 
37 30 1 1 18.00 0.081 1.389 3 4 10 13 0 
38 30 1 1 16.00 0.050 1.221 3 4 10 13 0 
39 30 1 1 20.00 0.117 1.463 3 4 10 13 0 
40 30 1 1 20.00 0.121 1.513 3 4 10 13 0 
41 30 1 2 16.00 0.066 1.611 3 4 9 11 0 
42 30 1 2 17.00 0.086 1.750 3 4 9 11 0 
43 30 1 2 14.00 0.044 1.603 3 4 9 11 0 
44 30 1 2 12.00 0.032 1.852 3 4 9 11 0 
45 30 1 2 13.00 0.023 1.047 3 4 9 11 0 
46 30 1 2 12.00 0.025 1.447 3 4 9 11 0 
47 30 1 2 11.00 0.022 1.653 3 4 9 11 0 
48 30 1 2 13.00 0.028 1.274 3 4 9 11 0 
49 30 1 2 13.00 0.027 1.229 3 4 9 11 0 
50 30 1 2 12.00 0.045 2.604 3 4 9 11 0 
51 30 1 3 17.00 0.070 1.425 3 4 10 14 0 
52 30 1 3 14.00 0.040 1.458 3 4 10 14 0 
53 30 1 3 12.00 0.020 1.157 3 4 10 14 0 
54 30 1 3 18.00 0.030 0.514 3 4 10 14 0 
55 30 1 3 14.00 0.040 1.458 3 4 10 14 0 
56 30 1 3 14.00 0.030 1.093 3 4 10 14 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
57 30 1 3 14.00 0.070 2.551 3 4 10 14 0 
58 30 1 3 12.50 0.050 2.560 3 4 10 14 0 
59 30 1 3 10.00 0.030 3.000 3 4 10 14 0 
60 30 1 3 15.00 0.050 1.481 3 4 10 14 0 
61 30 1 4 13.00 0.027 1.229 3 4 8 11 0 
62 30 1 4 14.00 0.037 1.348 3 4 8 11 0 
63 30 1 4 14.00 0.030 1.093 3 4 8 11 0 
64 30 1 4 13.00 0.032 1.457 3 4 8 11 0 
65 30 1 4 11.50 0.024 1.578 3 4 8 11 1 
66 30 1 4 14.00 0.041 1.494 3 4 8 11 0 
67 30 1 4 14.00 0.035 1.276 3 4 8 11 0 
68 30 1 4 12.00 0.018 1.042 3 4 8 11 0 
69 30 1 4 12.00 0.022 1.273 3 4 8 11 0 
70 30 1 4 13.00 0.024 1.092 3 4 8 11 0 
71 60 1 1 38.00 0.995 1.813 3 4 10 13 0 
72 60 1 1 34.00 0.652 1.659 3 4 10 13 0 
73 60 1 1 13.00 0.045 2.048 3 4 10 13 0 
74 60 1 1 41.00 1.116 1.619 3 4 10 13 0 
75 60 1 1 15.00 0.054 1.600 3 4 10 13 0 
76 60 1 2 17.00 0.071 1.445 3 4 9 11 0 
77 60 1 2 33.00 0.629 1.750 3 4 9 11 0 
78 60 1 2 37.00 0.966 1.907 3 4 9 11 0 
79 60 1 2 31.00 0.602 2.021 3 4 9 11 0 
80 60 1 2 32.00 0.548 1.672 3 4 9 11 0 
81 60 1 2 28.00 0.386 1.758 3 4 9 11 0 
82 60 1 2 23.00 0.221 1.816 3 4 9 11 0 
83 60 1 2 24.00 0.260 1.881 3 4 9 11 0 
84 60 1 2 32.00 0.527 1.608 3 4 9 11 0 
85 60 1 2 20.00 0.124 1.550 3 4 9 11 0 
86 60 1 2 26.00 0.309 1.758 3 4 9 14 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
87 60 1 3 26.00 0.328 1.866 3 4 10 14 0 
88 60 1 3 23.00 0.212 1.742 3 4 10 14 0 
89 60 1 3 32.00 0.521 1.590 3 4 10 14 0 
90 60 1 3 21.00 0.510 5.507 3 4 10 14 0 
91 60 1 3 39.00 0.957 1.613 3 4 10 14 0 
92 60 1 3 26.00 0.335 1.906 3 4 10 14 0 
93 60 1 3 27.00 0.334 1.697 3 4 10 14 0 
94 60 1 3 22.00 0.170 1.597 3 4 10 14 0 
95 60 1 3 36.00 0.762 1.633 3 4 10 14 0 
96 60 1 3 27.00 0.373 1.895 3 4 10 11 0 
97 60 1 3 32.00 0.526 1.605 3 4 10 11 0 
98 60 1 3 26.00 0.339 1.929 3 4 10 11 0 
99 60 1 3 34.00 0.735 1.870 3 4 10 11 0 
100 60 1 3 22.00 0.360 3.381 3 4 10 11 0 
101 60 1 3 36.00 0.768 1.646 3 4 10 11 0 
102 60 1 4 32.00 0.506 1.544 3 4 9 11 0 
103 60 1 4 25.00 0.230 1.472 3 4 9 11 0 
104 60 1 4 14.00 0.032 1.166 3 4 9 11 0 
105 60 1 4 14.00 0.037 1.348 3 4 9 11 0 
106 60 1 4 33.00 0.619 1.722 3 4 9 13 0 
107 60 1 4 25.00 0.249 1.594 3 4 9 13 0 
108 60 1 4 16.00 0.062 1.514 3 4 9 13 0 
109 60 1 4 13.00 0.037 1.684 3 4 9 13 0 
110 60 1 4 36.00 0.734 1.573 3 4 9 13 0 
111 60 1 4 15.00 0.056 1.659 3 4 9 11 0 
112 60 1 4 21.00 0.143 1.544 3 4 9 11 0 
113 60 1 4 31.00 0.400 1.343 3 4 9 11 0 
114 60 1 4 37.00 0.853 1.684 3 4 9 11 0 
115 60 1 4 19.00 0.111 1.618 3 4 9 11 0 
116 60 1 4 15.00 0.047 1.393 3 4 9 11 0 
 Uwineza Marie Clémentine Nibamureke    2019 193 
 
 ANNEXURES 
Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
117 1 2 1 5.00 0.0040 3.200 3 4 10 13 0 
118 1 2 1 6.00 0.0030 1.389 3 4 10 13 0 
119 1 2 1 6.00 0.0040 1.852 3 4 10 13 0 
120 1 2 1 7.00 0.0040 1.166 3 4 10 13 0 
121 1 2 1 6.00 0.0030 1.389 3 4 10 13 0 
122 1 2 2 6.00 0.0030 1.389 3 4 9 11 0 
123 1 2 2 4.00 0.0030 4.688 3 4 9 11 0 
124 1 2 2 5.00 0.0030 2.400 3 4 9 11 0 
125 1 2 2 5.00 0.0040 3.200 3 4 9 11 0 
126 1 2 2 4.00 0.0030 4.688 3 4 9 11 0 
127 1 2 2 3.00 0.0030 11.111 3 4 9 11 0 
128 1 2 2 6.00 0.0044 2.037 3 4 9 11 0 
129 1 2 2 4.00 0.0039 6.094 3 4 9 11 0 
130 1 2 2 7.00 0.0042 1.224 3 4 9 11 0 
131 1 2 2 6.00 0.0038 1.759 3 4 9 11 0 
132 1 2 3 6.00 0.0030 1.389 3 4 10 14 0 
133 1 2 3 6.00 0.0030 1.389 3 4 10 14 0 
134 1 2 3 5.40 0.0030 1.905 3 4 10 14 0 
135 1 2 3 6.00 0.0040 1.852 3 4 10 14 0 
136 1 2 3 5.00 0.0040 3.200 3 4 10 14 0 
137 1 2 3 6.00 0.0030 1.389 3 4 10 14 0 
138 1 2 3 5.20 0.0030 2.134 3 4 10 14 0 
139 1 2 3 6.00 0.0040 1.852 3 4 10 14 0 
140 1 2 3 6.00 0.0040 1.852 3 4 10 14 0 
141 1 2 3 4.00 0.0040 6.250 3 4 10 14 0 
142 1 2 4 5.00 0.0040 3.200 4 5 8 11 0 
143 1 2 4 5.00 0.0044 3.520 4 5 8 11 0 
144 1 2 4 4.50 0.0039 4.280 4 5 8 11 0 
145 1 2 4 5.00 0.0042 3.360 4 5 8 11 0 
146 1 2 4 5.00 0.0038 3.040 4 5 8 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
147 1 2 4 3.00 0.0034 12.593 4 5 8 11 0 
148 1 2 4 5.00 0.0047 3.760 4 5 8 11 0 
149 1 2 4 3.00 0.0042 15.556 4 5 8 11 0 
150 1 2 4 4.00 0.0038 5.938 4 5 8 11 0 
151 1 2 4 4.00 0.0040 6.250 4 5 8 11 0 
152 30 2 1 17.00 0.070 1.425 3 4 10 13 0 
153 30 2 1 17.00 0.079 1.608 3 4 10 13 0 
154 30 2 1 19.00 0.103 1.502 3 4 10 13 0 
155 30 2 1 17.00 0.080 1.628 3 4 10 13 0 
156 30 2 1 16.00 0.054 1.318 3 4 10 13 0 
157 30 2 2 17.00 0.095 1.934 3 4 9 11 0 
158 30 2 2 14.50 0.064 2.099 3 4 9 11 0 
159 30 2 2 15.00 0.056 1.659 3 4 9 11 0 
160 30 2 2 12.00 0.027 1.563 3 4 9 11 0 
161 30 2 2 16.00 0.030 0.732 3 4 9 11 0 
162 30 2 2 18.00 0.029 0.497 3 4 9 11 0 
163 30 2 2 14.00 0.024 0.875 3 4 9 11 0 
164 30 2 2 13.00 0.021 0.956 3 4 9 11 0 
165 30 2 2 12.00 0.024 1.389 3 4 9 11 0 
166 30 2 2 11.00 0.015 1.127 3 4 9 11 0 
167 30 2 3 12.00 0.030 1.736 3 4 10 14 0 
168 30 2 3 12.00 0.020 1.157 3 4 10 14 0 
169 30 2 3 11.00 0.040 3.005 3 4 10 14 0 
170 30 2 3 14.00 0.030 1.093 3 4 10 14 0 
171 30 2 3 13.00 0.020 0.910 3 4 10 14 0 
172 30 2 3 13.00 0.020 0.910 3 4 10 14 0 
173 30 2 3 13.00 0.030 1.365 3 4 10 14 0 
174 30 2 3 12.00 0.030 1.736 3 4 10 14 0 
175 30 2 3 11.00 0.030 2.254 3 4 10 14 0 
176 30 2 3 12.00 0.030 1.736 3 4 10 14 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
177 30 2 4 17.00 0.067 1.364 4 5 8 11 0 
178 30 2 4 15.00 0.048 1.422 4 5 8 11 0 
179 30 2 4 16.00 0.063 1.538 4 5 8 11 0 
180 30 2 4 11.00 0.019 1.427 4 5 8 11 0 
181 30 2 4 10.00 0.017 1.700 4 5 8 11 0 
182 30 2 4 15.00 0.050 1.481 4 5 8 11 0 
183 30 2 4 12.00 0.034 1.968 4 5 8 11 0 
184 30 2 4 13.00 0.028 1.274 4 5 8 11 0 
185 30 2 4 13.00 0.021 0.956 4 5 8 11 0 
186 30 2 4 11.50 0.016 1.052 4 5 8 11 0 
187 60 2 1 35.00 0.712 1.661 3 4 10 11 0 
188 60 2 1 33.00 0.620 1.725 3 4 10 11 0 
189 60 2 1 31.00 0.478 1.605 3 4 10 11 0 
190 60 2 1 32.00 0.526 1.605 3 4 10 11 0 
191 60 2 2 44.00 1.372 1.611 3 4 8 14 0 
192 60 2 2 25.00 0.282 1.805 3 4 8 14 0 
193 60 2 2 22.00 0.196 1.841 3 4 8 14 0 
194 60 2 2 23.00 0.225 1.849 3 4 8 14 0 
195 60 2 2 27.00 0.326 1.656 3 4 8 14 0 
196 60 2 2 28.00 0.341 1.553 3 4 8 14 0 
197 60 2 2 21.00 0.151 1.630 3 4 8 14 0 
198 60 2 2 19.00 0.107 1.560 3 4 8 14 0 
199 60 2 2 23.00 0.208 1.710 3 4 8 14 0 
200 60 2 2 28.00 0.336 1.531 3 4 8 14 0 
201 60 2 2 25.00 0.263 1.683 3 4 8 11 0 
202 60 2 2 20.00 0.116 1.450 3 4 8 11 0 
203 60 2 2 24.00 0.230 1.664 3 4 8 11 0 
204 60 2 3 28.00 0.370 1.685 3 4 10 11 0 
205 60 2 3 26.00 0.283 1.610 3 4 10 11 0 
206 60 2 3 24.00 0.237 1.714 3 4 10 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
207 60 2 3 17.00 0.076 1.547 3 4 10 11 0 
208 60 2 3 21.00 0.149 1.609 3 4 10 11 0 
209 60 2 3 31.00 0.471 1.581 3 4 10 11 0 
210 60 2 3 31.00 0.530 1.779 3 4 10 11 0 
211 60 2 3 26.00 0.315 1.792 3 4 10 13 0 
212 60 2 3 23.00 0.240 1.973 3 4 10 13 0 
213 60 2 3 17.00 0.068 1.384 3 4 10 13 0 
214 60 2 3 18.00 0.100 1.715 3 4 10 13 0 
215 60 2 3 27.00 0.342 1.738 3 4 10 13 0 
216 60 2 3 29.00 0.425 1.743 3 4 9 11 0 
217 60 2 3 22.00 0.177 1.662 3 4 9 11 0 
218 60 2 3 28.00 0.381 1.736 3 4 9 11 0 
219 60 2 4 34.00 0.589 1.499 3 4 10 11 0 
220 60 2 4 20.00 0.160 2.000 3 4 10 11 0 
221 60 2 4 23.00 0.216 1.775 3 4 10 11 0 
222 60 2 4 15.00 0.051 1.511 3 4 10 11 0 
223 60 2 4 35.00 0.661 1.542 3 4 10 11 0 
224 60 2 4 25.00 0.209 1.338 3 4 10 11 0 
225 60 2 4 17.00 0.094 1.913 3 4 10 11 0 
226 60 2 4 22.00 0.197 1.850 3 4 10 14 0 
227 60 2 4 38.00 0.795 1.449 3 4 10 14 0 
228 60 2 4 29.00 0.380 1.558 3 4 10 14 0 
229 60 2 4 19.00 0.098 1.429 3 4 10 14 0 
230 60 2 4 28.00 0.349 1.590 3 4 10 14 0 
231 60 2 4 35.00 0.709 1.654 3 4 10 14 0 
232 60 2 4 29.00 0.380 1.558 3 4 10 14 0 
233 60 2 4 24.00 0.236 1.707 3 4 10 14 0 
234 1 3 1 6.00 0.0040 1.852 4 5 10 13 0 
235 1 3 1 6.00 0.0030 1.389 4 5 10 13 0 
236 1 3 1 5.00 0.0030 2.400 4 5 10 13 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
237 1 3 1 6.00 0.0040 1.852 4 5 10 13 0 
238 1 3 1 6.00 0.0030 1.389 4 5 10 13 0 
239 1 3 2 6.00 0.0040 1.852 3 4 9 11 0 
240 1 3 2 4.00 0.0030 4.688 3 4 9 11 0 
241 1 3 2 5.00 0.0030 2.400 3 4 9 11 0 
242 1 3 2 5.00 0.0040 3.200 3 4 9 11 0 
243 1 3 2 4.00 0.0040 6.250 3 4 9 11 0 
244 1 3 2 6.00 0.0040 1.852 3 4 9 11 0 
245 1 3 2 5.00 0.0030 2.400 3 4 9 11 0 
246 1 3 2 4.00 0.0050 7.813 3 4 9 11 0 
247 1 3 2 4.00 0.0040 6.250 3 4 9 11 0 
248 1 3 2 3.00 0.0050 18.519 3 4 9 11 0 
249 1 3 3 6.00 0.0040 1.852 3 4 10 14 0 
250 1 3 3 5.10 0.0044 3.317 3 4 10 14 0 
251 1 3 3 6.50 0.0039 1.420 3 4 10 14 0 
252 1 3 3 6.00 0.0042 1.944 3 4 10 14 0 
253 1 3 3 5.00 0.0038 3.040 3 4 10 14 0 
254 1 3 3 5.00 0.0040 3.200 3 4 10 14 0 
255 1 3 3 5.00 0.0047 3.760 3 4 10 14 0 
256 1 3 3 6.00 0.0042 1.944 3 4 10 14 0 
257 1 3 3 6.00 0.0038 1.759 3 4 10 14 0 
258 1 3 3 4.60 0.0040 4.109 3 4 10 14 0 
259 1 3 4 5.00 0.0038 3.040 4 5 8 11 0 
260 1 3 4 5.00 0.0039 3.120 4 5 8 11 0 
261 1 3 4 5.00 0.0042 3.360 4 5 8 11 0 
262 1 3 4 5.00 0.0050 4.000 4 5 8 11 0 
263 1 3 4 4.00 0.0042 6.563 4 5 8 11 0 
264 1 3 4 5.00 0.0043 3.440 4 5 8 11 0 
265 1 3 4 5.00 0.0036 2.880 4 5 8 11 0 
266 1 3 4 5.00 0.0040 3.200 4 5 8 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
267 1 3 4 4.00 0.0039 6.094 4 5 8 11 0 
268 1 3 4 5.00 0.0038 3.040 4 5 8 11 0 
269 30 3 1 18.00 0.069 1.183 4 5 10 13 0 
270 30 3 1 20.00 0.142 1.775 4 5 10 13 0 
271 30 3 1 23.00 0.205 1.685 4 5 10 13 0 
272 30 3 1 15.00 0.050 1.481 4 5 10 13 0 
273 30 3 1 16.00 0.058 1.416 4 5 10 13 0 
274 30 3 2 19.00 0.130 1.895 3 4 9 11 0 
275 30 3 2 16.00 0.072 1.758 3 4 9 11 0 
276 30 3 2 15.00 0.068 2.015 3 4 9 11 0 
277 30 3 2 12.50 0.034 1.741 3 4 9 11 0 
278 30 3 2 12.00 0.021 1.215 3 4 9 11 0 
279 30 3 2 11.50 0.024 1.578 3 4 9 11 0 
280 30 3 2 12.00 0.070 4.051 3 4 9 11 0 
281 30 3 2 13.00 0.040 1.821 3 4 9 11 0 
282 30 3 2 16.00 0.020 0.488 3 4 9 11 0 
283 30 3 2 18.00 0.030 0.514 3 4 9 11 0 
284 30 3 3 13.00 0.030 1.365 3 4 10 14 0 
285 30 3 3 12.50 0.080 4.096 3 4 10 14 0 
286 30 3 3 12.50 0.020 1.024 3 4 10 14 0 
287 30 3 3 16.00 0.050 1.221 3 4 10 14 0 
288 30 3 3 14.00 0.110 4.009 3 4 10 14 0 
289 30 3 3 12.00 0.050 2.894 3 4 10 14 0 
290 30 3 3 17.00 0.050 1.018 3 4 10 14 0 
291 30 3 3 15.00 0.030 0.889 3 4 10 14 0 
292 30 3 3 12.50 0.020 1.024 3 4 10 14 0 
293 30 3 3 15.00 0.060 1.778 3 4 10 14 0 
294 30 3 4 12.00 0.026 1.505 4 5 8 11 0 
295 30 3 4 13.00 0.025 1.138 4 5 8 11 0 
296 30 3 4 16.00 0.050 1.221 4 5 8 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
297 30 3 4 12.00 0.022 1.273 4 5 8 11 0 
298 30 3 4 13.00 0.028 1.274 4 5 8 11 0 
299 30 3 4 11.50 0.017 1.118 4 5 8 11 0 
300 30 3 4 13.00 0.024 1.092 4 5 8 11 0 
301 30 3 4 12.00 0.019 1.100 4 5 8 11 0 
302 30 3 4 13.00 0.024 1.092 4 5 8 11 0 
303 30 3 4 10.00 0.015 1.500 4 5 8 11 0 
304 60 3 1 35.00 0.741 1.728 4 5 8 11 0 
305 60 3 1 33.00 0.602 1.675 4 5 8 11 0 
306 60 3 1 24.00 0.235 1.700 4 5 8 11 0 
307 60 3 1 31.00 0.543 1.823 4 5 8 11 0 
308 60 3 1 49.00 1.976 1.680 4 5 8 11 0 
309 60 3 2 31.00 0.597 2.004 4 5 8 11 0 
310 60 3 2 35.00 0.710 1.656 4 5 8 11 0 
311 60 3 2 36.00 0.859 1.841 4 5 8 11 0 
312 60 3 2 14.50 0.048 1.574 4 5 8 11 0 
313 60 3 2 21.00 0.141 1.523 4 5 8 11 0 
314 60 3 2 17.00 0.306 6.228 4 5 8 11 0 
315 60 3 2 21.00 0.149 1.609 4 5 8 11 0 
316 60 3 2 16.00 0.056 1.367 4 5 8 11 0 
317 60 3 2 29.00 0.445 1.825 4 5 8 11 0 
318 60 3 2 27.00 0.316 1.605 4 5 8 11 0 
319 60 3 2 21.00 0.153 1.652 4 5 8 11 0 
320 60 3 2 28.00 0.373 1.699 4 5 8 11 0 
321 60 3 3 18.00 0.098 1.680 4 5 8 11 0 
322 60 3 3 26.00 0.293 1.667 4 5 8 11 0 
323 60 3 3 21.00 0.132 1.425 4 5 8 11 0 
324 60 3 3 19.00 0.132 1.924 4 5 8 11 0 
325 60 3 3 37.00 0.855 1.688 4 5 8 11 0 
326 60 3 3 19.00 0.108 1.575 4 5 8 11 0 
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Fish 
No. 
AGE  
(Days PH) 
Groups Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch Day 
(PF) 
End Hatch Day 
(PF) 
Swim up (Day 
PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
327 60 3 3 27.00 0.349 1.773 4 5 8 11 0 
328 60 3 3 25.00 0.236 1.510 4 5 8 11 0 
329 60 3 3 32.00 0.505 1.541 4 5 8 11 0 
330 60 3 3 24.00 0.239 1.729 4 5 8 11 0 
331 60 3 3 20.00 0.114 1.425 4 5 8 11 0 
332 60 3 3 16.00 0.053 1.294 4 5 8 11 0 
333 60 3 3 33.00 0.570 1.586 4 5 8 11 0 
334 60 3 3 27.00 0.077 0.391 4 5 8 11 0 
335 60 3 3 29.00 0.054 0.221 4 5 8 11 0 
336 60 3 4 26.00 0.267 1.519 4 5 8 11 0 
337 60 3 4 22.00 0.167 1.568 4 5 8 11 0 
338 60 3 4 22.00 0.155 1.456 4 5 8 11 0 
339 60 3 4 17.00 0.083 1.689 4 5 8 11 0 
340 60 3 4 17.00 0.072 1.465 4 5 8 11 0 
341 60 3 4 24.00 0.227 1.642 4 5 8 11 0 
342 60 3 4 21.00 0.143 1.544 4 5 8 11 0 
343 60 3 4 21.00 0.145 1.566 4 5 8 11 0 
344 60 3 4 18.00 0.084 1.440 4 5 8 11 0 
345 60 3 4 18.00 0.088 1.509 4 5 8 11 0 
346 60 3 4 31.00 0.442 1.484 4 5 8 11 0 
347 60 3 4 22.00 0.162 1.521 4 5 8 11 0 
348 60 3 4 21.00 0.141 1.523 4 5 8 11 0 
349 60 3 4 27.00 0.465 2.362 4 5 8 11 0 
350 60 3 4 30.00 0.297 1.100 4 5 8 11 0 
     Groups: 
 
  
1 = Control 1  2 = Solvent control  3 = NVP L  
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HATCHING AND SURVIVAL 
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1 1 30 3 4 22 73.33 8 26.67 0.0 0.00 10 13 2.00 9.091 0 2 9.09 22 100.00 20 90.91 90.91 
2 1 60 3 4 60 100.00 0 0.00 1.0 1.67 9 11 18.00 30.000 0 18 30.00 59 98.33 41 68.33 68.33 
3 1 80 3 4 66 82.50 14 17.50 0.0 0.00 10 14 15.00 22.727 0 15 22.73 66 100.00 51 77.27 77.27 
4 1 80 3 4 68 85.00 12 15.00 3.0 4.41 8 11 11.00 16.176 0 11 16.18 65 95.59 54 79.41 79.41 
1 2 30 3 4 20 66.67 10 33.33 0.0 0.00 10 13 1.00 5.000 0 1 5.00 20 100.00 19 95.00 95.00 
2 2 60 3 4 55 91.67 5 8.33 0.0 0.00 9 11 12.00 21.818 0 12 21.82 55 100.00 43 78.18 78.18 
3 2 80 3 4 68 85.00 12 15.00 4.0 5.88 10 14 14.00 20.588 0 14 20.59 64 94.12 50 73.53 73.53 
4 2 80 4 5 66 82.50 4 5.00 2.0 3.03 8 11 10.00 15.152 0 10 15.15 64 96.97 54 81.82 81.82 
1 3 30 4 5 22 73.33 8 26.67 1.0 4.55 10 13 1.00 4.545 0 1 4.55 21 95.45 20 90.91 90.91 
2 3 60 3 4 60 100.00 0 0.00 2.0 3.33 9 11 16.00 26.667 0 16 26.67 58 96.67 42 70.00 70.00 
3 3 80 3 4 68 85.00 12 15.00 0.0 0.00 10 14 15.00 22.059 0 15 22.06 68 100.00 53 77.94 77.94 
4 3 80 4 5 64 80.00 16 20.00 2.0 3.13 8 11 13.00 20.313 0 13 20.31 62 96.88 49 76.56 76.56 
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DATA SUMMARY BY AGE 
Age (in days PH) Total Length (mm) Body Weight 
(g) 
Condition 
Factor 
1 
Control 1 
N 35.000 35.000 35.000 
Mean 5.023 0.004 3.859 
Median 5.000 0.004 3.200 
Std. Deviation 0.922 0.001 2.697 
Minimum 3.000 0.003 1.166 
Maximum 7.000 0.006 16.296 
Solvent control 
N 35.000 35.000 35.000 
Mean 5.117 0.004 3.780 
Median 5.000 0.004 3.040 
Std. Deviation 1.057 0.001 3.317 
Minimum 3.000 0.003 1.166 
Maximum 7.000 0.005 15.556 
NVP L 
N 35.000 35.000 35.000 
Mean 5.091 0.004 3.691 
Median 5.000 0.004 3.040 
Std. Deviation 0.807 0.001 3.049 
Minimum 3.000 0.003 1.389 
Maximum 6.500 0.005 18.519 
Total 
N 105.000 105.000 105.000 
Mean 5.077 0.004 3.777 
Median 5.000 0.004 3.200 
Std. Deviation 0.926 0.001 3.003 
Minimum 3.000 0.003 1.166 
Maximum 7.000 0.006 18.519 
30 Control 1 N 35.000 35.000 35.000 
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Age (in days PH) Total Length (mm) Body Weight 
(g) 
Condition 
Factor 
Mean 14.057 0.044 1.503 
Median 14.000 0.035 1.447 
Std. Deviation 2.391 0.026 0.496 
Minimum 10.000 0.018 0.514 
Maximum 20.000 0.121 3.000 
Solvent control 
N 35.000 35.000 35.000 
Mean 13.857 0.040 1.440 
Median 13.000 0.030 1.425 
Std. Deviation 2.381 0.024 0.479 
Minimum 10.000 0.015 0.497 
Maximum 19.000 0.103 3.005 
NVP L 
N 35.000 35.000 35.000 
Mean 14.343 0.051 1.607 
Median 13.000 0.034 1.365 
Std. Deviation 2.820 0.041 0.878 
Minimum 10.000 0.015 0.488 
Maximum 23.000 0.205 4.096 
Total 
N 105.000 105.000 105.000 
Mean 14.086 0.045 1.517 
Median 13.000 0.030 1.425 
Std. Deviation 2.522 0.031 0.642 
Minimum 10.000 0.015 0.488 
Maximum 23.000 0.205 4.096 
      
      
60 Control 1 N 46.000 46.000 46.000 
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Age (in days PH) Total Length (mm) Body Weight 
(g) 
Condition 
Factor 
Mean 26.500 0.410 1.788 
Median 26.000 0.350 1.659 
Std. Deviation 8.016 0.300 0.640 
Minimum 13.000 0.032 1.166 
Maximum 41.000 1.116 5.507 
Solvent control 
N 47.000 47.000 47.000 
Mean 25.979 0.336 1.655 
Median 25.000 0.282 1.656 
Std. Deviation 6.134 0.243 0.145 
Minimum 15.000 0.051 1.338 
Maximum 44.000 1.372 2.000 
NVP L 
N 47.000 47.000 47.000 
Mean 25.074 0.319 1.660 
Median 24.000 0.227 1.586 
Std. Deviation 7.009 0.332 0.757 
Minimum 14.500 0.048 0.221 
Maximum 49.000 1.976 6.228 
Total 
N 140.000 140.000 140.000 
Mean 25.846 0.355 1.700 
Median 25.500 0.283 1.644 
Std. Deviation 7.061 0.294 0.577 
Minimum 13.000 0.032 0.221 
Maximum 49.000 1.976 6.228 
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 ANNEXURES 
CORRELATION TEST 
 
  Total Length (mm) 
Weight 
 (g) 
Spearman's rho Total Length (mm) Correlation Coefficient 1.000 .958** 
Sig. (2-tailed)   0.000 
N 350 350 
Weight (g) Correlation Coefficient .958** 1.000 
Sig. (2-tailed) 0.000   
N 350 350 
**. Correlation is significant at the 0.01 level (2-tailed). 
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 ANNEXURES 
B. Early life stages biometric data – 2nd experiment 
 
Fish No. AGE  
(Days PH) 
Group Repeats Length 
(mm) 
Weight 
(g) 
CF Hatch 
Day (PF) 
End Hatch 
Day (PF) 
Swim up 
(Day PH) 
Start Feed 
(Day PH) 
Physical 
abnormality 
            
1 1 1 2 5 0.009 6.9 3 4 8 11 0 
2 1 1 2 6 0.008 3.5 3 4 8 11 0 
3 1 1 2 6 0.007 3.2 3 4 8 11 0 
4 1 1 2 6 0.008 3.8 3 4 8 11 0 
5 1 1 2 6 0.009 4.3 3 4 8 11 0 
6 1 1 2 6 0.008 3.7 3 4 8 11 0 
7 1 1 2 6 0.006 2.9 3 4 8 11 1 
8 1 1 2 6 0.006 2.6 3 4 8 11 1 
9 1 1 2 6 0.010 4.4 3 4 8 11 0 
10 1 1 2 6 0.009 4.2 3 4 8 11 0 
41 30 1 2 15.5 0.059 1.6 3 4 8 11 0 
42 30 1 2 20 0.106 1.3 3 4 8 11 0 
43 30 1 2 18 0.079 1.3 3 4 8 11 0 
44 30 1 2 15 0.045 1.3 3 4 8 11 0 
45 30 1 2 17 0.080 1.6 3 4 8 11 0 
46 30 1 2 18 0.084 1.4 3 4 8 11 0 
47 30 1 2 20.5 0.133 1.5 3 4 8 11 0 
48 30 1 2 18 0.096 1.7 3 4 8 11 0 
49 30 1 2 16 0.068 1.7 3 4 8 11 0 
50 30 1 2 18 0.086 1.5 3 4 8 11 0 
81 60 1 2 43 1.307 1.6 3 4 8 11 0 
82 60 1 2 27 0.351 1.8 3 4 8 11 0 
83 60 1 2 36 0.774 1.7 3 4 8 11 0 
84 60 1 2 28 0.379 1.7 3 4 8 11 0 
85 60 1 2 38 0.997 1.8 3 4 8 11 0 
86 60 1 2 28 0.372 1.7 3 4 8 11 0 
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87 60 1 2 34 0.726 1.8 3 4 8 11 0 
123 1 1 1 6 0.009 4.0 3 4 8 11 0 
124 1 1 1 6 0.008 3.5 3 4 8 11 0 
125 1 1 1 6 0.007 3.2 3 4 8 11 0 
126 1 1 1 6 0.008 3.8 3 4 8 11 0 
127 1 1 1 5 0.009 7.4 3 4 8 11 0 
128 1 1 1 6 0.008 3.7 3 4 8 11 0 
129 1 1 1 6 0.006 2.9 3 4 8 11 0 
130 1 1 1 6 0.006 2.6 3 4 8 11 0 
131 1 1 1 6 0.010 4.4 3 4 8 11 0 
132 1 1 1 6 0.009 4.2 3 4 8 11 0 
163 30 1 1 14 0.059 2.1 3 4 8 11 0 
164 30 1 1 20 0.106 1.3 3 4 8 11 0 
165 30 1 1 18 0.079 1.3 3 4 8 11 0 
166 30 1 1 15 0.045 1.3 3 4 8 11 0 
167 30 1 1 17 0.080 1.6 3 4 8 11 0 
168 30 1 1 18 0.084 1.4 3 4 8 11 0 
169 30 1 1 20 0.133 1.7 3 4 8 11 0 
170 30 1 1 18 0.096 1.7 3 4 8 11 0 
171 30 1 1 16 0.068 1.7 3 4 8 11 0 
172 30 1 1 18 0.086 1.5 3 4 8 11 0 
203 60 1 1 43 1.307 1.6 3 4 8 11 0 
204 60 1 1 27 0.351 1.8 3 4 8 11 0 
205 60 1 1 36 0.774 1.7 3 4 8 11 0 
206 60 1 1 28 0.379 1.7 3 4 8 11 0 
207 60 1 1 38 0.997 1.8 3 4 8 11 0 
208 60 1 1 28 0.372 1.7 3 4 8 11 0 
209 60 1 1 34 0.726 1.8 3 4 8 11 0 
210 60 1 1 41 1.143 1.7 3 4 8 11 0 
211 60 1 1 31 0.483 1.6 3 4 8 11 0 
212 60 1 1 27 0.316 1.6 3 4 8 11 0 
213 60 1 1 37 0.944 1.9 3 4 8 11 0 
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214 60 1 1 29 0.437 1.8 3 4 8 11 0 
215 60 1 1 23 0.200 1.6 3 4 8 11 0 
216 60 1 1 36 0.813 1.7 3 4 8 11 0 
217 60 1 1 35 0.760 1.8 3 4 8 11 0 
11 1 2 2 6 0.008 3.8 4 5 9 11 0 
12 1 2 2 6 0.009 4.2 4 5 9 11 0 
13 1 2 2 5 0.009 7.2 4 5 9 11 0 
14 1 2 2 6 0.009 4.2 4 5 9 11 0 
15 1 2 2 6 0.009 4.3 4 5 9 11 0 
16 1 2 2 6 0.009 4.3 4 5 9 11 0 
17 1 2 2 5 0.009 7.2 4 5 9 11 0 
18 1 2 2 6 0.009 4.3 4 5 9 11 0 
19 1 2 2 6 0.009 4.3 4 5 9 11 0 
20 1 2 2 6 0.009 4.3 4 5 9 11 0 
51 30 2 2 19 0.103 1.5 4 5 9 11 0 
52 30 2 2 18 0.099 1.7 4 5 9 11 0 
53 30 2 2 19 0.102 1.5 4 5 9 11 0 
54 30 2 2 15 0.038 1.1 4 5 9 11 1 
55 30 2 2 19 0.119 1.7 4 5 9 11 0 
56 30 2 2 17.5 0.083 1.5 4 5 9 11 0 
57 30 2 2 19 0.115 1.7 4 5 9 11 0 
58 30 2 2 17 0.077 1.6 4 5 9 11 0 
59 30 2 2 20 0.137 1.7 4 5 9 11 0 
60 30 2 2 18 0.100 1.7 4 5 9 11 0 
88 60 2 2 41 1.143 1.7 4 5 9 11 0 
89 60 2 2 31 0.483 1.6 4 5 9 11 0 
90 60 2 2 27 0.316 1.6 4 5 9 11 0 
91 60 2 2 37 0.944 1.9 4 5 9 11 0 
92 60 2 2 29 0.437 1.8 4 5 9 11 0 
93 60 2 2 23 0.200 1.6 4 5 9 11 0 
94 60 2 2 36 0.813 1.7 4 5 9 11 0 
95 60 2 2 35 0.760 1.8 4 5 9 11 0 
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96 60 2 2 38 0.939 1.7 4 5 9 11 0 
97 60 2 2 35 0.669 1.6 4 5 9 11 0 
98 60 2 2 38 0.903 1.6 4 5 9 11 0 
133 1 2 1 6 0.008 3.8 3 5 9 12 0 
134 1 2 1 6 0.009 4.2 3 5 9 12 0 
135 1 2 1 5 0.009 7.2 3 5 9 12 0 
136 1 2 1 6 0.009 4.2 3 5 9 12 0 
137 1 2 1 6 0.009 4.3 3 5 9 12 0 
138 1 2 1 6 0.009 4.3 3 5 9 12 0 
139 1 2 1 5 0.009 7.2 3 5 9 12 0 
140 1 2 1 6 0.009 4.3 3 5 9 12 0 
141 1 2 1 6 0.009 4.3 3 5 9 12 0 
142 1 2 1 6 0.009 4.3 3 5 9 12 0 
173 30 2 1 19 0.103 1.5 3 5 9 12 0 
174 30 2 1 18 0.099 1.7 3 5 9 12 0 
175 30 2 1 19 0.102 1.5 3 5 9 12 0 
176 30 2 1 15 0.037 1.3 3 5 9 12 1 
177 30 2 1 19 0.119 1.7 3 5 9 12 0 
178 30 2 1 18 0.083 1.4 3 5 9 12 0 
179 30 2 1 19 0.115 1.7 3 5 9 12 0 
180 30 2 1 17 0.077 1.6 3 5 9 12 0 
181 30 2 1 20 0.137 1.7 3 5 9 12 0 
182 30 2 1 18 0.100 1.7 3 5 9 12 0 
218 60 2 1 35 0.669 1.6 3 5 9 12 0 
219 60 2 1 38 0.903 1.6 3 5 9 12 0 
220 60 2 1 43 1.332 1.7 3 5 9 12 0 
221 60 2 1 18 0.115 2.0 3 5 9 12 0 
222 60 2 1 30 0.540 2.0 3 5 9 12 0 
223 60 2 1 26 0.333 1.9 3 5 9 12 0 
224 60 2 1 36 0.756 1.6 3 5 9 12 0 
225 60 2 1 36 0.823 1.8 3 5 9 12 0 
226 60 2 1 39 1.051 1.8 3 5 9 12 0 
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227 60 2 1 30 0.464 1.7 3 5 9 12 0 
228 60 2 1 29 0.394 1.6 3 5 9 12 0 
229 60 2 1 35 0.693 1.6 3 5 9 12 0 
230 60 2 1 28 0.397 1.8 3 5 9 12 0 
21 1 3 2 6 0.009 4.2 4 5 9 12 0 
22 1 3 2 6 0.009 4.4 4 5 9 12 0 
23 1 3 2 6 0.009 4.1 4 5 9 12 0 
24 1 3 2 5 0.009 7.3 4 5 9 12 0 
25 1 3 2 6 0.008 3.9 4 5 9 12 0 
26 1 3 2 6 0.009 4.1 4 5 9 12 0 
27 1 3 2 6 0.008 3.8 4 5 9 12 0 
28 1 3 2 6 0.008 3.7 4 5 9 12 0 
29 1 3 2 6 0.008 3.8 4 5 9 12 0 
30 1 3 2 6 0.007 3.1 4 5 9 12 1 
61 30 3 2 19.5 0.112 1.5 4 5 9 12 0 
62 30 3 2 21 0.135 1.5 4 5 9 12 0 
63 30 3 2 22 0.146 1.4 4 5 9 12 0 
64 30 3 2 20 0.130 1.6 4 5 9 12 0 
65 30 3 2 20 0.132 1.7 4 5 9 12 0 
66 30 3 2 19 0.113 1.6 4 5 9 12 0 
67 30 3 2 20 0.125 1.6 4 5 9 12 0 
68 30 3 2 13.5 0.036 1.5 4 5 9 12 1 
69 30 3 2 21 0.143 1.5 4 5 9 12 0 
70 30 3 2 18 0.091 1.6 4 5 9 12 0 
99 60 3 2 43 1.332 1.7 4 5 9 12 0 
100 60 3 2 18 0.115 2.0 4 5 9 12 0 
101 60 3 2 30 0.540 2.0 4 5 9 12 0 
102 60 3 2 26 0.333 1.9 4 5 9 12 0 
103 60 3 2 36 0.756 1.6 4 5 9 12 0 
104 60 3 2 36 0.823 1.8 4 5 9 12 0 
105 60 3 2 39 1.051 1.8 4 5 9 12 0 
106 60 3 2 30 0.464 1.7 4 5 9 12 0 
 Uwineza Marie Clémentine Nibamureke    2019 211 
 
 ANNEXURES 
107 60 3 2 29 0.394 1.6 4 5 9 12 0 
108 60 3 2 35 0.693 1.6 4 5 9 12 0 
109 60 3 2 28 0.397 1.8 4 5 9 12 0 
110 60 3 2 24 0.232 1.7 4 5 9 12 0 
111 60 3 2 35 0.705 1.6 4 5 9 12 0 
143 1 3 1 6 0.009 4.2 3 5 9 12 0 
144 1 3 1 6 0.009 4.4 3 5 9 12 0 
145 1 3 1 6 0.009 4.1 3 5 9 12 0 
146 1 3 1 5 0.009 7.3 3 5 9 12 0 
147 1 3 1 6 0.008 3.9 3 5 9 12 0 
148 1 3 1 6 0.009 4.1 3 5 9 12 0 
149 1 3 1 6 0.008 3.8 3 5 9 12 0 
150 1 3 1 5 0.008 6.4 3 5 9 12 0 
151 1 3 1 6 0.008 3.8 3 5 9 12 0 
152 1 3 1 6 0.007 3.1 3 5 9 12 0 
183 30 3 1 18 0.112 1.9 3 5 9 12 0 
184 30 3 1 21 0.135 1.5 3 5 9 12 0 
185 30 3 1 22 0.146 1.4 3 5 9 12 0 
186 30 3 1 20 0.130 1.6 3 5 9 12 0 
187 30 3 1 20 0.132 1.7 3 5 9 12 0 
188 30 3 1 19 0.113 1.6 3 5 9 12 0 
189 30 3 1 20 0.125 1.6 3 5 9 12 0 
190 30 3 1 14 0.036 1.3 3 5 9 12 0 
191 30 3 1 21 0.143 1.5 3 5 9 12 0 
192 30 3 1 18 0.091 1.6 3 5 9 12 0 
231 60 3 1 24 0.232 1.7 3 5 9 12 0 
232 60 3 1 35 0.705 1.6 3 5 9 12 0 
233 60 3 1 35 0.763 1.8 3 5 9 12 0 
234 60 3 1 30 0.443 1.6 3 5 9 12 0 
235 60 3 1 30 0.467 1.7 3 5 9 12 0 
236 60 3 1 33 0.593 1.7 3 5 9 12 0 
237 60 3 1 32 0.532 1.6 3 5 9 12 0 
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238 60 3 1 32 0.549 1.7 3 5 9 12 0 
239 60 3 1 33 0.636 1.8 3 5 9 12 0 
240 60 3 1 33 0.608 1.7 3 5 9 12 0 
241 60 3 1 33 0.595 1.7 3 5 9 12 0 
242 60 3 1 29 0.394 1.6 3 5 9 12 0 
31 1 4 2 5 0.009 7.0 4 5 10 13 0 
32 1 4 2 6 0.009 4.2 4 5 10 13 0 
33 1 4 2 6 0.009 4.2 4 5 10 13 0 
34 1 4 2 5 0.009 7.4 4 5 10 13 0 
35 1 4 2 6 0.009 4.0 4 5 10 13 0 
36 1 4 2 5 0.007 5.9 4 5 10 13 0 
37 1 4 2 5 0.008 6.2 4 5 10 13 0 
38 1 4 2 5 0.009 7.0 4 5 10 13 0 
39 1 4 2 5 0.009 7.3 4 5 10 13 0 
40 1 4 2 6 0.008 3.8 4 5 10 13 0 
71 30 4 2 21 0.153 1.7 4 5 10 13 0 
72 30 4 2 16 0.059 1.4 4 5 10 13 1 
73 30 4 2 17 0.075 1.5 4 5 10 13 0 
74 30 4 2 18 0.098 1.7 4 5 10 13 0 
75 30 4 2 20.5 0.132 1.5 4 5 10 13 0 
76 30 4 2 18 0.087 1.5 4 5 10 13 0 
77 30 4 2 20 0.129 1.6 4 5 10 13 0 
78 30 4 2 20 0.117 1.5 4 5 10 13 1 
79 30 4 2 17.5 0.090 1.7 4 5 10 13 1 
80 30 4 2 20 0.113 1.4 4 5 10 13 0 
112 60 4 2 35 0.763 1.8 4 5 10 13 0 
113 60 4 2 30 0.443 1.6 4 5 10 13 0 
114 60 4 2 30 0.467 1.7 4 5 10 13 0 
115 60 4 2 33 0.593 1.7 4 5 10 13 0 
116 60 4 2 32 0.532 1.6 4 5 10 13 0 
117 60 4 2 32 0.549 1.7 4 5 10 13 0 
118 60 4 2 32 0.625 1.9 4 5 10 13 0 
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119 60 4 2 30 0.427 1.6 4 5 10 13 0 
120 60 4 2 33 0.636 1.8 4 5 10 13 0 
121 60 4 2 33 0.608 1.7 4 5 10 13 0 
122 60 4 2 33 0.595 1.7 4 5 10 13 0 
153 1 4 1 5 0.009 7.0 3 4 9 12 0 
154 1 4 1 6 0.009 4.2 3 4 9 12 0 
155 1 4 1 6 0.009 4.2 3 4 9 12 0 
156 1 4 1 5 0.009 7.4 3 4 9 12 0 
157 1 4 1 6 0.009 4.0 3 4 9 12 0 
158 1 4 1 5 0.007 5.9 3 4 9 12 0 
159 1 4 1 6 0.008 3.6 3 4 9 12 0 
160 1 4 1 6 0.009 4.1 3 4 9 12 0 
161 1 4 1 6 0.009 4.2 3 4 9 12 0 
162 1 4 1 6 0.008 3.8 3 4 9 12 0 
193 30 4 1 21 0.153 1.7 3 4 9 12 0 
194 30 4 1 16 0.059 1.4 3 4 9 12 0 
195 30 4 1 17 0.075 1.5 3 4 9 12 0 
196 30 4 1 18 0.098 1.7 3 4 9 12 0 
197 30 4 1 21 0.132 1.4 3 4 9 12 0 
198 30 4 1 18 0.087 1.5 3 4 9 12 0 
199 30 4 1 20 0.129 1.6 3 4 9 12 0 
200 30 4 1 20 0.117 1.5 3 4 9 12 0 
201 30 4 1 17 0.090 1.8 3 4 9 12 0 
202 30 4 1 20 0.113 1.4 3 4 9 12 0 
243 60 4 1 24 0.232 1.7 3 4 9 12 0 
244 60 4 1 35 0.705 1.6 3 4 9 12 0 
245 60 4 1 35 0.763 1.8 3 4 9 12 0 
246 60 4 1 30 0.443 1.6 3 4 9 12 0 
247 60 4 1 30 0.467 1.7 3 4 9 12 0 
248 60 4 1 33 0.593 1.7 3 4 9 12 0 
249 60 4 1 32 0.532 1.6 3 4 9 12 0 
250 60 4 1 32 0.549 1.7 3 4 9 12 0 
 Uwineza Marie Clémentine Nibamureke    2019 214 
 
 ANNEXURES 
 
 
 
 
 
 
  
251 60 4 1 32 0.625 1.9 3 4 9 12 0 
252 60 4 1 30 0.427 1.6 3 4 9 12 0 
253 60 4 1 33 0.636 1.8 3 4 9 12 0 
254 60 4 1 33 0.608 1.7 3 4 9 12 0 
255 60 4 1 33 0.595 1.7 3 4 9 12 0 
256 60 4 1 24 0.232 1.7 3 4 9 12 0 
1 = control 2  
 
2 = NVP H  
 
4 = Mixture 2  
 
3 = Mixture 1  
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HATCHING SUCCESS AND SURVIVAL  
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1 1 40 3 4 36 90.00 4 10.00 8 11 1 2.78 1 2.78 1 2.78 35 97.22 35 97.22 35 97.22 
2 1 33 3 4 28 84.85 5 15.15 8 11 0 0.00 0 0.00 1 3.57 28 100.00 28 100.00 27 96.43 
1 2 40 3 5 34 85.00 6 15.00 9 12 2 5.88 2 5.88 2 5.88 32 94.12 32 94.12 32 94.12 
2 2 35 4 5 32 91.43 3 8.57 9 11 0 0.00 0 0.00 1 3.13 32 100.00 32 100.00 31 96.88 
1 3 40 3 5 36 90.00 4 10.00 9 12 4 11.11 4 11.11 4 11.11 32 88.89 32 88.89 32 88.89 
2 3 38 4 5 34 89.47 4 10.53 9 12 0 0.00 1 2.94 1 2.94 34 100.00 33 97.06 33 97.06 
1 4 41 3 4 36 87.80 5 12.20 9 12 2 5.56 2 5.56 2 5.56 34 94.44 34 94.44 34 94.44 
2 4 35 4 5 31 88.57 4 11.43 10 13 0 0.00 0 0.00 0 0.00 31 100.00 31 100.00 31 100.00 
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SUMMARY OF DATA BY AGE 
 
Age (Days post-hatching) Total Length (mm) Body weight (g) Condition Factor 
1 
Control 2 
N 20.00 20.000 20.00 
Mean 5.80 0.008 4.12 
Median 6.00 0.008 3.73 
Std. Deviation 0.41 0.001 1.30 
Minimum 5.00 0.006 2.59 
Maximum 6.00 0.009 7.36 
NVP H 
N 20.00 20.000 20.00 
Mean 5.75 0.009 4.93 
Median 6.00 0.009 4.26 
Std. Deviation 0.44 0.000 1.30 
Minimum 5.00 0.008 3.84 
Maximum 6.00 0.010 7.20 
Mixture 1 
N 20.00 20.000 20.00 
Mean 5.85 0.008 4.37 
Median 6.00 0.009 4.12 
Std. Deviation 0.37 0.001 1.18 
Minimum 5.00 0.007 3.15 
Maximum 6.00 0.009 7.28 
Mixture 2 
N 20.00 20.000 20.00 
Mean 5.55 0.009 5.26 
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Age (Days post-hatching) Total Length (mm) Body weight (g) Condition Factor 
Median 6.00 0.009 4.19 
Std. Deviation 0.51 0.001 1.48 
Minimum 5.00 0.007 3.56 
Maximum 6.00 0.009 7.36 
Total 
N 80.00 80.000 80.00 
Mean 5.74 0.008 4.67 
Median 6.00 0.009 4.17 
Std. Deviation 0.44 0.001 1.37 
Minimum 5.00 0.006 2.59 
Maximum 6.00 0.010 7.36 
30 
Control 2 
N 20.00 20.000 20.00 
Mean 17.50 0.084 1.53 
Median 18.00 0.082 1.51 
Std. Deviation 1.83 0.024 0.19 
Minimum 14.00 0.045 1.33 
Maximum 20.50 0.133 2.13 
NVP H 
N 20.00 20.000 20.00 
Mean 18.18 0.097 1.57 
Median 18.50 0.101 1.62 
Std. Deviation 1.37 0.026 0.18 
Minimum 15.00 0.038 1.12 
Maximum 20.00 0.137 1.73 
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Age (Days post-hatching) Total Length (mm) Body weight (g) Condition Factor 
Mixture 1 
N 20.00 20.000 20.00 
Mean 19.35 0.116 1.55 
Median 20.00 0.128 1.57 
Std. Deviation 2.25 0.032 0.13 
Minimum 13.50 0.036 1.33 
Maximum 22.00 0.146 1.91 
Mixture 2 
N 20.00 20.000 20.00 
Mean 18.80 0.105 1.55 
Median 19.00 0.105 1.52 
Std. Deviation 1.71 0.028 0.12 
Minimum 16.00 0.059 1.41 
Maximum 21.00 0.153 1.83 
Total 
N 80.00 80.000 80.00 
Mean 18.46 0.101 1.55 
Median 18.00 0.101 1.55 
Std. Deviation 1.91 0.030 0.16 
Minimum 13.50 0.036 1.12 
Maximum 22.00 0.153 2.13 
  
    
60 Control 2 
N 22.00 22.000 22.00 
Mean 33.05 0.678 1.73 
Median 34.00 0.726 1.73 
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Age (Days post-hatching) Total Length (mm) Body weight (g) Condition Factor 
Std. Deviation 5.74 0.336 0.08 
Minimum 23.00 0.200 1.61 
Maximum 43.00 1.307 1.86 
NVP H 
N 24.00 24.000 24.00 
Mean 33.04 0.670 1.72 
Median 35.00 0.681 1.69 
Std. Deviation 5.98 0.309 0.12 
Minimum 18.00 0.115 1.56 
Maximum 43.00 1.332 2.00 
Mixture 1 
N 25.00 25.000 25.00 
Mean 31.44 0.574 1.73 
Median 32.00 0.549 1.68 
Std. Deviation 5.17 0.261 0.12 
Minimum 18.00 0.115 1.62 
Maximum 43.00 1.332 2.00 
Mixture 2 
N 25.00 25.000 25.00 
Mean 31.60 0.546 1.69 
Median 32.00 0.593 1.68 
Std. Deviation 2.78 0.133 0.11 
Minimum 24.00 0.232 1.48 
Maximum 35.00 0.763 1.93 
Total 
N 96.00 96.000 96.00 
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Age (Days post-hatching) Total Length (mm) Body weight (g) Condition Factor 
Mean 32.25 0.614 1.72 
Median 32.00 0.594 1.68 
Std. Deviation 5.02 0.270 0.11 
Minimum 18.00 0.115 1.48 
Maximum 43.00 1.332 2.00 
 
 
 
CORRELATION TEST 
  
Total Length (mm) 
Body weight 
(g) 
Age (Days post-
hatching) 
Spearman's rho Total Length (mm) Correlation Coefficient 1.000 .974** .942** 
Sig. (2-tailed)   0.000 0.000 
N 256 256 256 
Body weight (g) Correlation Coefficient .974** 1.000 .938** 
Sig. (2-tailed) 0.000   0.000 
N 256 256 256 
Age (Days post-
hatching) 
Correlation Coefficient .942** .938** 1.000 
Sig. (2-tailed) 0.000 0.000   
N 256 256 256 
**. Correlation is significant at the 0.01 level (2-tailed). 
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A. Early life stages liver histology assessment data 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                      
Site: Laboratory Exposure 2015 - 2018                      
                      
A. Cytoplasmic characteristics                      
Clear cell hepatocytes (Majority) 0   0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Basophilic 0   0   1   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 1   1   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   1   1   1   1   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   0   
                      
B. Diffused or dispersed lesions 1 2 3 4 5 6 7 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0   0 
Regressive changes                      
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 2 1 2 
9. Vacuolation (non steatosis) 2 1 2 4 1 4 4 1 4 0 1 0 0 1 0 0 1 0 0 1 0 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   4   4   0   0   2   2 
Progressive changes                      
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
Inflammatory                      
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
Tumours                      
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                      
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
                      
Iorg INDEX:   2   4   4   0   0   2   2 
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Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   1   0   0   
Granular cell hepatocytes (Majority) - Basophilic 1   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   1   1   0   1   1   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 8 9 10 11 12 13 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 0 1 0 2 1 2 2 1 2 0 1 0 2 1 2 0 1 0 
9. Vacuolation (non steatosis) 2 1 2 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   2   2   2   2   0 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   2   2   2   2   2   0 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Basophilic 0   1   1   1   1   1   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 1   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 14 15 16 17 18 19 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 2 1 2 2 1 2 4 1 4 2 1 2 2 1 2 4 1 4 
9. Vacuolation (non steatosis) 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   4   6   4   4   6 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   2   4   6   4   4   6 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Basophilic 0   1   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 1   0   1   1   1   1   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 20 21 22 23 24 25 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 2 1 2 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 
9. Vacuolation (non steatosis) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   2   0   2   2   2 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   2   2   0   2   2   2 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   0   1   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   1   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 1   1   1   1   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 26 27 28 29 30 31 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 
8. Steatosis (fatty change) 4 1 4 2 1 2 2 1 2 2 1 2 0 1 0 2 1 2 
9. Vacuolation (non steatosis) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   8   2   2   2   0   8 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   8   2   2   2   0   8 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   1   1   1   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 1   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   1   1   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 32 33 34 35 36 37 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 
8. Steatosis (fatty change) 0 1 0 0 1 0 2 1 2 4 1 4 0 1 0 0 1 0 
9. Vacuolation (non steatosis) 2 1 2 0 1 0 0 1 0 2 1 2 4 1 4 2 1 2 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   0   2   6   8   2 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   2   0   2   6   8   2 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Basophilic 1   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   1   1   1   1   1   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
                   
B. Diffused or dispersed lesions 38 39 40 41 42 43 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 2 1 2 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 
Irp INDEX   2   0   0   2   0   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 2 1 2 4 1 4 0 1 0 2 1 2 0 1 0 0 1 0 
9. Vacuolation (non steatosis) 4 1 4 0 1 0 2 1 2 4 1 4 2 1 2 2 1 2 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6   4   2   10   2   2 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   8   4   2   12   2   2 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 1   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   1   1   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 0   0   0   1   1   1   
                   
B. Diffused or dispersed lesions 44 45 46 47 48 49 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 0 1 0 2 1 2 2 1 2 2 1 2 0 1 0 2 1 2 
Irp INDEX   0   2   2   2   0   2 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 2 2 4 2 2 4 2 2 4 0 2 0 2 2 4 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
8. Steatosis (fatty change) 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 2 1 2 
9. Vacuolation (non steatosis) 4 1 4 2 1 2 2 1 2 4 1 4 2 1 2 4 1 4 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   8   6   8   12   2   10 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   8   8   10   14   2   12 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   0   1   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   1   1   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 1   1   1   0   0   0   
                   
B. Diffused or dispersed lesions 50 51 52 53 54 55 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 
Irp INDEX   2   0   2   2   2   2 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 2 2 4 0 2 0 2 2 4 2 2 4 0 2 0 2 2 4 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 
8. Steatosis (fatty change) 0 1 0 0 1 0 2 1 2 0 1 0 2 1 2 2 1 2 
9. Vacuolation (non steatosis) 2 1 2 2 1 2 2 1 2 0 1 0 0 1 0 2 1 2 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6   2   8   4   2   12 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   8   2   10   6   4   14 
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 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)                   
Site: Laboratory Exposure 2015 - 2018                   
                   
A. Cytoplasmic characteristics                   
Clear cell hepatocytes (Majority) 0   0   0   0   1   1   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   1   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
Mixed cytoplasmic hepatocytes 1   1   1   0   0   0   
                   
B. Diffused or dispersed lesions 56 57 58 59 60 61 
Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 0 1 0 
Irp INDEX   2   0   2   2   2   0 
Regressive changes                   
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 2 2 4 0 2 0 2 2 4 2 2 4 0 2 0 0 2 0 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Steatosis (fatty change) 2 1 2 0 1 0 2 1 2 4 1 4 0 1 0 0 1 0 
9. Vacuolation (non steatosis) 2 1 2 0 1 0 4 1 4 0 1 0 4 1 4 0 1 0 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   8   0   10   8   4   0 
Progressive changes                   
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Inflammatory                   
1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
Tumours                   
1. Benign 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   4   0   0 
C. Foci of cellular alteration (FCA)                   
1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
                   
Iorg INDEX:   10   0   12   14   6   0 
 Uwineza Marie Clémentine Nibamureke    2019 231 
 
 ANNEXURES 
Liver Quantitative Histological Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (30 days old juveniles)          
Site: Laboratory Exposure 2015 - 2018          
          
A. Cytoplasmic characteristics          
Clear cell hepatocytes (Majority) 1   1   0   
Granular cell hepatocytes (Majority) - Basophilic 0   0   0   
Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   
Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   
Clumped cytoplasmic hepatocytes (Majority) 0   0   0   
Mixed cytoplasmic hepatocytes 0   0   1   
          
B. Diffused or dispersed lesions 62 63 64 
Circulatory distrubances Score IF Index Score IF Index Score IF Index 
1. Intercellular haemorrhage / Vascular congestion 2 1 2 0 1 0 0 1 0 
Irp INDEX   2   0   0 
Regressive changes          
1. Intracellular deposits 0 1 0 0 1 0 0 1 0 
2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 
3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 
4. Single cell necrosis 0 2 0 0 2 0 2 2 4 
5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 
6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 
7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 0 2 0 2 2 4 
8. Steatosis (fatty change) 0 1 0 0 1 0 0 1 0 
9. Vacuolation (non steatosis) 4 1 4 0 1 0 4 1 4 
10. Increase in Melano-macrophage centres 0 1 0 0 1 0 0 1 0 
11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 
12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 
Irp INDEX   8   0   12 
Progressive changes          
1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 
2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 
3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 
4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
Inflammatory          
1. Infiltration 0 2 0 0 2 0 0 2 0 
2. Granulomatosis 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
Tumours          
1. Benign 0 2 0 0 2 0 0 2 0 
2. Malignant 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
C. Foci of cellular alteration (FCA)          
1. Clear cell foci 0 2 0 0 2 0 0 2 0 
2. Steatosis foci 0 2 0 0 2 0 0 2 0 
3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 
4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 
5. Mixed foci 0 2 0 0 2 0 0 2 0 
6. Necrotic foci 0 3 0 0 3 0 0 3 0 
7. Hydropic foci 0 2 0 0 2 0 0 2 0 
8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
          
Iorg INDEX:   10   0   12 
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 ANNEXURES 
B. Early life stages kidney histology assessment data 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
Specimen no: 1 2 3 4 
RP Functional Unit Alterations Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2   4   0   0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0 
Iorg INDEX:   2   4   0   0 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
Specimen no: 5 6 7 8 
RP Functional Unit Alterations Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  0   0   0   0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0   0   0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0 
Iorg INDEX:   0   0   0   0 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  9  10 11              12 
RP Functional Unit Alterations  IF Index   Score IF Index   Score IF Index    Score   IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX  0  0  0  0 
RC Tubule Structural alterations  1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 1 0 0 1 0 0 1 0 0 1 0 
   Hyaline droplet degeneration 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  0  0  0  0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0  0  0  0 
I  Exudate  1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0  0  0 0 0 
T  Benign  2 0 0 2 0 0 2 0 0 2 0 
  Malignant  3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  0  0  0  0 
   Iorg INDEX:  0   0   0   0 
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 ANNEXURES 
 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  13  1
4 
1
5 
1
6 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF Index  
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX  0  0   0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 0 1 0 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  0 0 0 0  2  2 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0  0   0  0 
I  Exudate  0 1 0 0 1 0  1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0  0   0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   0   0   2   2 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  17  1
8 
1
9 
                 20 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF  Index  
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 2 1 2 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 0 1 0 0 1 0 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2  2  0  2 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   2   2   0   2 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  21  22 23 24 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF  Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 2 1 2 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 2 1 2 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  2  2  6 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   0   2   2   6 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  25  26 27              28 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 0 3 0 2 3 6 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   10  4  10  0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   10   4   10   0 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  29  30 31              32 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 2 1 2 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 2 2 4 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6  12  6  6 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   6   12   6   6 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  33  34 35 36 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 0 1 0 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6  8  10  10 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   6   8   10   10 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  37  38 39            40 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 2 3 6 2 3 6 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2         10  8  2 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   2   10   8   2 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  41  42 43           44 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   
Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 4 1 4 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   2          12  10  10 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   2   12   10   10 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  45  46 47                48 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 2 1 2 2 1 2 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 2 1 2 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   8  12  10  0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   8   12   10   0 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  49  50 51               52 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 2 1 2 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  2  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 0 1 0 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 0 1 0 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 2 1 2 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   10  8  0  4 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   10   10   0   4 
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 ANNEXURES 
Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  53  54 55                 56 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 0 1 0 2 1 2 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 0 1 0 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   10  8  8  8 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   10   8   8   8 
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Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  57  58 59                  60 
RP Functional Unit Alterations  Score IF Index   Score IF Index   Score IF Index   Score IF   Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 2 1 2 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  2  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 0 1 0 0 1 0 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 2 1 2 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  8  8  8 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
   Iorg INDEX:   0   10   8   8 
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Species: O. mossambicus (30 days old juveniles) 
PhD Project: 2015 - 2018 
   Specimen no:  61  62 63 64 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0  0  0  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 0 1 0 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 2 2 4 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  2  0  12 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0 
 
   Iorg INDEX:   0   2   0   12 
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 ANNEXURES 
ANNEXURE 5: ADULT FISH STUDIES DATA 
A. Adult fish standard necropsy data 
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1 M  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few Liver is pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
2  M 
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No  Liver is pale  
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few Kidney is pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
3  F 
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
4  F 
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  Liver pale 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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5 M  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Liver pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate Kidney pale 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
6 M  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
7 M  
C
o
n
to
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
8 F  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Mushy liver 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
 
 
 
 
 Uwineza Marie Clémentine Nibamureke    2019 250 
 
 ANNEXURES 
F
is
h
 #
 
G
e
n
d
e
r 
G
ro
u
p
s
 
E
y
e
s
 
S
k
in
 
F
in
s
 
O
p
e
rc
u
la
 
G
il
ls
 
B
il
e
 
M
e
s
e
n
te
ri
c
 F
a
t 
L
iv
e
r 
S
p
le
e
n
 
H
in
d
g
u
t 
K
id
n
e
y
 
P
a
ra
s
it
e
s
 
C
o
m
m
e
n
ts
 
9  M 
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate Liver pale 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
10 F  
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
11  M 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
12  F 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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13 M  
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
14 F  
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
15 M  
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  Kidney pale 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
16   
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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17 F  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
18 F  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
19  M 
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
20 M  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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21 M  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
22 F  
N
V
P
 L
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate Bile stones 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
23  F 
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  Mushy liver 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
24 M  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  Mushy liver 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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25  M 
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Bile stones 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
26 F  
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
27 F  
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
28  F 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
 
 
 Uwineza Marie Clémentine Nibamureke    2019 255 
 
 ANNEXURES 
F
is
h
 #
 
G
e
n
d
e
r 
G
ro
u
p
s
 
E
y
e
s
 
S
k
in
 
F
in
s
 
O
p
e
rc
u
la
 
G
il
ls
 
B
il
e
 
M
e
s
e
n
te
ri
c
 F
a
t 
L
iv
e
r 
S
p
le
e
n
 
H
in
d
g
u
t 
K
id
n
e
y
 
P
a
ra
s
it
e
s
 
C
o
m
m
e
n
ts
 
29 M  
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
30  F 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
31  M 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few 
 Empty 
gallbladder 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe  
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
32 F  
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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33 F  
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No  Darker liver 
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
34  F 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
35  M 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Red rash 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
36  F 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No  Red rash  
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe  Greenish 
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    swollen 
        Other     Other     Other    ovaries 
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37  M 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
38  F 
N
V
P
 H
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
39 F  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Liver pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
40 M  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate Darker liver  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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41 M  
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Liver pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
42 M  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Bile stones 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
43 M  
C
o
n
tr
o
l 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
44  F 
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Kidney pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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45 F  
S
o
lv
e
n
t 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Kidney pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
46  M 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Kidney pale 
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe  Bile stones 
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
47  F 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
48 M  
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No    
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
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49  F 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate  
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    
        Other     Other     Other     
50  F 
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few  Only one  
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate small ovary 
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe  Greenish  
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis    ovary 
        Other     Other     Other     
51 F  
M
ix
tu
re
 1
 
Normal Normal Normal Normal Normal L Straw None Normal Normal Normal Normal No   
Hemorr Aberration Erosion Shortening Frayed D Straw <50% Fatty Granular Inflam Swollen Few   
Missing Mild Mild    Clubbed L Green 50% Nodules/cysts Nodular Mild Mottled Moderate   
Other Moderate Moderate    Discolour D Green >50% Focal disc Enlarged Moderate Granular Severe   
  Severe Severe   Pale   100% Discolouration Other Severe Urolithiasis     
        Other     Other     Other     
Gender: M = Male; F = Female; Eyes: Hemorr = Hemorrage; Bile: L = Light; D = Dark; Hindgut: Inflam = Inflammation 
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 ANNEXURES 
B. Adult fish blood parameters and body indices data 
 
ID SEX Group Repeats Total Length (mm) Standard Length (mm) Body Mass (g) Condition Factor 
7 1 1 1 146.00 120.00 43.700 1.404 
8 2 1 1 130.00 103.00 29.600 1.347 
23 2 1 1 150.00 120.00 41.690 1.235 
24 1 1 1 146.00 117.00 42.230 1.357 
39 2 1 2 151.00 123.00 44.400 1.290 
40 1 1 2 143.50 115.00 37.700 1.276 
42 1 1 2 167.00 135.00 58.735 1.261 
43 1 1 2 130.00 105.00 31.820 1.448 
9 1 2 1 150.00 124.00 41.400 1.230 
10 2 2 1 160.00 130.00 52.673 1.286 
25 1 2 1 184.00 153.00 94.580 1.518 
26 2 2 1 124.00 94.00 30.600 1.605 
41 1 2 2 172.00 135.00 83.500 1.641 
44 2 2 2 127.00 115.00 30.163 1.473 
45 2 2 2 151.00 121.00 47.831 1.389 
1 1 3 1 149.00 122.00 47.800 1.445 
2 1 3 1 140.00 112.00 36.600 1.334 
3 2 3 1 157.00 130.00 49.800 1.287 
4 2 3 1 138.00 113.00 43.800 1.667 
5 1 3 1 137.00 115.00 35.800 1.392 
6 1 3 1 174.00 145.00 70.300 1.334 
17 2 3 2 132.00 105.00 40.350 1.754 
18 2 3 2 154.00 122.00 46.310 1.268 
19 1 3 2 152.00 122.00 47.810 1.361 
20 1 3 2 171.00 144.00 73.960 1.479 
21 1 3 2 141.00 117.00 36.850 1.315 
22 2 3 2 154.00 128.00 45.230 1.238 
11 1 4 1 148.00 120.00 43.926 1.355 
12 2 4 1 155.00 135.00 49.926 1.341 
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ID SEX Group Repeats Total Length (mm) Standard Length (mm) Body Mass (g) Condition Factor 
13 1 4 1 147.00 120.00 44.105 1.388 
14 2 4 1 153.00 126.00 48.525 1.355 
15 1 4 1 190.00 160.00 90.680 1.322 
16 2 4 1 154.00 124.00 44.478 1.218 
33 2 4 2 127.00 100.00 36.000 1.757 
34 2 4 2 115.00 90.00 25.600 1.683 
35 1 4 2 172.50 137.00 67.000 1.305 
36 2 4 2 138.00 110.00 44.000 1.674 
37 1 4 2 176.00 140.00 75.200 1.379 
38 2 4 2 141.00 114.00 36.000 1.284 
27 2 5 1 137.00 107.00 33.600 1.307 
28 2 5 1 131.00 102.00 27.400 1.219 
29 1 5 1 137.00 108.00 33.200 1.291 
30 2 5 1 123.00 100.00 25.000 1.343 
31 1 5 1 139.00 111.00 36.300 1.352 
32 2 5 1 122.00 98.00 24.700 1.360 
46 1 5 2 136.00 110.00 35.259 1.402 
47 2 5 2 178.00 145.00 89.500 1.587 
48 1 5 2 150.00 117.00 47.058 1.394 
49 2 5 2 158.00 130.00 54.400 1.379 
50 2 5 2 127.00 102.00 35.677 1.742 
51 2 5 2 201.00 167.00 109.140 1.344 
 
ID SEX Group Repeats H S I GSI SSI Hct Lct Hb 
7 1 1 1 1.06636 0.183 0.108 30.56 2.78 6.30 
8 2 1 1 0.93581 3.166 0.169 31.43 2.86 8.50 
23 2 1 1 0.87071 3.495 0.091 26.19 2.38 7.90 
24 1 1 1 0.74592 0.346 0.078 26.67 2.22 8.80 
39 2 1 2 0.6509 1.653 0.090 29.41 2.94 6.20 
40 1 1 2 0.38196 0.371 0.106 24.39 2.44 6.30 
42 1 1 2 0.74777 0.299 0.217 23.91 2.17 7.30 
43 1 1 2 0.65588 0.499 0.107 28.89 2.22 7.30 
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ID SEX Group Repeats H S I GSI SSI Hct Lct Hb 
9 1 2 1 1.01449 0.447 0.090 26.09 2.17 7.80 
10 2 2 1 1.04038 3.617 0.253 16.22 2.70 6.60 
25 1 2 1 0.5868 0.361 0.119 32.65 2.04 7.40 
26 2 2 1 1.04902 2.840 0.092 43.90 2.44 7.80 
41 1 2 2 0.54371 0.208 0.051 25.00 2.27 7.80 
44 2 2 2 1.02775 3.627 0.086 26.67 2.22 7.40 
45 2 2 2 1.08507 3.669 0.089 22.22 1.85 7.40 
1 1 3 1 1.17155 0.579 0.117 26.92 3.85 6.80 
2 1 3 1 1.24317 0.582 0.109 28.13 3.13 6.80 
3 2 3 1 1.29317 3.859 0.076 30.56 2.78 6.30 
4 2 3 1 1.36986 4.486 0.096 30.56 2.78 8.40 
5 1 3 1 1.13128 0.497 0.117 31.03 3.45 7.90 
6 1 3 1 0.87909 0.502 0.084 30.77 2.56 6.80 
17 2 3 2 1.08055 4.107 0.094 27.59 3.45 7.30 
18 2 3 2 1.31289 2.302 0.127 25.00 1.92 6.70 
19 1 3 2 2.03305 0.374 0.228 31.03 3.45 6.30 
20 1 3 2 1.33315 0.291 0.135 36.00 4.00 6.20 
21 1 3 2 1.36771 0.510 0.081 28.57 2.04 6.50 
22 2 3 2 1.23148 3.301 0.075 32.00 2.00 6.80 
11 1 4 1 1.37276 0.489 0.273 30.56 2.78 6.20 
12 2 4 1 1.70052 2.826 0.194 24.14 3.45 6.10 
13 1 4 1 1.59846 0.537 0.281 34.62 3.85 6.90 
14 2 4 1 1.59093 4.173 0.235 32.43 2.70 7.20 
15 1 4 1 1.35201 0.470 0.149 31.43 2.86 5.80 
16 2 4 1 1.30177 4.189 0.164 15.63 3.13 6.80 
33 2 4 2 1.02222 3.261 0.269 24.53 1.89 6.40 
34 2 4 2 1.12891 4.191 0.199 32.14 1.79 7.80 
35 1 4 2 1.11194 0.575 0.128 28.81 1.69 7.80 
36 2 4 2 0.89773 3.725 0.080 27.50 2.50 7.40 
37 1 4 2 1.28191 0.428 0.189 18.18 1.82 6.30 
38 2 4 2 1.06111 3.333 0.150 29.69 1.56 6.50 
27 2 5 1 0.792 3.229 0.188 21.43 2.38 7.70 
28 2 5 1 0.748 4.693 0.223 25.49 1.96 7.00 
29 1 5 1 0.633 0.223 0.154 22.22 1.85 6.30 
30 2 5 1 0.528 3.980 0.072 22.22 2.22 6.60 
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ID SEX Group Repeats H S I GSI SSI Hct Lct Hb 
31 1 5 1 0.54 0.444 0.074 31.58 5.26 8.70 
32 2 5 1 0.911 4.146 0.291 23.40 2.13 6.60 
46 1 5 2 1.452 0.667 0.195 21.15 1.92 8.20 
47 2 5 2 1.234 5.254 0.264 25.42 1.69 6.10 
48 1 5 2 1.238 0.436 0.094 24.14 1.72 9.80 
49 2 5 2 0.748 3.527 0.059 26.53 2.04 7.10 
50 2 5 2 1.814 0.611 0.105 32.81 1.56 7.40 
51 2 5 2 0.856 1.568 0.084 34.29 1.43 7.40 
 
ID SEX Group Repeats Liver index Kidney index Gonad index 
7 1 1 1 10 6 8 
8 2 1 1 10 8 18 
23 2 1 1 12 10 8 
24 1 1 1 6 8 8 
39 2 1 2 8 8 8 
40 1 1 2 6 10 8 
42 1 1 2 8 8 6 
43 1 1 2 10 8 16 
9 1 2 1 12 12 2 
10 2 2 1 10 8 0 
25 1 2 1 8 8 12 
26 2 2 1 14 8 8 
41 1 2 2 8 8 4 
44 2 2 2 8 8 6 
45 2 2 2 14 10 8 
1 1 3 1 32 14 6 
2 1 3 1 18 16 8 
3 2 3 1 24 16 14 
4 2 3 1 24 18 14 
5 1 3 1 34 16 8 
6 1 3 1 24 20 12 
17 2 3 2 24 10 8 
18 2 3 2 28 24 14 
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ID SEX Group Repeats Liver index Kidney index Gonad index 
19 1 3 2 30 28 6 
20 1 3 2 32 18 14 
21 1 3 2 24 24 12 
22 2 3 2 22 22 16 
11 1 4 1 28 22 16 
12 2 4 1 30 22 14 
13 1 4 1 32 20 8 
14 2 4 1 22 16 20 
15 1 4 1 30 22 6 
16 2 4 1 16 24 16 
33 2 4 2 32 16 16 
34 2 4 2 34 24 16 
35 1 4 2 34 20 16 
36 2 4 2 24 16 38 
37 1 4 2 34 18 12 
38 2 4 2 24 24 16 
27 2 5 1 36 22 16 
28 2 5 1 28 22 8 
29 1 5 1 32 16 16 
30 2 5 1 28 26 8 
31 1 5 1 36 18 2 
32 2 5 1 36 24 28 
46 1 5 2 26 22 18 
47 2 5 2 34 18 26 
48 1 5 2 32 20 8 
49 2 5 2 20 22 16 
50 2 5 2 30 22 8 
51 2 5 2 30 16 28 
 
 Sex:    1 = Male; 2 = Female 
 Groups:  1 = Control; 2 = Solvent control; 3 = NVP L; 4 = NVP H; 5 = Mixture 1 
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C. Adult fish data means and statistical analysis 
Mean and median values of adult female fish in the different groups 
Exposure Groups Total 
Length 
(mm) 
Standard 
Length 
(mm) 
Body 
Mass (g) 
Condition 
Factor 
HSI (%) GSI (%) SSI (%) Hct (%) Lct (%) Hb 
(mg/dl) 
Liver 
index 
Kidney 
index 
Gonad 
index 
Control n 3 3 3 3 3 3 3 3 3 3 3 3 3 
Mean 143.667 115.333 38.5633 1.2907 0.8191 2.7712 0.1167 29.0100 2.7267 7.5333 10.00 8.67 11.33 
Std. 
Deviation 
11.8462 10.7858 7.87985 0.05600 0.14929 0.98214 0.04530 2.64280 0.30288 1.19304 2.000 1.155 5.774 
Median 150.000 120.000 41.6900 1.2900 0.8707 3.1655 0.0910 29.4100 2.8600 7.9000 10.00 8.00 8.00 
Minimum 130.0 103.0 29.60 1.24 0.65 1.65 0.09 26.19 2.38 6.20 8 8 8 
Maximum 151.0 123.0 44.40 1.35 0.94 3.49 0.17 31.43 2.94 8.50 12 10 18 
Solvent 
control 
n 4 4 4 4 4 4 4 4 4 4 4 4 4 
Mean 140.500 115.000 40.3168 1.4383 1.0506 3.4382 0.1300 27.2525 2.3025 7.3000 11.50 8.50 5.50 
Std. 
Deviation 
17.7482 15.2971 11.64266 0.13493 0.02461 0.39951 0.08204 11.89567 0.35985 0.50332 3.000 1.000 3.786 
Median 139.000 118.000 39.2155 1.4310 1.0447 3.6218 0.0905 24.4450 2.3300 7.4000 12.00 8.00 7.00 
Minimum 124.0 94.0 30.16 1.29 1.03 2.84 0.09 16.22 1.85 6.60 8 8 0 
Maximum 160.0 130.0 52.67 1.61 1.09 3.67 0.25 43.90 2.70 7.80 14 10 8 
NVP L n 5 5 5 5 5 5 5 5 5 5 5 5 5 
Mean 147.000 119.600 45.0980 1.4428 1.2576 3.6110 0.0936 29.1420 2.5860 7.1000 24.40 18.00 13.20 
Std. 
Deviation 
11.2250 10.5024 3.45773 0.24692 0.11063 0.84903 0.02108 2.81756 0.63418 0.80932 2.191 5.477 3.033 
Median 154.000 122.000 45.2300 1.2870 1.2932 3.8594 0.0940 30.5600 2.7800 6.8000 24.00 18.00 14.00 
Minimum 132.0 105.0 40.35 1.24 1.08 2.30 0.08 25.00 1.92 6.30 22 10 8 
Maximum 157.0 130.0 49.80 1.75 1.37 4.49 0.13 32.00 3.45 8.40 28 24 16 
NVP H n 7 7 7 7 7 7 7 7 7 7 7 7 7 
Mean 140.429 114.143 40.6470 1.4731 1.2433 3.6713 0.1844 26.5800 2.4314 6.8857 26.00 20.29 19.43 
Std. 
Deviation 
15.2081 15.6677 8.59926 0.22258 0.30218 0.54613 0.06127 5.85538 0.71488 0.60671 6.325 4.071 8.384 
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Exposure Groups Total 
Length 
(mm) 
Standard 
Length 
(mm) 
Body 
Mass (g) 
Condition 
Factor 
HSI (%) GSI (%) SSI (%) Hct (%) Lct (%) Hb 
(mg/dl) 
Liver 
index 
Kidney 
index 
Gonad 
index 
Median 141.000 114.000 44.0000 1.3550 1.1289 3.7253 0.1940 27.5000 2.5000 6.8000 24.00 22.00 16.00 
Minimum 115.0 90.0 25.60 1.22 0.90 2.83 0.08 15.63 1.56 6.10 16 16 14 
Maximum 155.0 135.0 49.93 1.76 1.70 4.19 0.27 32.43 3.45 7.80 34 24 38 
Mixture 1 n 8 8 8 8 8 8 8 8 8 8 8 8 8 
Mean 147.125 118.875 49.9271 1.4101 0.9539 3.3760 0.1608 26.4488 1.9263 6.9875 30.25 21.50 17.25 
Std. 
Deviation 
29.1667 25.7040 32.35311 0.16943 0.40036 1.56651 0.09217 4.72531 0.33466 0.52763 5.285 3.162 9.004 
Median 134.000 104.500 34.6385 1.3520 0.8240 3.7535 0.1465 25.4550 2.0000 7.0500 30.00 22.00 16.00 
Minimum 122.0 98.0 24.70 1.22 0.53 0.61 0.06 21.43 1.43 6.10 20 16 8 
Maximum 201.0 167.0 109.14 1.74 1.81 5.25 0.29 34.29 2.38 7.70 36 26 28 
Total N 27 27 27 27 27 27 27 27 27 27 27 27 27 
Mean 144.000 116.815 43.9405 1.4234 1.0845 3.4381 0.1450 27.3852 2.3241 7.0889 23.04 17.19 14.67 
Std. 
Deviation 
18.9473 17.1151 18.45788 0.18369 0.30659 1.00296 0.07271 5.77539 0.56189 0.66583 8.812 6.307 8.152 
Median 141.000 115.000 43.8000 1.3470 1.0490 3.6167 0.1050 26.6700 2.2200 7.1000 24.00 18.00 14.00 
Minimum 115.0 90.0 24.70 1.22 0.53 0.61 0.06 15.63 1.43 6.10 8 8 0 
Maximum 201.0 167.0 109.14 1.76 1.81 5.25 0.29 43.90 3.45 8.50 36 26 38 
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 ANNEXURES 
Mean and median values of adult male fish in the different groups 
Exposure Groups Total 
Length 
(mm) 
Standard 
Length 
(mm) 
Body 
Mass (g) 
Condition 
Factor 
HSI (%) GSI (%) SSI (%) Hct (%) Lct (%) Hb 
(mg/dl) 
Liver 
index 
Kidney 
index 
Gonad 
index 
Control n 5 5 5 5 5 5 5 5 5 5 5 5 5 
Mean 146.500 118.400 42.8370 1.3492 0.7196 0.3396 0.1232 26.8840 2.3660 7.2000 8.00 8.00 9.20 
Std. 
Deviation 
13.2476 10.8536 10.02026 0.08056 0.24484 0.11470 0.05392 2.85690 0.25393 1.02470 2.000 1.414 3.899 
Median 146.000 117.000 42.2300 1.3570 0.7459 0.3457 0.1070 26.6700 2.2200 7.3000 8.00 8.00 8.00 
Minimum 130.0 105.0 31.82 1.26 0.38 0.18 0.08 23.91 2.17 6.30 6 6 6 
Maximum 167.0 135.0 58.74 1.45 1.07 0.50 0.22 30.56 2.78 8.80 10 10 16 
Solvent 
control 
n 3 3 3 3 3 3 3 3 3 3 3 3 3 
Mean 168.667 137.333 73.1600 1.4630 0.7150 0.3386 0.0867 27.9133 2.1600 7.6667 9.33 9.33 6.00 
Std. 
Deviation 
17.2434 14.6401 28.05735 0.21095 0.26026 0.12074 0.03412 4.13812 0.11533 0.23094 2.309 2.309 5.292 
Median 172.000 135.000 83.5000 1.5180 0.5868 0.3605 0.0900 26.0900 2.1700 7.8000 8.00 8.00 4.00 
Minimum 150.0 124.0 41.40 1.23 0.54 0.21 0.05 25.00 2.04 7.40 8 8 2 
Maximum 184.0 153.0 94.58 1.64 1.01 0.45 0.12 32.65 2.27 7.80 12 12 12 
NVP L n 7 7 7 7 7 7 7 7 7 7 7 7 7 
Mean 152.000 125.286 49.8743 1.3800 1.3084 0.4766 0.1244 30.3500 3.2114 6.7571 27.71 19.43 9.43 
Std. 
Deviation 
14.9666 13.6102 16.07182 0.06190 0.35775 0.10716 0.04951 2.96888 0.70080 0.56231 5.823 4.995 3.207 
Median 149.000 122.000 47.8000 1.3610 1.2432 0.5021 0.1170 30.7700 3.4500 6.8000 30.00 18.00 8.00 
Minimum 137.0 112.0 35.80 1.32 0.88 0.29 0.08 26.92 2.04 6.20 18 14 6 
Maximum 174.0 145.0 73.96 1.48 2.03 0.58 0.23 36.00 4.00 7.90 34 28 14 
NVP H n 5 5 5 5 5 5 5 5 5 5 5 5 5 
Mean 166.700 135.400 64.1822 1.3498 1.3434 0.4999 0.2040 28.7200 2.6000 6.6000 31.60 20.40 11.60 
Std. 
Deviation 
18.7136 16.6072 20.27852 0.03577 0.17560 0.05733 0.07021 6.25778 0.88020 0.77782 2.608 1.673 4.561 
Median 172.500 137.000 67.0000 1.3550 1.3520 0.4895 0.1890 30.5600 2.7800 6.3000 32.00 20.00 12.00 
Minimum 147.0 120.0 43.93 1.31 1.11 0.43 0.13 18.18 1.69 5.80 28 18 6 
 Uwineza Marie Clémentine Nibamureke    2019 269 
 
 ANNEXURES 
Exposure Groups Total 
Length 
(mm) 
Standard 
Length 
(mm) 
Body 
Mass (g) 
Condition 
Factor 
HSI (%) GSI (%) SSI (%) Hct (%) Lct (%) Hb 
(mg/dl) 
Liver 
index 
Kidney 
index 
Gonad 
index 
Maximum 190.0 160.0 90.68 1.39 1.60 0.57 0.28 34.62 3.85 7.80 34 22 16 
Mixture 1 n 4 4 4 4 4 4 4 4 4 4 4 4 4 
Mean 140.500 111.500 37.9543 1.3598 0.9658 0.4425 0.1293 24.7725 2.6875 8.2500 31.50 19.00 11.00 
Std. 
Deviation 
6.4550 3.8730 6.20436 0.05081 0.44816 0.18131 0.05547 4.70389 1.71700 1.46173 4.123 2.582 7.394 
Median 138.000 110.500 35.7795 1.3730 0.9355 0.4400 0.1240 23.1800 1.8850 8.4500 32.00 19.00 12.00 
Minimum 136.0 108.0 33.20 1.29 0.54 0.22 0.07 21.15 1.72 6.30 26 16 2 
Maximum 150.0 117.0 47.06 1.40 1.45 0.67 0.20 31.58 5.26 9.80 36 22 18 
Total N 24 24 24 24 24 24 24 24 24 24 24 24 24 
Mean 154.083 125.167 52.3130 1.3743 1.0617 0.4300 0.1368 28.0542 2.6892 7.1792 22.75 15.92 9.67 
Std. 
Deviation 
17.0119 14.8958 19.34774 0.08887 0.39971 0.12659 0.06254 4.33337 0.89651 1.00563 11.046 6.143 4.631 
Median 148.500 120.000 44.0155 1.3590 1.1216 0.4454 0.1170 28.6900 2.3550 6.8500 27.00 17.00 8.00 
Minimum 130.0 105.0 31.82 1.23 0.38 0.18 0.05 18.18 1.69 5.80 6 6 2 
Maximum 190.0 160.0 94.58 1.64 2.03 0.67 0.28 36.00 5.26 9.80 36 28 18 
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 ANNEXURES 
Kruskal -Wallis test for all the fish together (N = 51) 
 
 Mean ranks for all the biometric indices per group 
Exposure Groups n Mean Rank 
Total Length (mm) Control 8 23.56 
Solvent control 7 29.21 
NVP L 12 28.42 
NVP H 12 28.75 
Mixture 1 12 20.58 
Total 51   
Standard Length (mm) Control 8 23.56 
Solvent control 7 30.79 
NVP L 12 29.00 
NVP H 12 28.46 
Mixture 1 12 19.38 
Total 51   
Body Mass (g) Control 8 21.50 
Solvent control 7 29.57 
NVP L 12 29.33 
NVP H 12 29.75 
Mixture 1 12 19.83 
Total 51   
Condition Factor Control 8 19.50 
Solvent control 7 31.00 
NVP L 12 26.17 
NVP H 12 26.71 
Mixture 1 12 26.54 
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Exposure Groups n Mean Rank 
Total 51   
    
    
HSI (%) Control 8 11.88 
Solvent control 7 18.00 
NVP L 12 36.00 
NVP H 12 35.75 
Mixture 1 12 20.33 
Total 51   
GSI (%) Control 8 16.38 
Solvent control 7 24.14 
NVP L 12 25.67 
NVP H 12 29.92 
Mixture 1 12 29.92 
Total 51   
SSI (%) Control 8 23.13 
Solvent control 7 18.71 
NVP L 12 20.92 
NVP H 12 37.33 
Mixture 1 12 25.92 
Total 51   
Hct (%) Control 8 25.19 
Solvent control 7 23.29 
NVP L 12 33.04 
NVP H 12 27.38 
Mixture 1 12 19.71 
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Exposure Groups n Mean Rank 
Total 51   
Lct (%) Control 8 30.19 
Solvent control 7 22.79 
NVP L 12 35.58 
NVP H 12 25.83 
Mixture 1 12 15.67 
Total 51   
Hb (mg/dl) Control 8 28.31 
Solvent control 7 34.79 
NVP L 12 22.25 
NVP H 12 19.75 
Mixture 1 12 29.33 
Total 51   
Liver index Control 8 6.75 
Solvent control 7 9.43 
NVP L 12 29.08 
NVP H 12 33.58 
Mixture 1 12 37.83 
Total 51   
Kidney index Control 8 7.56 
Solvent control 7 8.86 
NVP L 12 30.54 
NVP H 12 34.50 
Mixture 1 12 35.25 
Total 51   
Gonad index Control 8 22.06 
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 ANNEXURES 
Exposure Groups n Mean Rank 
Solvent control 7 10.71 
NVP L 12 23.42 
NVP H 12 34.46 
Mixture 1 12 31.67 
Total 51   
 
 
 
Kruskal-Wallis test: 
  Total Length 
(mm) 
Standard 
Length (mm) 
Body Mass 
(g) 
Condition 
Factor 
HSI (%) GSI 
(%) 
SSI (%) Hct (%) Lct 
(%) 
Hb 
(mg/dl) 
Liver 
index 
Kidney 
index 
Gonad 
index 
Kruskal-Wallis H 2.866 4.147 4.569 2.366 21.586 5.135 10.360 5.206 11.772 6.161 33.627 31.945 14.499 
df 4 4 4 4 4 4 4 4 4 4 4 4 4 
Asymp. Sig. 0.581 0.386 0.334 0.669 0.000 0.274 0.035 0.267 0.019 0.187 0.000 0.000 0.006 
 
  
 Uwineza Marie Clémentine Nibamureke    2019 274 
 
 ANNEXURES 
D.  Adult fish liver histology assessment data 
E.  A B C D E F G H I J K L M N O P Q R S T U V 
1 LIVER Quantitative Histological Assessment                      
2 Assessor: UMC NIBAMUREKE                      
3 Species: O. mossambicus (adults)                      
4 Site: Laboratory Exposure study 2016 - 2018                      
5                       
6 A. Cytoplasmic characteristics                      
7 Clear cell hepatocytes (Majority) 0   0   0   0   0   1   0   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   1   1   0   0   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   1   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 1   0   0   1   1   0   0   
14                       
15 B. Diffused or dispersed lesions 1 2 3 4 5 6 7 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 2 1 2 0 1 0 0 1 0 2 1 2 2 1 2 0 1 0 
18 Irp INDEX   0   2   0   0   2   2   0 
19 Regressive changes                      
20 1. Intracellular deposits 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 0 1 0 
21 2. Hyalinized inclusions 2 1 2 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 2 2 4 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 2 2 4 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 
27 8. Steatosis (fatty change) 2 1 2 0 1 0 2 1 2 2 1 2 0 1 0 2 1 2 2 1 2 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 4 1 4 4 1 4 2 1 2 2 1 2 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   22   10   14   14   18   12   10 
33 Progressive changes                      
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 0 3 0 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   6   6   6   6   6   6   0 
39 Inflammatory                      
40 1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   0   0   0   0   4   0   0 
43 Tumours                      
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                      
48 1. Clear cell foci 2 2 4 0 2 0 2 2 4 2 2 4 2 2 4 0 2 0 0 2 0 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   4   0   4   4   4   4   0 
57                       
58 Iorg INDEX:   32   18   24   24   34   24   10 
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 ANNEXURES 
 A W X Y Z AA AB AC AD AE AF AG AH AI AJ AK AL AM AN 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 1   1   0   1   0   1   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   1   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   1   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
14                    
15 B. Diffused or dispersed lesions 8 9 10 11 12 13 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   2   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 0 1 0 0 1 0 0 1 0 2 1 2 2 1 2 2 1 2 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 
25 6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 2 2 4 2 2 4 4 2 8 4 2 8 4 2 8 
27 8. Steatosis (fatty change) 2 1 2 4 1 4 2 1 2 4 1 4 0 1 0 2 1 2 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 2 1 2 4 1 4 4 1 4 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   10   12   10   20   20   22 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 0 3 0 2 3 6 2 3 6 2 3 6 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   0   0   0   6   6   6 
39 Inflammatory                   
40 1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 2 2 4 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   0   0   0   0   4   4 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   0   0   0   0   0   0 
57                    
58 Iorg INDEX:   10   12   10   28   30   32 
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 A AO AP AQ AR AS AT AU AV AW AX AY AZ BA BB BC BD BE BF 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 0   1   0   0   0   1   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   1   0   1   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 1   0   0   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   0   0   1   0   0   
14                    
15 B. Diffused or dispersed lesions 14 15 16 17 18 19 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 2 1 2 0 1 0 4 1 4 2 1 2 0 1 0 2 1 2 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 2 2 4 0 2 0 2 2 4 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 4 2 8 2 2 4 2 2 4 4 2 8 4 2 8 
27 8. Steatosis (fatty change) 2 1 2 4 1 4 0 1 0 0 1 0 2 1 2 2 1 2 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   12   20   12   14   14   18 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 2 3 6 0 3 0 2 3 6 2 3 6 2 3 6 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   6   6   0   6   6   6 
39 Inflammatory                   
40 1. Infiltration 2 2 4 2 2 4 0 2 0 2 2 4 2 2 4 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   4   4   0   4   4   0 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 2 3 6 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   0   0   4   0   4   6 
57                    
58 Iorg INDEX:   22   30   16   24   28   30 
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 ANNEXURES 
 A BG BH BI BJ BK BL BM BN BO BP BQ BR BS BT BU BV BW BX 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 1   0   0   0   0   1   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   1   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   1   1   0   1   0   
14                    
15 B. Diffused or dispersed lesions 20 21 22 23 24 25 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 2 1 2 2 1 2 2 1 2 2 1 2 0 1 0 0 1 0 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 2 2 4 2 2 4 2 2 4 0 2 0 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 4 2 8 4 2 8 4 2 8 2 2 4 2 2 4 2 2 4 
27 8. Steatosis (fatty change) 2 1 2 2 1 2 2 1 2 0 1 0 0 1 0 0 1 0 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 2 1 2 0 1 0 0 1 0 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   20   20   20   8   6   8 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 2 1 2 0 1 0 2 1 2 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   8   0   2   0   0   0 
39 Inflammatory                   
40 1. Infiltration 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   4   0   0   0   0   0 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   0   4   0   4   0   0 
57                    
58 Iorg INDEX:   32   24   22   12   6   8 
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 ANNEXURES 
 A BY BZ CA CB CC CD CE CF CG CH CI CJ CK CL CM CN CO CP 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 0   0   0   0   0   0   
8 Granular cell hepatocytes (Majority) - Basophilic 1   1   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   0   1   1   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   1   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   1   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
14                    
15 B. Diffused or dispersed lesions 26 27 28 29 30 31 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 0 2 0 2 2 4 2 2 4 2 2 4 0 2 0 2 2 4 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 2 2 4 4 2 8 4 2 8 4 2 8 4 2 8 4 2 8 
27 8. Steatosis (fatty change) 0 1 0 4 1 4 0 1 0 0 1 0 0 1 0 2 1 2 
28 9. Vacuolation (non steatosis) 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   10   22   18   18   14   22 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   0   6   6   6   6   6 
39 Inflammatory                   
40 1. Infiltration 0 2 0 2 2 4 0 2 0 2 2 4 2 2 4 2 2 4 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   0   4   0   4   4   4 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 2 2 4 2 2 4 2 2 4 0 2 0 
49 2. Steatosis foci 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 2 2 4 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   4   4   4   4   4   4 
57                    
58 Iorg INDEX:   14   36   28   32   28   36 
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 ANNEXURES 
 A CQ CR CS CT CU CV CW CX CY CZ DA DB DC DD DE DF DG DH 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 0   0   1   1   0   1   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   1   0   0   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   0   1   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 1   0   0   0   0   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
14                    
15 B. Diffused or dispersed lesions 32 33 34 35 36 37 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 4 1 4 4 1 4 2 1 2 2 1 2 0 1 0 4 1 4 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 2 2 4 0 2 0 2 2 4 2 2 4 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 4 2 8 2 2 4 4 2 8 4 2 8 4 2 8 4 2 8 
27 8. Steatosis (fatty change) 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   22   14   20   24   14   24 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   6   6   6   6   6   6 
39 Inflammatory                   
40 1. Infiltration 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   4   4   4   4   4   4 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 4 2 8 0 2 0 0 2 0 0 2 0 0 2 0 
49 2. Steatosis foci 2 2 4 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   4   8   4   0   0   0 
57                    
58 Iorg INDEX:   36   32   34   34   24   34 
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 ANNEXURES 
 A DI DJ DK DL DM DN DO DP DQ DR DS DT DU DV DW DX DY DZ 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 0   0   1   1   0   0   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 1   0   0   0   1   1   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   1   0   0   0   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   0   0   0   0   0   
14                    
15 B. Diffused or dispersed lesions 38 39 40 41 42 43 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 4 1 4 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 4 2 8 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
27 8. Steatosis (fatty change) 0 1 0 2 1 2 0 1 0 0 1 0 2 1 2 2 1 2 
28 9. Vacuolation (non steatosis) 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 2 1 2 0 1 0 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   14   8   6   8   8   10 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   6   0   0   0   0   0 
39 Inflammatory                   
40 1. Infiltration 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   4   0   0   0   0   0 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   0   0   0   0   0   0 
57                    
58 Iorg INDEX:   24   8   6   8   8   10 
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 ANNEXURES 
 A EA EB EC ED EE EF EG EH EI EJ EK EL EM EN EO EP EQ ER 
1 LIVER Quantitative Histological Assessment                   
2 Assessor: UMC NIBAMUREKE                   
3 Species: O. mossambicus (adults)                   
4 Site: Laboratory Exposure study 2016 - 2018                   
5                    
6 A. Cytoplasmic characteristics                   
7 Clear cell hepatocytes (Majority) 0   0   0   0   1   0   
8 Granular cell hepatocytes (Majority) - Basophilic 0   0   0   0   0   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   1   0   0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 1   0   0   0   0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   0   0   0   1   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   0   0   0   0   
13 Mixed cytoplasmic hepatocytes 0   1   0   1   0   0   
14                    
15 B. Diffused or dispersed lesions 44 45 46 47 48 49 
16 Circulatory distrubances Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
18 Irp INDEX   0   0   0   0   0   0 
19 Regressive changes                   
20 1. Intracellular deposits 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
21 2. Hyalinized inclusions 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 0 2 0 4 2 8 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 0 2 0 0 2 0 0 2 0 2 2 4 2 2 4 2 2 4 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 0 2 0 2 2 4 4 2 8 2 2 4 4 2 8 2 2 4 
27 8. Steatosis (fatty change) 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 2 1 2 
28 9. Vacuolation (non steatosis) 2 1 2 2 1 2 4 1 4 2 1 2 2 1 2 2 1 2 
29 10. Increase in Melano-macrophage centres 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
32 Irp INDEX   8   10   18   24   22   16 
33 Progressive changes                   
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 0 3 0 0 3 0 2 3 6 2 3 6 2 3 6 0 3 0 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
38 Irp INDEX   0   0   8   6   6   0 
39 Inflammatory                   
40 1. Infiltration 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
42 Irp INDEX   0   0   0   0   0   0 
43 Tumours                   
44 1. Benign 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
46 Irp INDEX   0   0   0   0   0   0 
47 C. Foci of cellular alteration (FCA)                   
48 1. Clear cell foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 
49 2. Steatosis foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 0 2 0 0 2 0 2 2 4 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 2 2 4 0 2 0 2 2 4 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
56 Irp INDEX   0   4   0   4   4   4 
57                    
58 Iorg INDEX:   8   14   26   34   32   20 
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 A ES ET EU EV EW EX 
1 LIVER Quantitative Histological Assessment       
2 Assessor: UMC NIBAMUREKE       
3 Species: O. mossambicus (adults)       
4 Site: Laboratory Exposure study 2016 - 2018       
5        
6 A. Cytoplasmic characteristics       
7 Clear cell hepatocytes (Majority) 0   0   
8 Granular cell hepatocytes (Majority) - Basophilic 1   0   
9 Granular cell hepatocytes (Majority) - Eosinophilic 0   0   
10 Dense cytoplasmic hepatocytes (Majority) - Basophilic 0   0   
11 Dense cytoplasmic hepatocytes (Majority) - Eosinophilic 0   0   
12 Clumped cytoplasmic hepatocytes (Majority) 0   0   
13 Mixed cytoplasmic hepatocytes 0   1   
14        
15 B. Diffused or dispersed lesions 50 51 
16 Circulatory distrubances Score IF Index Score IF Index 
17 1. Intercellular haemorrhage / Vascular congestion 0 1 0 0 1 0 
18 Irp INDEX   0   0 
19 Regressive changes       
20 1. Intracellular deposits 2 1 2 2 1 2 
21 2. Hyalinized inclusions 0 1 0 0 1 0 
22 3. Atrophy (hepatocytes) 0 2 0 0 2 0 
23 4. Single cell necrosis 0 2 0 0 2 0 
24 5. Nuclear pleomorphism 0 2 0 0 2 0 
25 6. Hepatocellular pleomorphism 2 2 4 2 2 4 
26 7. Nuclear alterations (karyopyknosis; karyorrhexis; karyolysis) 4 2 8 4 2 8 
27 8. Steatosis (fatty change) 4 1 4 4 1 4 
28 9. Vacuolation (non steatosis) 0 1 0 0 1 0 
29 10. Increase in Melano-macrophage centres 2 1 2 2 1 2 
30 11. Fibrillar inclusions 0 2 0 0 2 0 
31 12. Bile duct necrosis 0 3 0 0 3 0 
32 Irp INDEX   20   20 
33 Progressive changes       
34 1. Hypertrophy (non-lipid) 0 1 0 0 1 0 
35 2. Hypertrophy: Steatosis 0 1 0 0 1 0 
36 3. Wall Proliferation (Bile ducts; blood vessels) / Fibrosis 2 3 6 2 3 6 
37 4. Hyperplasia (e.g. bile ducts; kupfler cells) 0 2 0 0 2 0 
38 Irp INDEX   6   6 
39 Inflammatory       
40 1. Infiltration 0 2 0 0 2 0 
41 2. Granulomatosis 0 2 0 0 2 0 
42 Irp INDEX   0   0 
43 Tumours       
44 1. Benign 0 2 0 0 2 0 
45 2. Malignant 0 3 0 0 3 0 
46 Irp INDEX   0   0 
47 C. Foci of cellular alteration (FCA)       
48 1. Clear cell foci 2 2 4 2 2 4 
49 2. Steatosis foci 0 2 0 0 2 0 
50 3. Eosinophilic foci (no change in cellular size) 0 2 0 0 2 0 
51 4. Basophilic foci (no change in cellular size) 0 2 0 0 2 0 
52 5. Mixed foci 0 2 0 0 2 0 
53 6. Necrotic foci 0 3 0 0 3 0 
54 7. Hydropic foci 0 2 0 0 2 0 
55 8. Hypertrophic foci (No change in cytoplasmic characteristics) 0 2 0 0 2 0 
56 Irp INDEX   4   4 
57        
58 Iorg INDEX:   30   30 
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F. Adult fish kidney histology assessment data 
Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
Specimen no: 1 2 3 4 5 
RP Functional Unit Alterations Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0  1 0 0 1 0  1 0 
  Intercellular oedema  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Dilation of glomerulus capillaries  0 1 0 2 1 2  1 0 2 1 2  1 0 
Irp INDEX   0  2  0  2 0 
RC Tubule Structural alterations  2 1 2 0 1 0  1 0 0 1 0  1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2  1 0 2 1 2  1 0 
   Hyaline droplet degeneration 0 1 0 2 1 2  1 0 2 1 2  1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0  1 0 0 1 0  1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0  1 0 0 1 0  1 0 
  Inter cellular deposits  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 0 2 0  2 0 2 2 4  2 0 
  Atrophy  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Necrosis  2 3 6 2 3 6  3 0 2 3 6  3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2  1 0 0 1 0  1 0 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0  1 0 0 1 0  1 0 
  Intercellular deposits  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Nuclear alterations  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Atrophy  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Necrosis  0 3 0 0 3 0  3 0 0 3 0  3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0  1 0 0 1 0  1 0 
  Intercellular deposits MMC 2 1 2 2 1 2  1 0 2 1 2  1 0 
  Nuclear alterations  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Atrophy  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Necrosis  0 3 0 0 3 0  3 0 0 3 0  3 0 
Irp INDEX   14  14  0  16 0 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0  1 0 0 1 0  1 0 
  Hyperplasia  0 2 0 0 2 0  2 0 0 2 0  2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Hypertrophy  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Hyperplasia  0 2 0 0 2 0  2 0 0 2 0  2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0  2 0 0 2 0  2 0 
Irp INDEX   0  0  0  0 0 
I  Exudate  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Activation of RES  0 1 0 0 1 0  1 0 0 1 0  1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0  2 0 0 2 0  2 0 
   e.g. granulocytes 0 2 0 0 2 0  2 0 0 2 0  2 0 
Irp INDEX   0  0  0  0 0 
T  Benign  0 2 0 0 2 0  2 0 0 2 0  2 0 
  Malignant  0 3 0 0 3 0  3 0 0 3 0  3 0 
Irp INDEX   0  0  0  0 0 
 
Iorg INDEX:   14   16   0   18   0 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  6  7 8 9 10 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
Irp INDEX   2  2  2  2  2 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 0 1 0 0 1 0 2 1 2 0 1 0 
   Hyaline droplet degeneration 2 1 2 0 1 0 2 1 2 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 0 2 0 0 2 0 2 2 4 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   18  4  6  10  6 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   20   6   8   12   8 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  11  12 13 14 15 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  2 1 2  1 0 2 1 2 2 1 2 2 1 2 
Irp INDEX   2  0  2  2  2 
RC Tubule Structural alterations  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2  1 0 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 2 1 2  1 0 0 1 0 2 1 2 0 1 0 
   Eosinophilic cytoplasm 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4  2 0 2 2 4 2 2 4 0 2 0 
  Atrophy  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6  3 0 2 3 6 0 3 0 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0  1 0 0 1 0 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0  2 0 0 2 0 0 2 0 2 2 4 
  Necrosis  0 3 0  3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 2 1 2  1 0 2 1 2 4 1 4 2 1 2 
  Nuclear alterations  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0  3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   16  0  14  14  16 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0  2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0  1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 2 2 4  2 0 2 2 4 0 2 0 2 2 4 
   e.g. granulocytes 0 2 0  2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   4  0  4  0  4 
T  Benign  0 2 0  2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0  3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   22   0   20   16   22 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  16  17 18 19 20 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  2 1 2 0 1 0 0 1 0 2 1 2 0 1 0 
Irp INDEX   2  0  0  2  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 0 3 0 2 3 6 2 3 6 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  2 2 4 0 2 0 2 2 4 2 2 4 2 2 4 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 0 1 0 2 1 2 2 1 2 4 1 4 4 1 4 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   18  10  20  22  18 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 2 2 4 0 2 0 2 2 4 2 2 4 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   4  0  4  4  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0  3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   24   10   24   28   18 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  21  22 23 24 25 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  2 1 2 2 1 2 0 1 0 2 1 2 2 1 2 
Irp INDEX   2  2  0  2  2 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  2 2 4 2 2 4 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 4 1 4 2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   22  20  10  6  6 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   24   22   10   8   8 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  26  27 28 29 30 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
Irp INDEX   2  2  2  2  2 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 2 1 2 2 1 2 2 1 2 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 0 2 0 2 2 4 0 2 0 0 2 0 2 2 4 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 4 1 4 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 2 2 4 2 2 4 0 2 0 2 2 4 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 
  Intercellular deposits MMC 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6  20  20  14  24 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   8   22   22   16   26 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  31  32 33 34 35 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 2 1 2 0 1 0 
Irp INDEX   0  0  0  2  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 2 1 2 0 1 0 2 1 2 2 1 2 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 2 2 4 0 2 0 2 2 4 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 2 1 2 2 1 2 0 1 0 0 1 0 2 1 2 
  Intercellular deposits MMC 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   18  24  16  22  20 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   18   24   16   24   20 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  36  37 38 39 40 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 2 1 2 0 1 0 0 1 0 2 1 2 
Irp INDEX   0  2  0  0  2 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 2 1 2 2 1 2 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 0 1 0 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 2 1 2 2 1 2 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 2 1 2 0 1 0 0 1 0 
  Intercellular deposits MMC 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   16  16  24  8  8 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   16   18   24   8   10 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  41  42 43 44 45 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 0 1 0 0 1 0 2 1 2 0 1 0 
Irp INDEX   0  0  0  2  0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Glomerulus Structural alterations Dilation of Bowman Space 0 1 0 2 1 2 0 1 0 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   8  4  4  6  6 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  0  0  0  0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 0 2 0 2 2 4 2 2 4 0 2 0 2 2 4 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0  4  4  0  4 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0  0  0  0  0 
 
Iorg INDEX:   8   8   8   8   10 
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Kidney Quantitative Histology Assessment 
Assessor: UMC Nibamureke 
Species: O. mossambicus (adults) 
PhD Project 2015 - 2018 
   Specimen no:  46 47 48 49 50 51 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Dilation of glomerulus capillaries  0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 0 1 0 
Irp INDEX  0 2  2  2  2   0 
RC Tubule Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Vacuolation 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
   Hyaline droplet degeneration 2 1 2 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Eosinophilic cytoplasm 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
   Granular degeneration / Deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations Pleomorphism / chromatin clearing / pyknosis 2 2 4 2 2 4 2 2 4 2 2 4 2 2 4 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 2 3 6 
 Glomerulus Structural alterations Dilation of Bowman Space 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 
  Plasma alterations Granular degeneration / intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 2 2 4 2 2 4 2 2 4 2 2 4 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations Granular degeneration / intra cellular deposits / vacuolation 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits MMC 2 1 2 2 1 2 0 1 0 2 1 2 2 1 2 2 1 2 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  18 16  18  20  20   16 
PC Tubule Hypertrophy e.g. albuminous degeneration (reversible) (cloudy swelling) 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Glomerulus Thickening of BC membrane  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia e.g. cirrhosis 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  0 0  0  0  0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration e.g. leucocytes (MNL) - lymphocytes 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   e.g. granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX  4 0  0  0  0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX  0 0  0  0  0   0 
    
Iorg INDEX:   22   18   20   22   22   16 
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G. Adult fish testis histology assessment data 
Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
   Specimen no:  1  2 5 6 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   0   0 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 2 1 2 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Developmental stages               
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 4 1 4 2 1 2 2 1 2 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 2 1 2 2 1 2 2 1 2 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
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  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   6   8   8   6 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Developmental stages               
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0 
IS  Intersex  0 3 0 0 3 0 0 3 0 2 3 6 
Irp INDEX   0   0   0   6 
                
   Iorg INDEX:   6   8   8   12 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 7 9 11 13 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 2 1 2 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0   0   2   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 2 1 2 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 Developmental stages   0            
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 2 1 2 2 1 2 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 4 1 4 2 1 2 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 
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Irp INDEX   2   2   8   6 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 Developmental stages               
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0  2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0 
IS  Intersex  2 3 6 0 3 0 2 3 6 0 3 0 
Irp INDEX   6   0   6   0 
                
   Iorg INDEX:   8   2   16   8 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 15 19 20 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 2 1 2 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 
Irp INDEX   0   2   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 0 1 0 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 Developmental stages            
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
Irp INDEX   6   4   6 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 
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  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 Developmental stages            
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
IS  Intersex  0 3 0 0 3 0 2 3 6 
Irp INDEX   0   0   6 
             
   Iorg INDEX:   6   6   14 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 21 24 25 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 2 1 2 2 1 2 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 
Irp INDEX   2   2   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 Developmental stages         0   
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 2 1 2 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
Irp INDEX   4   6   4 
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PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 Developmental stages            
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
IS  Intersex  2 3 6 0 3 0 2 3 6 
Irp INDEX   6   0   6 
             
   Iorg INDEX:   12   8   12 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
   Specimen no:  29  31 35 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 4 1 4 0 1 0 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 
Irp INDEX   4   0   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 0 1 0 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 Developmental stages            
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 2 2 4 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
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Irp INDEX   6   2   8 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 Developmental stages            
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
IS  Intersex  2 3 6 0 3 0 2 3 6 
Irp INDEX   6   0   6 
             
   Iorg INDEX:   16   2   16 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 37 40 41 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 2 1 2 0 1 0 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 
Irp INDEX   2   0   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 Developmental stages            
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  2 2 4 2 2 4 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
Irp INDEX   10   8   2 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 
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 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 Developmental stages            
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
IS  Intersex  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
             
   Iorg INDEX:   12   8   4 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 42 43 46 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 4 1 4 0 1 0 2 1 2 
  Intercellular oedema  0 1 0 0 1 0 0 1 0 
Irp INDEX   4   0   2 
RC Lobule cysts Disorganization of lobules  0 1 0 0 1 0 0 1 0 
  Detachment of basal membrane  0 1 0 0 1 0 0 1 0 
  Inhibition of spermatogenesis  0 3 0 0 3 0 0 3 0 
  Degeneration of Sertoli cells  0 2 0 0 2 0 0 2 0 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alteration in leydig cells 0 1 0 0 1 0 0 1 0 
  Deposits MMC 0 1 0 0 1 0 0 1 0 
  Vacuolation  2 1 2 2 1 2 2 1 2 
  Nuclear alterations in leydig cells 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 Developmental stages            
 (1) Spermatogonia Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 2 1 2 2 1 2 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 2 2 4 2 2 4 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (3) Spermatids Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 2 1 2 2 1 2 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 0 1 0 0 1 0 
  Vacuolation  0 1 0 0 1 0 0 1 0 
  Inter celllular deposits  0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 
Irp INDEX   2   10   10 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 0 1 0 0 1 0 
  Wall proliferation e.g. blood vessels 0 1 0 0 1 0 0 1 0 
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 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 Developmental stages            
 (1) Spermatogonia Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 
Irp INDEX 0 0 0 
I  Exudate  0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0 
IS  Intersex  0 3 0 2 3 6 2 3 6 
Irp INDEX   0   6   6 
             
   Iorg INDEX:   6   16   18 
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Testis Quantitative Histological Assessment  
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
Site: Laboratory Exposure study 2016 - 2018 
Specimen no: 48 
RP Functional Unit Alterations  Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 2 1 2 
  Intercellular oedema  0 1 0 
Irp INDEX   2 
RC Lobule cysts Disorganization of lobules  0 1 0 
  Detachment of basal membrane  0 1 0 
  Inhibition of spermatogenesis  0 3 0 
  Degeneration of Sertoli cells  0 2 0 
 Interstitial tissue Structural alterations  0 1 0 
  Plasma alteration in leydig cells 0 1 0 
  Deposits MMC 0 1 0 
  Vacuolation  2 1 2 
  Nuclear alterations in leydig cells 0 2 0 
  Atrophy  0 2 0 
  Necrosis  0 3 0 
 Developmental stages      
 (1) Spermatogonia Structural alterations  0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 
  Vacuolation  0 1 0 
  Inter cellular deposits  0 1 0 
  Nuclear alterations  0 2 0 
  Atrophy  0 2 0 
  Necrosis  0 3 0 
 (2) Spermatocytes Structural alterations  0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 
  Vacuolation  2 1 2 
  Inter cellular deposits  0 1 0 
  Nuclear alterations  0 2 0 
  Atrophy  0 2 0 
  Necrosis  0 3 0 
 (3) Spermatids Structural alterations  0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 
  Vacuolation  2 1 2 
  Inter celllular deposits  0 1 0 
  Nuclear alterations  0 2 0 
  Atrophy  0 2 0 
  Necrosis  0 3 0 
 (4) Spermatozoa Structural alterations  0 1 0 
  Plasma alterations e.g. intra cellular deposits 0 1 0 
  Vacuolation  0 1 0 
  Inter celllular deposits  0 1 0 
  Nuclear alterations  0 2 0 
  Atrophy  0 2 0 
  Necrosis  0 3 0 
Irp INDEX   6 
PC Lobule cysts Wall proliferation e.g. basal membrane / Tunica A 0 1 0 
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  Wall proliferation e.g. blood vessels 0 1 0 
 Interstitial tissue Hypertrophy  0 1 0 
  Hyperplasia  0 2 0 
 Developmental stages      
 (1) Spermatogonia Hypertrophy  0 1 0 
  Hyperplasia  0 2 0 
 (2) Spermatocytes Hypertrophy  0 1 0 
  Hyperplasia  0 2 0 
 (3) Spermatids Hypertrophy  0 1 0 
  Hyperplasia  0 2 0 
 (4) Spermatozoa Hypertrophy  0 1 0 
  Hyperplasia  0 2 0 
Irp INDEX   0 
I  Exudate  0 1 0 
  Activation of RES  0 1 0 
  Infiltration Leucocytes (MNL) 0 2 0 
Irp INDEX   0 
T  Benign  0 2 0 
  Malignant  0 3 0 
Irp INDEX   0 
IS  Intersex  0 3 0 
Irp INDEX   0 
       
   Iorg INDEX:   8 
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H. Adult fish ovary assessment data 
Ovary Quantitative Histological Assessment 
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
                      
Site: Laboratory Exposure study 2016 - 2018 
                     
   Specimen no:  3  4 8 10 12 14 16 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema Lifting 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX 0 0 0 0 0 0 0 
RC Ovary Inhibition of oogenesis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Develop. stages                        
 (1) Oogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
 Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Oocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations e.g. germinal vesicle 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis / Atresia  4 3 12 4 3 12 4 3 12 0 3 0 4 3 12 4 3 12 4 3 12 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. vacuolation 2 1 2 2 1 2 2 1 2 0 1 0 2 1 2 4 1 4 4 1 4 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX 14 14 14 0 14 16 16 
PC Develop. stages                        
 (1) Oogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Oocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Tunica Thickening  0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 2 2 4 0 2 0 
Irp INDEX   0   0   4   0   0   4   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   Granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX 0 0 0 0 0 0 0 
IS  Intersex  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0   0 
   Iorg INDEX:   4   14   18   0   14   20   16 
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Ovary Quantitative Histological Assessment 
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
                      
Site: Laboratory Exposure study 2016 - 2018 
                     
Specimen no: 17 18 22 23 26 27 28 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema Lifting 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 2 1 2 0 1 0 
Irp INDEX 0 0   0   0   0   2   0 
RC Ovary Inhibition of oogenesis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 Develop. stages                        
 (1) Oogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
 Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Oocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations e.g. germinal vesicle 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis / Atresia  2 3 6 4 3 12 4 3 12 2 3 6 2 3 6 4 3 12 2 3 6 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. vacuolation 2 1 2 2 1 2 4 1 4 2 1 2 2 1 2 2 1 2 2 1 2 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX 8 14   16   8   8   14   8 
PC Develop. stages                       
 (1) Oogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Oocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Tunica Thickening  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   Granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX 0 0   0   0   0   0   0 
IS  Intersex  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0   0 
   Iorg INDEX:   8   14   16   8   8   16   8 
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Ovary Quantitative Histological Assessment 
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
                      
Site: Laboratory Exposure study 2016 - 2018 
    
Specimen no: 30 32 33 34 36 38 39 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 2 1 2 2 1 2 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular oedema Lifting 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX   0 2 2 0 0 0 0 
RC Ovary Inhibition of oogenesis  0 3 0 0 3 0 0 3 0 0 3 0 4 3 12 0 3 0 0 3 0 
 Develop. stages                        
 (1) Oogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
 Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Oocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations e.g. germinal vesicle 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis / Atresia  2 3 6 4 3 12 4 3 12 4 3 12 6 3 18 4 3 12 2 3 6 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. vacuolation 2 1 2 4 1 4 2 1 2 4 1 4 2 1 2 4 1 4 2 1 2 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 2 3 6 0 3 0 0 3 0 2 3 6 0 3 0 0 3 0 
Irp INDEX   8 22 14 16 38 16 8 
PC Develop. stages                        
 (1) Oogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Oocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Tunica Thickening  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) - lymphocytes 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
   Granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   4   0   0   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0 0 0 0 0 0 0 
IS  Intersex  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0   0 
   Iorg INDEX:   8   28   16   16   38   16   8 
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Ovary Quantitative Histological Assessment 
Assessor: UMC NIBAMUREKE 
Species: O. mossambicus (adult) 
                   
Site: Laboratory Exposure study 2016 - 2018 
                  
Specimen no: 44 45 47 49 50 51 
RP Functional Unit Alterations  Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index Score IF Index 
CD  Aneurysm/Haemorrhage e.g. induce congestion 0 1 0 0 1 0 2 1 2 2 1 2 0 1 0 0 1 0 
  Intercellular oedema Lifting 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
Irp INDEX 0 0 2 2 0 0 
RC Ovary Inhibition of oogenesis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 4 3 12 
 Develop. stages                     
 (1) Oogonia Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
 Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Inter cellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
 (2) Oocytes Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Intercellular deposits  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations e.g. germinal vesicle 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis / Atresia  2 3 6 2 3 6 4 3 12 4 3 12 2 3 6 4 3 12 
 Interstitial tissue Structural alterations  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Plasma alterations e.g. vacuolation 0 1 0 2 1 2 2 1 2 2 1 2 2 1 2 4 1 4 
  Intercellular deposits MMC 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Nuclear alterations  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Atrophy  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Necrosis  0 3 0 0 3 0 2 3 6 0 3 0 0 3 0 0 3 0 
Irp INDEX 6 8 20 14 8 28 
PC Develop. stages                   
 (1) Oogonia Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 (2) Oocytes Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Interstitial tissue Hypertrophy  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Hyperplasia  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
 Tunica Thickening  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   0   0   0   0 
I  Exudate  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Activation of RES  0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 
  Infiltration Leucocytes (MNL) - lymphocytes 0 2 0 0 2 0 2 2 4 0 2 0 0 2 0 0 2 0 
   Granulocytes 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
Irp INDEX   0   0   4   0   0   0 
T  Benign  0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 0 2 0 
  Malignant  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX 0 0 0 0 0 0 
IS  Intersex  0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 0 3 0 
Irp INDEX   0   0   0   0   0   0 
   Iorg INDEX:   6   8   26   16   8   28 
 
 
